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 Direct-to-consumer advertising of prescription medicines (DTCA), a disputed 
health communication strategy, has been legally developed only in New Zealand and the 
United States. DTCA has raised significant concerns in New Zealand, especially because it is 
self-regulated by the industry, which currently does not prevent it from offering incomplete 
and misleading information. Even in the United States, where DTCA is regulated and overseen 
by the Food and Drug Administration, violations by pharmaceutical companies are widespread 
and predominantly involve deceptive information. Given that regulation of DTCA has not 
been effective, the main purpose of this research was to explore how consumers respond to 
DTCA and whether DTCA is socially responsible. More specifically, this research aimed to 
examine the factors linking to individuals’ behavioural responses to DTCA, reveal the issues 
affecting consumers’ informed decision-making, conceptualise the characteristics of 
vulnerable consumers with regard to DTCA, and finally develop an ethical framework for 
DTCA based on the Corporate Social Responsibility model. To achieve this goal, this research 
comprised three studies. 
 Study one, built on communication inequality and the Structural Influence Model of 
health communication, identified factors associated with consumers’ self-reported behavioural 
responses to DTCA. By analysing survey data collected from a nationally representative 
sample of adults (n=2057), this study found that drug advertising was more likely to influence 
‘at-risk’ individuals (i.e., lower-income, poorer health status, older, less educated, and ethnic 
minorities), and those who had more positive attitudes toward DTCA, who were 
more materialistic and who rely on the internet for medical information. These individuals, 
therefore, may be more vulnerable to drug advertising and may make poorly informed 
decisions accordingly. The findings raise major concerns regarding the ethicality of medicine 
advertising and highlight the requirement for stricter regulations to ensure that medicine 
advertisements offered by pharmaceutical firms are ethical. Preliminary findings from this 
study were presented at the EMAC Conference, 2016 and developed into a journal paper that 
was published in the BMJ Open in 2017.  
Study two, based on the same sample as study one, extended study one and examined 
the link between healthy/unhealthy lifestyle habits and individuals’ responses to DTCA. This 
study revealed that individuals with unhealthier lifestyles were more likely to respond to DTCA 
and thus might be more vulnerable to DTCA. The link between unhealthy lifestyle behaviours 
and being influenced by drug advertising raises concerns about the misuse or overuse of 
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medicines for health problems that may be solved with a healthier lifestyle. Individuals with 
risky lifestyle behaviours should be fully informed to be able to make appropriate health 
decisions. These findings were published in the Australian & New Zealand Journal of Public 
Health in 2019. Collectively, the outcomes from study one and study two informed the design 
of study three.  
Study three focused on social responsibility, and more specifically ethicality, in DTCA 
in New Zealand. The study involved 29 in-depth interviews with health professionals to explore 
their thoughts and recommendations regarding the advertising of prescription medicines. The 
findings revealed that most informants had concerns regarding consumers’ autonomy in 
decision-making, their ability to understand/interpret the information presented, and their 
ability to make informed decisions. According to informants’ perspectives and experiences, 
consumers’ capability, self-efficacy and other characteristics could play an essential role in 
their fully informed decision-making. The health professionals thought that although most 
consumers are vulnerable to DTCA and are not able to make informed decisions, there are 
specific consumers who are even more vulnerable to DTCA. The unethical nature of DTCA 
was underlined. Of importance, the thematic analysis of informants’ opinions showed the 
existence of persuasion and opportunism in DTCA, which informants thought consumers 
would generally not be able to detect. From the findings, a framework of criteria for socially 
responsible DTCA was proposed to help individuals make informed decisions and improve 
their well-being. Recommendations pertained to the content of DTCA, types of advertising 
channels employed, types of advertised medications, social responsibility/ethicality of DTCA 
providers, as well as stricter regulations and supervision of DTCA. The research outcomes have 
important implications for the regulation of DTCA. The findings could also help 
pharmaceutical advertisers to fulfil the consumers’ right to be informed and to choose. The 
principal theoretical implications of this study were that the findings provided new perspectives 
for conceptualising socially responsible DTCA, informed decision-making and vulnerable 
consumers in the DTCA context. Initial findings from study three were presented at the 
Macromarketing Conference, 2017. 
 Taken together, the three studies showed that consumers, especially those who are at 
risk, are more likely to be influenced by DTCA and may not be able to make fully informed 
decisions. Moreover, findings revealed that DTCA is not socially responsible in its current 
form, and changes need to be made to help consumers’ informed decision-making. 
Recommendations drawn from the three studies, to improve the regulation and ethicality of 
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DTCA, are presented in the concluding discussion and helped to inform a submission to the 



































 The preliminary motivation for this Ph.D. research came from my masters in marketing, 
master’s thesis on the pharmaceutical industry, and from my job experience in the marketing 
field in pharmaceutical companies. My academic background and job experience, along with 
continuous discussions with my father, who is a Doctor of Pharmacy, regarding existing issues 
in the pharmaceutical industry helped me to know this industry and its challenges and inspired 
me to start this multidisciplinary Ph.D. program. 
 The theoretical approach to this Ph.D. research was inspired by the Corporate Social 
Responsibility concept (Carroll, 1991) and the combined lenses of “informed decision-
making,” “corporate social responsibility,” “ethicality,” and “vulnerability” concepts, 
important subject matters in the context of DTCA, were used to direct the research. Reviewing 
the DTCA literature revealed an ongoing debate among scholars –those in favour of DTCA 
and those against it. However, there was a dearth of research regarding the social 
responsibility of DTCA as well as consumers’ ability to make informed decisions after exposure 
to DTCA. This background inspired me to explore social responsibility, more specifically, the 
ethicality of DTCA, and informed decision-making in response to DTCA. 
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CHAPTER ONE: INTRODUCTION AND OVERVIEW 
 
 The introduction chapter sets the background, motivations, and literature review of this 
Ph.D. research. The pertinent empirical gaps in the literature are discussed and the questions 
addressed in three studies are illustrated. It explains the methodology chosen for each study 
and highlights the research contributions by outlining the main outcomes and related 
theoretical, managerial, and public health implications of the research. 
 
 1.1 Background to the Research  
 DTCA (direct-to-consumer advertising of prescription medicines) is currently the most 
controversial type of health communication (Greene & Herzberg, 2010; Kuehn, 2010; 
Pharmaguy, 2010), and is only legal in New Zealand and the United States (Kontos & 
Viswanath, 2011). The main objectives of DTCA “are to inform, persuade, and remind 
consumers to take prescribed actions towards advertised drugs–to learn, to prefer, to ask for, 
and to ask for again” (Huh, DeLorme, & Reid, 2004, p. 30). There are four kinds of DTCA: 
(1) Help-seeking ads, which offer information regarding a medical condition and encourage 
individuals to contact their doctor, but do not present the medicine’s name (Morgan, 2007; 
Ventola, 2011). (2) Reminder ads, which comprise the medicine’s name and may offer 
information about the medicine’s dosage, strength, and even price, but do not declare the 
indications of the medicine (Morgan, 2007; Ventola, 2011). (3) Product claim ads, which are 
the most common kind of DTCA and present almost everything about the advertised medicine; 
i.e., the medicine’s name, indications, risk information, and efficacy claims (Morgan, 2007; 
Ventola, 2011). (4) Persuasive brand advertising, which aims to encourage a preference for a 
specific brand over generic or alternate brands of the same type of medicines (Samaranayaka 
& Green, 2019). While there are subtle differences in the types of DTCA, empirical research 
typically refers to DTCA as one form of advertising rather than focussing on a specific type. 
DTCA can be offered through different channels including, TV, radio, print media, and the 
Internet (Mackey, Cuomo, & Liang, 2015). “The adoption and use of digital forms of direct-
to-consumer advertising (also known as ‘eDTCA’) is on the rise” (Mackey, 2016, p. 271). 
However, existing studies raised concerns regarding the inequality between the presentation of 
risk and benefit information on medicines’ websites (Huh & Cude, 2004). For instance, 
research has shown that risk information is not clearly available on the medicines’ websites, 
although companies have access to limitless pages and space to present information (Kim, 
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2015). Past research has also shown that nearly half of the websites did not offer risk 
information about the advertised medications on their homepage (Sheehan, 2007). Huh & Cude 
(2004) revealed that “benefit information was more accessible than risk information. While 
most websites had a direct link to benefit information in the main navigational button set on 
the homepage, only 8% of websites provided the same tool for risk information” (p.538). 
Accordingly, in the regulatory guideline for eDTCA, “fair balance of information, as well as 
visibility and accessibility of information, should be considered to protect consumers from 
misleading information” (Kim, 2015, p. 813). “The universe of eDTCA is expanding, as 
technology on Internet-based platforms continues to evolve, from static websites, to social 
media” (Mackey, 2016, p. 271). Social media can be a complicated form of marketing channel, 
so that advertisers cannot fully monitor their advertising messaging (Liang, 2011). Advertising 
through social media thus merits more attentions (Kim, 2015). Consequently, new regulatory 
strategies, such as supervision of independent third-party to ensure individuals’ safety, are 
required to control eDTCA specially through social media (Gibson, 2014). However, the 
present thesis looks at DTCA in general rather than focussing on a particular channel. 
DTCA began with Boots, the pharmaceutical company that promoted its prescription 
pain reliever Rufen in 1981 (Donohue, 2006). In fact, DTCA is relatively new, only becoming 
commonplace in the United States during the early 1980s and in New Zealand in the early 
1990s (Hoek, Gendall, & Calfee, 2004; Morris & Griffin, 1992; Spake & Joseph, 2007). The 
regulation of DTCA differs between the United States and New Zealand. In New Zealand, there 
is no systematic evaluation of, or strict control on, DTCA and regulation depend on a self-
regulatory framework (Hoek, 2008; Toop & Mangin, 2006). This system relies on the industry, 
business, and individuals instead of the government (Gibson, 2014), and was driven by a move 
from social well-being to a market model, and a change from government social responsibilities 
to individual responsibilities (Auton, 2004). This system has not prevented misleading 
advertisements (Toop et al., 2003) and has caused significant concerns (Toop & Mangin, 2006). 
Even in the United States, where DTCA is regulated and overseen by the Food and Drug 
Administration, violations by pharmaceutical companies are common, mainly for providing 
misleading information (Donohue, Cevasco & Rosenthal, 2007; Faerber & Kreling, 2014; Kim, 
2015; Klara, Kim & Ross, 2018). A primary challenge lies therefore in individuals’ safe and 
informed decision-making based on DTCA. Hence, in the absence of strict and/or effective 
regulation, it is important to consider whether and to what extent the medicine advertisements 
offered by pharmaceutical companies are ethical. Policymakers should hence protect 
consumers’ right of accessing the information in addition to protecting them from partial and 
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false information (Womack, 2013). This illustrates the need for some regulatory changes 
regarding the advertising of medicines in New Zealand. 
 
1.2 General Literature Review 
 To provide a thorough understanding of the subject being researched, this literature 
review has been built upon three main research streams on DTCA: consumers’ behavioural 
responses to DTCA, social responsibility in DTCA, and consumers’ informed decision-
making. These literature streams and the pertinent challenges that were addressed in three 
separate phases/studies of this Ph.D. research are clarified below. 
 
1.2.1 Consumers’ Behavioural Responses to DTCA 
 Research has shown that DTCA can influence consumers’ behavioural responses to 
drug advertising, such as visiting a physician, and/or requesting the advertised drugs (Chen & 
Carroll, 2007; Khanfar, Polen, & Clauson, 2009; Mintzes et al., 2003). However, different 
people comprehend health information differently (Kontos & Viswanath, 2011). Thus, it is 
fundamental to find out the factors that can influence consumers’ behavioural responses to 
DTCA. Two theories help to explain variations in responding to health information as a 
function of individual characteristics. The knowledge gap hypothesis “suggests that 
information flow into society is more likely to be acquired by high socio-economic groups at 
a faster rate than lower socio-economic groups, thus widening gaps in knowledge between 
them” (Kontos & Viswanath, 2011, p. 143). Similarly, the Structural Influence Model (SIM) 
of health communication proposes that social factors are associated with health communication 
outcomes and theorises that health communication differences can be seen in terms of 
disparities in how individuals respond to health information (Viswanath & Ackerson, 2011). 
Previous studies on health communication have shown that the socio-demographic and socio-
economic position of individuals may explain health behaviour inequalities. For example, 
social determinants, including ethnicity and social class can affect individuals’ cancer-related 
information seeking (Ramanadhan & Viswanath, 2006). Differences between women and men 
are also evident. Women are more likely than men to search for health information, which 
could be due to gender dissimilarities in the sociocultural setting (Jung, 2014; Rutten, Squiers, 
& Hesse, 2006) or because of female-specific conditions (Suominen-Taipale, Martelin, 
Koskinen, Holmen, & Johnsen, 2006). Age has also been found to influence communication 
disparities. Older, less educated, and lower-income individuals are potentially more susceptible 
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than others to the medical information gap (Foley & Gross, 2000). For instance, older people 
who ask for medications after exposure to medicine advertisements can unintentionally 
complicate the patient-physician relationship, particularly if an advertisement has misinformed 
them about the effectiveness of the medicine (Grenard et al., 2011).  
Given that there may be dissimilarities between social groups in their capability to 
process and respond to DTCA, it is important to examine the outcomes of exposure to medicine 
advertising between various social groups (Kontos & Viswanath, 2011). There is, however, a 
dearth of research examining probable communication disparities in response to medicine 
advertising (Ramanadhan & Viswanath, 2006). Given the growing concern about the role of 
social imbalance in health-related outcomes, more studies have to be conducted to map the 
paths between social determinants and health-related consequences (Ackerson & Viswanath, 
2009; Bekalu & Eggermont, 2014). Thus, the first phase of this Ph.D. addressed the issue of 
whether there are differences between social groups in their behavioural responses to DTCA, 
focusing in particular on ‘at-risk’ individuals’ responses. Drawing on the Structural Influence 
Model of health communication, the study explored whether there was any social imbalance as 
a function of individual characteristics with regard to responding to medicine advertising.  
 Past research has also examined the influence of attitudes on behavioural responses to 
DTCA. Earlier studies showed that positive attitudes towards medicine advertising predict 
behavioural intentions and responses to such advertising (Handlin, Mosca, Forgione, & Pitta, 
2003; Herzenstein et al., 2004; Lee et al., 2015). Hence, the first phase of this Ph.D. also 
examined the effects of individuals’ attitudes towards medicine advertising on their 
behavioural responses to DTCA. Extending past research, materialism was considered as a 
potential factor influencing behavioural responses. Despite existing knowledge about the role 
of attitudes towards medicine advertising on responses to such advertising, no previous 
research has explored the influence of materialistic attitudes on behavioural responses to 
medicine advertising. Materialism, a trait that emphasises the importance placed on goods and 
their purchase to help achieve desired goals or situations (Richins & Dawson, 1992), is 
associated with purchasing and consumption behaviour in general (Kasser, 2003; Podoshen & 
Andrzejewski, 2012; Türk & Erciş, 2017). Given that drugs are advertised similarly to other 
consumer goods, and materialism is associated with consumption, greater attention to 
advertising (Graham, 1999), and susceptibility to advertising (Kasser et al., 2004), it seems 
reasonable to assume that materialistic individuals might be more likely than others to respond 
to DTCA.  Furthermore, “A defining characteristic of highly materialistic individuals is a belief 
that well-being can be enhanced through one’s relationships with objects” (Burroughs & 
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Rindfleisch, 2002, p. 349). Assuming that materialistic individuals might be more willing to 
respond to DTCA, it is, therefore, reasonable to consider materialism as a potential factor 
influencing behavioural responses to DTCA. 
 Reviewing existing research also revealed the importance of examining the effects of 
lifestyle behaviours on behavioural responses to DTCA. Although research on individual 
characteristics tends to focus on demographics, the study of lifestyle behaviours may provide 
more information about, and a better picture of, individuals than their demographics alone 
(Cooper, 1984; Krishnan, 2011). In addition to demographic and socio-economic factors 
(World Health Organization, 2009), individuals’ lifestyle behaviours can result in health 
inequalities (Farhud, 2015; Floud et al., 2016; Fuchs, 1986). Health lifestyles are outlined as 
health-related behaviours according to individuals’ preferences from available options 
(Cockerham, 2000). Major lifestyle challenges threatening people’s health include substance 
abuse (such as tobacco, illicit drug, and alcohol consumption), unhealthy eating behaviours, 
and physical inactivity (McGinnis & Foege, 1993; Poortinga, 2007; Sapranaviciute-
Zabazlajeva, Luksiene, Virviciute, Bobak, & Tamosiunas, 2017; Satcher, 2000). Positive 
lifestyle practices, including healthy nutrition, exercise, low-risk alcohol consumption, and 
smoking abstinence influence individuals’ health positively (National Center for Health 
Statistics, 2001; U.S. Department of Health and Human Services, 2000). Krishnan (2011) 
found that lifestyle characteristics significantly affect consumers’ buying behaviour and their 
lifestyle is associated with the products, services, and activities that they select. Considering 
that drugs are advertised similarly to other consumer goods in New Zealand, individuals’ 
lifestyle factors may influence their behavioural responses to DTCA. Moreover, extant research 
has argued that medicine advertising could influence “non-clinical health behaviours” (Kruger, 
Niederdeppe, Byrne, & Avery, 2015, p. 1151). Bolton, Reed, Volpp & Armstrong (2007) 
argued that drug marketing could decrease individuals’ intention to adopt healthy lifestyle 
behaviours. Since DTCA can be misleading and emotive (Toop & Mangin, 2015), and focuses 
on taking medications rather than changing lifestyle behaviours (Auton, 2004), individuals 
with less healthy lifestyle behaviours might be more ‘at risk’ of responding to DTCA, a 
relationship that is yet to be empirically explored. The second phase of this research 
accordingly extended the first phase and addressed an important gap in the literature on DTCA 
by examining the effects of individuals’ lifestyle habits on their behavioural responses to 
DTCA. 
 Of particular concern, DTCA has changed healthcare-seeking behaviours by 
encouraging individuals to request advertised medicines (Toop & Mangin, 2006). Past research 
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showed that DTCA leads to the advertised medicines being pursued by individuals (Donohue 
et al., 2007) and doctors then feel pressured to prescribe the requested medicines (Wilkes, Bell, 
& Kravitz, 2000). Given that consumers push for specific medicines as a result of advertising, 
a pertinent question is whether DTC advertisements are responsible and present information 
that can help consumers to make informed decisions. Despite the importance placed on 
behavioural responses to medicine advertising, to the best of my knowledge, research has failed 
to explore the concept of social responsibility and more specifically ethicality in the context of 
DTCA. It is important to identify how to evolve DTCA from a business-level profit-oriented 
system to a socially responsible society-level system that improves the health and well-being 
of society. The following sections first discuss social responsibility in general, and then outline 
social responsibility and more specifically ethicality in the context of DTCA.  
 
1.2.2 Corporate Social Responsibility  
 Corporate Social Responsibility (CSR) has been used to explain and understand various 
business practices and responsibilities of companies (Fatma & Rahman, 2015). CSR “is a 
general name for any theory of the corporation that emphasizes both the responsibility to make 
money and the responsibility to interact ethically with the surrounding community” (Brussea, 
2011, p. 324). The notion that “profit maximisation is the only legitimate goal of management 
has been recognised as one end of a continuum, while at the other end is the recognition that 
corporations are the trustees of societal property that should be managed for the public good” 
(Okpara & Idowu, 2013, p. 4). Carroll (1979) outlined four scopes for CSR, which are 
economic, legal, ethical, and discretionary (philanthropic) responsibilities that have been 
widely employed by scholars and experts for many years (Carroll, 2016; Okpara & Idowu, 
2013). The economic responsibility of a corporation is “to produce goods and services that 
society desires and to sell them at a profit” (Carroll, 1979, p. 500), so that companies achieve 
their main responsibility as profitable elements of society (Okpara & Idowu, 2013). The legal 
responsibility of a corporation is expressed as the responsibilities of companies that are set by 
laws (Carroll, 1991). The ethical responsibility refers to do what is right and perform as 
expected by the public, beyond what is set by law (Carroll, 1991; Carroll, 2016). The 
philanthropic responsibility refers to companies’ voluntary practices to improve public welfare 
and contribute to the community (Carroll, 1991; Carroll, 2016). In advertising activities, like 
any other business activities, corporations need to achieve their business goals while meeting 
consumers’ perceptions of responsibility (Miles & Manilla, 2004). Corporations are not 
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considered to be responsible if they focus solely on increasing their returns (Polonsky & 
Hyman, 2007); they need to reach acceptable profits while acting socially responsible and 
morally (Miles & Manilla, 2004). 
 
1.2.2.1 Socially Responsible Advertising 
 Responsible advertising happens once promoters care about the consequences of their 
advertising on all stakeholders in a network (Polonsky & Hyman, 2007), and it has been defined 
as the corporations’ practices to present key product usage as well as risk and safety issues to 
consumers (Argo & Main, 2004; Torres et al., 2007). “Identifying responsible advertising 
requires that all stakeholders’ interests be considered and integrated into a firm’s advertising 
strategy and tactics” (Polonsky & Hyman, 2007, p. 5). One of the main requirements of 
responsible practices is offering precise information that can be understood by consumers. 
Showing that a product is beneficial for consumers when it is not, is deceptive and irresponsible 
(Polonsky & Hyman, 2007). Past research has discussed that it is in pharmaceutical companies’ 
lasting interest to interact responsively, fairly, and precisely with customers (Carroll & 
Shabana, 2010; Wilkes et al., 2000). Accordingly, it is in the interest of both pharmaceutical 
corporations and consumers if pharmaceutical companies offer responsible advertising. In the 
context of DTCA, however, there is a challenge for pharmaceutical companies in how to offer 
DTCA to balance their commercial goals with public health goals. These objectives can 
sometimes conflict, and questions have been raised about the effects and ethics of DTCA.  
 
Ethicality of DTCA 
 As discussed earlier, according to the CSR concept, companies need to act both legally 
and ethically within society (Carroll, 1991). CSR has been increasingly implemented in the 
pharmaceutical industry since its products are directly associated with the well-being of people 
(Van de Pol & de Bakker, 2010). The pharmaceutical marketing system should consequently 
be grounded within a value framework that considers both the corporate goals of the 
organisation and the social consequences of marketing activities (Brennan, Eagle, & Rice, 
2010). Pharmaceutical companies are required to meet ethical responsibilities to well inform 
or educate their consumers (Perry, Cox, & Cox, 2013). Considering the unique features of 
prescription medicines, that can help or harm consumers’ well-being; assuring consumers’ 
informed decision-making can be viewed as the essential element of implementing CSR in 
DTCA (Van de Pol & de Bakker, 2010). Thus, if the practices of the pharmaceutical marketing 
system are ethical, the resulting outcome will be well-informed consumers. However, the 
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practice of advertising prescription medicines directly to consumers has raised ethical concerns 
(Carbonell, 2014). Thus, in this Ph.D. research, one focus is to explore whether DTCA is ethical 
and explore whether DTCA leads to well-informed individuals. 
 
The Debates on DTCA from a CSR Perspective 
 DTCA is a highly controversial type of advertising (Tan, 2015) and previous research 
discussions regarding the benefits and drawbacks of DTCA have been inconsistent and 
contradictory. The literature has been trying to resolve the conflict between consumers’ 
autonomy and consumers’ safe decision-making. Some benefits and drawbacks of DTCA can 
be linked to its social responsibility (van de Pol & de Bakker, 2010). However, only a few 
studies have discussed DTCA from a CSR perspective (van de Pol & de Bakker, 2009). In 
order to analyse both positions (support of and opposition to DTCA) from a CSR perspective, 
we can concentrate on the debate from a commercial (cost-effectiveness) and social (consumer 
empowerment and safety) standpoint (van de Pol & de Bakker, 2010).  
 From an economic viewpoint, supporters of DTCA argue that prohibition of DTCA 
would limit competition; and that competition can result in higher quality, lower prices,  
development of novel products, and finally, superior decision-making (van de Pol & de Bakker, 
2010; Vickers, 2002). Moreover, DTCA can reduce healthcare expenses by contributing to 
consumers’ treatment and adherence through preventing costly medical alternatives, including 
hospitalisation and operations (Auton, 2007). Opponents, however, argue that DTCA may 
harm competition in the pharmaceutical industry since massive expenditures on DTCA may 
result in more expensive medicines and are barriers to new entrants (Almasi, Stafford, Kravitz, 
& Mansfield, 2006).  
 From a societal perspective, advocates of DTCA think that DTCA contributes to the 
safety and well-being of consumers; whereas opponents believe that pharmaceutical companies 
do not meet their stated aim of the education and empowerment of consumers. Advocates of 
DTCA state that advertising of medicines increases patients’ awareness of illnesses, which can 
lead to superior decision-making (Adams, 2016). The pharmaceutical industry claims that 
DTCA could increase patients’ autonomy in their wellbeing (Chaar & Kwong, 2010). 
Supporters argue that all people in the world should be offered the same information in order 
to make decisions about prescription medicines (Sullivan, 2000). These advertising strategies 
may generate emotionally conditioned responses and expectations, increasing a placebo effect 
that happens when the drug is consumed. DTCA aligns with two theories used to explain the 
placebo effect (Almasi et al., 2006). The first theory, Pavlovian conditioning theory, explains 
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that preceding experiences with appropriate treatments prompt a response similar to the active 
agents (Voudouris, Peck, & Coleman, 1985). Likewise, DTCA could improve the medicine’s 
clinical effect by presenting conditioned stimuli to relate each medicine with positive emotions: 
the pleasure of playing on pretty grounds for allergy sufferers or the relief of performing desired 
activities by elderly patients with arthritis (Almasi et al., 2006). This conditioned response may 
improve the effectiveness of drugs further than what is anticipated from the drugs’ biological 
mechanisms (Almasi et al., 2006). The second theory, the expectancy-value theory, emphasises 
the expectancies shaped by the information offered (Kirsch, 1997). “Based on this theory, 
individuals are receptive to signals confirming their primary expectations after administration 
of a placebo treatment” (Almasi et al., 2006, p. 0284). Similarly, many drug advertisements 
demonstrate to audiences what to expect from the drug (Cline & Young, 2004). 
 Opponents, however, claim that exposure to health information through DTCA does 
not necessarily lead to knowledge or well-informed consumers (Carbonell, 2014; Womack, 
2013) and the intention of DTCA is not to educate individuals, but rather increase sales of 
advertised medicines (Ministry of Health, 2006). Access to more health information does not 
simply lead to more agency for individuals; this association is very complex (Womack, 2013). 
The content in DTCA commonly surpasses the suggested reading difficulty threshold - eighth-
grade - for dispensing information to the public (Frosch, Grande, Tarn, & Kravitz, 2010). 
Mehta and Purvis (2003) revealed that people generally think DTCA offers more important 
information than other kinds of advertisements. DTCA might cause them to think that the 
advertised drugs are improved compared to existing medications, whereas older treatments 
may actually be a superior option (Appel, 2002). Thus, individuals can believe that they are 
well-informed inaccurately (Almasi et al., 2006). DTCA may also lead patients to pressure 
their doctors to change an appropriate existing medicine to a new advertised one, with less 
information on benefits and risks (Wilkes et al., 2000). An example of the advertised medicine 
is Vioxx (Rofecoxib), where people switched from an appropriate existing medicine to the one 
that turned out to have serious side effects (Bradford et al., 2006). DTCA may raise unnecessary 
diagnoses (Conrad & Leiter, 2004) and lead to excessive prescriptions (Frosch et al., 2010). 
 Even if the consumer’s best interests are the chief objective of both positions on DTCA, 
what is missing is an emphasis on how to ensure that present and forthcoming guidelines for 
DTCA protect consumer interests (Royne & Myers, 2008). From a CSR perspective, 
pharmaceutical companies should fulfil both the right to choose and the right to be educated in 
order to respect consumers’ autonomy (van de Pol & de Bakker, 2010). However, from an 
ethical perspective of CSR, medicine advertising raises concerns regarding consumers’ 
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autonomy and safety of choice (Van de Pol & de Bakker, 2010). Further, there is not enough 
evidence to conclude that DTCA as it currently exists is informative (Frosch et al., 2010). It is 
uncertain as to whether the current form of medicine advertising is ethical and whether 
consumers have the ability to understand the information in medicine advertising and make 
informed decisions. Thus, this research intended to explore and find out answers to these 
uncertainties. In order to better comprehend the phenomena under study, the following section 
will review the literature on individuals’ informed decision-making as a result of DTCA. 
 
1.2.3 Consumers’ Informed Decision-making 
 Considering that “the role of consumers in medical decision-making has changed in 
recent decades” (Frosch et al., 2010, p. 24) and the information provided in DTCA reaches 
consumers directly, it is important to explore consumers’ ability in making informed decisions 
as a result of DTCA. DTCA is compatible with the notion of informed consent (which stresses 
consumer/patient autonomy in health-related decision-making; Beauchamp & Childress, 
2013). Both the concepts of autonomy and informed consent consider patients’ contributions 
alongside their doctors in their decision-making process (Perry et al., 2013).  
 Autonomy is where competent individuals are free to decide about their actions and 
their lives, especially with regard to their wellbeing and medical decisions (Carbonell, 2014). 
“Liberty (independence from controlling influences) and agency (capacity for intentional 
action)” are the essentials for individuals’ autonomous decision-making regarding medical 
issues (Beauchamp & Childress, 2013, p. 102). However, the public is often vulnerable to 
“manipulation of their anxieties and hopes, which undermines the goals of informed consent 
and shared decision-making” (Gigerenzer, Gaissmaier, Kurz-Milcke, Schwartz, & Woloshin, 
2008, p. 53). By stimulating requests for medicines, DTCA can trigger consumers’ 
contributions to their medical decisions; though, the following outcomes may differ 
considerably (Frosch et al., 2010). Medicine requests can be caused by ads that include unfair 
and deceptive information or by ads that contain enough and credible information. If consumers 
ask for medicines improperly, and doctors are incapable or reluctant to correct the consumers’ 
request, it may result in an excessive or risky prescription. In contrast, if a consumers’ request 
is aligned with their health interests, it may decrease under treatment and increase adherence 
(Frosch et al., 2010). Accordingly, there is a need to find out how to offer information with a 
customer-centric approach to avoid consumer harm (Royne & Myers, 2008). To offer a guide 
for ethical DTCA that helps consumers make safe choices, it is important first to seriously 
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consider DTCA’s negative effects on consumers’ informed decision-making and well-being. 
 
1.2.4 Concerns regarding Consumers’ Informed Decision-making 
 As discussed earlier, to offer ethical DTCA, pharmaceutical companies need to provide 
DTCA in a way that helps enhance consumers’ informed decision-making. To reach this goal, 
it is necessary first to consider the main concerns affecting consumers’ informed decision-
making. The review of the literature has highlighted how DTCA may have negative impacts 
on consumers’ informed decision-making, which can be related to the nature of DTCA, or 
characteristics of consumers. The related theories and concepts from both perspectives are 
discussed.   
 
1.2.4.1 DTCA-related Factors 
 In this section, evidence of the negative impact of DTCA on consumers’ decision-
making is reviewed. According to Deselle and Aparasu (2000), “the principles of advertising 
are not synonymous with patient education” (p. 104). Existing studies have argued that DTCA 
as industry-funded drug advertising could not help consumers to make informed choices due 
to its persuasive, manipulative, and misleading nature (Abel et al., 2006; Almasi et al., 2006; 
Toop & Mangin, 2007). This section thus discusses the main concerns regarding DTCA; i.e., 
medicalisation, persuasion, and opportunism, and explains how these issues may negatively 
influence consumers’ informed decision-making. 
 
Medicalisation 
 Existing research has criticised DTCA for resulting in the medicalisation of normal 
conditions and the pharmaceuticalisation of health (Barker & Vasquez Guzman, 2015; 
Bonaccorso & Sturchio, 2002). Medicalisation is when boundaries of ill-health are expanded 
to areas that previously were not medically treated. This develops pharmaceutical markets and 
increases the utilisation of healthcare services rather than improving individuals’ health 
(Mintzes, 2002). DTCA can contribute to misconsumption or over-consumption of medicines 
and cause medicalising conditions that are related to normal human problems such as obesity, 
and erectile dysfunction, which could potentially be alleviated through lifestyle changes rather 
than medicines (Brennan et al., 2010). Toop and Mangin (2007) argued that  
… allowing industry-funded information will serve only to manipulate consumer 
choices and it will not help consumers make better decisions about medicines but will 
increase the pharmaceuticalisation of health and will expose more of the population 
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to new medicines (many of which offer little benefit over existing medicines) at a time 




 The ultimate goal of advertising is “persuading target consumers to adopt a particular 
product, service, or idea” (Meyers-Levy & Malaviya, 1999, p. 45). Persuasive advertising 
methods and biased information can lead to overestimation of benefits, and subsequently, 
consumer vulnerability (Schwartz, Woloshin, & Welch, 2009). Likewise, DTCA may persuade 
rather than educate and offer partial information that exaggerates the potential benefits of 
medicines (Frosch et al., 2010; Gilbody, Wilson & Watt; 2005; Kravitz et al., 2005; Mansfield, 
Mintzes, Richards & Toop, 2005; Toop & Mangin, 2006; Woloshin, Schwartz, & Welch, 
2004). Consumers are facing persuasive advertising techniques and selective presentation of 
information intended to trigger demand for new drugs (Frosch et al., 2007; Kravitz et al., 2005; 
Woloshin et al., 2004). Different theories exist in the literature that can help explain the 
persuasive nature of DTCA and its effects on consumers’ decision-making. 
 Three types of advertising appeals are used to influence consumers: informative, 
emotional, and mixed appeals (Koinig, 2016; Okazaki, Mueller, & Taylor, 2010). Informative 
appeals are rather clear, straight, factual, and based on proof; and present accurate product 
information (Okazaki et al., 2010). Emotional appeals are often visual and offer emotional 
messages (Okazaki et al., 2010), which can be either positive or negative (Main, Argo, & 
Huhman, 2004). Positive emotional appeals use humour, nostalgia, sex, and fantasy, while 
negative emotional appeals try to invoke fear, shame, or anger (Koinig, 2016; Main et al., 
2004). Mixed appeals include both informational and emotional messages (Koinig, 2016). The 
distinction between informative and emotional appeals is consistent with the Elaboration 
Likelihood Model of persuasion (ELM; Petty & Cacioppo, 1981; 2018). ELM proposes two 
types of persuasive messages: (1) The central route, when information on tangible features of 
the product are incorporated to influence consumers (Koinig, 2016; Rucker & Petty, 2006). (2) 
The peripheral route, when positive or negative emotional appeals are used. Frequently, 
peripheral cues of an advertisement prompt heuristics and persuade individuals to make speedy 
decisions (Chaiken, 1980; Koinig, 2016; Petty, Cacioppo & Schumann, 1983; Petty & 
Cacioppo, 1986). In heuristic processing, individuals are usually not consciously aware of the 
cues and their effects on a decision (Sundar, Oeldorf-Hirsch, & Garga, 2008).  
13 
 
 Of concern, DTCA often uses emotional appeals rather than rational appeals in its main 
messaging; i.e., headlines and images (Main et al., 2004). This lack of appropriate and rational 
information, in addition to the emphasis on emotional appeals, can limit the informative value 
of DTCA (Royne & Myers, 2008). DTCA can be persuasive by using positive emotional 
appeals to cause people to request the drug (Koinig, 2016; Main et al., 2004). Furthermore, 
DTCA can use persuasive negative emotional appeals to arouse fear, which affects individuals’ 
perception of susceptibility to a threat – the amount of vulnerability or risk people allocate to 
a specific health problem, and/or their perception of the severity of consequences regarding the 
disease – perceived severity, consistent with the Health Belief Model1 (Becker, 1974; Belcher 
et al., 2005; de Wit, Vet, Schutten, & van Steenbergen, 2005; Koinig, 2016; Rosenstock, 1974). 
Consequently, there is a need for continuing research to examine the existence and the potential 
negative effects of persuasion in DTCA. 
 
Opportunism 
 Opportunism is “the incomplete or distorted disclosure of information, to mislead, 
distort, disguise, obfuscate, or otherwise confuse” (Williamson, 1985, p. 47). Opportunism in 
DTCA could affect consumers’ decision-making. Even though DTCA may inform individuals, 
it may also mislead them (Abel et al., 2006). Advocates support consumer empowerment 
resulting from having access to information, while critics highlight the adverse consequences 
of misleading or incomplete drug information (Womack, 2013).  
 Opportunism can be classified as active and/or passive (Seggie, Griffith, & Jap, 2013). 
Passive opportunism is “opportunism by omission” (Seggie et al., 2013, p. 74; Wathne & 
Heide, 2000), including concealing information (Dahlstrom & Nygaard, 1999; Seggie et al., 
2013) or presenting partial truths (Anderson, 1988; Seggie et al., 2013). In DTCA, this can 
happen when a pharmaceutical company does not provide enough/complete information about 
the advertised medicine. Offering partial information to exaggerate the benefits of the drug and 
understate its risks is a noteworthy ethical breach (Beltramini, 2006). Thus, DTCA should offer 
enough information to consumers to help them make an autonomous and safe decision about 
 
1 The Health Belief Model proposes that whether or not people take action to protect their health is influenced by 
whether they: (1) think that they are susceptible to a disease/condition (perceived susceptibility); (2) consider that 
the disease/condition would have severe consequences (perceived severity); (3) believe that they have a course of 
action available to them that will help them avoid the disease/condition or lessen its severity (perceived benefits); 
and (4) believe that the benefits of taking action prevail over the costs/barriers of the action (perceived barriers); 
(5) are exposed to factors that trigger action, such as a doctor’s advice or a TV advertisement (cue to action); (6) 
and believe that they are able to effectively accomplish an action (self-efficacy; Becker, 1974; Champion & 
Skinner, 2008; Rimer & Glanz, 2005; Rosenstock, 1974; Rosenstock, Strecher, & Becker, 1988).  
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prescription medicines (Mello et al., 2003).  
 Active opportunism happens when a company acts in its own favour by breaking clear 
or implied boundaries (Seggie et al., 2013; Wathne & Heide, 2000). Examples include lying 
(Lee, 1998; Seggie et al., 2013), changing realities (John, 1984; Seggie et al., 2013), presenting 
false claims (Jap & Anderson, 2003; Seggie et al., 2013), and overstating problems (Anderson, 
1988). In the DTCA context, it happens when a medicine advertisement presents misleading 
and inaccurate information. DTCA can mislead individuals about the usages, indications, and 
efficacy of the advertised drugs (Kallen, Woloshin, Shu, Juhl, & Schwartz, 2007; Woloshin, 
Schwartz, Tremmel, & Welch, 2001; Woloshin et al., 2004), and most consumers do not have 
enough knowledge to identify misleading advertising (Toop & Mangin, 2007, p. 694). Since 
not all individuals may be able to perceive imprecision (active opportunism) and 
incompleteness (passive opportunism) in DTCA, the main challenge lies therefore in finding a 
way to protect consumers from unfair or deceptive information while respecting consumers’ 
right to receive enough information (Womack, 2013). The existence of passive and active 
opportunism in DTCA, and related consequences on consumers’ informed decision-making are 
explored and discussed in the third part of this Ph.D. research.  
 
1.2.4.2 Consumer-related Factors 
 In addition to the problems related to the nature of the advertisements themselves, 
individual characteristics can affect their decision-making. Individuals might not have the 
knowledge required to fully understand and assess medical information presented in medicine 
advertisements, even if it has been offered appropriately (Abel et al., 2006). If the information 
is not suitably fitted to individuals’ needs and knowledge, it can limit their ability to make 
informed decisions instead of strengthening it (Womack, 2013). People need not only to have 
health agency (the “ability to achieve health goals”; Ruger, 2009, p. 42), but also health 
capability to make informed health decisions, which requires keeping a balance between 
individuals’ “autonomy” and “paternalism” (Ruger, 2009, p. 41). “An examination of health 
capability involves considering “the individual, structural, socio-economic and other obstacles 
that can impede people’s abilities to make health choices” (Womack, 2013, p. 277). Thus, the 
following sections discuss consumers’ lack of capacity, low health literacy, vulnerability, and 







 A review of the literature revealed individuals’ lack of capacity in making informed 
choices after exposure to DTCA. Almasi et al. (2006) argued that lay individuals generally do 
not have enough skills to realise the true purpose, and the financial goal of DTCA 
advertisements. Different theories exist in the literature that can help to explain limitations in 
individuals’ ability to process health information. These theories are presented and discussed 
below. 
 The Capacity Theory of Attention suggests that the amount of accessible cognitive 
resources is restricted (Kahneman, 1973). These limited resources can be assigned to a single 
activity or to simultaneous activities, such as talking while watching an advertisement (Rodgers 
& Thorson, 2012), but these simultaneous activities may exceed individuals’ capacity. A 
similar theory, Simon’s Theory of Bounded Rationality (Simon, 1957; 1972; 1997), discusses 
the limitations of the individuals’ “information-processing capacities” (Simon, 1972, p. 162), 
and explains that the rationality of individuals decision-making is restricted by the cognitive 
limits of their minds, as well as the limited amount of time and information that they have to 
make a decision (Simon, 1957; 1972; 1990). According to the Theory of Bounded Rationality, 
individuals cannot have access to all necessary information, but even if they could, they would 
be incapable of processing it accurately (Simon, 2009). Following from these theories of 
cognitive capacity, even if DTCA provides complete information to consumers, they will likely 
not understand it completely.  
 Found in the advertising rather than psychology literature, Message Response 
Involvement Theory describes “the degree to which the cognitive responses evoked by the ad 
deal with the brand attribute assertions in the ad, for reasons of motivation, ability, or 
opportunity” (Batra & Ray, 1985, p. 20). Individuals can be “more motivated to process a 
particular ad due to their own individual needs or interests” (Rodgers & Thorson, 2012, p. 342). 
Individuals may have restricted the opportunity to process an advertisement if the message is 
short or if there are distractions or competing priorities (Rodgers & Thorson, 2012). This theory 
also links individuals’ responses to advertising to their ability to understand and process the 
information. Ability refers to “the capacity for a message recipient to process marketing 
communications due to insufficient product knowledge/experience, limited intelligence, or 
complex message design” (Rodgers & Thorson, 2012, p. 567). Accordingly, consumers with 
restricted ability may have insufficient knowledge or processing resources to fully understand 
an advertisement; for instance, when an advertisement’s message is complicated or hard to read 
(Rodgers & Thorson, 2012). Message Response Involvement Theory overlaps with both 
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Capacity Theory of Attention and Theory of Bounded Rationality, as all discuss the 
individuals’ limited ability or capacity to process the information completely and correctly. In 
particular, both Message Response Involvement Theory and Capacity Theory of Attention 
emphasise that distractions and/or doing simultaneous activities can limit individuals’ 
opportunity to process the information (Kahneman, 1973; Rodgers & Thorson, 2012). 
 Reviewing the literature on health literacy gives us a deeper insight into consumers’ 
capacity in making informed choices after exposure to DTCA. In the health domain, health 
literacy is the term used to describe an individual’s capacity to apprehend and act on health 
communication and information (Thompson, 2016; Wynia & Osborn, 2010). Health literacy 
can be defined as the individuals’ capacity to acquire, comprehend and process health 
information to make proper health decisions and improve health conditions (Baker, 2006; 
Nutbeam, 1998; 2000). It can be broken into three broad levels: “functional health literacy, 
interactive health literacy, and critical health literacy” (Koinig, 2016, p. 41; Nutbeam, 2000). 
Basic/functional literacy comprises reading and writing abilities required for message 
understanding and medical decisions (Koinig, 2016; Nutbeam, 2000; Nutbeam, 2008). 
Communicative/interactive literacy refers to advanced cognitive and interaction abilities 
contributing to health-related activities, understanding, using, and sharing new information 
from various sources, such as professionals (Koinig, 2016; Nutbeam, 2000; Nutbeam, 2008). 
Critical literacy requires the most advanced skills that empower individuals to critically 
analyse and evaluate medical information in order to have superior control over happenings 
and circumstances in life (Koinig, 2016; Nutbeam, 2000; Nutbeam, 2008). Similarly, in the 
context of DTCA, individuals with low health literacy can have a limited capacity to 
comprehend the message and make informed decisions. Notably, research has shown that 
recalling and understanding of provided information in DTCA can be challenging even for 
individuals with normal health literacy (Frosch et al., 2010).  
 The reviewed theories all highlight constraints on individuals’ ability to understand the 
information presented in DTCA and their subsequent capability to make informed decisions. 
In addition, consumers’ limited time and skills required to comprehend pharmacological 
techniques as well as the persuasive psychology, semiotics, and reasoning behind DTCA 
(Almasi et al., 2006; Mansfield, 2003) show further constraints. The public is likely to be more 
vulnerable than health providers to the appealing effects of unfair and emotional information 
in DTCA (Toop & Mangin, 2015). Average consumers may not be familiar with DTCA 
regulations (Wilkes et al., 2000) and may inaccurately think that the government passes and 
monitors DTCA, and only the drugs that are “completely safe” and “extremely effective” could 
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be advertised in DTCA (Bell, Kravitz & Wilkes, 1999, p. 656). Advertising can affect even 
sceptical individuals (Almasi et al., 2006) so that even individuals who are more cynical 
towards drug advertising and advertised drugs can be highly influenced by DTCA. 
Accordingly, another issue of DTCA involves the question of whether and to what extent 
individuals are able to make safe and informed decisions. In addition to these general capacity-
related vulnerabilities, continuing research should focus on subsets of the population who may 
be more vulnerable to DTCA. The following section thus discusses the vulnerability of 
consumers to DTCA.  
 
Consumers’ Vulnerability 
 Consumers’ vulnerability is another factor that can affect their informed choices after 
exposure to DTCA. Even though the public are generally susceptible to persuasion from 
DTCA, the evidence presented below supports the idea that there may be some types of 
consumers with particular personal characteristics who are more vulnerable to DTCA.  
 Brenkert (1998) described four kinds of vulnerability: “physical,” “cognitive,” 
“motivational,” and “social” (p. 302) that are related to the concepts of susceptibility and 
disadvantage. Susceptibility refers to easily being influenced by something or someone (p. 
298). Disadvantaged refers to those “who are unequal in the marketplace because of 
characteristics that are not of their own choosing, including their age, race, ethnic minority 
status, and (sometimes) gender” (Andreasen, 1993, p. 273). In discussing DTCA, susceptible 
and disadvantaged consumers may be more likely to be influenced by DTCA. Reviewing 
existing studies on consumer vulnerability revealed another classification for consumers who 
are more vulnerable and less critical to DTCA by Carter et al. (2010). They studied types of 
consumers’ vulnerability to DTCA, and classified vulnerable consumers into three groups:  
(1) ‘compliant consumers’, who “were easily controlled, insufficiently self-protective, 
weak, or unable to stand up for themselves”; (2) ‘suggestible questing consumers’, 
who “were always looking for a new ‘cure’ and could be led by advertising to act 
against their own best interests (that is, demand medicine they didn’t need)”; and (3) 
‘seriously ill consumers’, who “were driven by the severity of their illness to 
completely trust their doctors or accept any treatment” (Carter et al., 2010, p. 14–
15).  
Similarly, people who are economically or educationally disadvantaged, old, minor, or 
have a serious or chronic illness, psychological issue, or physical impairment could be 
classified as vulnerable (Chiang & Jackson, 2012). For instance, Toop et al. (2003) argued 
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“many patients suffering from chronic diseases are vulnerable to advertising, which use 
emotional appeals to promise relief” (p.10). Individuals with serious illness need reliable 
physicians, not advertising of medicines (Carter et al., 2010). Moreover, Socioemotional 
Selectivity Theory declares that goal managing behaviours vary according to one’s supposed 
time perspective (Carstensen, 1992; Carstensen, Isaacowitz & Charles, 1999). Thus, because 
older individuals are more likely to expect a shorter life than younger people (Carstensen et al., 
1999), they are more likely to pay attention to positive rather than negative incentives, and 
comprehensive processing of information is not perceived as crucial.  
 In submissions regarding proper standards for DTCA to the Ministry of Health in New 
Zealand, a concern was raised that DTCA frequently targets vulnerable individuals and 
possibly results in their seeking or asking for drugs that may be inappropriate for their illness 
(Ministry of Health, 2006). Vulnerable individuals may inappropriately think that an advertised 
medication is more effective than less expensive, non-advertised options (Ministry of Health, 
2006). According to Carter et al. (2010), “a closer examination of the concept of vulnerability 
and its conditions and implications can make useful and critical contributions to the 
development of policies about consumer marketing of medicines” (p. 18). It is also important 
to offer solutions for advertising balance to help policymakers protect consumers, especially 
those who are more vulnerable and ensure their best interests. The third phase of the research 
thus scrutinized the types of consumers that may be more vulnerable to DTCA and less able to 
make informed choices in response to DTCA.  
 
Consumers’ Self-efficacy 
 Based on the reviewed literature, this Ph.D. research explores consumers’ self-efficacy 
as another issue affecting their informed decision-making. According to Bandura’s Social 
Cognitive Theory (1976; 2007), self-efficacy can be defined as a perceived operational 
capability, which includes individuals’ perception of their ability to accomplish an action as 
well as motivation to engage in that action (Koinig, 2016; Rodgers & Thorson, 2012). 
Likewise, perceived self-efficacy refers to “beliefs in one’s capabilities to organize and execute 
the courses of action required to produce given levels of attainments” (Bandura, 1997, p. 3).  
 Health messages and shared decision-making may increase individuals’ perceived self-
efficacy (Meyerowitz & Chaiken, 1987; Zoffmann, Harder, & Kirkevold, 2008). Both 
commercial and educational advertising may initiate and reinforce self-efficacy (Koinig, 2016). 
More specifically, perceived self-efficacy is a factor influencing consumers’ health behaviour 
(Schwarzer & Luszczynska, 2008; Strecher, McEvoy DeVellis, Becker, & Rosenstock, 1986). 
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Consumers’ responses to media can also be influenced by their perceived self-efficacy 
(Nutbeam, 2008). If individuals think that the desired result can be achieved, they are more 
likely to take on a specific behaviour (Miller, 2005). In the health domain, self-efficacy can be 
about trying a medication for a disease (Koinig, 2016). DTCA might influence consumers’ 
perceived self-efficacy if it suggests the ability to execute a specific task or proposes that the 
advertised drug can positively influence their health (Rodgers & Thorson, 2012). It is not 
known, however, whether increased self-efficacy can positively influence consumers’ 
decision-making. Research discussed that people who think that they are not susceptible to 
being misled could be even more vulnerable (Sagarin, Cialdini, Rice, & Serna, 2002). There is 
accordingly a need for continuing research to explore the effects of DTCA on consumers’ self-
efficacy and subsequently, the effect of their self-efficacy on their behavioural responses and 
decision-making. The third phase of this Ph.D. research thus addressed these issues. 
 To summarise, according to the reviewed literature, two main concerns that arise are 
whether the current form of medicine advertising is ethical and whether consumers are able to 
understand the information in medicine advertising and make informed decisions. These issues 
are even more critical in New Zealand due to its self-regulation system. Further research is 
required to find a way to make the process more consumer-centred (Royne & Myers, 2008). It 
is central to know how pharmaceutical companies should offer their self-regulated 
advertisements more ethically and to identify the factors that may contribute to consumers’ 
informed decision-making regarding DTCA. 
 
1.2.5 Helping Consumers’ Informed Decision-making 
 As discussed earlier, offering ethical DTCA aimed at helping consumers’ informed 
decision-making is of particular importance. Pharmaceuticals differ from other products since 
they are essential necessities for individuals’ well-being, which may improve or harm people’s 
health and their advertising language thus need to be different from other products (Berger et 
al., 2001). The ultimate goal of all groups that are involved in the process of advertising 
medicines should be to make this media as helpful to individuals as possible (Wilkes et al., 
2000). The reviewed deficits of DTCA and consumers’ limited abilities in the decision-making 
process heightens the need to determine the factors influencing consumers’ informed decision-
making. The extensive literature review underpinning this thesis revealed a number of 




 The existing research has tended to focus mainly on recommendations on quality and 
amount of information in DTCA. The quality and quantity of the information provided in 
DTCA are important for helping individuals’ informed decision-making and improving their 
health (Frosch et al., 2010). Both the type and amount of information required to assist 
individuals’ decision-making need to be explored (Royne & Myers, 2008). Even though high-
quality information presented in DTCA is itself not enough to guarantee proper medical 
decisions, it is an essential element to improve DTCA-triggered prescribing (Frosch et al., 
2010).  
 Previous studies have made recommendations for DTCA, especially on how to make 
important information more accessible. For instance, research has suggested that larger font 
size could advance individuals’ retention of the risk information presented in DTCA (Hoek, 
Gendall, Rapson, & Louviere, 2011; Wogalter, Conzola, & Smith-Jackson, 2002; Wogalter & 
Shaver, 2001). Moreover, earlier research has suggested that, to be more comprehensible for 
consumers, the information in DTCA should be quantitative rather than qualitative. For 
instance, DTCA should offer informative and quantitative facts about the probable benefits of 
medications rather than misleading, emotional and qualitative representations (Frosch et al., 
2010; Schwartz, Woloshin, & Welch, 2007; Woloshin et al., 2001). Providing tabular 
information is recommended considering that individuals, even those with a lower educational 
level, could comprehend and use the tabular information about the benefits and side effects of 
medications (Schwartz et al., 2007).  
 Research has also broadly discussed that DTCA should provide balanced information 
regarding the risks and benefits of medicines, especially since people are more likely to have a 
positive perception of advertised drugs when they are provided with less information about 
their side effects (Davis, 2000). Moreover, individuals generally recall benefit information 
better than negative effects after exposure to DTCA (Kaphingst, Rudd, Dejong & Daltroy, 
2005; Morris, Mazis & Brinberg, 1989). As an illustration, research has shown that consumers’ 
knowledge and judgments can be improved by a complete drug facts box, providing 
information on the disease, the drug’s benefits and risks compared with other treatments, as 
well as data on the percentage of people who benefited from the medication in key trials and 
percentage of people who had adverse experience (Perry et al., 2013; Schwartz et al., 2009). It 
could also help consumers choose a medicine that is more appropriate for their condition 
(Schwartz et al., 2009).  
 The existing literature also has focused particularly on the proper presentation style of 
medicine side effects. DTCA needs a balance between verbal and visual messages on the risks 
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of the advertised drugs (Frosch et al., 2010), since visual information often direct individuals’ 
information processing (Grimes, 1991). DTCA should provide the risk information of the 
advertised drug with the “fact density and pace of information provision not significantly 
different from the remainder of the ad” and with “no background music, to reduce distraction 
from the information” (Frosch et al., 2010, p. 29). Presenting the side effects information at the 
end of DTCA has been suggested since it may increase its recall (Glinert & Schommer, 2005).  
 Research has established additional recommendations that might help consumers’ safe 
decision-making. For example, DTCA needs to refer individuals to a doctor or pharmacist as 
the “best source of information” (Wilkes et al., 2000, p. 124) so that individuals perceive that 
they are not informed enough to decide about the best treatment just based on DTCA. In order 
to avoid the consumption of medicines for conditions that might be treated with lifestyle 
changes, DTCA should provide information about lifestyle changes where applicable 
(PhRMA, 2005). Currently, however, it hardly ever refers to lifestyle behaviours (Bell, Wilkes 
& Kravitz, 1999). Furthermore, DTCA should also be less “drug-centric” and more 
“disease/medical condition–centric” (Wilkes et al., 2000, p. 124). This can motivate individuals 
to pursue more information about their medical conditions rather than asking for a specific – 
potentially inappropriate – medicine. Although no proper approach is available for price 
comparisons of various medicines (Gencarelli, 2002), existing research suggested that 
information about costs and price comparisons should be included in DTCA (Frosch et al., 
2010; Wilkes et al., 2000). DTCA thus could, at least, mention, where appropriate, that generic 
substitutes are less expensive (Frosch et al., 2010) and equally effective.  
 In addition to the types and amount of information that are required for ethical DTCA, 
the types of medicines that can be advertised to consumers need to be controlled (Carbonell, 
2014). Advertising some types of medicines to consumers could be more harmful. For instance, 
treatments for serious diseases should not be promoted, to protect the patients (Carter et al., 
2010) as they could be more vulnerable to be misled by DTCA. The European Parliament 
rejected a scheme to permit DTCA for medicines that treat AIDS, diabetes, and asthma 
(Mansfield et al., 2005). It is thus important to scrutinise the types of medicines that might be 
riskier and thus less ethical to be advertised directly to consumers. 
 Although recommendations have been made to improve DTCA to help consumers 
make more informed decisions, some researchers argue that the prescription of medicines needs 
to be based on prescribers’ judgement, not demands driven by DTCA. They argue that it is the 
responsibility of physicians, not the pharmaceutical industry, to educate the consumer (Van de 
Pol & De Bakker, 2010). Health providers play an important role in informing and supporting 
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peoples’ health behaviour changes (Ryan, 2009). It has also been argued that health 
professionals should screen the content of DTCA for precision and fairness (Wilkes et al., 
2000), and should advise individuals of the nature of medicine advertising, particularly that it 
does not necessarily provide impartial information (Wilkes et al., 2000).  
  Despite the mentioned body of research on modifications for improving DTCA, 
existing research has failed to create an inclusive framework for ethical DTCA. Research has 
discussed that “as one of the most controversial modern business practices in history, direct-
to-consumer advertising of prescription medications is a critical topic for consumer advocates, 
but the current body of literature falls short of providing practical guidance for the … policy 
change” (Royne & Myers, 2008, p. 60). And thus, the unanswered question is ‘what should 
pharmaceutical companies do from a CSR perspective (Van de Pol & de Bakker, 2010), and 
more specifically ethical perspective?’  
The main challenge for this Ph.D. research was therefore to determine how medicine 
advertising could be offered more ethically to ensure consumers’ informed decision-making 
and well-being. Accordingly, the third phase of this research, grounded in CSR theory (which 
applies to corporations’ practices that go beyond what is set by laws and are mostly based on 
ethics) aims to enhance the literature on medicine advertising by establishing a comprehensive 
framework, including criteria, for ethical DTCA.  
 
1.2.6 Summary  
 A number of conclusions can be drawn from the discussed literature review. Assuming 
that there may be differences between social groups in their ability to respond to DTCA, it is 
important to determine whether individuals’ characteristics are associated with their 
behavioural responses to DTCA. Moreover, considering the nature of advertising, coupled with 
materialistic individuals’ greater attention to advertising (Graham, 1999), proneness to 
compulsive consumption (Dittmar, 2005; Dittmar, Bond, Hurst, & Kasser, 2014; Eren, Eroğlu, 
& Hacioglu, 2012; Kasser, 2003; Ridgway, Kukar-Kinney, & Monroe, 2008) and susceptibility 
to advertising (Kasser et al., 2004), it is reasonable to speculate that materialistic individuals 
might be more likely to respond to DTCA, especially given that DTCA markets drugs to 
individuals in the same fashion as other fast-moving consumer goods. Secondly, since lifestyle 
characteristics significantly affect consumers’ health (National Center for Health Statistics, 
2001; Poortinga, 2007; Sapranaviciute-Zabazlajeva et al., 2017) and buying behaviour 
(Krishnan, 2011), lifestyle factors linking to behavioural responses triggered by DTCA must 
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be explored. Both individual characteristics and lifestyle behaviours may establish the types of 
individuals who are most vulnerable to DTCA. Thirdly, the main challenges affecting 
consumers’ informed decision-making in response to DTCA need to be acknowledged. In line 
with the critiques of the nature of DTCA as well as the limited ability of individuals to make 
informed choices based on DTCA, it is necessary to examine the ethicality of DTCA. To 
understand what makes DTCA ethical, the factors helping individuals make informed decisions 
need to be acknowledged. This Ph.D. research aims to extend the field by addressing these 
issues.  
 
1.3 Research Objectives and Questions  
 The main purpose of this research was to explore social responsibility in direct to 
consumer advertising (DTCA) of prescription medicine in New Zealand. Specifically, the 
research intended to examine the factors associated with individuals’ (especially vulnerable 
individuals’) behavioural responses to DTCA of prescription medicine, reveal the factors 
affecting consumers’ informed decision-making, conceptualise the characteristics of 
consumers who were less able to make informed decisions, and finally develop an ethical 
framework for DTCA based on the CSR model (Carroll, 1999). To achieve this goal, this thesis 
comprised three studies and five main research questions:  
 
RQ 1 (Study 1): 
1. What are the factors associated with individuals’ self-reported behavioural responses to 
DTCA (with an emphasis on ‘at risk’ individuals’ responses)? 
RQ 2 (Study 2):  
2. What is the association between lifestyle determinants and self-reported behavioural 
responses triggered by DTCA? 
RQ 3, 4, and 5 (Study 3): 
3. What are health professionals’ perceived factors affecting consumers’ informed decision-
making, in response to DTCA? 
4. What are the health professionals’ perceived characteristics of consumers who are less able 
to make informed decisions in response to DTCA (who are more vulnerable)? 
5. Is DTCA perceived ethical in its current format in New Zealand? 





 This section provides a broad understanding of the methodology that was applied to 
perform each study of this thesis and describes the mixed-method research approach adopted 
to meet the overall objectives and questions. It begins with an explanation of the philosophical 
position, which the methodology of the research is based upon. Subsequently, the research 
approach and research paradigm of the thesis is explained. Following which, the research 
design, including the methods used for data collection and data analysis, as well as ethical 
considerations in both qualitative and quantitative studies, are discussed. 
 
1.4.1 Philosophical Stance 
 Paradigm, a term commonly applied in the social sciences, is an approach for 
investigating “social phenomena” from which specific knowledge of these phenomena can be 
obtained (Saunders, Lewis & Thornhill, 2009, p. 14). According to Maxwell (2008), deciding 
on the paradigm is a critical decision when designing research. The concept of paradigm, 
derived from Kuhn’s (1970) book, is founded upon its own ontological assumptions –
assumptions that focus on the nature of the world – and epistemological assumptions – 
assumptions that focus on the way we can recognise it (Denzin & Lincoln, 2005; Scotland, 
2012). Paradigms usually comprise definite “methodology and methods” related to these 
assumptions (Scotland, 2012, p. 9). “Epistemology concerns what constitutes acceptable 
knowledge in a field of study. Ontology is a branch of philosophy which is concerned with 
social beings” (Saunders et al., 2009, p. 24). Generally, philosophical worldviews are 
positivism/postpositivism, constructivism, transformative, interpretivism, and pragmatism 
(Creswell, 2013), and each exemplifies diverse views regarding reality (ontology) and the way 
we can obtain knowledge out of it (epistemology; Maxwell, 2008; Scotland, 2012). More 
specifically, quantitative research is based on assumptions that align with the positivist 
paradigm, while qualitative research is interpretivist or constructivist (Maxwell, 2008; 
Scotland, 2012). The paradigm is pragmatic when mixed methods – both qualitative and 
quantitative – are sequentially applicable in a study (Creswell, 2003).  
Pragmatism argues that the most important determinant of the research philosophy 
adopted is the research question – one approach may be ‘better’ than the other for 
answering particular questions. Moreover, if the research question does not suggest 
unambiguously that either a positivist or interpretivist philosophy is adopted this 
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confirms the pragmatist’s view that it is perfectly possible to work with both 
philosophies (Saunders et al., 2009, p. 12). 
 
1.4.1.1 Research Approach 
 The purposes of a study may be achieved using quantitative, qualitative, or mixed 
methods approaches (Creswell, 2003). The quantitative research approach is used to quantify 
the data by utilising various methods of statistical analyses. The qualitative research approach 
is used to provide deep understandings and insights into the research phenomena (Creswell, 
2007; Malhotra, 2006). Qualitative research includes: 
 …an interpretive, naturalistic approach to the world. Qualitative researchers study 
things in their natural settings, attempting to make sense of, or interpret, phenomena 
in terms of the meanings people bring to them (Denzin & Lincoln, 2005, p. 3).  
The basis of qualitative research lies in the interpretive approach to social reality 
(Holloway, 1997, p. 2).  
 However, “in mixed methods research, investigators use both quantitative and 
qualitative data because they work to provide the best understanding of a research problem” 
(Creswell, 2003, p. 12). It is possible to apply mixed methods simultaneously, or in a row 
(Creswell, 2003). “It is an expansive and creative form of research, not a limiting form of 
research” (Johnson & Onwuegbuzie, 2004, p. 17). For instance, “a researcher may want to both 
generalise the findings to a population and develop a detailed view of the meaning of a 
phenomenon or concept for individuals” (Creswell, 2003, p. 22). This thesis used a mixed 
methods research approach with quantitative methods for the first and second studies, and a 
qualitative approach for study three, to obtain a more comprehensive and deeper understanding 
of the phenomenon. 
 
1.4.1.2 Pragmatism Philosophy  
 Pragmatism illuminates how “research approaches should be mixed in ways that offer 
the best opportunities for answering important research questions” (Johnson & Onwuegbuzie, 
2004, p. 16). The use of both quantitative and qualitative data enriches the material based on 
the interpretivist goal of “understanding the complex world of lived experiences from the point 
of view of those who live it” (Schwandt, 1994, p. 118). The approach of this study was 
pragmatic since I initiated the research with a quantitative phase in order to measure 
individuals’ attitudes and behaviours in response to DTCA in a large scale sample, followed 
by in-depth interviews to explore health experts’ thoughts on consumers’ informed decision- 
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making in response to DTCA, in addition to exploring the ethicality of DTCA in New Zealand. 
Since I conducted mixed-methods research, employed a primarily sequential design 
(quantitative then qualitative), and used the quantitative study results to inform the 
development of the interview protocol, the paradigm, in this case, is pragmatic-interpretivist. 
 
1.4.2 Research Design 
 The research design is a chief plan that guides the data gathering and analysis of the 
research (Parahoo, 1997). In this section, practical aspects of the research design and 
implementation for the quantitative and qualitative studies are discussed: sampling, data 
collection, ethical consideration, and data analysis. 
 
1.4.2.1 Phase One: Quantitative Research  
 The first study of the quantitative phase examined the factors determining individuals’ 
self-reported behavioural responses to DTCA, and study two examined whether responses to 
drug advertising varies as a function of lifestyle behaviours. Both questions were answered by 
using a cross-sectional design implemented through an online survey. 
 
Participants and Ethics Approval 
 The first two studies analysed data gathered by a leading Australasian market research 
company through an online survey of 2057 adults in New Zealand (Khalil Zadeh, Robertson, 
& Green, 2017; Khalil Zadeh, Robertson, & Green, 2019). A quota sampling method was used 
to ensure that the sample was nationally representative of the New Zealand population to allow 
for generalisability of the results. The data presented in the first two studies were drawn from 
a larger survey on consumer behaviour, attitudes and lifestyles, and only information on 
pharmaceutical-related, health-related, lifestyle, and sociodemographic questions are presented 
in this thesis. The whole survey took around 40 minutes to complete (Khalil Zadeh et al., 2017). 
The survey had ethical approval from the University of Otago.  
 
Variables, Measures, and Data Analysis 
 Dependent variables in both studies were four self-reported behavioural responses to 
drug advertising, including “asking a physician for a prescription, asking a physician for more 
information about an illness, searching the Internet for more information regarding an illness, 
and asking a pharmacist for more information about a drug” (Khalil Zadeh et al., 2017, p. 1; 
Khalil Zadeh et al., 2019). In study one, multivariate binary logistic regressions were used to 
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explore whether respondents’ self-reported behavioural responses to medicine advertising were 
predicted by attitudes towards advertising and medicine advertising, knowledge about the 
effectiveness and safety of advertised medicines, self-reported health status, materialism, 
online search behaviour, in addition to sociodemographic variables (Khalil Zadeh et al., 2017). 
In study two, multivariate binary logistic regressions determined whether demographics, 
lifestyle behaviours (dietary habits, alcohol consumption, illegal drug consumption, physical 
activity), and attitudes towards doing exercise were linked to self-reported behavioural 
responses to drug advertising (Khalil Zadeh et al., 2019). In both studies, each estimate was 
controlled for all other included variables. 
 
1.4.2.2 Phase Two: Qualitative Research 
 Qualitative methods are reflected most helpful when a real-life setting is examined 
(Sinkovics et al., 2005; Sykes, 1990). Due to the exploratory nature of qualitative research, this 
approach lets participants openly discuss their views and improves the researchers’ ability to 
understand the depth of their thoughts and opinions (Creswell, 2008). Exploratory qualitative 
research seemed to be an appropriate approach for this study since health professionals’ 
thoughts on consumers’ informed decision-making, consumers’ vulnerability toward DTCA, 
and the ethicality of DTCA in New Zealand are rather unexplored and multifaceted 
(Drumwright, 1996; Öberseder, Schlegelmilch, & Gruber, 2013). Although the characteristics 
of consumers who were more vulnerable to DTCA was partly addressed through the 
quantitative phase of this research, the qualitative study provided a more in-depth 
understanding. The common qualitative research approaches are case study, narrative 
research, phenomenology, grounded theory, and ethnography (Creswell & Poth, 2006; Savin-
Baden & Major, 2013). “A phenomenology provides a deep understanding of a phenomenon 
as experienced by several individuals” (Creswell 2007, p. 62). In this study, an exploratory 
phenomenological study was employed to understand the phenomena through the experience 
and views of health professionals. 
 
Research Instrument 
 In this research, in-depth interviews with informants were considered to be most 
appropriate, as they help to obtain a clear and comprehensive picture of informants’ thoughts 
and positions (Ghauri & Gronhaug, 2002). Specifically, participants’ views on the ethicality of 
DTCA based on the concept of corporate social responsibility, factors influencing consumers’ 
informed decision-making in response to DTCA, and the characteristics of consumers who are 
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more vulnerable to DTCA were captured. In order to have open but concentrated conversations, 
semi-structured interviews were used based on an organised protocol, and questions were 
designed from broad to more in-depth ones (Ahamat, 2013; Herman, Georgescu, & Georgescu, 
2012; Öberseder et al., 2011; Savin-Baden & Major, 2013). “Semi-structured interviews are a 
good approach when the researcher has only one opportunity to interview someone” (Savin-
Baden & Major, 2013, p. 359). “A strength of this approach is that it allows the researcher to 
decide how best to use the limited time available and keeps the interaction focused” (Savin-
Baden & Major, 2013, p. 359). Interviews were conducted based on a designed interview 
protocol (Appendix A). The interview protocol was prepared, reviewed by two supervisors, six 
Ph.D. students, and seven academics, and revised before data collection. The interview 
questions were also continually refined during the data collection process (Ahamat, 2013; 
Herman et al., 2012; McCracken, 1988; Öberseder et al., 2011; Savin-Baden & Major, 2013). 
The following multi-step process was carried out to systematically develop, review, and revise 
the interview protocol (Castillo-Montoya, 2016): 
• The interview protocol and questions were reviewed and revised by two supervisors (one 
in the Department of Marketing and one at the School of Pharmacy). 
• The interview protocol and questions were revised after being reviewed by six Ph.D. 
students (two in their final year, and two in their final stage). 
• The interview protocol and questions were also reviewed by seven academics, (three 
professors, one associate professor, two senior lecturers (one methodologist), and one 
lecturer). They commented on the wording, comprehension, clarity, concepts, theories, 
communication of the message, and length of interviews. After each review, changes were 
made to improve the questions, in association with discussions with both supervisors. Some 
questions were removed, some were changed, and some questions were added.  
• This interview protocol was then piloted on three physicians and four community 
pharmacists. After each interview, the questions were reviewed to ensure their suitability 
based on the objectives of the research. 
• After these seven interviews, and based on the confirmation of supervisors, I paused data 
collection to analyse the data, see the results, and decide whether the questions were 
appropriate or needed further revision. After preliminary coding and thematic analysis, 
questions found to be difficult to answer or not very useful for the purpose of the study 
were removed or revised to increase the clarity and to match the objectives. 
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• The revised questions were reviewed by both supervisors, and additional required changes 
were made. After discussion with, and approval of, both supervisors, a final version of the 
interview protocol was used for the second phase of the data collection.  
• 22 interviews were conducted, and after each interview, further minor changes were made 
to questions to ensure the greatest depth of information to reach the research objectives. 
 
 Participants and Ethical Considerations 
 As qualitative research concentrates on an in-depth investigation, a small but diverse 
sample is suggested (Cooper & Schindler, 2013; Öberseder et al., 2011). Cooper and Schindler 
(2013) suggested to “keep sampling as long as your breadth and depth of knowledge of the 
issue under study are expanding; stop when you gain no new knowledge or insights” (p. 151). 
McCracken (1988) stated that eight long interviews are a satisfactory foundation for qualitative 
research. Moreover, gathering data from various kinds of people (triangulation strategy) will 
decrease the possibility of by chance and biased responses. Thus, this study selected 
interviewees from diverse groups of health professionals since they have the knowledge and/or 
experience with DTCA. It was initially assumed that 30 in-depth interviews with physicians 
(e.g., GP, surgeon, ED), pharmacists, academics in health science, and dentists might be 
adequate to reach data saturation. Indeed, after 29 interviews (7 from the initial phase and 22 
from the second phase of data collection), I reached information redundancy, and no additional 
information or themes emerged/developed from new interviews. Qualitative research 
encompasses nonprobability sampling so that it is not required to have a representative sample 
(Cooper & Schindler, 2013; Gobo, 2004). Informants were selected through purposive 
sampling and snowball sampling techniques (Valerio et al., 2016; Miles & Huberman, 1994; 
O'Donoghue & Punch, 2003).  
 The choice of professionals (informants) was based on their ability to provide 
comprehensive and profound information about DTCA in New Zealand. The ethicality of 
DTCA is a specialised and complicated context. Health experts are thus suitable informants for 
this research since they are often involved with both patients and the pharmaceutical industry 
and are familiar with the positive and negative aspects of DTCA, public health issues, as well 
as consumers’ capability and vulnerability. The snowball sampling method is suitable when 
research focuses on a small number of professional participants who are familiar with the topic 
(Aaker & Day, 1990; Neuman, 2000; Patton, 1990). 
 Places that were quiet and suited the participants were chosen for the interview setting, 
to help make respondents feel comfortable. The interviews lasted between 20 and 63 minutes. 
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With the informants’ permission, all interviews were audio-recorded, and transcribed verbatim, 
resulting in about 250 pages of text. More information about participants is provided in 
Appendix B. 
 Category B ethical approval was granted for this study by the Department of Marketing, 
and the University of Otago’s Ethics Committee (Appendix F). An information sheet was 
provided for participants, including a brief explanation of the research, interview process and 
the participants’ rights. Interviewees were assured that the gathered data would be confidential 
and anonymous. Interviewees were advised that their participation in the interview was 
voluntary, and that they could withdraw at any time. Interviewees provided their informed 
consent before participating in the interview (Alshenqeeti, 2014).  
 
Data Analysis 
 The main phases of data analysis in qualitative studies are often data coding, integrating 
the codes into the themes, and interpreting the outcomes (Creswell, 2007; Sinkovics et al. 
2005). “A theme is an outcome of coding, categorisation, and analytic reflection” (Saldaña, 
2009, p. 139). A phenomenologist needs to perform a thematic analysis to identify the themes 
or “structures of experience” (Van Manen, 1990, p. 79). Thematic analysis is “an independent 
and reliable qualitative approach” (Vaismoradi, Turunen, & Bondas, 2013, p. 400) used for 
“identifying, analysing and reporting” themes and categories in an iterative process (Braun & 
Clarke, 2006, p. 79; Vaismoradi et al., 2013). An advantage of thematic analysis over other 
qualitative analytic techniques is its flexibility (Braun & Clarke, 2006). It can be used in various 
theoretical frameworks and epistemological approaches since it is not linked to a particular 
theory or epistemology (Braun & Clarke, 2006). Thematic analysis “allows for social and 
psychological interpretations of data,” and “can be useful for producing qualitative analyses 
suited to informing policy development” (Braun & Clarke, 2006, p. 97). As the main questions 
of this study were epistemological and aimed to explore the perceptions of participants, 
thematic analysis seemed to be a suitable coding method (Saldaña, 2009). Accordingly, 
thematic analysis was conducted on all 29 interviews to identify the factors affecting the 
ethicality of DTCA and consumers’ informed decision-making, and to identify the 
characteristics of individuals who are vulnerable to DTCA. Both inductive and deductive 
approaches were employed in this study. The coding of this study developed from the 
qualitative interpretation provided by informants, existing related literature, and my own 
evaluative standpoint (Saldaña, 2009). I conducted an intensive review and analysis of the 
entire interview texts and developed an initial coding scheme, based on the research questions 
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(Dey, 1993; Miles & Huberman, 1994). Successively, iterative analyses revealed themes and 
sub-themes beyond those addressed in the research questions (Gray, Hoek, & Edwards, 2014). 
Accordingly, themes and sub-themes evolved throughout this inclusive and comprehensive 
coding process. During data analysis, a recursive approach was used, including going back and 
forth between dataset, findings, memos, emerging themes, and theoretical foundations in earlier 
research (Kazadi, Lievens, & Mahr, 2016). An independent second coder (a supervisor) coded 
five interview transcripts to ensure the findings were reproducible. The entire coding process 
was checked for agreement by both supervisors. The validity of codes, dimensions, themes, 
and subthemes was also confirmed by both supervisors. Several meetings were held to discuss 
and confirm all themes (Gray et al., 2014).  
Overall, the thematic analysis adapted the six-phase model presented by Braun and 
Clarke (2006). A summary of the whole process is demonstrated in Table 1.1 below: 
 
Table 1.1: Thematic analysis process (Adapted from Braun & Clarke, 2006, p. 87; Clarke, & 
Braun, 2013) 
Phase Description of the process 
“Familiarising yourself with 
your data” 
Data were transcribed, read and re-read, and initial ideas and analytical 
notes were written. 
“Generating initial codes” According to the research questions, “interesting features of the data” were 
found, labelled, and coded in a systematic process throughout the whole data 
set to provide both semantic and conceptual interpretations of the data. Each 
code was linked to related data extracts. 
“Searching for themes” The codes were combined and linked to “potential themes”, and then “all 
data relevant to each potential theme” were identified. In this stage, 
overarching themes, and sub-themes were identified. 
“Reviewing themes” The themes were checked with regard to the codes and the entire data set. 
As a result, some themes were merged together, some themes were divided 
into several sub-themes, and some themes were removed in a recursive 
process. In this stage, the revealed central themes, and sub-themes were 
reviewed. 
“Defining and naming 
themes” 
Ongoing and detailed analysis of each theme was conducted to check the 
aspects of the data that each theme captured and refined the specifics and 
story of each theme. Some themes were linked with the existing literature 
and theories, where applicable. An informative and simple name was 
defined for each theme.  
Writing the report Convincing extract examples were selected for each theme in an iterative 
process. The final analysis of themes and selected extracts was conducted 
by relating back to the research question and literature. An interpretative 
academic report of the analysis and discussion was produced, and thematic 
analysis charts were generated. 
 
Assessment of the Qualitative Study 






 Dependability (reliability), credibility (internal validity), transferability (external 
validity), construct validity, and confirmability (objectivity) are the most common methods to 
confirm the trustworthiness and rigour of qualitative studies (Lincoln & Guba, 1985; Rao & 
Perry, 2003; Shah & Corley, 2006).  
 
Dependability  
 Dependability can be achieved through the consistency of outcomes (Guba, 1981). To 
increase the dependability of the study, an interview protocol was carefully developed and 
reviewed several times, and was pretested before initiating the main interviews. In addition, a 
structured process was organised for gathering, writing and interpreting data (Guba & Lincoln, 
1994; Rao & Perry, 2003; Yin, 2009). Research dependability was also attained by comparing 
the findings of the current study with existing studies (Rao & Perry, 2003). Another procedure 
to increase the dependability of the study is to perform a code-recode technique on data during 
the whole analysis so that after coding a part of data, the researcher should stop for a while, 
code the same part of data again, and compare the findings. In this study, the code-recode 
technique was performed (Krefting, 1991). “The use of colleagues and methodological experts 
(peer examination) to check the research plan and implementation is another means of ensuring 
dependability” (Krefting, 1991, p. 221). In this study, the research plan, as well as the interview 
protocol and questions, was reviewed by six Ph.D. students and seven academics (one 
methodologist). Two supervisors checked and confirmed the research plan and implementation 
continuously (Rao & Perry, 2003). Moreover, participants’ confidentiality was ensured in this 
study (Lincoln & Guba, 1985; Shah & Corley, 2006). 
 
Credibility  
 To reach high credibility in this study, I avoided “asking leading questions”, conducted 
pilot interviews, and asked the interviewees to sum up the main points they had mentioned 
(Alshenqeeti, 2014, p. 44). This study also applied triangulation (Lincoln & Guba, 1985) which 
is a technique for achieving credibility in qualitative studies (Lincoln & Guba, 1985; Patton, 
1999; Shah & Corley, 2006). Denzin (1988) categorised four kinds of triangulation: 
1) Data triangulation, which is collecting data through several sampling approaches; i.e., to 
gather data at different times and places, as well as on a variety of people. I collected data 




2) Observer/researcher triangulation, which is having more than one observer in the research 
(Guba & Lincoln, 1994; Rao & Perry, 2003; Yin, 2009). In this case, three researchers (one 
Ph.D. student and two supervisors) were involved in designing, managing, and checking 
the whole process. 
3) Methodological triangulation, which means combining qualitative and quantitative 
approaches in the same study in order to apply more than one method of data gathering, 
was also used. This thesis is mixed methods, using both a quantitative survey and 
qualitative in-depth interviews. However, Chapter Four, which discusses study three, is 
qualitative only. 
4) Theory triangulation, which means employing several theoretical schemes in the 
interpretation of a phenomenon, was also employed in this study. This study was formed 
upon a variety of concepts and theories.  
 
Transferability 
 To address transferability in this study, the structures, concepts and categories were 
explained throughout the analysis process (Lincoln & Guba, 1985; Shah & Corley, 2006).  
 
Construct Validity 
 Construct validity was achieved by forming a chain of evidence, including interview 
protocol, transcripts, researchers’ notes, memos, and analytical reports, to illustrate how 
conclusions were reached from research questions (Yin, 2009). Research also suggested using 
multiple sources to increase the validity of the outcomes (Gaikwad, 2017; Yin, 2009; Rao & 
Perry, 2003). In this study, I selected experts from several areas of the field of health science, 
to obtain a cross-section of thoughts. 
 
Confirmability 
 Confirmability is showing that the outcomes and interpretation are reached from the 
data (Tobin & Begley, 2004). In this study, the findings and discussion sections clearly showed 
how findings and interpretations were derived from the data, which ensured the confirmability 
of this study. Confirmability was also achieved through detailed data organisation and 
recording, such as precise records of informants, transcription of interviews, and memos (Shah 





Social Desirability Bias 
 Owing to the fact that the examination of ethics-related topics is susceptible to social 
desirability bias, great care is needed while gathering data (Brunk, 2010; Mohr, Webb, & 
Harris, 2001; Öberseder et al., 2011). To decrease social desirability bias, several measures 
were taken in the present study. A convenient and trusted place for the respondent was selected 
for the interview setting, as well as the use of a focused but open semi-structured interview 
protocol, to help stimulate the conversations and facilitate honest and open discussion (Brunk, 
2010; Öberseder et al., 2011). Preceding the interview, the interviewees were informed that the 
emphasis of the study is to explore their perceptions and views and importantly, that there were 
no correct and incorrect responses to the questions (Öberseder et al., 2011). 
 
Goodness of Thematic Analysis 
 Overall, the following steps confirmed the goodness of the performed thematic analysis 
in this study (Braun & Clarke, 2006). 
• The interviews were transcribed to a proper level of detail. 
• Equal attention was allocated to each interview and piece of data in the coding procedure. 
• Themes were not based on a small number of glowing instances. The coding process has 
been detailed, all-encompassing and complete. 
• All associated quotations for each theme were collated. 
• All themes were reviewed several times and compared to each other, according to the data 
set, and literature review. 
• Themes were clear and consistent. 
• Data were comprehended and interpreted, instead of just paraphrased or summarised. 
• Adequate and appropriate time was allotted to accomplish all steps of the thematic analysis, 
so as not to rush through a step or complete it superficially. 
• I was active during the whole process. 
 
1.5 Structure of the Thesis  
 The research presented in this thesis found and addressed several unanswered questions 
in the area of consumers’ behavioural responses to DTCA, consumers’ informed decision-
making, consumers’ vulnerability, and ethicality in DTCA. The structure of the thesis is 
outlined in Figure 1.1.  
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 Chapter One covers the research background, the extant literature and theoretical 
foundations for the research and provides an explanation for the chosen methodology and 
research design of each study, as well as discussing the contribution of the research in helping 
individuals make informed decisions and improve their well-being.  
 Chapter Two (study one) answered the first research question: “What are the factors 
associated with individuals’ self-reported behavioural responses to DTCA (with an emphasis 
on ‘at risk’ individuals’ responses)?”. It used data gathered via an online survey from a large 
representative sample of the New Zealand population. This study was published in the BMJ 
Open in 2017. 
 Chapter Three (study two) answered the second research question: “What is the 
association between lifestyle determinants and self-reported behavioural responses triggered 
by DTCA?”. This built on the findings of study one and further investigated the lifestyle 
determinants of self-reported behavioural responses to direct to consumer advertising of 
prescription medicines. This study was published in the Australian and New Zealand Journal 
of Public Health in 2019. 
 Chapter Four (study three) used qualitative data collected through in-depth interviews 
with diverse groups of health professionals to explore the ethicality of DTCA in New Zealand, 
as well as consumers’ vulnerability and informed decision-making. This study answered the 
following research questions: “What are health professionals’ perceived factors affecting 
consumers’ informed decision-making, in response to DTCA?”; “What are health 
professionals’ perceived characteristics of consumers who are less able to make informed 
decisions in response to DTCA (who are more vulnerable)?”; “Is DTCA perceived ethical in 
its current format in New Zealand?” and “How to offer ethical DTCA in order to help 
individuals make informed decisions?” 
 In Chapter Five, the three studies are drawn together in the Discussion and Conclusions. 
In particular, this chapter includes the socially responsible (ethical) framework developed from 
study three and presents the theoretical contribution of the research. This chapter also offers 
practical implications for pharmaceutical companies, and public health policymakers. 
 This thesis also encompasses five appendices; Appendix (A) contains the interview 
guide/protocol of study three; Appendix (B) contains a table depicting sample characteristics 
for the participants in study three; Appendix (C) includes samples of quotes, themes, sub-
themes and dimensions of the interviews from study three; Appendix (D) offers the submission 
for the Therapeutic Products Regulatory Scheme Consultation; and Appendix (E) includes a 




Figure 1.1: Structure of the thesis 
 
1.5.1 Academic Papers 
 This doctoral thesis encompasses three studies written in the format of three academic 
papers, two of which have been published in academic journals. The details of the three papers 
are presented in Table 1.2. I am the first author, and the main contributor to all papers and the 
co-authors are my Ph.D. supervisors. The working paper of study three was presented and 
published as conference proceedings at the Macromarketing Conference, 2017. The third paper 
will also be submitted to the Journal of Business Ethics. An additional output from this doctoral 
thesis was one working paper presented at the EMAC (European Marketing Academy) 
conference, 2016. This research has also informed the submission to the Therapeutic Products 
Regulatory Scheme Consultation in New Zealand in April 2019 (see Appendix D). 
 Owing to this structure, there are some repetitions in some chapters, particularly 
regarding the overview of DTCA in the Background to the Research section in the Introduction 
Chapter, and the Literature Reviews of Chapter Two, Three, and Four, as well as the Research 
Contributions section in the Introduction Chapter, and the Discussion sections of Chapter Two, 
Chapter 1 (Introduction): Research background, existing
literature, theoretical foundations, research questions,
methodology, structure of the thesis, and research
contributions
Chapter 2 (Study 1): ‘At-risk’ individuals’ responses to
direct to consumer advertising of prescription drugs: a
nationally representative cross-sectional study
Chapter 3 (Study 2): Lifestyle determinants of self-reported
behavioural outcomes triggered by direct to consumer
advertising of prescription medicines: a cross-sectional study
Chapter 4 (Study 3): Social responsibility in direct to
consumer advertising of prescription medicines: consumers’
autonomy and informed decision making
Chapter 5 (Discussions and Conclusions): Consulsions, a
review of findings, theoretical implications and proposed
framework, managerial/practical implications, research
limitations and suggestions for future research
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Three, and Four. Moreover, there are some duplications in the Method sections of Chapter Two 
and Three, since both studies used the data collected through an online survey in New Zealand. 
 
Table 1.2: Academic papers and conferences 
Chapter Paper Title Authors Journal/ 
Conference 
Status 
2  ‘At-risk’ individuals’ 
responses to direct to 
consumer advertising 




Neda Khalil Zadeh 
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Kirsten Robertson 
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1.6 Research Contributions  
 As discussed earlier, DTCA is contentious (Gu, Williams, Aslani, & Chaar, 2011). 
DTCA changes healthcare-seeking behaviours by encouraging individuals to pursue and 
request advertised medications (Donohue et al., 2007; Toop & Mangin, 2006). Of concern, the 
vast and disparate information in DTCA bypasses central gatekeepers (physicians, pharmacists, 
and other healthcare professionals), reaching consumers directly (Kontos & Viswanath, 2011), 
and challenges individuals trying to make informed choices. This illustrates the need to 
understand the effects of DTCA on consumers and society, find strategies for improving 
consumers’ decision-making, and the need for guidance on how to offer ethical DTCA.  
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 The findings from this research have made several theoretical contributions to the 
current literature and provided a new perspective for conceptualising consumers’ behavioural 
responses to DTCA, informed decision-making, vulnerable consumers, and ethical DTCA. 
Although much attention has been paid to self-reported behavioural responses to DTCA in the 
existing literature, to the best of my knowledge, no research has reported ‘at-risk’ people’s self-
reported behavioural responses to DTCA (Khalil Zadeh et al., 2017). The quantitative part of 
this Ph.D. research, based on an online survey of a nationally representative sample in New 
Zealand and grounded in the Structural Influence Model of health communication, provided 
new insights into the factors predicting individuals’ behavioural responses to drug advertising, 
including “asking a physician for a prescription, asking a physician for more information about 
an illness, searching the internet for more information regarding an illness and asking a 
pharmacist for more information about a drug” (Khalil Zadeh et al., 2017, p. 1). In brief, the 
results revealed communication inequalities in response to medicine advertising with ‘at-risk’ 
individuals (i.e., older, less educated, ethnic minorities, poorer self-reported health status, and 
lower-income) being more likely to respond to medicine advertising. These vulnerable 
population groups’ behavioural responses to DTCA raised significant concerns relating to their 
ability to make informed choices. Moreover, the outcomes showed that a favourable attitude 
towards medicine advertising predicted behavioural responses, which could leave individuals 
susceptible to medicine advertising and at risk of making uninformed choices accordingly 
(Khalil Zadeh et al., 2017). This Ph.D. research further added to the understanding of 
individuals’ responses to DTCA by investigating the links between lifestyle habits and DTCA-
triggered behavioural responses. This research revealed that individuals with unhealthier 
lifestyles (i.e., less physical activity, higher levels of alcohol consumption, unhealthier 
nutritional habits, and higher levels of illegal drug use) were more likely to respond to DTCA, 
which may cause them to be more susceptible towards DTCA. The results raised concerns 
about misuse or overuse of medicines for health issues that might otherwise be solved with a 
healthier lifestyle (Khalil Zadeh et al., 2019). 
 The qualitative study of this Ph.D. research, which involved interviews with diverse 
groups of medical professionals, set out to assess DTCA in New Zealand, primarily through 
the lens of the CSR concept. The findings suggested that consumers’ capability, self-efficacy, 
and characteristics could play an essential role in their informed decision-making. Major 
concerns were raised by informants regarding consumers’ autonomy in decision-making, and 
their ability to understand/interpret the information presented in medicine advertisements and 
make informed decisions accordingly. There was also debate about the effects of DTCA on 
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consumers’ self-efficacy and the effects of consumers’ self-efficacy on their informed choices 
about medicines. Of importance, the outcomes acknowledged potential forms of persuasion 
and opportunism in DTCA, which consumers are generally not able to detect (or counteract), 
and its negative consequences on consumers’ decision-making. The outcomes illustrated that 
even though most consumers are vulnerable to DTCA and are not able to make informed 
decisions, there are some types of consumers who are even more vulnerable to DTCA. In 
summary, this study provided a broader understanding of the factors affecting consumers’ 
vulnerability to DTCA. Further, although DTCA is legal in New Zealand, it is not ethical in its 
current format. The study finally offered an inclusive framework of factors contributing to 
socially responsible DTCA, and more specifically ethical DTCA, to ensure safe and informed 
decision-making for consumers.  
 The findings of this Ph.D. research also have a number of practical implications. The 
results have important implications for policymakers by informing a guide for future policy 
frameworks. The outcomes informed the submission to the Therapeutic Products Bill in New 
Zealand (Appendix D). The outcomes extended previous research that argued the self-
regulatory body system of Advertising Standards Authority (ASA) in New Zealand is not a 
suitable enough mechanism to protect the public from misleading information on advertised 
drugs (Toop & Richards, 2004). The findings showed that the patient-centred medicine 
philosophy of DTCA is imperfect and does not always lead to informed decision-making. It 
showed that there is a need for stricter guidelines and supervision of DTCA to ensure 
consumers’ informed decision-making, especially since ‘at-risk’ individuals are more 
vulnerable to such advertising. The findings suggest the government should monitor the 
advertising of medicines, and ensure that DTCA is more beneficial than harmful. Evaluating 
the advertisements should not be left to the consumer; instead, there should be a committee in 
the governing body to filter out DTCA. An independent advisory board of health professionals 
should watch pharmaceutical companies and control all drug advertisements before reaching 
consumers. Health policymakers should focus on increasing individuals’ health literacy and 
knowledge regarding DTCA and advise that advertised drugs are not inevitably safe and 
effective. Health policymakers can also focus on individuals’ attitudes towards DTCA and help 
them realise that it is a paid promotion delivered by pharmaceutical firms (Khalil Zadeh et al., 
2017).  
 The outcomes also have important implications for pharmaceutical companies and 
healthcare professionals. The presented framework of factors contributing to ethical DTCA can 
help pharmaceutical advertisers to fulfil the consumers’ right to choose and to be educated. On 
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a practical level, a deeper understanding of ethical DTCA could enable consumers’ informed 
decision-making. Overall, the results inferred that pharmaceutical companies should promote 
their medicines responsibly and educate people about therapies constructively since 
individuals, especially ‘at risk’ ones, may request an inappropriate or unnecessary medicine 
(Khalil Zadeh et al., 2017). Pharmaceutical companies should offer accurate and complete 
information; and should not target ‘at risk’ individuals, position their products based on 
individuals’ lifestyle characteristics, and depict their product as a wonder drug. Where 
applicable, DTCA should mention lifestyle alternatives to taking medications and declare that 
there are other medicines accessible, which may have similar or often identical results (Khalil 
Zadeh et al., 2017; 2019). Communications on lifestyle changes in DTCA need to target those 
with unhealthy lifestyles more specifically. Pharmaceutical companies should avoid 
advertising some types of medicines, such as controlled drugs, addictive medicines, medicines 
for life-threatening conditions, medications that have serious side effects, psychiatric drugs, 
and medications targeted at kids, as their advertising was considered unethical. On the whole, 
pharmaceutical companies need to balance their commercial goals and their public health goals 
in order to be socially responsible. Offering ethical DTCA can benefit not only consumers to 
make informed decisions and subsequently improve their wellbeing, but also pharmaceutical 
companies to improve their companies’ image. This study also highlights the need for 
interprofessional collaborations to educate individuals about advertised medicines and convey 
the value of health behaviour changes to help people, particularly ‘disadvantaged’ groups, 
make more informed health-related decisions.  
 
1.6.1 Summary of Ph.D. Contributions 
 This Ph.D. research combined different theoretical lenses to explore and broaden the 
scope of consumers’ behavioural responses, decision-making and vulnerability, as well as 
social responsibility in the context of DTCA. In summary, the findings of this Ph.D. thesis:  
• Provided a comprehensive understanding of factors associated with consumers’ 
(specifically at-risk consumers’) behavioural responses to DTCA. 
• Revealed the associations between unhealthy lifestyle factors and being influenced by 
DTCA. 
• Contributed to the body of knowledge on consumers’ decision-making regarding DTCA 
according to health professionals’ opinions. 
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• Established the characteristics of consumers who are more vulnerable to DTCA according 
to health professionals’ opinions. 
• Provided new insights into the nature of DTCA and the ethicality of DTCA. 
• Developed criteria to guide ethical DTCA aimed at helping individuals make informed 
decisions and improve their well-being. 
 
1.7 Key Definitions  
DTCA: In this research, DTCA (Direct to consumer advertising of prescription medicines) 
refers to “pharmaceutical‐company sponsored advertising of prescription medicines that 
directly targets consumers via the mass media” (Hall & Jones, 2008, p. 471). 
Consumers: As patients can be considered as health-care consumers (Mold, 2011), and by 
their being targeted by advertising, the pharmaceutical companies are treating them as 
consumers; in this research the terms consumers, individuals, patients, and potential patients 
used interchangeably.  
CSR: Corporate Social Responsibility was defined as “the managerial obligation to take action 
to protect and improve both the welfare of society as a whole and the interest of organisations” 
(Davis & Blomstrom 1975, p. 6). Carroll (1979) outlined four scopes for CSR, which are 
economic, legal, ethical, and philanthropic responsibilities. The main focus of this study was 
on ethical responsibilities in DTCA. 
Informed decision-making: Informed decision-making refers to when individuals are fully 
informed of the whole treatment process and able to make an appropriate and safe choice. It is 
defined as individuals’ understanding their medical conditions, and for suggested treatments, 
understanding the benefits, efficacy, drawbacks, limitations, harms, and side effects of the 
suggested treatments and potential alternatives, during their shared medical decision-making 
procedure (Briss et al., 2004; Mullen et al., 2006). 
Opportunism: Opportunism referred to “the incomplete or distorted disclosure of information, 
to mislead, distort, disguise, obfuscate, or otherwise confuse” (Williamson, 1985, p. 47). Active 
opportunism happens when a company acts in its own favour by breaking clear or implied 
boundaries (Seggie et al., 2013; Wathne & Heide, 2000). Examples include lying (Lee, 1998; 
Seggie et al., 2013), changing realities (John, 1984; Seggie et al., 2013), presenting false claims 
(Jap & Anderson, 2003; Seggie et al., 2013), and overstating problems (Anderson, 1988; 
Seggie et al., 2013). Passive opportunism is opportunism by omission (Seggie et al., 2013; 
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Wathne & Heide, 2000), including concealing information (Dahlstrom & Nygaard, 1999; 





























CHAPTER TWO: ‘AT-RISK’ INDIVIDUALS’ RESPONSES TO DIRECT 
TO CONSUMER ADVERTISING OF PRESCRIPTION DRUGS: A 
NATIONALLY REPRESENTATIVE CROSS-SECTIONAL STUDY 
 
Preface  
 Reviewing existing literature showed the importance of examining social imbalance in 
response to DTCA. Study one of this Ph.D. thesis thus explored whether there are differences 
between social groups in their behavioural responses to DTCA, focusing in particular on ‘at-
risk’ individuals’ responses, and answered the first research question: 
RQ 1. What are the factors associated with individuals’ self-reported behavioural responses to 
DTCA (with an emphasis on ‘at risk’ individuals’ responses)? 
 Preliminary outcomes from study one presented at the EMAC Conference 2016, in 






















 This study set out to explore the factors determining individuals’ self-reported 
behavioural responses to direct to consumer advertising of prescription drugs, with an emphasis 
on ‘at-risk’ individuals’ responses. Data were gathered through a nationally representative 
cross-sectional survey of 2050 participants in New Zealand. Multivariate logistic regressions 
determined whether participants’ self-reported behavioural responses to drug advertising 
(asking a physician for a prescription, asking a physician for more information about an illness, 
searching the internet for more information regarding an illness and asking a pharmacist for 
more information about a drug) were predicted by attitudes towards advertising and drug 
advertising, knowledge about the safety and effectiveness of advertised drugs, self-reported 
health status, materialism, online search behaviour, as well as demographic variables. 
Identifying as Indian and to a less extent Chinese, Māori and ‘other’ ethnicities were the 
strongest predictors of one or more self-reported responses (ORs 1.76–5.00, P values <0.05). 
Poorer self-reported health status (ORs 0.90–0.94, all P values <0.05), favourable attitude 
towards drug advertising (ORs 1.34–1.61, all P values <0.001) and searching for medical 
information online (ORs 1.32–2.35, all P values <0.01) predicted all self-reported behavioural 
outcomes. Older age (ORs 1.01–1.02, P values <0.01), less education (OR 0.89, P value <0.01), 
lower-income (ORs 0.89–0.91, P values <0.05) and higher materialism (ORs 1.02–1.03, P 
values <0.01) also predicted one or more self-reported responses. Taken together, the findings 
suggest individuals, especially those who are ‘at-risk’ (i.e., with poorer self-reported health 
status, older, less educated, lower-income and ethnic minorities), may be more vulnerable to 
drug advertising and may make uninformed decisions accordingly. The outcomes raise 
significant concerns relating to the ethicality of drug advertising and suggest a need for stricter 
guidelines to ensure that drug advertisements provided by pharmaceutical companies are 
ethical. 
 
2.1 Research Background  
2.1.1 Introduction 
 Direct to consumer advertising (DTCA) of prescription drugs is a debated 
pharmaceutical marketing strategy (Gu et al., 2011). Currently, it is only legal in New Zealand 
and the USA (Delbaere, 2013; Mintzes, 2006; Spake & Joseph, 2007; Toop & Mangin, 2007; 
Wilkinson, Vail, & Roberts, 2017), although advertising on the internet can cross geographical 
boundaries, and the European Commission has considered a proposal for drug advertising 
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(Magrini, 2007). A health communication tool, such as DTCA can have positive or negative 
consequences (Almasi et al., 2006). The outcomes of DTCA depend on the types of advertised 
drugs and the nature of the illnesses to be treated. “DTCA is most likely to deliver public health 
benefits when the condition to be treated is serious and when the treatment is safe, effective, 
and underused. However, DTCA will tend to deliver net harms when the condition is mild or 
trivial and when the treatment is potentially dangerous, marginally effective, or overused” 
(Almasi et al., 2006, p. 0286).  
 Furthermore, the effect of DTCA varies depending on how individuals interpret and 
respond to the information. Of concern, the vast and disparate information in drug advertising 
reaches individuals directly and poses challenges to individuals to make informed choices on 
whether the advertised drugs will be beneficial or deleterious (Kontos & Viswanath, 2011). 
Supporters of drug advertising claim that it improves individuals’ autonomy by increasing 
awareness of medical problems, symptoms and existing treatments; accordingly, it can assist 
patients in making superior medical decisions (Adams, 2016). However, exposure to health 
information through DTCA does not necessarily lead to knowledge (Carbonell, 2014) and can 
result in individuals requesting a drug that they do not actually need (Every-Palmer, Duggal, 
& Menkes, 2014). Studies show that individuals typically understand the benefits far better 
than the risks (Kaphingst & DeJong, 2004). Furthermore, new drugs presented in DTCA may 
have unknown side effects or safety issues (Shuchman, 2007). Opponents of DTCA argue that 
the primary motive of the pharmaceutical industry is to increase profit rather than to help 
individuals make informed health-related decisions (Abel et al., 2006; Hoen, 1998; Schwartz 
et al., 2009; Sumpradit, Ascione, & Bagozzi, 2004).  
 
2.1.2 Industry Funded Advertising 
 The pharmaceutical industry spends billions of dollars annually on promotion (Gagnon 
& Lexchin, 2008) to push consumers to buy the advertised medications, spending more on 
promotion than research and development (Chao, 2005). Such advertising has been blamed for 
changing the pattern of use of healthcare services (Mintzes, 2002), including medicalising 
normal human conditions (Mintzes, 2002), driving overconsumption of new prescription drugs, 
and motivating requests for more expensive medications (Roth, 2003; Wilkinson et al., 2017). 
For instance, in countries with a socialised health system, such as New Zealand, where the 
government subsidises generic drugs, advertising can convince patients to request a non-
subsidised branded medication over a subsidised generic one. The prescription charge for each 
subsidised medication is $NZ5, whereas there may be an additional (sometimes substantial) 
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cost if the drug is not fully subsidised (Ministry of Health, 2015). Prescription drugs must be 
prescribed by physicians, and medical professionals act as gatekeepers between DTCA and 
individuals. However, as a result of drug advertising, patients may pressure physicians to 
prescribe the advertised branded drugs, and patients’ requests for specific drugs significantly 
increase the likelihood that requested drugs are prescribed (Almasi et al., 2006; McKinlay, 
Trachtenberg, Marceau, Katz, & Fischer, 2014; Toop et al., 2003). Physicians also report that 
DTCA negatively influences the physician-patient relationship because patients challenge their 
knowledge based on information they have received through drug advertising (Abel et al., 
2006; Delbaere & Smith, 2006). The interference in the physician-patient relationship can 
result in ill-informed patients and treatments that are not fully tailored to the patients’ 
conditions (Foley & Gross, 2000). Furthermore, some drugs that are advertised directly to 
consumers have serious side effects. For instance, Vioxx (rofecoxib) was heavily marketed for 
five years in more than 80 countries, such as New Zealand. It was consequently withdrawn 
from international market in 2004 because of safety issues concerning enhanced risks of heart 
attack and stroke (Bradford et al., 2006; Evans, Thornton, & Chalmers, 2011). Consequently, 
the question arises as to whether individuals are able to make informed decisions in response 
to drug advertising. 
 
2.1.3 Individuals’ Responses to DTCA 
 There is a lack of research examining possible communication disparities in response 
to drug advertising (Ramanadhan & Viswanath, 2006), and researchers have suggested the 
need for detailed examinations of responses of various social groups (Kontos & Viswanath, 
2011). However, if the information is not suitably fitted to individuals’ needs and knowledge, 
it can limit their ability to make informed decisions instead of strengthening it (Womack, 
2013). The Structural Influence Model (SIM) of health communication suggests that social 
determinants are linked to health communication outcomes and theorises that health 
communication disparities can be seen in terms of inequalities in how people act on health 
information (Viswanath & Ackerson, 2011). Similarly, there might be disparities in 
individuals’ responses to drug advertising. Assuming that there might be differences between 
social groups in their ability to process and respond to drug advertising, it is important to 
understand the outcomes of exposure to DTCA between different social groups (Kontos & 
Viswanath, 2011). The current study, therefore, explored how respondents with different social 




2.1.3.1 ‘At-risk’ Individuals’ Responses to DTCA 
 In healthcare, the terms ‘vulnerable’ or potentially ‘at-risk’ are used to refer to 
individuals who are ethnic minorities, children, elderly, those with certain medical conditions, 
as well as socio-economically disadvantaged individuals, such as those with a lower level of 
education and/or a lower level of income (Aday, 2001; National Center for Health Statistics, 
2005; Waisel, 2013). ‘At-risk’ individuals are more likely to experience a medical information 
gap. For instance, older individuals are more vulnerable to DTCA than are younger individuals 
because they tend to obtain less information from the advertisements (Foley & Gross, 2000) 
and are more likely to misinterpret information on the effectiveness of advertised drugs 
(Grenard, Uy, Pagán, & Frosch, 2011). The misinterpretation of a drug’s effectiveness can 
complicate the physician-patient relationship if the patient requests the advertised drug 
(Grenard et al., 2011). While younger adults might also misinterpret information in DTCA, 
older adults are more likely to have several medical conditions requiring more prescription 
drugs and are therefore more likely to be affected by communication gaps in drug 
advertisements (Foley & Gross, 2000). Less educated and lower-income individuals may 
obtain less information from drug advertisements and may be more vulnerable than others to 
the medication information gap (Foley & Gross, 2000). People with poorer health may 
similarly be more vulnerable to drug advertising as they have also been defined as vulnerable 
populations in the medical domain (Aday, 2001; National Center for Health Statistics, 2005), 
and they may need to use more prescription drugs. Furthermore, research typically shows that 
health outcomes for ethnic minorities are poorer compared with the majority populations 
(Ajwani, Blakely, Robson, Tobias, & Bonne, 2003; Bramley, Hebert, Tuzzio, & Chassin, 2005; 
Marriott & Sim, 2015; National Center for Health Statistics, 2005; Waisel, 2013). For example, 
earlier research has reported dissimilarities in health outcomes of different ethnicities in the 
USA and New Zealand. In both countries, poorer health outcomes were found among the 
minority populations. Ethnic minorities can, therefore, be considered as vulnerable or ‘at-risk’ 
people (Bramley et al., 2005). Given the growing concern about the role of health literacy and 
social imbalance in health-related outcomes, more studies have to be conducted to map the 
paths between social determinants and health-related consequences (Ackerson & Viswanath, 
2009; Bekalu & Eggermont, 2014). Drawing on the SIM of health communication, the present 
study explored whether there was any social imbalance as a function of individual 
characteristics with regard to responding to drug advertising. Using a representative sample 
within New Zealand, this study examined whether ‘at-risk’ individuals (with poorer self-
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reported health status, older, less educated, lower-income, lower occupational status and ethnic 
minorities) were more likely to be influenced by drug advertising. 
 
2.1.4 Individuals’ Attitudes and Personal Characteristics 
 Research has also focused on the role of attitudes and personal characteristics in 
determining responses to advertising. Positive attitudes towards drug advertising predict 
behavioural intentions and responses to such advertising (Handlin et al., 2003; Herzenstein, 
Misra, & Posavac, 2004; Lee, Kin, & Reid, 2015). Thus, the present study examined the 
influence of attitudes towards advertising and DTCA on perceived behavioural responses to 
drug advertising. In addition, this study explored the personal trait of materialism to examine 
whether there was a relationship between materialistic traits and responding to drug 
advertising. Materialism emphasises the importance placed on goods and their purchase to help 
achieve desired goals or situations (Richins & Dawson, 1992). Drug advertising uses emotional 
appeals, for instance, showing a character in a fearful state, followed by a happy state after 
using the product, to communicate that purchasing the product is a way to overcome insecurity 
(Dumit, 2010). The association between feelings of insecurity and materialistic behaviour was 
discussed as early as the 1950s (Maslow, 1954). Materialism is also linked with poorer health 
status, including physical symptoms, drug use (Kasser & Ryan, 1996; Kasser & Ryan, 2001), 
and lower subjective well-being (Chan & Joseph, 2000; Dittmar et al., 2014; Kasser & Ahuvia, 
2002; Kasser, Ryan, Couchman, & Sheldon, 2004; Kim, Kasser, & Lee, 2003; Saunders & 
Munro, 2000; Schmuck, Kasser, & Ryan, 2000). Considering the nature of advertising, coupled 
with materialistic individuals’ greater attention to advertising (Graham, 1999), proneness to 
compulsive consumption (Dittmar, 2005; Dittmar et al., 2014; Eren, Eroğlu, & Hacioglu, 2012; 
Kasser, 2003; Ridgway, Kukar-Kinney, & Monroe, 2008) and susceptibility to advertising 
(Kasser et al., 2004), it is reasonable to speculate that materialistic individuals might be more 
likely to respond to DTCA, especially given that DTCA markets drugs to individuals in the 
same fashion as other fast-moving consumer goods. However, no previous research has 
explored the relationships between materialism and responses to drug advertising. Therefore, 
the current study examined the effects of materialism on self-reported behavioural responses 
to drug advertising. In addition, people are increasingly searching for medical information on 
the internet (Mackey & Liang, 2012), but this may differ by education, income and ethnicity. 
These inequalities in internet usage may intensify health inequalities among different groups 
(Koch-Weser, Bradshaw, Gualtieri, & Gallagher, 2010; Rains, 2008; Viswanath & Kreuter, 
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2007). Therefore, this study also examined the influence of the use of the internet to search for 
medical information on self-reported behavioural responses to drug advertising. 
 
2.2 Method  
2.2.1 Data Collection 
 This study analysed a range of attitude, behaviour, and consumption questions from a 
large online survey of a nationally representative sample of 2057 adults in New Zealand. Data 
collection was performed in late 2013 by Research Now, a leading market research company 
operating in more than 40 countries with over 11 million panellists. Quota sampling was used 
for selecting the survey participants. The full-survey instrument took approximately 40 minutes 
to complete. All participants answered all of the questions used in this study since the questions 
were not based on a response logic of any earlier item in the questionnaire. This study had 
ethics approval from the University of Otago, and all participants gave their written consent. 
 
2.2.2 Variables 
2.2.2.1 Dependent Variables 
 Perceived effects of DTCA on individuals were measured by asking participants to 
report their behavioural responses after exposure to a drug advertisement through four yes/no 
questions drawn from previous studies: (1) ‘As a result of seeing an advertisement for a drug, 
have you asked your physician for a prescription?’ (Huh, DeLorme, & Reid, 2005); (2) ‘As a 
result of seeing an advertisement for a drug, have you asked your physician for more 
information about an illness?’ (Huh et al., 2005); (3) ‘As a result of seeing an advertisement 
for a drug, have you searched the internet for more information regarding an illness?’ (Menon, 
Deshpande, Perri III, & Zinkhan, 2003); (4) ‘As a result of seeing an advertisement for a drug, 
have you asked your pharmacist for more information about a drug?’ (Huh et al., 2005).  
 
2.2.2.2 Independent Variables (Predictors) 
 Measures of attitudes and knowledge were made on a 5-point Likert scale from 1 
(strongly disagree) to 5 (strongly agree) and the related data were treated as quasi-interval. 
Participants were asked about their general attitude towards advertising (Ball, Manika, & Stout, 
2016), attitude towards DTCA (Lee et al., 2015; Morris, Brinberg, Klimberg, Rivera, & 
Millstein, 1986), knowledge about the safety of advertised drugs (Huh & Becker, 2005; Wilkes 
et al., 2000) and knowledge about the effectiveness of drugs (Wilkes et al., 2000). Self-
reported/subjective health status, a valid and widely used indicator of health conditions 
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(Banerjee, Perry, Tran, & Arafat, 2010; Idler & Benyamini, 1997; Kuhn, Rahman, & Menken, 
2006; McCallum, Shadbolt, & Wang, 1994) was measured by asking respondents’ self-rated 
satisfaction with their health on a 10-point Likert scale from 1 (completely dissatisfied) to 10 
(completely satisfied) (Huh & Becker, 2005). Materialism was measured by means of Richins 
and Dawson’s Materialism Value Scale, including 18 statements on a 5-point Likert scale from 
1 (strongly disagree) to 5 (strongly agree) (Richins & Dawson, 1992). Richins and Dawson’s 
Scale has been broadly employed in consumer research and shown robust psychometric 
properties in international research (Dittmar et al., 2014; Eastman, Fredenberger, Campbell, & 
Calvert, 1997; Fitzmaurice & Comegys, 2006; Kamal, Chu, & Pedram, 2013; Otero-López, 
Pol, Bolaño, & Mariño, 2011; Roberts, Tanner, & Manolis, 2005). This scale was originally 
argued to have three subscales (centrality, happiness, and success), but this dimensional 
structure is not consistently found in the data (Lipovčan, Prizmić-Larsen, & Brkljačić, 2015; 
Richins, 2004). In this study, the exploratory factor analysis/confirmatory factor analysis found 
evidence for a 2-factor model, but with all the negatively expressed items loading on the second 
factor, suggesting that this factor is an artefactual factor, based on the positive or negative 
wording of items, rather than a real latent dimension (Schmitt & Allik, 2005; Spector, Van 
Katwyk, Brannick, & Chen, 1997). Moreover, previous research has revealed that although 
there are three dimensions in the original scale, items can be summed to reflect an overall 
materialism score (Bearden, Netemeyer, & Haws, 2011). Accordingly, in line with common 
practice, a total materialism score was computed (Bearden et al., 2011; Giacomantonio, 
Mannetti, & Pierro, 2013; Opree, 2014; Slater & Tiggemann, 2016; Watson, 2003). Based on 
omega and alpha estimates, the internal consistency (reliability) of the scale was good (ω=0.81 
(95% CI 0.80 to 0.82), α=0.81 (0.80 to 0.82)). Use of the internet to search for medical 
information was measured by the sum of two yes/no items; i.e., searching for medical advice 
online and visiting a health-related blog (ω=0.72 (0.70 to 0.74), α=0.70 (0.67 to 0.72)). 
Demographic information on age (as a continuous variable), gender, ethnicity (as multiple 
dummy variables, with New Zealand European as the reference level), education, income and 
occupation (as multiple dummy variables, with unemployed as the reference level) were also 
used. Each estimate was controlled for all other included variables. 
 
Data Analysis 
 Data were analysed with IBM SPSS Statistics for Windows, V.22.0, IBM. Descriptive 
statistics were used to calculate frequencies, mean, and SD of items. Omega and alpha 
estimates of reliability were calculated using the ‘MBESS’ package in R. Multivariate binary 
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logistic regression models were used to show independent variables predicting self-reported 
behavioural responses to DTCA and subsequently to reveal the factors determining self-
reported behavioural outcomes. The outcomes of the logistic regression analyses were 
presented as ORs with 95% CIs. Predictive accuracy and overall appropriateness of the models 
were examined by non-significant (P>0.05) Hosmer-Lemeshow tests (Hosmer, Lemeshow, & 
Sturdivant, 2013) and significant (P<0.01) Omnibus test of model coefficients. 
 
2.3 Results 
2.3.1 Sample Characteristics 
 The demographics of the sample are presented in Table 2.1. Table 2.2 shows the means 
and standard deviations for non-demographic independent variables. About 60% of 
respondents considered themselves in good health, 5.2% were completely satisfied with their 
overall health, 25% were dissatisfied, and only 3.4% were completely dissatisfied with their 
overall health. 48% had looked for medical information online. Almost a third of the sample 
(30.7%) believed that DTCA was helpful for consumers, 43.7% thought that only drugs that 
are completely safe could be advertised and 35.3% believed that only drugs that are extremely 
effective could be advertised. Moreover, as a result of seeing DTCA, 11.4% of participants 
asked their physicians for a prescription, 15.9% asked their physicians for more information, 
34.4% searched the internet for more information and 16.2% asked their pharmacists for more 
information. 
 
Table 2.1: Demographics of the sample (n=2057) 
Variable Frequency (%) Mean  S.D. 
Age (yr) 
(Continuous variable) 
 44.2  17.6 
Education    … 
  No secondary schooling 61 (3.0)    
  School examinations only 165 (8.0)    
  School certificate examination only 355 (17.3)    
  University entrance/ Matriculation only 277 (13.5)    
  Technical or trade certificates 329 (16.0)    
  Professional training 215 (10.5)    
  University qualifications 655 (31.8)    
Ethnicity    … 
  New Zealand European 1290 (62.7)    
  Maori 218 (10.6)    
  Chinese 74 (3.6)    
  Indian 79 (3.8)    
  Pacific Islands 68 (3.3)    
  ‘Other’ Ethnicities 328 (15.9)    
Gender    … 
  Male 1001 (48.7)    
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  Female 1056 (51.3)    
Income    … 
 Less than $NZ20,000 199 (9.7)    
 $20,000 to $NZ39,999 460 (22.4)    
 $40,000 to $NZ59,999 413 (20.1)    
 $60,000 to $NZ79,999 338 (16.4)    
 $80,000 to $NZ99,999 212 (10.3)    
 $100,000 to $NZ119,999 202 (9.8)    
 Over $NZ120,000 232 (11.3)    
Occupation    … 
 Working for someone else full time 684 (33.3)    
 Working for someone else part time 275 (13.4)    
 Self-employed 166 (8.1)    
 Temporarily unemployed  144 (7.0)    
 Retired 337 (16.4)    
 Student 273 (13.3)    
 Full-time homemaker 178 (8.7)    
 
Table 2.2: Non-demographic independent variables 
Items Scale Range Mean (SD) 
Only drugs that are completely safe can be advertised in NZ                        1-5 3.28 (1.18) 
Only drugs that are extremely effective can be advertised in NZ                     1-5 3.11 (1.12) 
Overall, I believe that advertising of medicine is good for consumers   1-5 3.00 (1.02) 
Overall, I consider advertising a good thing                                                        1-5 3.07 (0.92) 
Self-reported health status 1-10 5.98 (2.47) 
Materialism 18-90 48.89 (9.32) 
Searching online health information                                                                   0-2 0.71 (0.82) 
 
2.3.2 Predictors of Self-reported Behavioural Outcomes 
 Results of the logistic regression analyses predicting each self-reported behavioural 
outcomes are shown in Table 2.3. 
 
2.3.2.1 Asking a Physician for a Prescription  
 Having asked a physician for a prescription after seeing a drug advertisement was most 
strongly predicted by identifying as Indian (OR 5.00; 95% CI 2.81 to 8.91, P<0.001) or Chinese 
(OR 2.23; 95% CI 1.14 to 4.39, P<0.05), followed by more positive attitudes towards DTCA 
(OR 1.61; 95% CI 1.35 to 1.91, P<0.001). Searching for health information online (OR 1.32; 
95% CI 1.11 to 1.57, P<0.01) was a moderate strength predictor. Weaker predictors were higher 
materialism (OR 1.03; 95% CI 1.01 to 1.05, P<0.001), poorer self-reported health status (OR 
0.94; 95% CI 0.89 to 0.99, P<0.05), lower-income (OR 0.89; 95% CI 0.81 to 0.97, P<0.05) and 
less education (OR 0.89; 95% CI 0.82 to 0.96, P<0.01). Students (OR 0.48; 95% CI 0.24 to 
0.96, P<0.05) were less likely to report asking a physician for a prescription than were 
unemployed respondents. This model correctly classified the outcome for 89% of the cases and 
explained 14.3% (Nagelkerke R2) of the variation in asking a physician for a prescription. The 
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non-significant result of the Hosmer-Lemeshow test (χ2=4.78, df=8, P=0.78) and the 
significant result of the Omnibus Tests of Model Coefficients (P<0.001) demonstrated that the 
model had a good fit to the data.  
 
2.3.2.2 Asking a Physician for More Information about an Illness  
 Having asked a physician about an illness after seeing a drug advertisement was most 
strongly predicted by identifying as Indian (OR 3.88; 95% CI 2.21 to 6.81, P<0.001), Chinese 
(OR 1.99; 95% CI 1.04 to 3.80, P<0.05) or Māori (OR 1.76; 95% CI 1.19 to 2.60, P<0.01), 
followed by searching for health information online (OR 1.67; 95% CI 1.44 to 1.93, P<0.001) 
and more positive attitudes towards DTCA (OR 1.53; 95% CI 1.31 to 1.77, P<0.001). It was 
weakly predicted by older age (OR 1.02; 95% CI 1.01 to 1.03, P<0.001), poorer self-reported 
health status (OR 0.93; 95% CI 0.89 to 0.98, P<0.01) and lower-income (OR 0.89; 95% CI 
0.82 to 0.96, P<0.01). This model correctly classified the outcome for 84.2% of the cases and 
explained 14.5% (Nagelkerke R2) of the variation in asking a physician about an illness. The 
non-significant result of the Hosmer-Lemeshow test (χ2=10.22, df=8, P=0.25) and the 
significant result of the Omnibus Tests of Model Coefficients (P<0.001) again showed a good 
model fit. 
 
2.3.2.3 Searching the Internet for More Information regarding an Illness 
 Having searched the Internet for more information regarding an illness after seeing a 
drug advertisement was strongly predicted by searching for health information online (OR 
2.35; 95% CI 2.08 to 2.65, P<0.001), moderately predicted by more positive attitudes 
towards DTCA (OR 1.34; 95% CI 1.19 to 1.51, P<0.001) and weakly predicted by higher 
materialism (OR 1.02; 95% CI 1.01 to 1.03, P<0.01), in addition to poorer self-reported health 
status (OR 0.90; 95% CI 0.86 to 0.93, P<0.001). Women were somewhat (OR 
1.36; 95% CI 1.09 to 1.70, P<0.01) more likely than men to report searching the internet for 
more information regarding an illness after exposure to DTCA. This model correctly classified 
the outcome for 71.3% of the cases and explained 20.7% (Nagelkerke R2) of the variation in 
searching the internet for more information regarding an illness. The non-significant result of 
the Hosmer-Lemeshow test (χ2=20.03, df=8, P=0.01) and the significant result of the Omnibus 






2.3.2.4 Asking a Pharmacist for More Information about an Advertised Drug 
 Having asked a pharmacist for more information about an advertised drug after seeing 
a drug advertisement was most strongly predicted by identifying as Chinese (OR 2.55; 95% CI 
1.40 to 4.63, P<0.01), Māori (OR 2.06; 95% CI 1.41 to 3.01, P<0.001) or ‘other’ ethnicities 
(OR 1.78; 95% CI 1.27 to 2.50, P<0.01). More positive attitudes towards DTCA (OR 1.39; 
95% CI 1.21 to 1.61, P<0.001) and searching for health information online (OR 1.32; 95% CI 
1.14 to 1.53, P<0.001) were moderate strength predictors. Weaker predictors were older age 
(OR 1.01; 95% CI 1.004 to 1.03, P<0.01), poorer self-reported health status (OR 0.94; 95% CI 
0.90 to 0.99, P<0.05) and lower-income (OR 0.91; 95% CI 0.84 to 0.98, P<0.05). This model 
correctly classified the outcome for 83.9% of the cases and explained 10.2% (Nagelkerke R2) 
of the variation in asking a pharmacist for more information about an advertised drug. Model 
fit was again good with a non-significant result of the Hosmer-Lemeshow test (χ2=7.01, df=8, 
P=0.53) and significant result of the Omnibus Tests of Model Coefficients (P<0.001). 
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OR (95% CI) 
 
Searching the 








about a drug: 
OR (95% CI) 
Age 
 
1.00 (0.99-1.01) 1.02 (1.01-1.03)*** 1.01 (0.99-1.02) 1.01 (1.004-1.03)** 













Maori 1.33 (0.84-2.10) 1.76 (1.19-2.60)** 1.08 (0.77-1.52) 2.06 (1.41-3.01)*** 
Chinese 2.23 (1.14-4.39)* 1.99 (1.04-3.80)* 1.22 (0.71-2.08) 2.55 (1.40-4.63)** 
Indian 5.00 (2.81-8.91)*** 3.88 (2.21-6.81)*** 1.58 (0.93-2.67) 1.77 (0.96-3.25) 
Pacific Island 0.87 (0.39-1.96) 1.29 (0.64-2.58) 1.08 (0.62-1.87) 1.64 (0.86-3.15) 
‘Other’ Ethnicities 1.24 (0.80-1.91) 1.35 (0.94-1.95) 1.28 (0.96-1.70) 1.78 (1.27-2.50)** 
Gender 0.74 (0.53-1.02) 0.81 (0.61-1.07) 1.36 (1.09-1.70)** 1.08 (0.82-1.42) 
Self-Reported 
Health Status 












Working Fulltime 0.89 (0.52-1.55) 0.94 (0.57-1.54) 1.46 (0.94-2.26) 1.18 (0.71-1.95) 
Working Part-Time 0.68 (0.37-1.26) 0.78 (0.45-1.34) 1.13 (0.71-1.82) 0.74 (0.42-1.29) 
Self-Employed 1.05 (0.53-2.06) 0.52 (0.27-1.002) 1.07 (0.63-1.82) 0.99 (0.53-1.84) 
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Retired     0.67 (0.34-1.34) 0.57 (0.32-1.03) 1.10 (0.66-1.84) 0.77 (0.43-1.39) 
Student 0.48 (0.24-0.96)* 1.10 (0.61-2.00) 1.52 (0.92-2.52) 0.77 (0.41-1.44) 
Fulltime 
Homemaker 
0.81 (0.41-1.59) 0.57 (0.30-1.09) 0.93 (0.55-1.56) 0.95 (0.52-1.74) 




1.01 (0.85-1.19) 1.09 (0.94-1.26) 1.09 (0.97-1.23) 1.15 (0.99-1.33) 
Attitude toward 
DTCA 
1.61 (1.35-1.91)*** 1.53 (1.31-1.77)*** 1.34 (1.19-1.51)*** 1.39 (1.21-1.61)*** 
Materialism 1.03 (1.01-1.05)*** 1.01 (0.99-1.03) 1.02 (1.01-1.03)** 1.005 (0.99-1.02) 
Searching Online 
Health Info 




1.19 (0.96-1.48) 1.06 (0.88-1.28) 1.02 (0.88-1.18) 1.04 (0.87-1.24) 
View on Safety of 
Advertised Drugs 
0.87 (0.71-1.07) 0.90 (0.75-1.07) 0.94 (0.81-1.08) 1.02 (0.86-1.21) 
*p < 0.05  **p < 0.01  ***p < 0.001 
 
2.4 Discussion 
 Individuals lacked knowledge regarding the regulation and safety of drug advertising, 
with nearly half of all participants believing that only drugs that are completely safe could be 
advertised. Similarly, a substantial proportion thought that only drugs that are extremely 
effective could be advertised. Individuals are often vulnerable to misinformation (Mansfield, 
2004) and do not try to process the rest of the provided information if a drug advertisement 
presents a drug as effective (Delbaere & Smith, 2006). Inaccurate positive belief regarding the 
safety and efficacy of advertised drugs is concerning given that advertising may induce 
unwarranted inferences and change individuals’ beliefs over time (Frosch, May, Tietbohl, & 
Pagán, 2011), the main goal of drug advertising is to influence rather than to educate (Frosch 
et al., 2007; Mansfield et al., 2005; Toop & Mangin, 2006), and research shows that drug 
advertising is usually effective at persuasion (Gilbody et al., 2005; Kravitz et al., 2005).  
 Participants reported responding to drug advertising by seeking the medication or 
further information because of seeing a drug advertisement, indicating a general effect of 
DTCA. Such reported behaviour can have varied outcomes; requesting a prescription drug may 
lead to either appropriate treatment or inappropriate and excessive prescribing (Almasi et al., 
2006). Moreover, searching or asking for more information can increase individuals’ awareness 
of medical conditions and potential treatments, but it can also lead to seeking medications for 
irrelevant, non-medical, or minor medical problems (Moynihan & Cassels, 2006). Discussions 
about inappropriate drugs or unrelated medical conditions can take time away from necessary 
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medical examinations or prevent communications regarding healthy lifestyle changes or mental 
health issues, which can consequently influence patients’ well-being (Frosch et al., 2007; 
Stange, 2007). Furthermore, finding reliable information on the internet is challenging ‘(like 
finding a needle in a haystack), and the noise of DTCA just makes the haystack larger’ (Almasi 
et al., 2006, p. 0286).  
 To the best of my knowledge, no study has documented characteristics of ‘at risk’ 
individuals in response to DTCA. This study found disparities in self-reported behavioural 
responses to drug advertising with ‘vulnerable’ or ‘at-risk’ individuals (i.e., poorer subjective 
health status, older, less educated, lower-income and ethnic minorities) being more likely to 
report responses to drug advertising. In particular, respondents’ ethnicity influenced self-
reported behavioural responses, so that some ethnic minorities were more likely to report 
behavioural responses, relative to New Zealand Europeans. This study extends the handful of 
studies, which have examined responses of ethnic minorities to DTCA (Lee & Begley, 2010), 
and shows the disparate effects of drug advertising on vulnerable populations outside of North 
America. Respondents who had lower levels of satisfaction with their health status were more 
likely than other individuals to report engaging in all four behavioural responses. Older 
individuals were also more likely than others to seek more information from a physician or 
pharmacist as a result of seeing a drug advertisement. While health issues and associated needs 
for prescriptions might explain self-reported behavioural responses of older individuals and 
those who were less satisfied with their health status, other individuals classed as ‘vulnerable’ 
due to social determinants were also more likely to respond to drug advertising. Respondents 
with lower levels of education were more likely to ask a physician for a prescription. Those 
with lower levels of income were more likely to report all behavioural responses except for 
searching the internet, and unemployed respondents were more likely than students to ask a 
physician for a prescription. Women were more likely than men to engage in searching the 
internet for more information regarding an illness. Taken together, the current findings showed 
communication inequalities in response to drug advertising, with ‘vulnerable’ or ‘at-risk’ 
individuals being more likely to respond to such advertising. These findings are consistent with 
the SIM of health communication, which suggests that differences in health behaviours among 
different social groups can be explained by focusing on how social determinants are linked to 
health communication outcomes (Kontos & Viswanath, 2011; Viswanath, Ramanadhan, & 
Kontos, 2007). The imbalance in self-reported behavioural responses of ‘at-risk’ individuals 
raises concerns regarding the ethicality of drug advertising in its present form and exemplifies 
the need for DTCA to be executed ethically. Although physicians play the role of gatekeepers 
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and moderate the effects of drug advertising on individuals, patients’ requests can drive 
physicians’ medication choices (McKinlay et al., 2014). Many physicians have reported that 
assuring patients that a requested medication is not suitable is challenging and onerous 
(Connors, 2009).  
 In the current study, a favourable attitude towards drug advertising predicted all self-
reported behavioural outcomes. The fact that individuals might respond to drug advertising 
based on their favourable attitudes, coupled with the fact that participants had inaccurate 
knowledge regarding the safety and effectiveness of advertised drugs, suggests that individuals 
are at risk of being influenced by the promotional nature of the advertisements. This is a 
significant concern since drug advertising is self-regulated in New Zealand (Mintzes, 2006; 
Toop & Mangin, 2015), and medicine advertisements often present patient success stories, 
which can mislead the public (Perry et al., 2013). This risk is further evident by the finding that 
materialism positively predicted self-reported behavioural responses to DTCA, including 
asking a physician for a prescription and searching the internet for more information. Previous 
studies have revealed that materialism is associated with lower psychological well-being, more 
physical symptoms, more drug use, more attention to advertising, as well as purchasing 
behaviour (Chan & Joseph, 2000; Dittmar, 2005; Dittmar et al., 2014; Eren et al., 2012; 
Graham, 1999; Kasser, 2003; Kasser & Ahuvia, 2002; Kasser & Ryan, 2001; Kasser et al., 
2004; Kim et al., 2003; Maslow, 1954; Saunders & Munro, 2000; Schmuck et al., 2000; 
Ridgway et al., 2008). The current findings linking materialism to responding to drug 
advertising align with earlier research showing that materialism is closely related to excessive 
and uncontrollable shopping and compulsive consumption (Dittmar, 2005; Dittmar et al., 2014; 
Eren et al., 2012; Ridgway et al., 2008). DTCA is thus creating demand amongst a group who 
is highly attuned to advertising, and already at-risk due to poorer health indicators. These 
outcomes add to this body of research by suggesting that materialistic individuals might be 
more likely than others to treat prescription drugs similarly to other consumer goods. Given 
past research has shown materialistic individuals are more prone to drug use, and the current 
findings that they are more likely to respond to DTCA, the questions arise that whether DTCA 
is ethical in its current form and whether pharmaceuticals should be advertised to consumers 
at all. Of note, reliance on the internet for medical information predicted all self-reported 
behavioural responses to DTCA. Thus, pharmaceutical companies could improve the ethicality 
of their advertising by using the internet to develop patient support and offer informative online 




2.4.1 Research Limitations and Strengths 
 The current findings were based on cross-sectional data; thus, causal inferences could 
not be made. Future longitudinal studies could further explore the effects of social 
determinants, personal characteristics and exposure to drug advertisements on health 
communication outcomes, including prescription drug purchasing. Even though this research 
used anonymous survey responses, it could not completely mitigate the issue of social 
desirability biases. However, the amount of bias would be roughly similar across respondents. 
Moreover, the findings were based on self-reported behavioural responses and might not reflect 
individuals’ actual behavioural responses. Experimental studies should be conducted to extend 
the outcomes and contributions of this study. Since this study focused on perceived behavioural 
responses, perceptions of the informativeness of DTCA and motivations for responding to 
DTCA were not explored and could be examined in future research. 
 The outcomes from a large representative sample can be generalised to the national 
population in New Zealand and have important implications for both healthcare policymakers 
and pharmaceutical companies. This research suggests that regulations on drug advertising 
should be tightened. Moreover, health policymakers should increase knowledge regarding drug 
advertising and let individuals know that advertised medications are not necessarily safe and 
effective. Health policymakers can also concentrate on people’s attitudes towards advertising 
of prescription drugs and let them know that it is a paid promotion conveyed by pharmaceutical 
companies. Health professionals need to be well informed of all medications prior to them 
being advertised to help individuals make safe choices. Furthermore, pharmaceutical 
companies should not target ‘at risk’ individuals. They should advertise their medications 
responsibly and educate individuals about treatments constructively since people, especially 
those who are more vulnerable, may ask for a medication that they do not need. Drug 
advertisements can discuss lifestyle alternatives to taking drugs and state that there are other 
medications available, which may have identical effects. 
 
2.4.2 Conclusions 
 While much attention has been paid to perceived behavioural responses to drug 
advertising, to the best of my knowledge, no study has documented ‘at-risk’ individuals’ 
perceived behavioural responses to drug advertising. This study, therefore, grounded in 
communication inequality and the SIM, presented the factors predicting individuals’ self-
reported behavioural responses to drug advertising. This research found that ‘at-risk’ 
individuals were more vulnerable to drug advertising as supported by the representative 
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empirical findings. Furthermore, the outcomes revealed the importance of attitudes towards 
DTCA over and above knowledge of regulation and safety of advertised drugs, which can leave 
individuals vulnerable to drug advertising and at risk of making uninformed decisions 
accordingly. The current research also addressed the important question of whether materialism 
has effects on self-reported behavioural responses to drug advertising. The findings revealed 
that respondents higher in materialism were more likely to be affected by drug advertising, 
suggesting that they might pay more attention to advertisements, or DTCA might be appealing 
to their consumerism, a trait that is associated with lower psychological well-being (Kasser, 
2003).  
 Taken together, the outcomes suggest that drug advertising affects the most ‘at-risk’ 
individuals, who base their decisions on their attitudes, who are motivated to consume, and 
who rely on the internet for medical information. The findings raise significant concerns 
regarding the ethicality of DTCA and suggest a need for policy developments to ensure 


















CHAPTER THREE: LIFESTYLE DETERMINANTS OF BEHAVIOURAL 
OUTCOMES TRIGGERED BY DIRECT-TO-CONSUMER 




 Study one of this Ph.D. thesis found that medicine advertising was more likely to 
influence ‘at-risk’ people (i.e., lower-income, poorer self-reported health status, older, less 
educated, and ethnic minorities), who had more positive attitudes toward DTCA, and who were 
more materialistic. The imbalance in behavioural responses of ‘at-risk’ individuals causes 
concern regarding their informed decision-making, as well as the ethicality of medicine 
advertising.  
 Furthermore, reviewing existing literature on the subject matter raised the question of 
whether individuals with less healthy lifestyle behaviours could be more vulnerable to DTCA. 
Study two thus extended the findings of study one and examined the effects of 
healthy/unhealthy lifestyle habits on individuals’ responses to DTCA. This study answered the 
following research question: 
RQ 2. What is the association between lifestyle determinants and self-reported behavioural 
responses triggered by DTCA? 
















 Direct-to-consumer advertising of prescription medicines encourages individuals to 
search for or request advertised medicines, can stimulate taking medications rather than making 
lifestyle behaviour changes, and may target individuals with poorer demographic and socio-
economic status and riskier health-related behaviours. This study thus explored whether 
responses to medicine advertising vary as a function of lifestyle behaviours, and demographic 
and socio-economic factors. Data were collected through an online survey of a nationally 
representative sample of 2057 adults in New Zealand. Multivariate binary logistic regressions 
were used to explore whether lifestyle behaviours, including nutritional habits, alcohol 
consumption, illegal drug consumption, physical activity, attitudes towards doing exercise, as 
well as demographic and socio-economic status were associated with self-reported behavioural 
responses to medicine advertising. Individuals who had unhealthier lifestyle behaviours were 
more likely to respond to medicine advertising. The findings raise concerns regarding the 
misuse or overuse of medications for diseases that may otherwise be improved by a healthier 
lifestyle. To improve the public health and wellbeing of society, we call for regulatory changes 
regarding the advertising of medicines. Where applicable, lifestyle changes should be 
advertised as potential substitutes for the advertised medicines. Interprofessional collaboration 
is also recommended to educate individuals and convey the value of health behaviour changes.  
 
3.1 Background to the Research 
 Advertising attempts to sell products by encouraging people to buy them. Medicine 
advertising similarly aims to persuade individuals to search or ask for a medicine (Huh & 
Becker, 2005). Direct-to-consumer advertising of prescription medicines (DTCA), a 
controversial type of advertising, has grown swiftly over the past few decades (Greene & 
Herzberg, 2010; Kuehn, 2010; Pharmaguy, 2010). DTCA has only been legally developed in 
New Zealand and the United States (Hall & Jones, 2008; Kontos & Viswanath, 2011). These 
two countries have different economies and health systems. New Zealand has mostly public 
healthcare and self-regulated DTCA (Hoek et al., 2004). In New Zealand, advertisements are 
not independently evaluated for the quality and validity of scientific statements unless someone 
complains (Toop & Mangin, 2007), and this system has not prevented misleading 
advertisements (Toop et al., 2003). Even in the United States, which has mostly privately-
funded healthcare (Hoek et al., 2004) and DTCA is regulated and overseen by the Food and 
Drug Administration, violations by pharmaceutical companies are prevalent, predominantly 
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for providing misleading information (Donohue et al., 2007; Faerber & Kreling, 2014; Kim, 
2015; Klara et al., 2018).  
DTCA is hypothesized to both benefit and harm public health (Abel et al., 2006; Almasi 
et al., 2006; Frosch et al., 2010; Murray, Lo, Pollack, Donelan, & Lee, 2003). Given that some 
medications are underused and some are overused, DTCA that increases prescribing may have 
positive or negative effects (Almasi et al., 2006; Frosch et al., 2010). DTCA can have positive 
outcomes when the disease to be treated is severe and the medicine is safe, effective and 
underused; whereas, when the condition is not serious and the medicine is potentially unsafe, 
less effective or overused, the effects of DTCA will be negative (Almasi et al., 2006). 
Supporters argue that DTCA can inform and empower the public and increase their autonomy 
by educating them about medical conditions and possible treatments (Adams, 2016). However, 
even though DTCA may inform individuals, it may also mislead them (Abel et al., 2006). 
Critics argue that DTCA is persuasive rather than informative because it presents partial and 
biased information that exaggerates the potential benefits of medicines (Frosch et al., 2010; 
Gilbody et al., 2005; Kravitz et al., 2005; Toop & Mangin, 2006; Woloshin et al., 2004). DTCA 
has also been criticised for using ‘scare-mongering’ tactics to encourage patients to start a 
treatment (Chaar & Kwong, 2010; McAll, 2005). 
 Past research has shown that DTCA leads to the advertised medicines being sought and 
requested by individuals (Donohue et al., 2007; Khalil Zadeh et al., 2017; Mintzes, 2003; Toop 
& Mangin, 2006). Of note, studies reveal that when a message shows a medicine as very 
effective, individuals do not try to process the rest of the information presented in the message 
(Delbaere & Smith, 2007). Doctors may face extra work and frustration if a patient discusses 
the medicine with them as a result of ‘evidence’ from an advertisement (Abel et al., 2006; 
Delbaere & Smith, 2007). Research has also shown that when patients ask for a specific 
medicine, doctors usually prescribe it (Kravitz et al., 2005; McKinlay, Trachtenberg, Marceau, 
Katz, & Fischer, 2014; Mintzes et al., 2002). Further, advertising a medication as the solution 
to a health condition may cause audiences to think that healthy lifestyles, such as proper 
nutrition and exercise, are ineffective or needless (Shaw, 2008). Hence, the influence of 
medicine advertising on consumers with unhealthier lifestyle practices is of particular concern.  
 
3.1.1 Lifestyle Behaviours and Health Inequalities 
 Research has discussed that DTCA can change people’s views on normal and medical 
conditions by encouraging the use of medicine to cure ‘every ill’ (Hoek & Gendall; 2002; 
Ministry of Health, 2006). Aspects of bodily experiences, which are normally reflections of 
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individuals’ lifestyles, have been medicalised by the pharmaceutical industry’s efforts to find 
treatments for these ‘new’ illnesses (Koinig, 2016; Zola, 1972). Lifestyle behaviours can affect 
both consumer behaviour (Krishnan, 2011) and consumer health (Lisspers et al., 2005; 
McGinnis & Foege, 1993; National Center for Health Statistics, 2001; Poortinga, 2007; 
Sapranaviciute-Zabazlajeva et al., 2017; U.S. Department of Health and Human Services, 
2000). Lifestyle has been studied as a leading contributor to health outcomes by researchers 
(Farhud, 2015). Previous research has established that the study of lifestyle behaviours can 
provide more information about, and a better picture of, individuals than their demographics 
(Krishnan, J. (2011). Lifestyle comprises people’s daily behaviours, such as activities, fun, and 
nutrition (Farhud, 2015). Health lifestyles are defined as health-related behaviours according 
to individuals’ preferences from available options (Cockerham, 2000). Unhealthy nutrition, 
physical inactivity, drug abuse, smoking, alcohol consumption, and medicine abuse are 
common indicators of an unhealthy lifestyle (Farhud, 2015; Poortinga, 2007; Sapranaviciute-
Zabazlajeva et al., 2017; Satcher, 2000). According to existing studies, engaging in one or more 
unhealthy lifestyle behaviours advances the risk of death (Ford, Zhao, Tsai, & 2011; 
Hoevenaar-Blom, Spijkerman, Kromhout, & Verschuren, 2014; Loef, & Walach, 2012; 
Martínez-Gómez, Guallar-Castillón, León-Muñoz, López-García, & Rodríguez-Artalejo, 
2013). A meta-analysis revealed that having a healthy lifestyle is linked to a lower risk of death 
so that a mix of healthy lifestyle behaviours, such as not smoking, moderate alcohol drinking, 
healthy nutrition, regular physical activity, and having an optimal weight, was linked to a 66% 
decrease in mortality (Loef & Walach, 2012). 
 
3.1.2 Demographic and Socio-economic Characteristics and Health 
Inequalities 
 “Demographic and socio-economic factors are major determinants of health” (World 
Health Organization, 2009, p. 131). The social determinants of health, “the conditions in which 
people are born, grow, live, work and age” (p. 36), can result in health inequalities (Department 
of Health and Human Services, 2015). Research has demonstrated that people with lower socio-
economic status have poorer health conditions (Department of Health and Human Services, 
2015). “Health behaviour is greatly influenced by peoples’ environmental, socio-economic and 
cultural settings” (Baum & Fisher, 2014, p. 213). Earlier studies show that being socially or 
economically disadvantaged (e.g., having low income) is associated with unhealthy lifestyle 
factors (e.g., physical inactivity, smoking, and being obese; Baum & Fisher, 2014; Department 
of Health and Human Services, 2015; Layte & Whelan, 2009; Link & Phelan, 2005). Moreover, 
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disparities in health information seeking have been associated with gender, education, age and 
ethnicity (Jacobs, Amuta, & Jeon, 2017; Khalil Zadeh et al., 2017; Lorence, Park, & Fox, 2006; 
Rutten et al., 2006; Suominen-Taipale et al., 2006). For instance, women and individuals who 
had lower income and were less educated, older, and ethnic minorities were more likely to 
respond to DTCA (Khalil Zadeh et al., 2017).  
 
3.1.3 Summary 
 Individuals with less healthy lifestyle behaviours and poorer socio-economic 
characteristics are more likely to have health issues (Ford et al., 2011; Martínez-Gómez et al., 
2013; Tsai et al., 2010). Given their poorer health and the fact that DTCA can be misleading 
and emotive (Toop & Mangin, 2015), and focuses on taking medications rather than changing 
lifestyle behaviours (Auton, 2004), such individuals may be at higher risk of responding to 
DTCA and hence may be at higher risk of being medicalised. DTCA may thus lead to the 
misuse or overuse of medications for diseases that may otherwise be improved by a healthier 
lifestyle. The present study thus extends previous research, which found demographic and 
socio-economic factors associated with responding to DTCA (Khalil Zadeh et al., 2017), to 
examine whether lifestyle factors also help to explain individuals’ responses to DTCA. 
Specifically, this study examines whether individuals who have unhealthier lifestyles are more 
likely to report being influenced by medicine advertising. 
 
3.2 Method  
3.2.1 Study Sample  
 This exploratory study analysed data collected by an Australasian market research 
company through an online survey of 2057 adults in New Zealand in 2013. A quota sampling 
method was used, capturing a nationally representative sample of the population in New 
Zealand, to allow for generalisability of the results. The survey obtained ethical approval from 
the University of Otago, and all respondents gave their informed consent.  
 
3.2.2 Variables and Measures  
 The data used in this study came from a larger research project on consumer behaviour 
and lifestyle. In this study, measures and variables relevant to demographics, socio-economics, 




3.2.2.1 Dependent Variables 
  Self-reported behaviours in response to seeing an advertisement for a medicine (Khalil 
Zadeh et al., 2017) were measured by four yes/no questions adapted from prior studies: ‘As a 
result of seeing an advertisement for a drug, have you asked your doctor for a prescription?’ 
(Huh et al., 2005); ‘As a result of seeing an advertisement for a drug, have you asked your 
doctor for more information about an illness?’ (Huh et al., 2005); ‘As a result of seeing an 
advertisement for a drug, have you searched the Internet for more information regarding an 
illness?’ (Menon et al., 2003); and ‘As a result of seeing an advertisement for a drug, have you 
asked your pharmacist for more information about a drug?’ (Huh & Becker, 2005; Huh et al., 
2005). 
 
3.2.2.2 Independent Variables  
 Common indicators of a healthy/unhealthy lifestyle; i.e., nutritional habits, substance 
abuse (including consumption of illicit drugs and alcohol), physical activity (Poortinga, 2007; 
Sapranaviciute-Zabazlajeva, 2017; Satcher, 2000), as well as attitude towards doing exercise 
were independent variables. Nutritional habits were evaluated using a summed index of twelve 
yes (1)/no (2) statements pertaining to the consumption of different food categories in the past 
24 hours; higher values indicate more healthy nutritional habits. Healthy food habits included 
eating: vegetables, fruit, breakfast, a meal at home that was made from scratch (i.e., no pre-
prepared packets were used). Healthy food habits were subsequently reverse scored. Unhealthy 
food habits included eating: confectionery (e.g., lollies, sweets), potato chips and/or chocolate; 
fast food (e.g., McDonalds, fish, and chips); takeaways (e.g., Thai, Indian); at a restaurant or 
café; a meal at home made from pre-prepared food/sauces (e.g., frozen chips, pre-prepared rice 
risotto from a packet, pasta sauce); biscuits, cakes, or pastries; dessert or ice cream; and 
drinking fizzy drink containing sugar (e.g., Coke, Sprite; Food Standards Agency, 2007).  
 Illegal drug consumption was assessed by a summed index of two statements, made on 
a five-point scale: 0 (never), 1 (rarely), 2 (occasionally), 3 (often) to 4 (daily), regarding 
consumption of marijuana and consumption of speed, ecstasy or magic mushrooms (modified 
from past research; Shapiro, Siegel, Scovill, & Hays, 1998) in the past 12 months. Higher 
values indicate more consumption. For measuring alcohol consumption, participants were 
asked to indicate the type and volume of standard drinks consumed on their heaviest drinking 
situation in the past seven days (De Visser & Birch, 2012; Greenfield & Kerr, 2008; Robertson, 
Thyne, & Hibbert, 2017).  
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This measure has been noted to represent ‘at risk’ drinking (Greenfield & Kerr, 2008) and the 
period of seven days provides a thorough picture of alcohol consumption (Dawson, 2003) and 
moderates the chances of under-reporting, even though it does not consider the occasional 
drinking of participants (Bloomfield, Hope, & Kraus, 2013). Before the estimation of alcohol 
consumption, the alcohol percentage by volume (ABV) was reviewed and revised for each 
record (Robertson et al., 2017b). Standard drink consumption was measured by applying the 
equation indicated by the Food Standards Authority Australia and New Zealand (FSANZ) and 
used in an earlier study: “volume of the container in liters × % alcohol by volume (ml/100 ml) 
× 0.789” (Robertson et al., 2017b; Robertson, Forbes, & Thyne, 2017). 
 Physical activity was determined through a summed index of four statements (0: not 
selected / 1: going to/participating in) measuring engagement in physical activities in an 
average month, including going to the gym/run/walk, participating in individual sport (e.g., 
swimming, golf), participating in a team sport, and going tramping or camping. Higher values 
indicate more physical activities. Consumers’ attitude towards doing exercise was measured 
by a single item measuring attitude towards the importance of doing exercise, made on a five-
point Likert scale from 1 (strongly disagree) to 5 (strongly agree). All questions came from the 
New Zealand lifestyle survey, which is a part of an ongoing project performed by the University 
of Otago since 1979. Demographic and socio-economic variables were also considered in the 
models: gender, “age (as a continuous variable)”, “ethnicity (as multiple dummy variables, 
with New Zealand European as the reference level)”, level of education (as ordered categorical 
variables, and income (Khalil Zadeh et al., 2017, p. 4). Each estimate was controlled for all 
other included variables. 
 
3.2.3 Statistical Analysis  
 Data were analysed with IBM SPSS Statistics, Version 22.0. Descriptive statistics were 
employed to estimate frequencies, in addition to the mean, and standard deviation of items 
(Khalil Zadeh et al., 2017). Multivariate binary logistic regression models were used to reveal 
the factors determining self-reported behavioural outcomes. For each model, odds ratios (ORs) 
with 95% confidence intervals (CIs) were examined. Accuracy of prediction and “overall 
appropriateness of the models” were assessed by “significant (p<0.01) Omnibus test of model 
coefficients, and nonsignificant (p>0.05) Hosmer–Lemeshow tests” (Hosmer Jr, Lemeshow, & 




3.3 Results  
3.3.1 Descriptive Statistics  
 The demographics and socio-economics of the sample are shown in Table 3.1 (Khalil 
Zadeh et al., 2017). The means and standard deviations for non-demographic independent 
variables (Khalil Zadeh et al., 2017) are demonstrated in Table 3.2.  
 
Table 3.1: Demographics and socio-economics of the Sample (n=2,057) 
Variable Frequency (%) Mean   S.D. 
Age (years) 
(Continuous variable) 
 44.21   17.60 
Education n (%)     … 
  No secondary schooling 61 (3.0)     
  School examinations only 165 (8.0)     
  School certificate examination only 355 (17.3)     
  University entrance/ Matriculation only 277 (13.5)     
  Technical or trade certificates 329 (16.0)     
  Professional training 215 (10.5)     
  University qualifications 655 (31.8)     
Ethnicity n (%)     … 
  New Zealand European 1290 (62.7)     
  Maori 218 (10.6)     
  Chinese 74 (3.6)     
  Indian 79 (3.8)     
  Pacific Islands 68 (3.3)     
  ‘Other’ Ethnicities 328 (15.9)     
Gender n (%)     … 
  Male 1001 (48.7)     
  Female 1056 (51.3)     
Income (annual) n (%) 
Less than $NZ20,000                                          199 (9.7)                         
$20,000 to $NZ39,999                                        460 (22.4) 
$40,000 to $NZ59,999                                        413 (20.1) 
$60,000 to $NZ79,999                                        338 (16.4) 
$80,000 to $NZ99,999                                        212 (10.3) 
$100,000 to $NZ119,999                                    202 (9.8) 
Over $NZ120,000                                               232 (11.3) 
  




Table 3.2: Non-demographic independent variables 
Items  Scale Range Mean (SD) 
Alcohol consumption 0-61.3 3.16 (5.90) 
Attitudes towards doing exercise 1-5 4.26 (0.80) 
Healthy eating habits 









3.3.2 Predictors of Behavioural Outcomes  
 Results of the multivariate binary logistic regression models predicting self-reported 
behavioural responses to DTCA (Khalil Zadeh et al., 2017) are presented in Table 3.3.  
 
3.3.2.1 Asking a Doctor for a Prescription  
 Asking a doctor for a prescription was associated with older age (OR=1.01, 95%CI 
1.001-1.02), higher alcohol consumption (OR=1.03, 95%CI 1.01-1.05), more illegal drug 
consumption (OR=1.29, 95%CI 1.17-1.42); lower education (OR=0.90, 95%CI 0.83- 0.97), 
less positive attitudes toward doing exercise (OR=0.79, 95%CI 0.66-0.94), doing less exercise 
(OR=0.78, 95%CI 0.69-0.89), and less healthy eating habits (OR=0.84, 95%CI 0.78-0.91). 
Chinese (OR=2.24, 95%CI 1.11-4.51), and Indian (OR=6.05, 95%CI 3.37-10.86) respondents 
were more likely to ask a doctor for a prescription than New Zealand Europeans. Gender and 
income did not have any influence on asking a doctor for a prescription. This model correctly 
classified the outcome for 88.6% of the cases and demonstrated a good fit to the data (Table 
3.3). 
 
3.3.2.2 Asking a Doctor for More Information about an Illness  
 Asking a doctor about an illness was associated with more illegal drug consumption 
(OR=1.11, 95%CI 1.01-1.23), older age (OR=1.02, 95%CI 1.01-1.03), lower-income 
(OR=0.89, 95%CI 0.83-0.96), doing less exercise (OR=0.78, 95%CI 0.70-0.88), and less 
healthy eating habits (OR=0.88, 95%CI 0.82-0.94). Maori (OR=2.06, 95%CI 1.42-2.99), 
Chinese (OR=2.05, 95%CI 1.07-3.91), Indian (OR=4.14, 95%CI 2.40-7.12), and ‘Other’ 
ethnicities (OR=1.52, 95%CI 1.06-2.16) were more likely than New Zealand Europeans to ask 
a doctor for more information about an illness. Alcohol consumption, attitudes toward doing 
exercise, education, and gender did not have any influence on asking a doctor about an illness. 
This model correctly classified the outcome for 84.1% of the cases and showed a good model 
fit (Table 3.3). 
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3.3.2.3 Searching the Internet for More Information Regarding an Illness  
 Seeking more information from the Internet regarding an illness was associated with 
more positive attitudes toward doing exercise (OR=1.15, 95%CI 1.02-1.30), doing less exercise 
(OR=0.84, 95%CI 0.77-0.92), and less healthy eating habits (OR=0.93, 95%CI 0.89-0.98). 
Indian (OR=1.71, 95%CI 1.06-2.77), and ‘Other’ ethnicities (OR=1.31, 95%CI 1.01-1.70) 
were more likely than New Zealand Europeans to search the Internet for more information. 
Moreover, women were more likely than men to search the Internet for more information 
(OR=1.48, 95%CI 1.21-1.82). Illegal drug consumption, alcohol consumption, education, age, 
and income did not have any influence on searching the Internet for more information. This 
model correctly classified the outcome for 65.7% of the cases and demonstrated a good fit to 
the data (Table 3.3). 
 
3.3.2.4 Asking a Pharmacist for More Information about a Drug  
 Asking a pharmacist for more information about an advertised drug was associated with 
older age (OR=1.02, 95%CI 1.01-1.03), more illegal drug consumption (OR=1.22, 95%CI 
1.11-1.34), doing less exercise (OR=0.87, 95%CI 0.77-0.97), and less healthy eating habits 
(OR=0.91, 95%CI 0.86-0.97). All ethnic minorities, including Maori (OR=2.32, 95%CI 1.61-
3.34), Chinese (OR=2.55, 95%CI 1.40-4.61), Indian (OR=1.93, 95%CI 1.06-3.53), Pacific 
Islands (OR=2.11, 95%CI 1.12-3.98) and Other ethnicities (OR=1.98, 95%CI 1.42-2.76), were 
more likely to ask a pharmacist for more information about a drug than New Zealand 
Europeans. Alcohol consumption, attitudes toward doing exercise, education, gender and 
income did not have any influence on asking a pharmacist for more information. This model 
precisely classified the outcome for 83.9% of the cases and showed a good model fit (Table 
3.3). 
 
Table 3.3: Multivariate binary logistic regression models predicting self-reported behavioural 




Asking a doctor for 
a prescriptionª: 
OR (95% CI) 
 
Asking a doctor for 
more information 
about an illnessb: 
OR (95% CI) 
Searching the 








about a drugd: 
OR (95% CI) 
Age 1.01 (1.001-1.02)*  1.02 (1.01-1.03)*** 1.003 (0.997-1.01)  1.02 (1.01-1.03)*** 





0.79 (0.66-0.94)* * 0.99 (0.85-1.16) 1.15 (1.02-1.30)*  1.07 (0.91-1.26) 
Ethnicity  










Maori 1.53 (0.98-2.40) 2.06 (1.42-2.99)*** 1.20 (0.89-1.64) 2.32 (1.61-3.34)*** 




4.14 (2.40-7.12)*** 1.71 (1.06-2.77)* 1.93 (1.06-3.53)* 
Pacific Island 1.18 (0.52-2.69) 1.70 (0.87-3.33) 1.33 (0.79-2.22) 2.11 (1.12-3.98)* 
‘Other’ Ethnicities 1.47 (0.95-2.25) 1.52 (1.06-2.16)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            1.31 (1.01-1.70)* 1.98 (1.42-2.76)***
Gender 0.89 (0.65-1.21) 0.93 (0.72-1.22) 1.48 (1.21-1.82)*** 1.17 (0.90-1.52) 
Illegal drug 
consumption 
1.29 (1.17-1.42)*** 1.11 (1.01-1.23)* 1.02 (0.94-1.10) 1.22 (1.11-1.34)*** 





0.98 (0.93-1.04) 0.95 (0.88-1.01) 
Level of Education 0.90 (0.83-0.97)*  0.96 (0.90-1.04) 0.997 (0.94-1.05) 1.02 (0.95-1.10) 
Nutritional habits 0.84 (0.78-0.91)***  0.88 (0.82-0.94)***  0.93 (0.89-0.98)**  0.91 (0.86-0.97)** 
Physical activity 0.78 (0.69-0.89)***  0.78 (0.70-0.88)*** 0.84 (0.77-0.92)***  0.87 (0.77-0.97)* 
*p < 0.05 **p < 0.01 ***p < 0.001 
a. R2=0.14 (Nagelkerke), 0.07 (Cox-Snell); Hosmer–Lemeshow test (χ² = 11.83, d.f. = 8, p = 0.16); Omnibus 
Tests of Model Coefficients (p < 0.001) 
b. R2=0.08 (Nagelkerke), 0.05 (Cox-Snell); Hosmer–Lemeshow test (χ² = 6.71, d.f. = 8, p = 0.57); Omnibus 
Tests of Model Coefficients (p < 0.001) 
c. R2=0.04% (Nagelkerke), 0.03 (Cox-Snell); Hosmer–Lemeshow test (χ² = 5.37, d.f. = 8, p = 0.72); Omnibus 
Tests of Model Coefficients (p < 0.001) 
d. R2=0.07 (Nagelkerke), 0.04 (Cox-Snell); Hosmer–Lemeshow test (χ² = 10.98, d.f. = 8, p = 0.20); Omnibus 
Tests of Model Coefficients (p < 0.001) 
 
3.4 Discussion 
 DTCA has been criticised for altering individuals’ perceptions of health and illness, 
including encouraging the medicalisation of normal conditions and pharmaceuticalisation over 
healthy lifestyle choices (Abraham, 2010; Almasi et al., 2006); while unhealthier lifestyle 
behaviours have been linked to a higher possibility of poorer health (Duncan et al., 2014; 
Lopez, Mathers, Ezzati, Jamison, & Murray, 2006). Previous research revealed that women 
and individuals who had lower income and were less educated, older, and ethnic minorities 
were more likely to report behavioural responses to DTCA (Khalil Zadeh et al., 2017). The 
current study extended earlier research by examining the links between individuals’ healthy/ 
unhealthy lifestyle practices, in addition to already established demographic and socio-
economic factors, and their self-reported behavioural responses to DTCA. The findings of the 
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current exploratory study revealed that individuals with unhealthier lifestyles were more likely 
to be influenced by DTCA. Physical inactivity and unhealthy eating behaviours predicted all 
self-reported behavioural responses to DTCA. Illegal drug consumption predicted all self-
reported behavioural responses except for searching the Internet for more information 
regarding an illness. Higher alcohol consumption and less positive attitudes toward doing 
exercise predicted asking a doctor for a prescription. However, more positive attitudes toward 
doing exercise predicted searching the Internet for more information, which could be owing to 
a mediating factor that can be explored in future research. Studies on health inequalities have 
attempted to reveal the behavioural factors that are associated with health outcomes, 
particularly lifestyle behaviours (e.g., physical inactivity, drug or alcohol consumption, 
unhealthy nutrition; Hämmig, Gutzwiller, & Kawachi, 2014). Earlier research has indicated 
that personal lifestyle causes health disparities (Farhud, 2015; Floud, 2016; Fuchs, 1986); 
individuals’ risk of poor health advances when they undertake unhealthy lifestyle behaviours 
(Ford, 2011; Martínez-Gómez et al., 2013; Tsai, 2010). An alternative explanation is that these 
unhealthy lifestyle behaviours and health inequalities may be caused by socio-economic and 
cultural disparities (Basu, 2004; Baum & Fisher, 2014; Browne, 2017; Watt, 2007). 
 This is, however, the first study to reveal the association between lifestyle factors and 
behavioural responses to DTCA. The present findings extend existing research by showing that 
individuals who have a tendency towards poorer lifestyle choices, are more receptive to 
medicine advertising than those with healthier lifestyles. This association could be due to 
individuals with poorer lifestyle behaviours being more likely to have poorer health (Duncan 
et al., 2014; Lopez et al., 2006), and/or their desire to take a medicine rather than changing 
lifestyle behaviours. 
 The finding that individuals with less healthy lifestyles are more likely to be influenced 
by DTCA is of significant concern given that DTCA does not usually focus on public health 
issues such as nutrition, exercise, addictions, and appropriate consumption of current 
medications (Almasi, 2006). Thus, DTCA can result in public pharmaceuticalisation, which 
leads to the use of lifestyle medicines (e.g., weight loss pills), perceived by individuals “as a 
‘magic bullet’ to resolve problems of daily life” (Fox & Ward, 2008, p. 856). Accordingly, 
DTCA may stimulate taking medicines rather than making lifestyle behavioural changes and 
may be more appealing to individuals with less healthy lifestyles, as evidenced in the current 
study. DTCA can even result in doctors being pressured to prescribe a medication (Toop & 
Mangin, 2006; e.g., where lifestyle changes would be more appropriate). Research has shown 
that the main goal of medicine advertising is to persuade and influence rather than to educate, 
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and it has been successful at persuasion (Gilbody et al., 2005; Kravitz et al., 2005; Mansfield 
et al., 2005; Toop & Mangin, 2006). Thus, the public needs to be informed that DTCA is a 
marketing tool, predominantly aimed at affecting prescribing behaviour, driving choice, and 
increasing profit (Mangin & Toop, 2006; Toop & Richards, 2003; Toop & Richards, 2004). 
 
3.4.1 Research Limitations  
 The current findings were based on a cross-sectional survey; thus, causal conclusions 
cannot be made. Moreover, the respondents’ self-reported lifestyle behaviours, as well as self-
reported behavioural responses to DTCA, might not reflect individuals’ actual behaviours and 
might result in under- or over-reporting of some behaviours (Robertson et al., 2017a). 
Nonetheless, the anonymity that was assured by the online survey platform, a method that is 
more effective than traditional approaches (McCabe, Boyd, Couper, Crawford, & d'Arcy, 
2002), would have assisted respondents’ truthful responses (Robertson et al., 2017a). This 
study was exploratory research and included a large pool of potential predictors, which should 
be useful in guiding future, more confirmatory work. However, this issue can increase the 
chance of observing a Type I error.  Although this study employed anonymous survey 
responses, it could not entirely mitigate the issue of social desirability biases. However, the 
amount of bias would be roughly similar across respondents. Furthermore, since the study was 
based on a secondary analysis of survey data that did not include tobacco use behaviours, future 
research could extend the current findings by exploring the relationship between smoking as 
an unhealthy lifestyle factor and behavioural responses to medicine advertising.  
 
3.5 Conclusions  
 While much attention has been paid to the effects of lifestyles on individuals’ behaviour 
(e.g., buying behaviour; Krishnan, 2011), and health inequalities (Lisspers et al., 2005; 
McGinnis & Foege, 1993; National Center for Health Statistics, 2001; Poortinga, 2007; 
Sapranaviciute-Zabazlajeva et al., 2017; Satcher, 2000; U.S. Department of Health and Human 
Services, 2000), to the best of my knowledge, no study has documented DTCA-triggered 
behavioural responses of individuals with less healthy lifestyle habits. This study primarily 
revealed that individuals with unhealthier lifestyles, that is, less physical activity, higher levels 
of alcohol consumption, unhealthier nutritional habits, and higher levels of illegal drug use, 
were more likely to respond to DTCA. The negative attitude towards doing exercise also 
influenced asking a doctor for a prescription. Overall, these associations, along with previously 
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reported findings (Khalil Zadeh et al., 2017) linking being a woman, increasing age, lower-
income, lower education and belonging to an ethnic minority suggest that these ‘at risk’ or 
‘disadvantaged’ groups can be more susceptible towards DTCA and may not be able to make 
informed decisions. This raises concerns regarding the ethicality of DTCA in its current form, 
especially given that DTCA is self-regulated by the industry in New Zealand. 
 
3.5.1 Research Implications 
 The findings of a representative sample employed in this study can be generalised to 
the population in New Zealand and have significant implications for pharmaceutical firms 
(Khalil Zadeh et al., 2017) and public health legislators. Considering the findings of this study 
together with the outcomes of earlier studies regarding individuals’ positive attitudes towards 
medicine advertising (Khalil Zadeh et al., 2017), awareness of lifestyle changes should be 
supported through a combination of efforts to facilitate healthy behaviours (Hivert et al., 2016).  
Based on the findings, I call for the pharmaceutical industry to stress healthy lifestyle 
behaviours (such as having a healthy diet, doing exercise,…) as an alternative to taking 
medications, where applicable. Furthermore, pharmaceutical companies should offer 
informative rather than persuasive and attractive messages in DTCA and not target ‘at risk’ 
individuals, position their products based on individuals’ lifestyle characteristics, or depict 
their product as a wonder drug. Instead, they need to make DTCA more ethical by explicitly 
and impartially stating that behavioural changes could be as effective as taking the advertised 
medicine. Communications on lifestyle changes in DTCA need to more specifically target 
those with unhealthy lifestyles. Pharmaceutical companies should also stress healthy lifestyle 
behaviours through new campaigns. For instance, Novo Nordisk Company has made Team 
Novo Nordisk, a diabetes professional sports team, organising and sponsoring various races, to 
motivate and inform patients with diabetes around the world (Novo Nordisk, 2018). 
Pharmaceutical companies can also match their drug advertisement spending with donations to 
independent health information. They can highlight and anonymously compare their ethical 
behaviours with competitors in their messages. Taking these measures would add value to their 
brand and products. Overall, being socially responsible and ethical would improve the 
companies’ image, which can result in their long-term benefit. It is in the companies’ lasting 
interest to advertise responsively, fairly, and truthfully (Carroll & Shabana, 2010; Wilkes et 
al., 2000). It is a competitive advantage for a corporation to improve its relationships with its 
customers and increase its loyal customers on account of its favourable image (Okpara & 
Idowu, 2013). This study also highlights the need for interprofessional collaborations to 
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educate individuals and convey the value of health behaviour changes to help ‘disadvantaged’ 
groups make more informed health-related decisions. Healthcare professionals thus can 
become “both gatekeepers and influencers over the purchase of the prescription medicine, and 
make the purchase not only a cognitive process, but also a social process” (Rodgers & Thorson, 
2012, p. 275). They can play an important role in informing and supporting peoples’ health 
behaviour changes (Ryan, 2009), as well as moderating the potential negative effects of DTCA 
and its persuasion process on individuals’ decision-making, consistent with consumer 
socialisation theory that highlights the influence of socialisation agents in consumers’ decision-
making process (Brim, 1966; McLeod & O’Keefe, 1972; Rodgers & Thorson, 2012). 
 Since social and economic disparities can result in health behaviour and health 
inequalities (Department of Health and Human Services, 2015), health promotion policy 
should also consider social determinants in addition to motivating individual actions for 
changing unhealthy behaviours (Baum & Fisher, 2014). Previous research has discussed that 
rules that may harm individuals’ health should be changed (Marmot, 2005). In line with 
existing research (Applequist & Ball, 2018), the findings of this study suggest that the current 
rules on DTCA are not sufficient to protect consumers, and reinforce the need for tighter control 
and regulatory actions on DTCA. This study also proposes that the government should focus 
on increasing individuals’ health literacy. As an illustration, the government can identify the 
characteristics of vulnerable consumers (e.g., individuals with less healthy lifestyle behaviours) 
in order to choose effective communication tools and channels to reach and educate them about 
medicine advertising and its probable effects on public health. For instance, this can be 
accomplished and conveyed through Internet portables, social media, SMS, or mobile 
applications. Vulnerable consumers can be visited by regional health centers and be educated 
by their periodic programs. They can be informed through mass media, such as Radio and TV 
programs, or printed brochures and leaflets in health centers and pharmacies. In New Zealand 
and the United States, where DTCA is allowed, students should be trained at schools so that 
even if they are categorised as at-risk groups henceforward, they will be well-informed and 
more sensitive about medicine advertising. The government should also monitor advertising of 
lifestyle medicines, which may be improved by changing lifestyle behaviours and ensure that 
DTCA is more beneficial than harmful, to help individuals make informed decisions. It is 





CHAPTER FOUR: SOCIAL RESPONSIBILITY IN DIRECT TO 
CONSUMER ADVERTISING OF PRESCRIPTION MEDICINES: 
CONSUMERS’ AUTONOMY AND INFORMED DECISION-MAKING  
 
Preface 
 The first two studies of this Ph.D. research, according to a consumer-based survey, 
found consumers hold misperceptions about the safety and efficacy of advertised drugs,  and 
‘at risk’ or ‘disadvantaged’ groups, those who have more positive attitudes toward DTCA, 
those who are more materialistic, and those who have unhealthier lifestyles can be more 
vulnerable to DTCA. These findings combined with a further literature review on the subject 
raised concerns regarding consumers’ informed decision-making, as well as the social 
responsibility - more specifically ethicality - of DTCA in its current form. Study three, focusing 
on the viewpoint of the health professions, helped to further inform understanding of the survey 
results by conceptualising the characteristics of ‘at risk’ or vulnerable individuals. This study 
also aimed to explore the social responsibility in DTCA and identify factors that help 
consumers make informed decisions. Study three, therefore, aimed to answer the following 
research questions: 
RQ 3. What are health professionals’ perceived factors affecting consumers’ informed 
decision-making, in response to DTCA? 
RQ 4. What are health professionals’ perceived characteristics of consumers who are less able 
to make informed decisions in response to DTCA (who are more vulnerable)? 
RQ 5. Is DTCA perceived ethical in its current format in New Zealand? 
RQ 5.1. How to offer socially responsible/ethical DTCA in order to help individuals make 
informed decisions? 
 Preliminary findings from study three were presented at the Macromarketing 
Conference 2017, in Queenstown, New Zealand. Moreover, suggestions to improve the 
regulation and ethicality of DTCA helped to inform a New Zealand parliamentary submission 







 This research examined health professionals’ views and experiences regarding the 
social responsibility of DTCA and the impact of DTCA on consumers and society. In 
particular, it aimed to identify factors that help consumers make informed decisions and 
provide recommendations for pharmaceutical companies, and DTCA policies and ethics. In-
depth interviews with 29 health professionals were conducted to explore their insights on: 
DTCA, consumers’ ability to understand the information in DTCA and make informed 
decisions, characteristics of vulnerable individuals, and recommendations on how to offer 
socially responsible DTCA aimed at helping consumers make informed decisions. Findings 
suggested that although DTCA is legal in New Zealand, it is not perceived to be ethical in its 
current format. Concerns were raised regarding persuasion and opportunism in DTCA. Results 
demonstrated that even if DTCA provides factual and sufficient information, laypeople can not 
make informed choices, which makes them vulnerable to DTCA. Individuals; i.e., those with 
health problems, unhealthy lifestyles, and disadvantaged demographic and/or socio-economic 
status were identified as less able to make informed choices and thus were perceived to be more 
vulnerable to DTCA. In addition, personal characteristics, including being materialistic, 
trusting, and impulsive, were also perceived to increase vulnerability to DTCA. Based on the 
findings, recommendations for regulatory and ethical changes to DTCA are presented to 
facilitate consumers’ informed decision-making. Recommendations pertain to the content of 
DTCA, types of advertising channels, types of advertised medications, social 
responsibility/ethicality of DTCA providers, as well as stricter regulations and supervision of 
DTCA. Consumers’ informed decision-making and social responsibility in DTCA are complex 
issues that lack theoretical frameworks. This research extends knowledge on factors affecting 
consumers’ informed decision-making and outlines the options that could guide more ethical 
DTCA. The findings could inform health policy frameworks and have important implications 




 Direct to consumer advertising of prescription medicines (DTCA) is a pharmaceutical 
marketing strategy banned worldwide with the exception of the United States and New Zealand 
(Hoek et al., 2004; Kontos & Viswanath, 2011; Spake & Joseph, 2007). Although research has 
shown that DTCA offers information that is appreciated by the public, there is not enough 
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evidence to infer that DTCA is informative (Frosch et al., 2010), especially in New Zealand 
where DTCA is self-regulated by the industry, and businesses and individuals rather than the 
government are responsible for the regulation and ethicality of DTCA (Gibson, 2014). Even in 
the United States, where DTCA is regulated and pharmaceutical companies’ actions are 
overseen by the Food and Drug Administration, violations by pharmaceutical companies are 
prevalent, predominantly for providing misleading information (Donohue et al., 2007; Faerber 
& Kreling, 2014; Kim, 2015; Klara et al., 2018). For instance, a report by Public Citizen (2018) 
discussed the United States’ legal cases in which companies have been charged with criminal 
and civil penalties (e.g., for fraudulent marketing). “From 1991 through 2017, a total of 412 
settlements were reached between the federal and state governments and pharmaceutical 
manufacturers, for a total of $38.6 billion” (Public Citizen, 2018, p. 4). 
 There have been continuous debates for and against DTCA in the literature. According 
to Kravitz’s viewpoint in a study by Almasi et al. (2006), “DTCA is neither good nor evil; it is 
both. A little regulatory ingenuity could harness the enormous power of DTCA or DTCA-like 
public service announcements to improve the public health” (p. 0285). However, advocates 
think that DTCA contributes to the safety and well-being of consumers; whereas others believe 
that pharmaceutical companies do not meet their stated aim of educating and empowering 
consumers (Perry et al., 2013). Supporters of DTCA address it as a way of empowering2 
patients/consumers to take a proactive role in their healthcare (Adams, 2016), a principal goal 
of patient autonomy (Carbonell, 2014). They claim that DTCA can improve individuals’ 
compliance with their treatment and inform them of their medical conditions, as well as 
informing them about novel and accessible medications (Adams, 2016; Desselle & Aparasu, 
2000; FDA, 2014). Opponents, on the other hand, argue that DTCA compromises the safety of 
consumers’ decision-making (van de Pol & de Bakker, 2010). They argue that the information 
included in DTCA is biased, results in a naïve outlook on the benefits of medicines (Gilbody 
et al., 2005), leads to the advertised medicines being pursued by consumers (Donohue et al., 
2007) and to doctors feeling pressured to prescribe the requested medicines (Wilkes et al., 
2000). More specifically, critics of drug advertising in New Zealand claim that DTCA is not 
about informing individuals, but about increasing sales of advertised medicines (Ministry of 
Health, 2006). Given consumers push doctors to prescribe specific medicines as a result of 
 
2 Empowerment refers to the acquisition of motivation and capacity (skills and knowledge) to participate 
in decision-making and reducing the power imbalance in a patient-doctor relationship (Fumagalli et al., 2015). 
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advertising, a pertinent question is whether the information presented in DTCA helps 
consumers to make informed decisions.  
 In the absence of strict regulation, it is necessary to find out whether DTCA provided 
by pharmaceutical companies is ethical in New Zealand. Thus, this study explored the ethicality 
of DTCA according to informants’ perspectives. This study was consequently grounded within 
the concept of Corporate Social Responsibility (CSR), which applies to corporations’ practices 
that go beyond what is set by laws and are mostly based on ethics. The main goal was to identify 
how to evolve DTCA from a profit-oriented system to a socially responsible system that 
improves the health of society, if this is possible.  
 
4.2 Literature Review and Theoretical Foundation  
 In the following sections, first, theoretical concepts and their potential significance for 
consumers’ informed decision-making are presented, including an investigation of the 
characteristics of individuals who are less able to make informed decisions regarding drugs, 
followed by discussions on CSR and especially ethicality in DTCA. Finally, suggestions on 
factors contributing to consumers’ safe and informed decisions are indicated. 
  
4.2.1 Informed Decision-making  
 Informed decision-making refers to when patients recognise their medical problems, in 
addition to the benefits, threats, and limitations of the suggested treatment and available 
alternatives, seek additional information (if necessary), and define their preferences (Rimer, 
Briss, Zeller, Chan & Woolf, 2004; Sheridan, Harris & Woolf, 2004). DTCA of prescription 
medicines is compatible with the concept of informed consent, which stresses consumer 
autonomy in health-related decision-making (Beauchamp & Childress, 2001). People with a 
more controlled perspective think that consumers need help to make informed decisions 
(Vallgårda, 2012) because of their limited knowledge and ability to decide safely (Thaler & 
Sunstein, 2008). Libertarians are against this viewpoint (Mitchell, 2005). Some libertarians, on 
the contrary, think that even if individuals make inappropriate decisions, decision-making 
liberty is more important than the threat of performing it (Vallgårda, 2012).  Consumers need 
a health system that lets them be actively involved in their medical decisions (Kravitz & 
Halpern, 2006). However, they should be educated by receiving educational information 
(Kravitz & Halpern, 2006). Informing consumers about medicines through independent 
consumer health information both respects consumers’ autonomy and helps improve peoples’ 
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health (Kravitz & Halpern, 2006). Various forms of health information are provided in different 
countries. NPSMedicineWise, for instance, is a not-for-profit organisation in Australia that 
offers independent health information about medicines to consumers and physicians 
(Department of Health, 2013). Public Citizen’s ‘Worst Pills, Best Pills News’ newsletter in the 
U.S. is a monthly newsletter that offers comprehensive safety information about medicines 
(Public Citizen, 2020). Nevertheless, DTCA of prescription medicines delivers limited 
educational information (Bell et al., 2000).  According to Mansfield’s viewpoint in a study by 
Almasi et al. (2006), “Such advertising can lead some people to falsely believe they are well 
informed, so it reduces their motivation to search for more reliable information” (p. 0286). 
Since the emergence of DTCA of prescription medicines, especially in New Zealand, where it 
is self-regulated by the industry, there is growing concern regarding individuals’ safe and 
informed decision-making after exposure to DTCA. Considering that “the role of consumers 
in medical decision-making has changed in recent decades” (Frosch et al., 2010, p. 24) and the 
information provided in DTCA reaches consumers directly, it is important to explore factors 
affecting informed decision-making as a result of DTCA.  
 
4.2.1.1 Factors Affecting Informed Decision-making regarding DTCA of 
Prescription Medicines 
 The present study classified issues affecting informed decision-making into the features 
of DTCA and consumer-related factors, and drew on related theories and concepts from both 
perspectives.  
 
The Role of DTCA 
Reviewing past research on DTCA revealed significant concerns about the existence of 
persuasion and opportunism in DTCA, factors that can affect consumers’ informed decision-
making. According to Menkes’ viewpoint, “For many years, doctors have been concerned that 
DTCA presents a biased, overly optimistic picture of advertised medicines and prompts 
patients to request treatments they don’t need. Advertised products are usually new, branded 
medicines with a premium price tag…” (Menkes, 2019). 
 
Persuasion in DTCA 
  Three types of advertising appeals are used to influence consumers; informative, 
emotional, and mixed appeals (including both informational and emotional messages; Koinig, 
80 
 
2016). The distinction between informative and emotional appeals is consistent with two types 
of persuasive messages in the Elaboration Likelihood Model (ELM) of persuasion (Petty & 
Cacioppo, 1981; 2018): (1) The central route is when information on product attributes are 
presented to influence consumers (Koinig, 2016; Rucker & Petty, 2006). (2) The peripheral 
route applies when emotional appeals are used (Koinig, 2016).  
 Emotional cues of advertisements often prompt heuristics and cause individuals to 
make quick decisions (Chaiken, 1980; Petty & Cacioppo, 1986). This suggests that individuals 
do not tend to process the key message of an emotional advertisement systematically and 
actively (Rodgers & Thorson, 2012). Emotional appeals are common in medicine advertising 
(Main et al., 2004). DTCA can be persuasive by using positive emotional appeals to cause false 
hope (Ministry of Health, 2006). This can lead to consumers’ seeking or requesting drugs that 
may not be appropriate for their condition (Ministry of Health, 2006) since people are 
commonly vulnerable to manipulation of their hopes (Gigerenzer et al., 2007). DTCA has also 
been criticised for using negative emotional appeals to raise fear and influence consumers’ 
perceived susceptibility to risk or a threat (Belcher et al., 2005; de Wit et al., 2005; Koinig, 
2016; Main et al., 2004). It is thus important to explore how these emotional appeals in DTCA 
can affect consumers’ decision-making. 
 
Opportunism in DTCA 
 People are susceptible to being misled by both false information and incomplete 
information in drug advertising (Copi & Cohen, 1990; Mansfield, 2005). DTCA can misinform 
consumers by offering biased and deceptive information or hiding information on the risks and 
side effects (Abel et al., 2006; Almasi et al., 2006; 2014; Gilbody et al., 2005). DTCA usually 
fails to offer important information that consumers require for making informed choices; such 
as information on how well the medicine works, and a detailed balance of information on a 
drug’s adverse effects and benefits (Hoek & Gendall, 2002; Schwartz et al., 2009). Offering 
partial information that exaggerates the benefits of the drug and understates its risks can be 
considered as a noteworthy ethical breach (Beltramini, 2006). It can cause misunderstanding 
and incorrect perceptions of medicine’s efficacy and safety (Wilkes et al., 2000). The current 
study linked these criticisms to the concept of opportunism that was initially defined as “self-
regard-seeking behaviour with guile3” (Williamson, 1975, p. 255). Opportunism was later 
referred to as “the incomplete or distorted disclosure of information, to mislead, distort, 
 
3 Guile has been defined as “lying, stealing, cheating, and calculated efforts to mislead, distort, disguise, 
obfuscate, or otherwise confuse” (Williamson, 1985, p. 47). 
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disguise, obfuscate, or otherwise confuse” (Williamson, 1985, p. 47), and can be divided into 
active and/or passive (Seggie et al., 2013). Passive opportunism is “opportunism by omission” 
(Seggie et al., 2013, p. 74; Wathne & Heide, 2000), including concealing information 
(Dahlstrom & Nygaard, 1999; Seggie et al., 2013) and presenting partial truths (Anderson, 
1988; Seggie et al., 2013). Active opportunism happens when a company acts in its own favour 
by breaking clear or implied boundaries (Seggie et al., 2013; Wathne & Heide, 2000). 
Examples include lying (Lee, 1998; Seggie et al., 2013), changing realities (John, 1984; Seggie 
et al., 2013), presenting false claims (Jap & Anderson, 2003), and overstating problems 
(Anderson, 1988; Seggie et al., 2013). The present study explored, for the first time, health 
professionals’ perspectives on consumers’ informed decision-making and the ethicality of 
DTCA through the lens of opportunism in DTCA. 
 
The Role of Consumers 
Overall, the following review of the literature reveals how consumers’ information-
processing boundaries could affect their abilities to make informed choices.  
 
Consumers’ Capability 
 Reviewing past research raises concerns about consumers’ ability to make informed 
decisions in response to DTCA. Although DTCA may offer information, exposure to further 
information does not inevitably elevate the capacity of consumers and does not mean that 
consumers are better informed (Carbonell, 2014; Womack, 2013). Even if DTCA provides full 
information, consumers usually do not have enough knowledge to understand and assess all 
information (Abel et al., 2006).  
 Extant research has discussed that the capacity for intentional and informed action is 
essential for individuals’ autonomous decision-making (Beauchamp & Childress 2013). 
However, several theories question individuals’ capacity for intentional and informed decision- 
making. For instance, the Capacity Theory of Attention proposes that the accessible cognitive 
resources of humans are restricted (Kahneman, 1973). Likewise, Simon’s Theory of Bounded 
Rationality (Simon, 1957; 1972; 1997) explains that the rationality of individuals in decision-
making is restricted by the ‘cognitive limits’ of their minds, as well as by the limited amount 
of time and information that they have (Simon, 1957; Simon, 1972; Simon, 1990). Similarly, 
in the medical domain, individuals may have limited health literacy, which alludes to the 
capacity to acquire, comprehend and process health information to make proper health 
decisions (Baker, 2006; Nutbeam, 1998; 2000; Selden et al., 2000). Low health literacy may 
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limit consumers’ capacity to have an active role in medical decision-making owing to limited 
knowledge of medical information (Davis et al., 2002; Street, 2001).  
Theories also posit individuals’ compromised ability to make decisions in response to 
advertising. Message Response Involvement links individuals’ responses to advertising to their 
ability to understand and process the information. This advertising theory describes that 
individuals’ information processing and cognitive responses to an advertisement can be linked 
to their motivation, ability, or opportunity (Batra & Ray, 1985; Rodgers & Thorson, 2012). 
Individuals can be “more motivated to process a particular ad due to their own individual needs 
or interests” (Rodgers & Thorson, 2012, p. 342). Specific features of an advertisement might 
also influence consumers’ ability to process information presented in the ad. Ability refers to 
“the capacity for a message recipient to process marketing communications due to insufficient 
product knowledge/experience, limited intelligence, or complex message design” (Rodgers & 
Thorson, 2012, p. 567). Moreover, individuals may have restricted the opportunity to process 
the advertisement if the message is short or if there are distractions or competing priorities 
(Rodgers & Thorson, 2012).  
Consistent with these theories, this study extends the existing literature by exploring 
informants’ perception of consumers’ ability to understand the information presented in DTCA 
and consequently capability to make informed decisions. 
 
Consumers’ Self-efficacy 
 In addition to research questioning individuals’ capability to make informed decisions, 
research has also discussed the role of individuals’ self-efficacy in decision-making. According 
to Bandura’s Social Cognitive Theory (1976; 2007), self-efficacy can be defined as a perceived 
operative capability, which includes individuals’ perception of their ability to accomplish an 
action as well as motivation to engage in that action (Koinig, 2016; Rodgers & Thorson, 2012). 
Previous studies have shown that self-efficacy is a predictor of behavioural change (Rimal & 
Adkins, 2010), specifically, if individuals think that the desired result can be achieved, they are 
more likely to take on a specific behaviour (Miller, 2005). In the health domain, self-efficacy 
includes trying a medication for a disease (Koinig, 2016). DTCA may enhance consumers’ 
self-efficacy if they feel that the advertised drug can positively influence their health, and 
increases their perceived operative capacity (Rodgers & Thorson, 2012). To further explore 
consumers’ informed decision-making based on DTCA, this study interpreted informants’ 
views on the effects of DTCA on consumers’ perceived self-efficacy and subsequently the 




 While capability and self-efficacy can affect all individuals to differing extents, 
according to the vulnerability literature, there are types of consumers who might be more 
vulnerable than others. Individuals who are economically or educationally disadvantaged; who 
have a serious illness, psychological or physical impairment; or who are older or a minor could 
be considered as vulnerable (Chiang & Jackson, 2012). However, there is still a dearth of 
research conceptualising vulnerable consumers with regard to DTCA. As argued by Carter et 
al. (2010), “a closer examination of the concept of vulnerability and its conditions and 
implications can make useful and critical contributions to the development of policies about 
consumer marketing of medicines” (p. 18). Illuminating the characteristics and types of 
vulnerable individuals is important to examine the effects of DTCA on consumers. This 
research, therefore, addressed this gap by exploring the types of consumers who are less able 
to make informed choices and thus more vulnerable to DTCA according to health 
professionals’ perspectives. 
 To sum up, considering the issues regarding the nature of DTCA as well as consumers’ 
cognitive limitations in understanding and processing advertising messages, it is arguably 
necessary for pharmaceutical companies to offer ethical DTCA to help consumers’ informed 
choices. 
 
4.2.2 Ethical DTCA 
 According to the CSR concept, which emphasises the companies’ responsibility to 
make money and the responsibility to interact legally and ethically within society (Carroll, 
1991), all decisions and activities of corporations ought to be ethical from initiation (Carroll, 
1991; Okpara & Idowu, 2013). Marketing practices of pharmaceutical companies, like any 
other practice, should be grounded within a value framework that considers both the corporate 
goals of the organisation and the social consequences of marketing activities (Brennan et al., 
2010). Pharmaceutical companies are required to meet both legal and ethical responsibilities to 
inform or educate individuals (Perry et al., 2013); however, it is still questionable whether they 
advertise ethically. Considering the unique feature of prescription drugs that can help or harm 
consumers’ well-being, safety in choice or informed decision-making can be viewed as the 
essential element of evaluating CSR (Van de Pol & de Bakker, 2010). Consumer autonomy 
and informed decision-making concepts are leading ethical paradigms guiding public health 
policy (Perry et al., 2013). Some are respecting consumers’ autonomy, empowering, and direct 
involvement in the health-related decision-making of consumers who are considered as 
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partners of their physicians in looking for medical treatments (Perry et al., 2013). The concerns, 
however, that arise are whether consumers can understand the information in DTCA, whether 
consumers’ autonomy and access to the information in DTCA can lead to their safe and 
informed decision-making, and whether the current form of DTCA is ethical. The current 
literature falls short of providing a framework of socially responsible - more specifically ethical 
- DTCA, and the unanswered question is ‘what should pharmaceutical companies do from both 
an ethical and legal perspective?’ (Van de Pol & de Bakker, 2010). Hence, in the lack of firm 
regulation and guidelines, this study aimed to offer important insights into factors contributing 
to socially responsible and more specifically, ethical DTCA to help consumers’ informed 
decision-making. 
 
4.2.3 Factors Contributing to Consumers’ Safe and Informed Decisions 
As discussed earlier, according to the concept of CSR (Carroll, 1991), DTCA needs to 
be both legal and ethical to be socially responsible. Advertising ethics alludes to “what is right 
and good in the conduct of the advertising function. It is concerned with questions of what 
ought to be done, not just what legally must be done” (Cunningham, 1999, p. 500). Ethical 
decision-making about advertising in a corporation involves issues related to the message and 
its creation, the channel (e.g., the mass media), and ethical issues related to the business 
(Drumwright & Murphy, 2009; Rodgers & Thorson, 2012). However, DTCA “poses a 
regulatory challenge framed by both ethical and legal considerations” (Perry et al., 2013, p. 
732). Pharmaceuticals differ from other products since they are necessities for individuals’ 
well-being, which may improve or harm people’s health, and their advertising languages thus 
need to be different from other products (Berger et al., 2001). Several studies have addressed 
the drawbacks of DTCA and suggested ways to improve it, including controlling the type and 
amount of information, and the types of medicines allowed to be advertised.  
The type and amount of information that individuals require to make a rational decision 
are important (Royne & Myers, 2008). DTCA could be improved through improving the 
quality, amount and types of information (Womack, 2013). The content, display of information, 
and highlighting the outcomes of treatment versus no treatment influence individuals’ 
decisions regarding medicines (Womack, 2013). Responsible DTCA needs to be free of biased 
and false information, deliver enough information, and lead to an informed decision (Perry et 
al., 2013; Van de Pol & de Bakker, 2010). Past research has argued that information in DTCA 
is frequently offered unclearly and through qualitative phrases about the benefits of the 
advertised medicine, rather than including any data (Frosch et al., 2010; Woloshin et al., 2001). 
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Research has suggested that DTCA should offer correct and detailed information about the 
potential benefits of medicines rather than emotion-prompted pictures that show deceptively 
positive effects paired with a lack of quantification (Frosch et al., 2010; Schwartz et al., 2007; 
Woloshin et al., 2001). Research has also discussed that quantitative representations are more 
effective in helping individuals to assess adverse effects (Büchter, Fechtelpeter, Knelangen, 
Ehrlich & Waltering, 2014), although understanding quantitative information may require 
statistical literacy in health (Gigerenzer et al., 2007). The size of the presented information is 
also very important so that a larger font size can help individuals to recall information on side 
effects (Hoek, Gendall, Rapson, & Louviere, 2011; Wogalter, Conzola, & Smith-Jackson, 
2002; Wogalter & Shaver, 2001). Moreover, DTCA should include information about the 
drug’s cost. DTCA could mention, where appropriate, that generic substitutes are less 
expensive (Frosch et al., 2010). DTCA should state that the doctor or pharmacist is the best 
source of information to ask about the suitability of the treatment (Wilkes et al., 2000). 
Including information about other existing choices such as doing exercise, following a 
particular dietary guideline, and other lifestyle alterations where applicable, can be a practical 
resolution to offer ethical DTCA (PhRMA, 2005).  
 In addition to the types of information that should be presented in ads, the types of 
medicines that can be advertised need to be examined (Carbonell, 2014). For instance, to 
protect “seriously ill” patients, a prior study on the ethics of advertising prescription drugs 
claim that medications for treating life-threatening conditions should not be promoted (Carter 
et al., 2010, p. 16). Likewise, “the European Parliament rejected a proposal to allow advertising 
for drugs used to treat asthma, AIDS, and diabetes directly to the consumer” (Mansfield et al., 
2005, p. 5). 
 As summarised here, several recommendations for improving DTCA have been made, 
but there is no overarching framework to promote socially responsible DTCA. The present 
study explored health professionals’ opinions about DTCA to propose an initial framework for 
providing socially responsible and particularly ethical DTCA to help consumers’ informed 
decision-making about DTCA. Specifically, informants were asked about the social 
responsibility of pharmaceutical companies advertising their products directly to consumers, 
the content and features/attributes that would be required in a medicine advertisement to make 
it more ethical, the types of medicines that are more ethical to advertise, in addition to the 





4.3.1 Rationale for Method 
 In this study, qualitative research was undertaken to explore informants’ views and 
positions on DTCA. The study of social responsibility in DTCA, consumers’ informed 
decision-making, as well as characteristics of vulnerable individuals regarding DTCA required 
deep understanding since they are complex issues. Considering the capacity of in-depth 
interviews to discover and apprehend perceptions and opinions (Diamond et al., 2009; 
Viswanathan et al., 2010), and provide rich data to understand a complex or new phenomenon 
(Eisenhardt, 1989; Eisenhardt & Graebner, 2007), in-depth interviews were deemed 
appropriate for this study.  
 
4.3.2 Participants  
 In line with previous research, both purposive and snowball sampling were used to 
recruit participants (Miles & Huberman, 1994; O'Donoghue & Punch, 2003; Valerio et al., 
2016). Purposive sampling was based on my subjective reflections according to the objective 
of the study. Health professionals (informants) were chosen from different professions and 
both sexes to explore diverse perceptions and views on DTCA. The choice of informants was 
based on their ability to provide comprehensive and profound information about DTCA in New 
Zealand. Since the ethicality of DTCA is a specialised and complicated context, health experts 
are suitable informants as they are often involved with both patients and the pharmaceutical 
industry, and are familiar with the positive and negative aspects of DTCA, public health issues, 
as well as consumers’ capability and vulnerability. A strength of the study was accordingly the 
experience of health professionals with DTCA. The advertisements circulated directly at 
pharmacies, libraries (such as the medical library), medical clinics, hospital, School of 
Pharmacy, Faculty of Dentistry, Department of General Practice and Rural Health, the board 
of the university lecture theatre complexes, residential colleges, Gym, as well as to PhD friends. 
I also contacted a few informants directly. Since health professionals were hard to reach and 
persuade to participate in an interview (as they are commonly very busy), snowball sampling 
was also applied in this study. The snowball sampling method is suitable when research focuses 
on a small number of professional participants who are familiar with the topic (Aaker & Day, 
1990; Neuman, 2000; Patton, 1990). Participants were thus asked to help in identifying other 
health professionals. Informants were 15 females and 14 males; three academics in health 
science, nine physicians (e.g., GP, surgeon, ED; four physicians were also academics), five 
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dentists (four were also academics), and 12 pharmacists (see Appendix B for more 
information). They were working in Dunedin, Christchurch, Hamilton, and Auckland. A total 
of 29 in-depth interviews with health professionals in New Zealand were performed. Seven 
interviews were conducted during a pilot phase and 22 interviews were conducted during the 
main study. Interviews were conducted from mid-2016 until late 2017 and stopped when no 
additional information or themes emerged/developed from new interviews (Öberseder et al., 
2011).  
Ethics approval was obtained from the University of Otago’s Human Ethics Committee 
(Appendix F). Before the interviews, all participants were provided with an information sheet 
about the research and gave their informed consent. Informants were told that the main purpose 
of the interview was to explore their views on social responsibility and especially ethicality in 
direct to consumer advertising of prescription medicines in New Zealand to help consumers’ 
informed decision-making. With the permission of the interviewees, interviews were audio-
taped and transcribed verbatim. Informants received a small grocery voucher for participating. 
All participants were assured of their anonymity. 
 
4.3.3 Materials 
Due to “the exploratory nature” of the study, “semi-structured interviews with open-
ended questions” were used (Kazadi et al., p. 530) to achieve enough information and to 
provide profound insight into the research questions (Rowley, 2012; Siggelkow, 2001). Open-
ended semi-structured interviews enabled an interview protocol while allowing interviewees 
to freely discuss their thoughts and opinions regarding each question (Brunk, 2010; Öberseder 
et al., 2011). Hence, an open-ended semi-structured interview protocol/guideline (Appendix 
A) was carefully prepared. The interview protocol and questions were revised after being 
reviewed by several professionals (two supervisors, six Ph.D. students and seven academics). 
The interview protocol was then piloted on three physicians and four community pharmacists. 
Interview questions were designed based on the gaps in the literature, existing concerns in New 
Zealand identified in earlier studies, and the objectives of the research. Specific attention was 
paid to social responsibility (especially ethicality) in DTCA, informed decision-making, and 
vulnerability concepts. Moreover, probing questions were used, in particular, “why” questions 
(e.g., “Please explain why?” and “Why is that important?”) to follow up on answers and obtain 
a deeper understanding of informants’ views and reflections on DTCA and to prompt them to 
talk openly and in detail. Interviews started with initial questions, such as “What is your general 
view on direct to consumer advertising of medicine in New Zealand”; “Please explain”, and 
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followed by further questions to gather in-depth data, such as “What do you think about 
consumers/patients’ capability of making informed decisions after being exposed to a medicine 
ad”; “Please explain why”. Question development was an ongoing process with the protocol 
being updated when new ideas came to light through the interview process.  
 
4.3.4 Data Analysis and Interpretation 
 Since the aim of this study was to make sense and interpret the opinions of informants, 
an interpretive qualitative approach was chosen for this study (Creswell, 2007). Transcripts 
were “interpreted and made sense of” rather than just summarised or paraphrased (Braun & 
Clarke, 2006, p. 96). In the first phase, seven interviews from a pilot study were coded into 
initial notes and then merged into themes (Miles & Huberman, 1984; 1994). During the second 
phase, all 29 interviews were analysed in QSR Nvivo 11 Pro. The analysis evolved 
continuously throughout the data gathering procedure so that the preliminary analysis of the 
interviews enabled the refinement of the protocol, analysis, and interpretation of succeeding 
interviews (Öberseder et al., 2011; Strauss & Corbin 1990). One supervisor independently 
analysed and coded five interviews. Moreover, the developed themes and interpretations were 
reviewed several times by two supervisors and discussed in a number of meetings. An 
agreement was reached on all themes after minor modifications.  
 
4.3.4.1 Thematic Analysis  
 In this research, both inductive and deductive approaches were applied in the coding 
process (Braun & Clarke, 2006; Vaismoradi et al., 2013). Predominantly, an inductive 
approach was applied to find themes that evolved from the data, rather than fitting the data into 
predefined concepts or theories from the literature (Hsu, Cai, & Wong, 2007; Tung & Ritchie, 
2011). In a few cases, however, a deductive approach was also employed based on theories or 
concepts existing in literature, where applicable. Interpretations were recurrently shaped and 
revised through an iterative back and forth process of probing and data analysis. The framework 
was developed gradually and iteratively through empirical evidence and theoretical concepts 
(Gioia, Corley, & Hamilton, 2013). This recursive process of coding and theme identification 
was initiated at the very early stage of data gathering, continued until theoretical saturation 






Theme Constructing  
 Following an intensive review of the transcripts, an initial descriptive open coding 
process was conducted by identifying and labelling important comments in the data and 
classifying them into categories (Dey, 1993; Miles & Huberman 1994). Subsequent iterative 
analyses using axial coding extended the initial coding, merged or classified the codes into 
themes and dimensions, and identified the relationships between the themes and existing 
concepts or theories in an interpretative way (Gioia & Chittipeddi, 1991; Saldaña, 2009). All 
sub-themes and categories were analytically linked to the core themes, which “appears to have 
the greatest explanatory relevance” for the subject matter (Corbin & Strauss, 2008, p. 104; 
Saldaña, 2009).  
Themes were recursively interpreted along with the data, findings, memos, emerging 
themes, as well as concepts and theoretical insights from existing literature (e.g., autonomy, 
persuasion, opportunism, health literacy), where applicable, to form the foundation of the 
developing framework (Gilliam & Flaherty, 2015; Kazadi et al., 2016). For example, the initial 
codes of “getting money from people’s desire for their health”, “selling rather than therapeutic 
goal”, “most of the driving force is money” and “focused on selling a product rather than 
providing people with information” were combined into one sub-theme called “health is 
becoming a business” that was related to the overall theme of “unethical objective of DTCA”. 
Similarly, the initial codes of “manipulation”, “misinformation”, “the content is betrayed now”, 
“claiming as a foremost treatment”, “showing suitable for everyone”, “skewing the force and 
opinion”, “risky”, “give a false sense of security”, “causing unrealistic expectations” were all 
combined into the theme of “misleading and deceiving”, which then was linked to the “active 
opportunism” concept. Likewise, the initial codes of “not enough side effects”, “rush through 
side effects”, “very short and fast”, “displaying the side effects at the bottom”, “displaying the 
side effects in tiny font”, “negatives are not obvious”; “displaying generic content in small 
script”, were collated into one theme called “incomplete/partial information”, which was 
subsequently linked to the “passive opportunism” concept. Samples of illustrative quotes 
related to each dimension/theme/sub-theme of this study are thoroughly presented in Tables 
C.1, C.2, and C.3 in Appendix C.  
 
4.4 Findings 
 Most health professionals had seen DTCA before the interview. Even the ones that did 
not remember seeing a medicine ad were quite familiar with the subject of the interview and 
had knowledge about DTCA and its probable effects on consumers and society.  
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In this study, first, positive and negative themes on consumers’ informed decision-making 
were investigated. This study then conceptualised vulnerable consumers with regard to DTCA. 
And finally, recommendations on how to offer ethical DTCA to help improve consumers’ 
decision-making were offered. 
 
4.4.1 Part One: Informed Decision-making 
 This section presents health professionals’ views on informed decision-making in 
response to DTCA in New Zealand. The interviews revealed that only a few informants thought 
DTCA could increase consumers’ autonomy; most informants argued that consumers could not 
make informed decisions based on DTCA. A schematic of the dimensions/themes’ hierarchy 
related to the factors affecting consumers’ informed decision-making is presented in Figure 
4.1. 
 








4.4.1.1 Positive Views: Factors Affecting Informed Decision-making 
Dimension: Increasing Consumer Autonomy  
 A minority of informants believed that it is the consumers’ right to have access to 
DTCA. These informants were in favour of autonomy in consumers’ medical decisions and 
patient-centred medicine4 in New Zealand. The themes pertaining to the dimension of 
consumer autonomy are discussed.  
 
Theme: Consumers’ Empowerment/Proactivity 
 A few informants perceived DTCA to increase consumer empowerment/proactivity. 
For instance, one informant expressed that:  
Basically, patients become more informed; they are thinking about their 
health and be[come] more proactive in terms of their own health and looking 
after themselves (f, physician).  
A small number of informants associated consumer empowerment with feelings of 
control over treatments and with consumers being more involved in the decision-making 
process. The following excerpt exemplifies this link:  
They feel more empowered after seeing the ad. They think that the doctors 
[are] not the only one who knows about the medications and I am also 
involved in it (f, pharmacist).  
Informants also perceived feelings of control to be linked to important outcomes such 
as adherence to therapy, for instance:  
I think it’s good to have that feeling that you have control over your 
medications because it might make you more likely to adhere to your therapy. 
I think it would probably influence their decision-making positively in the 
sense that they are more committed to their medication therapy (f, 
pharmacist).  
 Involvement and control through empowerment were also perceived by some 
informants to be associated with prompting consumers to seek medical advice and with 
creating dialogues between patients and doctors; for instance, one informant stated:  
 
 4 “A philosophy of practising medicine based on a partnership between clinicians and patients that is 
characterised by informed, shared decision-making, development of patient knowledge, self-management skills 
and preventive behaviours” (Kontos & Viswanath, 2011, p. 143). 
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My patients who have seen advertisements are much more likely to come and 
ask me for the medicines that they have seen in particular advertisements. 
So, maybe that’s a positive thing because then they’re discussing other 
treatment options with me and perhaps learning a little bit more about why 
their medicine is better for them, or you know, sometimes it’s appropriate to 
change. So, that might be good because it’s encouraging the dialogue (f, 
physician & academic).  
 Informants also perceived DTCA to lessen the hierarchy and power gap between 
doctors and consumers: 
I can see the positive side of it. They decrease [the] hierarchy. Usually, 
patients often step back because it is not quite an equal relationship. So, 
advertising empowers them (f, pharmacist). 
Reducing the “power gap” was seen as a government initiative, similar to the US model, 
and DTCA as one tool to do so:  
We have to look at how the New Zealand government is looking at it. The 
New Zealand government is seeing that there is a power gap, between the 
doctors and the patient. … the earlier treatment until the late 80s or 90s was 
that if you were a patient you go to a doctor then you were given a 
prescription and you go back and get it, and you don't question the doctor. 
And it was a professional responsibility of the doctor, and it was the 
professional responsibility of the organisation which he was representing… 
So it happened mostly in the Western world that they tried to decrease the 
power gap between the doctor and the patient… So I think this particular 
kind of decreasing the power gap is a very U.S. model (m, pharmacist). 
 
Theme: Consumers’ Awareness  
 Informants in favour of DTCA argued that it is the consumers’ right to be aware of the 
available treatment options. A common view amongst informants with positive views on 
DTCA was that it could increase awareness about available alternatives and novel 
treatments:  
I think a positive effect is people are more aware of what is out there, or what 
researchers have been done to improve, like for asthma, what inhalers are 
out there or what's coming into the market (m, dentist & academic). 
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Some informants stated that being aware of available alternatives could help consumers think 
critically about the medications prescribed to them. For instance:  
I think the positive aspects could be, just being aware that there are options… 
kind of not just blindly accepting whatever the doctor prescribes. I guess that 
would be positive that people are aware that if for some reason they’re not 
happy, they have some kind of side effects, for example, there could be 
another option that I could try (f, pharmacist). 
 There was also the opinion that it is not fair to “restrict knowledge” of medicines, as shown in 
the following statement:  
I don’t think it is fair to just restrict knowledge about medicines. I think it is 
not fair pharmacists or doctors keep all the information for themselves. It is 
ok for people to have access to information, knowledge about medicine and 
these days it’s the media that provides this access (f, physician).  
DTCA was considered as a way of delivering information and knowledge to consumers but 
only if it does not include any misleading information:  
DTCA is information. It is good. So, people know what is available in the 
market… It is a way of delivering information to the patient…The general 
view is good as long as there is not any misleading information (f, 
pharmacist). 
It was reported that DTCA could increase awareness of diseases or medical problems. 
The following statement illuminates this opinion:  
It increases general publics’ awareness; the more there is of medications 
being advertised about asthma, the more aware the public is that asthma can 
be a problem, and it can be life-threatening if you don’t get to the bottom of 
it. Just basically makes people aware of the condition and also that there are 
medications that can help with that (f, pharmacist). 
 
4.4.1.2 Negative Views: Factors Affecting Informed Decision-making 
 Most informants reported negative opinions and major concerns with regard to DTCA. 
Three overarching dimensions emerging from the data are discussed below, namely, the 






Dimension: Ethicality of DTCA 
 The majority of informants were concerned about the ethicality of DTCA, in particular, 
how it affects consumers’ informed decision-making. This overarching dimension was divided 
into the themes of the unethical objective of DTCA, and distorted or incomplete disclosure 
of information (opportunism). 
 
Theme: The Unethical Objective of DTCA  
 Many informants were concerned that health is becoming a business and argued that 
profit is the primary goal of DTCA. That is, DTCA focuses mainly on selling rather than 
informing or therapeutic goals:  
The whole purpose of it is to make money for the company, that is why they 
spend money for advertising for their brand. I’d like to think it is for helping 
people, but I don’t know if it is the truth. I think it is for companies to make 
money more than anything else as just the benefits of products are only 
promoted, so that is the number one objective for them (m, pharmacist). 
DTCA was seen as an effective marketing/advertising tool that pharmaceutical companies are 
using to make more money:  
I think it’s more selling, I do. It’s marketing so it is convincing, it’s put in a 
convincing way so it’s not like a documentary, you know where you’re 
offering facts, it’s a tool to sell something (f, pharmacist).  
The consumer might often get lost in the message because these guys are 
going through a lot more money and try to influence the decision of the 
consumer to buy their medication (m, dentist & academic). 
Many informants believed that DTCA is persuasive, resulting in consumers being heavily 
influenced by drug advertising, especially if the message is relevant to them. This 
persuasiveness was linked to the emotional nature of the appeals. Examples of data coded under 
this theme included references to DTCA as “bamboozling people”, “luring patients”, “not 
providing any real information at all”, “inducing emotions”, “more of an emotional kind of 
claim”, and “very persuading.” These perceptions are illustrated by the following quote:  
The real money is in persuading the whole bunch of people who don’t need 
to take it. That is where the real money is; in extending the indications! So it 
is not very helpful (m, physician & academic).  
Similarly, an informant who had negative views on DTCA emphasised that it is not ethical to 
try to persuade individuals into a specific drug:  
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There is an ethical issue in terms of the treatment that you are trying to lure 
patients into a particular medication, which I think is very bad, and it’s 
contrary to a belief of the public health system (m, pharmacist). 
 The thematic analysis also showed that DTCA is persuasive because advertisers use 
‘the appeal to authority’ to express knowledge/expertise:  
I think that they probably a lot of the time would believe whatever’s being 
presented to them because they get like a person standing, you know like a 
white coat, it makes them look very professional or a good looking woman 
that’s you know, also standing like with a nice coat and she looks like she 
knows what she’s doing and so they probably would be more inclined to just 
believe what’s said rather than look it up (m, dentist & academic).  
 Some informants highlighted that DTCA is unethical because of the use of persuasive 
positive emotional appeals. An informant who argued that drug advertisements usually try to 
psychologically influence people by associating the medication with positive aspects of life 
like “happiness” and “freedom”, linked this technique to classical conditioning5:  
It doesn’t tell you much about the medication or exactly how it works, it tells 
you what it can potentially do but what they usually do is they show you 
somebody running or somebody happy, so they psychologically try to 
associate the happiness, the freedom with the medication, even though it has 
nothing to do with that so just when you’re asthmatic for example, it shows 
oh you can’t run because you’re asthmatic when in fact it could be for 
example that you’re severely obese, that’s why you’re asthmatic, but if you 
start exercising, that will reduce it, so I guess you can think of it as like 
Pavlov’s dog kind of effect where you have this, they skip the step where they 
have to do the thing, so for example, the pill just causes salivation instead of 
you exercise, and then you get that freedom of feeling (m, dentist & 
academic). 
It was likewise expressed by another informant that the ads often focus on positive emotional 
appeals such as “happy people”, and general words rather than providing helpful information:  
 
 5 Classical conditioning alludes to a learning practice where an unconditioned stimulus (e.g., food) is 
linked with a conditioned or neutral stimulus (e.g., a bell) and suggests that the latter stimulus will cause the same 




Often they have smiley, happy people that are helped by the medication, and 
I don’t know that, is that really helpful. I think it’s more the information, you 
know what is this medication, as opposed to just happy people running 
around on a TV advertisement, yeah like clear words about what it can do 
and what it can’t do …, like specific words rather than just general airy-
fairy... (f, pharmacist). 
The above opinion was similarly expressed by several informants who discussed the different 
ways that the advertisements can be “evocative” or promising. For instance, an informant 
explained that DTCA is always emotional and positive, and tries to illustrate consumers having 
“a positive experience”:  
They’re emotive, they are evocative, they’re this is great, this is fabulous, 
this will make you amazing, the images are always very positive, and so 
they’re trying to give you a positive experience so you’ll end up feeling more 
positive about what you’re seeing (f, pharmacist). 
This opinion was also evident in this quote that demonstrates how the ads draw focus away 
from actual information by ‘focussing on emotions’:  
It’s playing on your emotions so in some ways you’re not thinking; you’re 
already on the journey of becoming well by taking this medicine (f, 
pharmacist).  
Another informant discussed that DTCA uses ‘sexual success’ by featuring a ‘young woman’ 
to induce individuals into the advertised drug:  
I’m always intrigued at how lovely the erectile dysfunction ads always seem 
to have a younger-looking woman compared with a 50 year something, 60-
year-old male; I thought ok so is the message the drug is good for you, it’ll 
improve your sex life or get you a younger wife, I’m not sure (f, pharmacist).  
  It was also expressed that DTCA uses persuasive negative emotional appeals to 
arouse fear. For example, showing “how terrible it is to be overweight” may persuade 
consumers to seek the advertised drug:  
The ones in New Zealand, they are often really emotional. … most 
advertisements are appealing to peoples’ emotions more than their logic or 
their thought, and so the ones that really stick to my mind are the ones for 
Xenical years ago. They were very emotive about, and you know how terrible 
it is to be overweight and then Xenical will sort of solving this problem…that 
sort of lifestyle rather than a drug (f, academic).   
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Theme: Distorted or Incomplete Disclosure of Information (Opportunism) 
 Some informants who had negative views on DTCA explained that most people could 
not make informed decisions based on DTCA since it misinforms individuals by 
misrepresenting the truth, and/or presenting partial information. 
 It was stated that the information presented in DTCA is not factual; instead, it is often 
misleading and deceiving (active opportunism). For instance, it was stated that:  
I think they’re misleading a lot of the time, and they take advantage of the 
public’s lack of knowledge in these areas (m, dentist & academic).  
Major concerns were expressed regarding ‘inaccurate’ and ‘false’ information offered in 
DTCA:  
I think that mostly it is inaccurate…I don’t think DTCA really helps. It 
probably just gives them false information (f, academic).  
 DTCA can also be misleading by overplaying the effectiveness and causing a positive 
perception of the drug as illustrated by the following statements:  
It can sometimes make misleading comments about drugs; often it can 
overplay the effectiveness by using inappropriate graphs and inappropriate 
measures, so for example, relative risk is often used as opposed to absolute 
risk (m, physician & academic). 
They do seem quite misleading, and the adverts make it sound like this is a 
really good medicine for you. You know even though they do have this 
disclaimer, talk to your health care professional, you’re already sending this 
person into that healthcare environment with the perception that this 
medicine is good for them, and that’s what I don’t like... (f, pharmacist).  
Similarly, analysis of informants’ views revealed that DTCA often generates “false beliefs” 
that might not be met, which can be too risky: 
I think many patients would look at something that they haven’t been exposed 
to before, you know a new drug for weight loss, a new drug for asthma, a 
new drug for anxiety, for instance, you’ve tried something for a long period 
of time for yourself, for your partner, for your parents, it hasn’t been 
working, you’re suddenly exposed to something that’s never been out in the 
market before, they claim that it’s made them a completely different 
ingredient to what was researched in the market in the past as well so you 
are tempted to think that all this can you know, this will change my life so 
you then make that decision that yes, this has the ability to affect my belief 
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in the medication as well, but it’s dangerous because it might not necessarily 
be true (m, dentist & academic). 
 Likewise, some informants reported that DTCA might give “a false sense of security”:  
The audio has a big effect so having that calm music play in the background, 
you kind of get a sense that it is something associated with a pharmacy or it 
is something associated with a reliable medical source, so it’s trustworthy I 
think it gives a false sense of security (m, pharmacist). 
An informant stressed that DTCA could also result in “a false sense of knowledge”:  
I think it would probably give them a false sense of knowledge because 
they’ve seen the ad, they feel like they’ve had some kind of education (f, 
physician & academic).  
It was also discussed that DTCA could cause unrealistic expectations, such as making life 
“fantastic” and “perfect”, which is not ethical:  
 …I can just think of one ad that we saw recently and I think the words were 
it’ll revolutionise your life…(f, pharmacist). 
[DTCA] probably just gives them false information and makes them think 
that this medicine is awesome and makes life fantastic (f, academic). 
…They just make it sound idealistic, and your life will be perfect, and better 
if you have this (f, pharmacist). 
Some informants expressed that the information presented in DTCA is often too 
“general” and makes patients believe one pill is the right one for “everybody” with a specific 
problem, or it is the right drug for ‘everything’:  
They are trying to generalise the advertisement, but then it can be misleading 
at times because not all asthma inhalers are appropriate for everybody. And 
they also need to take into account that not everyone is healthy and just has 
asthma. They may have other health complications that these inhalers 
wouldn't be appropriate for. So, I find that it's very general…(m, dentist & 
academic). 
It was likewise discussed that DTCA lies by suggesting the advertised drug will solve ‘all 
problems’:  
I think 99% of the advertisements are lying… You cannot have one medicine 




 Several informants argued that DTCA often provides biased and incomplete/partial 
information (passive opportunism). This opinion was evident when many professionals 
mentioned that DTCA is not intended to present the full picture, and pharmaceutical companies 
are always ‘concise with the truth’:  
I think a lot of time they present just the data that they want to … because 
with most research they select healthy patients. For example, for diabetes, 
they select people with diabetes only, maybe without any complications with 
diabetes, and so the numbers that they represent are specific to a particular 
group of patients, but they say only all diabetics. So, I think in that way they 
are not lying, they are avoiding the complete picture (m, physician). 
Some informants similarly expressed that DTCA often provides biased, selective and 
incomplete information about the drug, and consumers cannot make judgements based on 
partial information. For instance, it emphasises the positives and minimises or even hides the 
exact use of the drug and its probable risks/side effects:  
I think the risk is that people are not informed about the drug and the 
advertising over-estimates benefit, under-estimates harm and promotes that 
drug, but potentially there are other drugs that are equally effective and 
probably may cost less money (m, physician & academic).  
I think that, well with most advertisements if there is any downside of it, they 
would try and mask it, because they are trying to promote their brand. So, 
they tend to miss out things like side effects or things like if it's being 
contraindicated, what sought of age that's appropriate for… (m, dentist & 
academic). 
This opinion was also evident when an informant emphasised that consumers cannot make an 
informed decision since DTCA presents only the “glossy happy” part of the story:  
Because they’re not given the full picture, they’re only given the glossy happy 
story, you know they don’t get told oh if your renal function isn’t very good, 
this medicine could kill you, they’re not told that sort of information, so you 
can’t make an informed decision by only being told a small part of the story 
(f, pharmacist). 
Likewise, some informants stated that DTCA often puts negative aspects in really small 
print that can hardly be seen, which is not ethical: 
Some of the worst examples have the little, absolutely minute text, 
particularly on the television, they have this minute little row of text at the 
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bottom that says this drug may not be appropriate for everybody, please 
consult your physician and things like that, and I know it’s minute. We’ve 
actually taken recordings, and we’ve actually stopped and tried to read, you 
know and if I can’t read it on my television, then how on earth can anybody 
else (f, pharmacist).  
Informants further discussed the effects of opportunism on decision-making and 
expressed that it can result in uninformed individuals:  
[Lying or hiding in DTCA] would probably lead to misinformation, which 
means if they go to the doctor, and the doctor does give it [the advertised 
drug] to them, then they gonna be taking the wrong medication (for the 
wrong condition or maybe they don’t have that condition) and they are 
gonna be taking extra medication that they don’t need and might lead to 
more side effects or adverse effects that would cost more money (m, 
pharmacist).  
It was similarly mentioned that opportunism causes consumers to think that they are well-
informed when in reality they are not because they have been provided with partial or distorted 
information:  
I think consumers believe they got this great information and a great new 
product that they can bring up. They believe they are well informed, but they 
are giving only one side of the coin when a product is advertised …the 
company’ advertising tries to say the product is good, while it is not…, but I 
don’t think they are well-informed (f, physician).  
Some informants likewise argued that opportunism in DTCA can “generate demands” by 
misinforming individuals:  
It [DTCA] is like all advertising, it works. It generates demands; it affects 
people…. The effects are the same; it generates demands because it is partial 
information and often misinforms through its partiality as much as anything; 
sometimes because what you get is incorrect, sometimes because you get a 
little piece of a picture (m, physician & academic). 
This opinion was highlighted when an informant illustrated that the existence of opportunism 
in DTCA might increase the demand particularly when drugs are affordable since people think 
there is no harm in trying the drug and some doctors would prescribe what patients ask for:  
Especially for something that is quite affordable that people think oh no 
harm trying and they are more likely to demand it and ask from their doctor 
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can you please just prescribe it and if the doctor says no it is not suitable, 
they will say that I definitely want this so I will change the doctor. And there 
are doctors out there who prescribe what patients want (f, pharmacist).  
 
Dimension: Individuals’ Capability to Make Informed Decisions  
 The present findings showed that in addition to the unethicality of DTCA, consumers’ 
limited capability can affect their informed decision-making about drugs. Most informants 
noted that people are not capable of making informed decisions based on the information in 
drug advertising. For the overarching dimension of consumers’ capability, two themes of 
health literacy and self-efficacy developed from the thematic analysis. 
 
Theme: Consumers’ Health Literacy 
 Even if DTCA provides factual and enough information, most consumers have limited 
capacity to comprehend and process medical information and employ it in their decision-
making. This can be associated with their lower health literacy:  
A lot of patients they don’t even understand their own condition and so to 
say just because you gave somebody a label that they have this kind of 
condition with such a big variation in that condition as well, and you know 
for a patient to understand that takes time and to go on and make an informed 
decision about medication in that short amount of time is difficult (m, 
physician).  
I think that health literacy is probably quite poor overall (m, physician).  
I don’t think most consumers have the ability to understand what is medical 
information. I don’t think unless a person has like a background in pharmacy 
or even in health (f, academic). 
 Some informants mentioned that ordinary people are unlikely to understand drug 
metabolism, and the “biology”, “chemistry”, “pharmacokinetics”, and “medical terminology” 
offered in DTCA:  
Typically, I don’t think they’ll understand it [medical information presented 
in DTCA] very well at all.... People come to me, even people who are on 
medicines for a long time and they have no idea why they are taking the 
medicines. They might have, you know oh it’s my blood pressure pill, they 
don’t even know the name of it, I mean presenting complex information like 
that to almost everyone, even people with tertiary qualifications, like most 
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people, can’t understand what the medicines do. So, I think in general the 
ability is poor. People don’t understand the biology; they don’t understand 
the chemistry...They certainly don’t understand pharmacokinetics, so I think 
it’s impossible to reasonably you know, do a good job of that sort of thing (f, 
physician & academic).  
The above opinion was also expressed by several professionals who indicated that “… you 
definitely need to have a medical background to fully understand [the message and] what’s the 
benefits [to] your health,”   and generally the public do not have that capability.  
 Understanding medical information can sometimes be challenging even for medical 
experts:  
… and sometimes, doctors from different specialities cannot understand the 
information. Somebody gives me a medicine which is neurologically based; 
I think it would take me some time to understand, right (m, pharmacist).  
It was also noted that there might be some complicated medical issues that even health 
professionals may not agree on the appropriate medications:  
They could only ever understand the basic concepts of how the medicine 
works because in reality, comparing one medical treatment to another and 
saying the benefits and risks of them is a very complicated topic that even 
experts will disagree on. So, for a layperson to be able to give a fully 
informed choice is almost impossible (m, pharmacist).  
 Informants argued that most consumers cannot detect inaccuracy (active 
opportunism) and partiality (passive opportunism) in DTCA:  
I don’t think they [consumers] have the ability to detect deception; the 
advertisement is done by an advertising company, they know how to do it… 
(f, physician).  
This can be associated with their low health literacy as some informants argued that 
consumers’ ability to identify opportunism depends on their medical knowledge. Often 
people who do not have a medical background trust whatever they have been told:  
Patients are very vulnerable because they don’t have knowledge about 
drugs. They believe anything that they have been told. They just trust what 
people tell them (f, physician).  
It was discussed that the general public is not able to be sceptical – or even “cynical” – and 
find out whether advertising hides or lies about important facts since they usually do not 
question and analyse DTCA.  
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I think again the ability to sort of break down and be cynical with this 
advertising is overall probably very poor and again that increases the 
effectiveness of this advertising, which encourages more of it [the drug] (m, 
physician). 
If it’s an advertisement, it all looks the same, sometimes they catch our 
attention so we might listen to it more but we don’t go back and analyse it, 
so I think the ability to discern whether it’s misleading or if it’s factual is 
pretty low (m, pharmacist).  
An informant similarly argued that it is easy to lie to the average person or to withhold certain 
information:  
… a consumer seeing an advert for reflux or something like that, they’re not, 
the average person isn’t gonna know a whole lot about it, and so it’s easy to 
lie to that person or to withhold certain information so that you can sell more 
of your reflux tablets or whatever they might be (m, dentist & academic).  
The general public that do not have a medical background can be easily swept away by 
marketing and advertising techniques:  
… as a pharmacist, I don’t even know everything about all the medicines, 
and yet that’s my area of expertise so if you were a member of society where 
you didn’t have any medication training or knowledge or background, then 
I think you could quite easily be swept away in the marketing ad (f, 
pharmacist).  
It was stated that it is sometimes impossible even for medical experts to find out the truth:  
It’s almost impossible even for doctors to find out the truth about new 
medicines, about how safe they are, whether they’re effective or not, whether 
they cause harm..., and I really don’t think any consumers can hunt down 
that [partial or misleading] information because as a professional, we can’t 
do it (f, physician & academic).  
 
Theme: Self-efficacy  
 This study revealed informants’ views on the effects of DTCA on consumers’ beliefs 
in their ability to make informed choices about medicines (self-efficacy). Generally, a 
prevailing view was that DTCA could shape the way consumers’ think and could increase 
their self-efficacy. Examples of data coded under the effects of DTCA on consumers’ self-
efficacy were:  
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It [DTCA] definitely bolsters peoples’ opinions, well peoples’ belief in 
themselves to make informed decisions (m, pharmacist).  
Advertising ‘promotes choice’ and causes consumers to think they can make a decision about 
the drug:  
I would’ve thought the whole point around advertising is it is actually trying 
to get people to think they can make a decision … This manufacturer claims 
it’s a good drug to use, so they’re actually using this sort of information so 
that I think the advertiser is promoting choice (m, physician & academic).  
 Informants also discussed the effects of consumers’ beliefs in their ability to make 
informed decisions (self-efficacy) on their decision-making. Most informants had negative 
views on the effect of increased self-efficacy (consumers’ positive beliefs about their ability) 
on decision-making and argued that increased self-efficacy caused by DTCA can result in 
uninformed decision-making in different ways. When people feel very ‘adamant’ and 
‘passionate’ about a particular medication, and it becomes a “fixated idea” for them, it is hard 
for doctors to say no, so it may result in unnecessary or inappropriate prescribing:  
I think their beliefs affect their decision-making. Definitely, when they come 
to me, from my own personal experience, they feel very adamant and 
passionate about a particular medication, and it becomes a fixated idea for 
them. So, with that leaf in mind, it is very hard to persuade patients, once 
they come with a particular idea, it is very difficult to say them No, come and 
try this. A good chunk of them would say No, I believe this medication would 
help me. Yeah, they cannot be properly informed (f, physician).  
Likewise, it was argued that people would be highly influenced and inappropriately want the 
advertised drug rather than the one their doctor suggests:  
They [a lot of patients] turn up at the doctor and say I want the new orange 
inhaler, herbal inhaler, erectile dysfunction drug, … and so some patients 
are asking as an enquiry, others are being very very pushy because they think 
they’ve made the assessment that’s necessary, they’ve decided it’s what they 
want, and therefore they should have it (f, pharmacist).  
Individuals would be highly influenced especially if the advertisement features a celebrity:  
They can influence a person to go for a particular…, for example, if they ask, 
Richie McCaw, if he advertises something, like if these pharmaceuticals 
companies try to hook in or bring a national hero to advertise that particular 
medication, then the patient would just go, I mean they would be highly 
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influenced by that celebrity and go for that medication...rather than going 
with the medication which their care provider is prescribing them (m, 
physician).  
Consumers may inaccurately believe that they can manage their medical conditions with the 
advertised drug, whereas it may not be the right drug for them:  
If they believe that this medication can manage it [the medical condition], 
then you know they do take that idea on board. But the downside of it is trying 
to convince them that there are alternatives that are better… [or] it might 
not be the most appropriate medication for them (m, dentist & academic).  
An informant noted that consumers who do not have medical knowledge are more likely 
to be negatively influenced by their increased self-efficacy since they would believe all claims 
of DTCA:  
… I think when you don’t have the knowledge or when you’ve only got half 
the knowledge, it’s very dangerous because you tend to fall prey to all this 
advertising and that’s what advertising is, it’s like a, it’s not a gimmick but 
at the same time, they’re trying to buy your loyalty, they’re not doing it for 
the greater good of society, … More often than not it has the capability to 
increase it [self-efficacy] negatively rather than positively (m, dentist & 
academic).  
Some informants discussed that even people who may know something cannot make informed 
decisions since they are usually ‘overconfident’:  
I think it is a really specialised thing to be able to make a decision about a 
drug. So, I think that actually everybody is at risk of, everybody is not able 
to make informed decisions. Because some people they don’t know anything 
and other people they know something, but they are overconfident (f, 
academic).  
Likewise, the findings revealed that overconfidence does not mean that people are going to be 
successful in that task:  
I guess probably people who are well educated perhaps, in general, have 
more confidence in making decisions, but it doesn’t mean to say that they’re 
more right (m, pharmacist).  
This overconfidence thus can result in “frustration” when the doctor says no to their request:  
I think it could sort of overinflate the feel that I can just choose the best one 
for myself, people may feel that if they read through five different 
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medications for their condition, read through the advertisement but after 
that, they can decide what’s best out of those five, but I don’t think that is the 
case necessarily… I guess the negative side would be if the doctor feels no 
that’s not good for you, then it will lead to, just frustration because they can’t 
control what they feel they could (f, pharmacist).  
An informant emphasised that people who think they can make the best decisions and demand 
certain treatments can make doctors’ job “very tough”:  
They think they are in capacity and they do have much more understanding 
of what they can do. They mostly people who have less humility I think so. 
They are very quick and very rude, and they know what they are trying to do, 
and they always say Okay, this is what we want, this is what we are sure of, 
and it makes your job very tough (m, pharmacist).  
  
Dimension: Doctors’ Key Roles in Consumers’ Decision-making 
 Thematic analysis showed that consumers’ informed decision-making would be 
positively influenced by their trust in their doctor.  
 
Theme: Receiving Information from Doctors Rather Than DTCA 
  It was a dominant view that consumers cannot make informed choices based on 
information provided on DTCA, and they should get the required information from doctors:  
I do lean towards preferring not to have it actually... Then the doctors can 
give information to patients in a patient/doctor consultation rather than 
patients seeing things in the media and making up their own mind without 
speaking with a doctor (f, pharmacist). 
It was similarly argued that individuals have “the right of autonomy” in decision-making but 
not based on DTCA, and only after discussion with doctors. Doctors should educate patients 
about medical conditions and available treatments. Some informants also mentioned that 
although consumers need to be informed of all information about their conditions and the 
treatments, the choice of drugs should be left to the doctors:  
All the patients have got the right to make an informed decision about a 
particular treatment, about a particular medication. They have the right of 
autonomy, they can decide which treatment is good for them, but I think this 
can be done only after a discussion with the prescriber or with the care 
provider and television is not a care provider. …So your answer is a patient 
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can do, like he can get information, he can make an informed decision each 
and every time, but he can do it only with his care provider and not with the 
idiot box [TV] (m, physician).  
 An informant noted that consumers’ informed decisions regarding DTCA are 
influenced by their relationship with their doctor. If consumers have high “trust” in their doctor, 
then they are more able to make an informed choice:  
… on the one hand, they’ve got an advertisement which is telling them 
something, on the other hand, they’ve got a doctor that they presumably 
trust; otherwise they wouldn’t have gone to that doctor, and they have to 
weigh up that balance between, do I trust the person that I’ve trusted or do I 
believe what I’ve been told here, and I guess the greater the trust and 
confidence that they hold in their doctor, the greater the ability to manage 
that informed choice (m, physician).  
 In summary, according to health professionals’ thoughts, most consumers are not 
capable of making informed decisions based on DTCA, which makes them vulnerable to 
DTCA. Further thematic analysis revealed the types of individuals who are less able to make 
informed choices and thus are more vulnerable to DTCA. 
 
4.4.2 Part Two: Consumers’ Vulnerability  
 Although in this study, a number of informants mentioned that everybody is at risk of 
being misled by DTCA, some informants stated there are specific groups of individuals who 
are even more vulnerable to DTCA. The following statements illustrate this point:  
There’ll be a big spectrum, a broad spectrum of people who cannot 
understand much at all to those who understand a lot about their condition 
(f, academic). 
I know different people are affected by advertising differently… I think it 
depends on the person (f, pharmacist).  
This phase of the study thus focused on characteristics/types of individuals who are less able 
to make informed decisions. A schematic of the dimensions/themes hierarchy regarding the 





Figure 4.2: Characteristics of vulnerable consumer 
 
Dimension: Characteristics of Vulnerable Consumers  
 Vulnerable individuals were classified based on five core themes: health conditions, 
lifestyle, demographic status, socio-economic status, and personal characteristics/traits, 
which are discussed below.  
 
Theme: Health Conditions 
 Many respondents mentioned that people with health problems could be more 
vulnerable to DTCA. Desperation was highlighted as one of the factors causing the 
vulnerability of these individuals to DTCA. Unwell people may be more likely to be influenced 
by DTCA since they may be willing to try anything to improve their conditions:  
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I think it's a very normal behaviour. Anybody who is in a desperate condition 
would try to find a solution to it as fast as he can, and especially in surgery 
and cancer surgery. I have seen people doing everything, just to get over that 
(m, pharmacist).  
For instance, when doctors cannot do anything to solve patients’ medical issues, they 
might be more willing to try the advertised drug and thus can be more vulnerable toward 
DTCA:  
For example, if you had arthritic pain in your knee, and you’d been to your 
doctor, and your doctor said oh look I’m really sorry, but there’s nothing 
more we can do; we just need to wait for the knee replacement, and then 
something’s advertised on TV, then you go back to your doctor and being 
annoyed, like oh I saw this ad on TV, and this is supposed to be really good 
for me, why are you not giving it to me (f, pharmacist). 
 Informants also linked having serious health conditions to being more vulnerable to 
DTCA. People who have serious health issues may feel distressed or scared, and may be more 
likely to believe the benefits of drugs claimed by advertising. Thus, DTCA may give them 
unrealistic hope. They accordingly may be less able to make an appropriate judgement:  
People who have serious health conditions are very vulnerable to you know; 
they want to hear that this medicine is gonna give them some hope. I think if 
they’re very ill or say you’ve got a family member who’s ill, you’re probably 
a lot more vulnerable to hearing the good things about medicines (f, 
physician & academic).  
People who have multiple serious health issues tend to be more prompted to try new drugs:  
People who are having multiple diseases. Like a concoction of like diabetes, 
hypertension, high cholesterol. So, …they are much more easily lured to a 
new line of treatment, than anyone else (m, pharmacist). 
 Psychological disorders showed up consistently throughout the data as a factor 
affecting consumers’ vulnerability to DTCA. Many informants stated that people with 
psychological issues are more likely to be influenced by drug advertising since they are usually 
less able to make a proper decision:  
People with mental illness, mental impairment, intellectual impairment, 
intellectual disability, people with dementia, people with potential psychosis 
or other illnesses that impair judgement and making a decision (m, physician 
& academic).  
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It was also emphasised that patients with psychological problems such as “depression” 
are not in the right place to make decisions about their medical conditions and treatments:  
I wonder if people who are depressed, or have some kind of mental 
conditions aren’t in the right place to diagnose themselves and make their 
own decision about what’s best for them and yeah, if you’re in that sickness, 
in that pain, in that place, you might not be thinking the same way that 
someone looking from the outside is looking, is thinking (f, pharmacist).  
 Thematic analysis revealed a strong link between having abnormal health anxiety and 
being more vulnerable to DTCA. Informants stated that people with anxiety are more likely to 
be misinformed and influenced by DTCA, and subsequently less able to make an informed 
decision:  
I think for the general population with high anxiety status; they do have a 
higher chance of being misinformed about medications... I feel that they 
cannot be fully informed. They cannot make a fully informed decision (f, 
physician).  
It was noted that DTCA might even increase the anxiety of anxious people, and cause “false 
impressions”:  
They [people with abnormal health anxiety] might think that they have that 
condition without really having it, so it will give them a false impression that 
they have that (f, pharmacist).  
DTCA can persuade anxious people to pursue the doctor and ask about the advertised drug:  
Anxious people say yes that’s me, and they want to try more things. It is 
encouraging them to pursue the doctor (m, pharmacist).  
Moreover, requesting the advertised drugs from the doctor could complicate relationships 
between these patients and physicians:  
DTCA has negative effects on people with anxiety. Because on the 
advertisement they say that this medication will work on this and this... and 
then the doctors know that it probably won’t work, so the option is whether 
he gives it to them to try and to find that it doesn’t work and they get angry 
about it. Or that the doctor would say no it is not going to work and tell them 
about side effects and you can take another medication with the same 
mechanism of action that does the same thing, the doctors would be unlikely 
to prescribe it (because he knows about the side effects from his past 
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experience) so the patients will be angry at doctors. In both ways, the patient 
will suffer more, and the doctors don’t (m, physician). 
 
Theme: Lifestyle  
 Some informants believed that people with less healthy lifestyles could be more 
vulnerable to DTCA. Three discrete reasons emerged from this.  
It was highlighted that those who have a less healthy lifestyle are more likely to have 
health issues and get sick. They thus are more likely to be influenced by DTCA since they 
may be ‘desperate’ to seek and try something to help their health problems:  
If they don’t do much exercise, that is why they are sick. People who do more 
exercise, who have a healthy lifestyle, they don’t get sick. I guess it can be 
because of their health status; they are desperate to try something to help 
them… I think they get affected more easily (m, physician).  
Hence, they might be exposed to more drug advertisements:  
I wonder if it’s because maybe they’ve been less healthy so therefore maybe 
they’ve been more sick, and so they’ve been exposed, they’ve taken more 
drugs maybe and so they’re maybe on the lookout for something that could 
be potentially beneficial to one of their problems that they might have (m, 
dentist & academic).  
 Some informants associated having a less healthy lifestyle with being reluctant to 
change. They discussed that DTCA can also increase the pill for every problem feel. It was 
mentioned that people with unhealthy lifestyles might look for an easy way or a “quick fix” to 
solve their problems and taking medicines is an easier and quicker option than making lifestyle 
changes: 
...perhaps they’re inclined more to look for a quick fix… Some people are of 
the opinion that I’ll just take a medicine and I won’t need to eat right, I won’t 
need to exercise, I won’t need to look after myself and rest and I can just take 
a medicine, that will fix all the bad things that I do so I guess those people 
can be more influenced by advertising (m, pharmacist).  
These people may think that why diet and exercise when you can easily take a pill instead, 
which is much easier:  
I think when people get desperate, they will try anything and I know that 
sounds, if you have an unhealthy lifestyle, people are reluctant to change, 
they know there are healthy options and eating differently and getting 
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exercise might be the answer but they would much rather take a pill. They’re 
too lazy (f, pharmacist).  
They may have also already tried and failed with lifestyle changes:  
It’s an easier way, yeah and I guess these are people that have also tried and 
failed on previous occasions and so they’re seeing another option (m, 
physician). 
 It was mentioned that people with a less healthy lifestyle might “overestimate the 
efficacy of drugs” so that they may think that drugs are an effective alternative to a healthy 
lifestyle and taking drugs can solve all their health issues:  
Some people overestimate how good drugs are. Like they think that you can 
eat what you want as long as you take this medicine, you won’t have a heart 
attack. They sort of overestimate the efficacy of drugs..., seeing one of them 
on TV and thinking that would solve all my problems (f, academics).  
Especially, it was stressed that people with an addictive personality might also overrate the 
effectiveness of drugs and think that taking the advertised drug can treat their addiction:  
People who might often have addictive personalities, a chronic smoker for 
instance or a drug abuser for instance... he or she might view these 
medications, … so they’ll think that you know, mark this next mediation 
because it says it can do everything, it’ll probably cure me of my drug 
addiction or my alcohol addiction or my cigarette addiction, which may or 
may not be necessarily the case (m, dentist & academic). 
 
Theme: Demographic Status  
 As claimed by most of the informants, people with a disadvantaged demographic 
status may be less able to make informed decisions. It was argued that demographic 
characteristics could affect consumers’ ability to understand and process medical information 
presented in DTCA.  
 Age was frequently discussed as a factor affecting consumers informed decision-
making, with both very young and old people being described as more vulnerable to DTCA:  
There is a problem, especially in two age groups. One is the age group that 
is less than 25 and the age group, which is plus 65 (m, pharmacist).  
 Some informants claimed that younger people are more vulnerable since they have not 
been exposed to many ads and they have not got enough skills and experience to understand 
the advertisements:  
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Very young [are less able to make informed decisions], because of their 
background, they don’t have all the information because they have not been 
exposed to many of them (f, pharmacist).  
They may be ‘more trusting’ and more likely to be influenced by drug advertising:  
Sometimes young, there is a large proportion of young people that are more 
trusting in what they see (f, pharmacist). 
An informant specifically argued that people under 25 are even more at risk of being influenced 
by DTCA because they think they are ‘indestructible’ and that taking pills won’t hurt them:  
Less than 25 age group is feeling that his body is potentially indestructible, 
so he just knows Okay, doesn't matter if I pop one more pill, you know, 
because this is easily available, so let me have that medication, it will be fine 
(m, pharmacist).  
 It was also highlighted that young girls who care about beauty and related products or 
medications might be more vulnerable, especially in response to positive persuasive appeals: 
… young teenage girls who look at acne medications, who look at weight 
loss supplements, who look at facial creams, for instance, you know things 
like Roaccutane, which are prescription medications (m, dentist & 
academic).  
 Elderly people, due to their health condition, and cognitive capability were also 
discussed as more vulnerable:  
Age might make a difference and cognitive functions, so you’ll get some 
people, as they get older, that they find it quite bad to assess all the 
information (f, academic).  
An informant emphasised that people over 65 are more vulnerable, partly because they have 
poorer health. For example, they may have to wait for a long time for operations through the 
public health system:  
After 65 age group has a long waiting list. A person is usually in a lot of pain 
before a proper treatment can be given to her. So, if a person with 
osteoarthritis has to live for…depending upon the place or the DHBs, it 
might take him almost two years or one and a half years to go for a knee 
replacement surgery, and for that whole time that person is dependent upon 
some kind of medication to keep himself out of pain (m, dentist & academic).  
It was also stated that older people might be more at risk because they are more “trusting” and 
less sceptical since they did not grow up with as much advertising. They are not used to 
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questioning the advertisements and think that if they have read something, then it must be true. 
The following verbatim illustrated this point:  
Age is an interesting one because I think older people are more trusting as 
well, so I guess the older generation didn’t grow up with advertising as 
heavily and as frequent I think as we have, as younger people have... (m, 
physician). 
 Gender also came up in discussions on the characteristics of vulnerable consumers. It 
was revealed that DTCA intentionally tries to manipulate the “gender confidence” of 
individuals:  
The choice of images and wording and stuff, it’s deliberate, and it’s designed 
to get your attention in gender confidence and make you want to rush out 
and convince your doctor what they should prescribe for you (f, pharmacist).  
A few informants argued that women could be more vulnerable to DTCA since they tend to be 
more influenced by advertising. Accordingly, drug ads for cosmetic reasons such as weight 
loss medications were also stated to be unsuitable because women were perceived to be more 
willing to try these products even if they have negative side effects. The following two quotes 
illustrate this point:  
I think that's a grey area, but [what] I don't like to talk about is medications, 
which are the gender focus in females. So, I think to a very large extent they 
are not able to [make informed decisions]... the focus is too much about the 
cosmetic availability or for them to reduce weight or things like this. So, it 
becomes a little shady area. I know a lot of people especially females who 
are having prescriptive medicines to reduce weight which is not good for 
them (m, pharmacist).  
It sounds sexist, but women, in general, tend to be a little bit more influenced 
in my opinion and… just from my general understanding, I think women, in 
general, tend to be a lot more noticeable of such things as opposed to men 
(m, dentist & academic). 
 A few informants noted that parents are very “susceptible” when they have sick 
children, and they may look for a quick fix for their children. Drug advertisements that are 
targeted at mothers for their children were perceived to be manipulating their feelings:  
One other area that bothers me a little bit is when the adverts are targeted 
at mothers for their children because yeah again like I said before, I think 
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they are manipulating the feelings of the mother sometimes into thinking that 
they need to give this medicine (m, pharmacist).  
Advertising drugs to parents can “increase demand” since parents may ask for unnecessary 
medication for their child:  
I guess probably it would be airing on the side of unethical to advertise 
medicines to parents with children I think, I’m a bit uneasy with that, because 
that’s another harm that can come from medicines, it may be parents feel 
like they’re not doing the right thing by their children if they don’t give the 
child this medication...whereas in actual fact, the child may not need the 
medication at all...they’re just trying to promote the medication to parents 
to increase demand instead of fixing a real need that’s there (m, pharmacist). 
 Some informants also linked consumers’ culture/ethnicity to their vulnerability to 
DTCA. They stated that there could be “cultural barriers” in informed decision-making. In 
some cultures, patients listen to their doctors’ advice, while in some cultures, patients are very 
argumentative in their interactions:  
There are cultural barriers... Patients in some cultures don’t like arguing, 
and they just say yes to everything and others are quite stroppy. There are 
certain Eastern, northern European countries, where you know, this is the 
way they have grown up. They are very adversarial in the way in which they 
interact. That makes more difficult shared decision-making (m, physician & 
academics). 
 
Theme: Socio-economic Status  
 It was a dominant view that socio-economic status could influence consumers’ 
vulnerability. The findings showed that individuals who belong to lower socio-economic strata 
might be more vulnerable to DTCA:  
Those with low socio-economic status. It is kind of a flip of a coin, I should 
not really say all people with low socio-economic status, but I think they are 
the most vulnerable, to be honest (f, physician). 
 Knowledge level, literacy, and analytical thinking ability can be correlated with socio-
economics and will affect consumers’ decision-making:  
The literacy and analytical thinking I think sometimes go hand in hand and 
is certainly correlated with socio-economics (m, physician).  
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Their socio-economic status may be linked to their knowledge anyway and 
their ability to deal with complex information so some people would find it 
quite hard to make any decisions (m, pharmacist). 
 Some informants likewise stated that education is an important factor influencing 
consumers’ vulnerability. Consumers with a lower level of education are more likely to be 
misled and affected by DTCA since they may not be able to understand, process, and evaluate 
the presented information and thus may be more likely to trust DTCA. The following statement 
illustrates these findings:  
If they have a low level of education, it could affect their ability to process 
the information that they’re being fed and even if they do use Google, or you 
know, look into it further, they might still not be able to process exactly what 
they’re getting and find the right answer at the end of it if they’ve got a low 
level of education (m, dentist & academic).  
On the contrary, people with a higher educational level are able to search for more 
information, understand medical information, and thus criticise the advertisement:  
Maybe as a generalisation, the more educated you are, you might have more 
tools to kind of critically evaluate what you are reading in an ad ... (f, 
pharmacist). 
 As discussed earlier, informants reflected that the general public commonly have 
limited health literacy, which affects their capacity to process DTCA and make informed 
choices. Overall, individuals’ health literacy can be conceptualised based on three levels: 
“Functional health literacy, interactive health literacy, and critical health literacy” (Koinig, 
2016, p. 41; Nutbeam, 2000). Basic/functional literacy comprises reading and writing abilities 
required for message understanding and medical decisions. Communicative/interactive literacy 
contains advanced cognitive and interaction abilities that contribute to health-related activities, 
understanding, using, and sharing new information from various sources, such as professionals. 
Critical literacy requires the most advanced cognitive skills that empower individuals to 
critically analyse and evaluate medical information in order to have greater control of events 
and circumstances in life (Koinig, 2016; Nutbeam, 2000; Nutbeam, 2008). Based on the three-
level conceptualisation of literacy, this study found poor health literacy as one of the factors 
affecting consumers’ vulnerability. All three levels of literacy were implicitly illustrated in 
informants’ statements.  
 An informant argued that people, for whom English is not the first language, are less 
able to make informed decisions based on DTCA. This can be associated with their poor 
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reading, writing, and listening skills, or understanding limitations (poor basic/functional 
literacy). The following statement illustrates this conclusion:  
I think people’s degree of literacy, health literacy is variable just try, I mean 
obviously if English is not the first language, it is not as easy to have that 
conversation, and that happens on both side of the table... and the harder it 
gets, the more there’s a language barrier (m, physician & academic).  
 Some informants expressed that people who do not have medical knowledge cannot 
understand the information presented in DTCA and thus are less able to make informed 
decisions (poor communicative/interactive literacy):  
I was gonna say like educated to understand what the ad is saying, you know 
if they don’t understand medical terminology, they might not actually 
understand what the ad’s telling them in full detail (f, pharmacist).  
Accordingly, consumers who do not have a medical background need doctors’ advice to be 
able to make the right choices:  
So many things they don’t understand because for them they are just one 
person, but their doctor/GP might have seen 20 people who took this drug, 
and they know that it is more likely to work for this person but probably not 
that much for that person, GPs have the experience and understanding of the 
body (physiology)… They [consumers] would need to be aware and have the 
understanding at the superficial level, but they need to be open to having 
their doctor or pharmacist explain to them (f, physician). 
 It was also discussed that the way a medical expert looks at an advertisement is very 
different from how laypeople look at the ad since they do not have the capability to evaluate it. 
Many informants thus articulated that people who do not have enough medical knowledge to 
interpret the information and evaluate the drug and advertisement are not able to make 
informed decisions (poor critical literacy). The following comments provide examples of the 
effects of poor critical health literacy on informed decision-making:  
We know that people who have low health literacy really will struggle to 
make, make good judgements (f, physician & academic).  
[The] ethical part of it I am sure is a bit of a grey area because consumers 
don’t have a clinical or scientific background, so not all the information can 
be interpreted. Consumers can be misled easily because they can’t interpret 
scientific information (f, pharmacist). 
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 Moreover, an informant noted that people who are not able to be critical of advertising 
subtleties (who have poor media literacy6) are more likely to be influenced by DTCA:  
I guess people are probably unaware of the subtleties of the way advertising 
operates, then rather than being critical of it, it’s going to influence what 
you see and how you perceive it (f, pharmacist). 
 Some informants also associated low income and unemployment with vulnerability 
to DTCA as a result of their poorer literacy and understanding:  
People who are poorer have lots of things that contribute to that and 
sometimes the literacy and ability to sort of analyse goes hand in hand with 
that sometimes (m, physician).  
Those who have got more ability to understand things tend to get into jobs 
where they earn a bit more, so there could be some link with income in that 
way (f, academic).  
It was also stated that unemployed people might be more exposed to DTCA as they probably 
have more free time:  
People who are unemployed, they watch TV a lot because they are 
unemployed, or they are at home and looking after children, and they see an 
ad and say oh this can happen and they think that oh this will work for me, 
these are the ones that more likely to be affected (f, pharmacist).  
 Limited Internet access7 was also mentioned as a factor contributing to individuals’ 
vulnerability since they cannot search for more information to validate the advertised claims:  
I suppose people that maybe without internet access can’t just sit on Google 
and quickly research and say you know, what is this product, is it good (m, 
dentist & academic).  
An informant also argued that “People who live in like rural areas; they are less likely to make 
an informed decision about drugs, yeah.” 
 
Theme: Personal Characteristics/Traits 
 Informants argued that personal characteristics such as materialism, excessive trust, 
and thinking emotionally could result in consumers’ vulnerability.  
 
6 Media literacy refers to people’s ability to use and evaluate media critically (Opree, 2017). 
7 Individuals’ technology use and internet access can be linked to their socio-economic status (Jackson 
et al., 2008; North, Snyder, & Bulfin, 2008) and neighbourhood (Australian Bureau of Statistics; 2011; Harris, 
Straker, & Pollock, 2017). 
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 Materialism was highlighted as a factor causing vulnerability to DTCA. It was 
discussed that materialistic consumers might be more vulnerable to DTCA since they may treat 
drugs as other consumer goods. A few informants explained that spending money and buying 
things, even medicines, may ‘bring happiness’ for materialistic people:  
I guess it’s this whole idea that buying stuff or things or spending money on 
something brings happiness or brings a positive outcome, so it’s the same 
kind of thing, it’s that by spending money and getting something, in this case, 
some medication, that will somehow bring a benefit (m, physician). 
Another informant emphasised that DTCA is dangerous for materialistic people 
because they may assume that health information provided through all sources are reliable 
and advertised drugs are safe:  
I think people who are materialistic usually define life in terms of logic, 
which is "if" and "what." Like if I do this, this happens… So they already 
have a logic model for their life. So, it's just not on the medication, they have 
got a prescriptive life, given the kind of selective information they are getting 
from an advertisement or literature, or even hearsay from people they are 
supposed to believe in. I think if you find that there is something which is 
written, you probably understand that nobody is trying or can play with your 
health… I think is particularly dangerous for the medical industry, that there 
is an earlier belief that you are going to a doctor, any information that is 
being provided to you in terms of media about a particular health issue is 
unadulterated and cannot have anything, which can be potentially harmful 
to you (m, physician & academic).  
 Some informants stated that people who are generally “trusting” (with a high level of 
‘ad trust’8), “gullible”, and “impressionable” are less able to make informed choices since 
they do not criticise the provided information and are more likely to be influenced by positive 
aspects of the advertised drug. The following verbatims illustrate these points:  
…The ethics I guess depends on who it’s being marketed to, if it’s being 
marketed to someone like myself or someone that is familiar with the way 
advertising works, then they can peel back the layers but if someone is more 
trusting or doesn’t normally think that way in terms of maybe isn’t as cynical 
 
8  ‘Ad trust’ refers to “the confidence that advertising is a reliable source of product/service information 
and willingness to act on the basis of information conveyed by advertising” (Soh, Reid, & King; 2009, p. 86). 
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with regard to advertising, then certainly they’re gonna be influenced by all 
the positive side of things without thinking that there may be any sort of 
negative side of things, so it’s like any advertising I guess, yeah (m, 
physician). 
 I think some people are more gullible than others; some people have more 
realistic or unrealistic expectations (m, physician & academic).  
…Someone else who’s very impressionable… almost invariably will fall prey 
towards them (m, dentist & academic). 
On the contrary, “savvy” or sophisticated9 consumers might be more capable of making 
informed decisions since they are more ‘critical’ toward advertising, may seek other sources to 
find more information, and thus are less likely to be swayed by drug advertising: The following 
two quotes are examples of data coded under this characteristic:  
There are some very savvy internet people and very savvy and very critical 
people out there; they don’t necessarily have to have University degrees to 
be like that, it’s just in their nature to want to know what’s happening (f, 
pharmacist).  
I know different people are affected by advertising differently, you know like 
I’ll just think of my husband, for example, he’s quite sceptical actually when 
he sees things, he’s like oh surely it doesn’t do what it says it can do. So, I 
think he would actually not just see one ad and go for it but he’d research 
and talk to his doctor and research some more to find out what’s appropriate 
but then some people might have different personalities and might be more 
swayed by one ad and might not make such a good decision based on one 
ad….I think it depends on the person (f, pharmacist). 
 Furthermore, being impulsive and having emotional thinking emerged from the 
data analysis regarding the characteristics of vulnerable consumers. An informant stated that 
consumers who are generally “impulsive” are less able to make informed decisions in 
response to DTCA:  
If someone’s impulsive and just sees an ad and goes for it, then they might 
not be making an informed decision if they’re not getting more information 
(f, pharmacist). 
 
9 “Sophisticated consumers are defined as those member of the market who have been exposed to many 
advertising and selling approaches and have attained cognitive abilities that serve as adequate defense against 
these techniques” (Almgren, 2014; Rittenburg & Parthasarathy, 1997, p. 52). 
121 
 
Likewise, consumers who think and decide emotionally rather than logically are less able to 
make informed decisions based on DTCA:  
I guess people who aren’t used to in their everyday thinking through 
decisions on a considered basis [are less able to make informed decisions],... 
you know some people make decisions very much based on emotional or 
some other sort of characteristic as opposed to actually thinking through 
analytically (m, physician).  
I’m not saying I or you can’t get influenced, but I think I’ll be a lot less likely 
to because I have a more scientific mind so I’ll be able to sift through the 
information and really tell if it’s all to my benefit or if they’re actually hiding 
the real deal as well but someone else, you know if they prey on your 









4.4.3 Part Three: Recommendation 
 Thematic analysis revealed that informants with negative views generally held one of 
two positions on DTCA: an absolute position or a relativist position. Those with an absolute 
position were in favour of banning DTCA. In contrast, informants with relativist views 
highlighted factors that could contribute to ethical DTCA that would enhance informed 
decision-making. These recommendations were arrived at by exploring informants’ thoughts 
and positions on the social responsibility and, in particular, the ethicality of DTCA in its current 
format in New Zealand. A schematic of all dimensions/themes hierarchy regarding ethicality 
and legality factors contributing to socially responsible DTCA is presented in Figure 4.3. 
 
 
Figure 4.3: Ethicality and legality factors contributing to socially responsible DTCA 
 
4.4.3.1 Absolute Position 
Dimension: Banning DTCA 
 A few informants held an absolute position (“strong ethical stance”) that DTCA cannot 
be offered ethically and suggested “a radical plan” to ban DTCA in New Zealand:  
I think you take quite a strong ethical stance, where you actually believe it is 
a matter of ethical principle because all drugs should not be advertised to 
patients if they’re prescription only (m, physician & academic). 
Personally, I would like to see no DTCA in New Zealand (f, academic). 
I think we should also come up with a radical plan to remove all the [ads]… 
because I think it is not ethical and it misinforms the patient… (m, physician). 
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For the dimension of banning DTCA, four themes developed from the analysis, namely: DTCA 
cannot be regulated; DTCA is unethical by nature; drugs should only be advertised to health 
professionals, and the public should be provided with independent consumer health 
information. 
 
Theme: DTCA Cannot be Regulated 
Some informants believed that DTCA should be banned since both central-regulation 
and self-regulation are problematic. Informants regarded self-regulation as time-consuming, 
ineffective and like “marking your own homework”:  
They have a massive, massive direct to consumer advertising [budget], and 
it still tends to rely on people making the claims rather than looking at that… 
If you look at the ad and try to check that ad, it is a big job! If you gotta go 
back to the references that are quoted and look them up to see if that’s a 
reasonable claim, that kind of peer review is extremely time-consuming. This 
self-regulation is not gonna be effective. Everybody decides what they are 
going to write. As someone said, it is like marking your own homework. And 
most governments won’t put the money in to do that. Self-regulation doesn’t 
work.  So the best thing is not to have it as the rest of the world has decided 
(m, physician & academic). 
Central government regulation was also seen as ineffective due to a lack of necessary 
resources to monitor DTCA in New Zealand:  
My general view is that it would be better if we didn’t have it. It is a poor 
substitute for independent consumer health information. It is largely 
unregulated... Central government doesn’t have the resource to monitor it, 
and it is of net harm (m, physician & academic).  
  
Theme: Unethical Nature of DTCA 
DTCA cannot be offered ethically because it exists to generate demand. 
I don’t think you can [make DTCA more ethical], I don’t think it is possible! 
As long as it is advertising, it cannot. They are mutually exclusive! Balanced 
information and advertising cannot live together. That is not how advertising 
works. Providing information is one thing; advertising is another. 
Advertising has a desire; it has an inbuilt end inside, which is to increase the 
124 
 
use of whatever it is being advertised and not just to the point, of what would 
be the benefits of it! It appears to go beyond that (m, physician & academic). 
 
Theme: Drugs Should Be Advertised Only to Health Professionals 
The delivery of medical information should be left to a doctor-patient interaction since 
every patient, and their conditions are different. One size fits all DTCA is therefore imperfect:  
It is a television set; it cannot deliver [the] same amount of information, 
which a doctor delivers when a patient sits with him [sic] because every 
patient is different, his [sic] condition is different. We just can’t give him 
[sic] a gentle medicine or a pill, which will cure his [sic] condition. So, I 
think these things should be left to a doctor/patient interaction rather than 
advertising something on the television (m, physician). 
 Some informants thought that patients did not have enough knowledge to make 
decisions: 
I think the government should not allow direct to consumer advertising… I 
mean the US and New Zealand are the only two countries, and I think that’s 
for a reason, I don’t think the public is discerning enough or has enough 
medical knowledge to be able to understand what’s right and what’s wrong 
(f, physician & academic). 
The public do not need to make decisions about medical treatment. Instead, they should 
decide about less professional issues like their lifestyle behaviours:  
I think the things that they should be making decisions about are their day-
to-day good healthy lifestyle, you know like a public health initiative rather 
than [as] a medication problem solver (f, pharmacist). 
 
Theme: Public Should Be Provided with Independent Consumer Health Information  
 Instead of DTCA, the public should be provided with impartial and independent 
consumer health information. Further, some suggested a strong consumer voice that works with 
health professionals would be a better use of public money than ineffective central regulation:  
So having a strong consumer voice that works with the profession to provide 
independent health information. … that’s a better use of the public money 
than try to ineffectively regulate advertisers who wouldn’t care to have the 
best for people (m, physician & academic). 
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Another informant argued that DTCA offered by industry medicalises normal conditions 
and thus suggested having a group of consumer associations to provide independent health 
information for consumers aimed at informing people about medical conditions and treatments:  
You can get a group of people together, who don’t have any interest. So, 
would you have lines of consumer associations, like consumer organisations, 
the Universities, Medsafe, clinical pharmacologist…. They do this in some 
Scandinavian countries. There is a public campaign to help people have 
reasonable expectations of what they can and what they cannot get from 
medicines. Explain to people about disease mongering, overdiagnosis, 
overtreatment, and that they don’t need a pill for everything. Because the 
industry is there and tries to medicalise normality. So, everybody is unhappy, 
they must be depressed. Everybody who has BMI over 26, they need 
something. If you go to the toilet more than twice, you have an overreacted 
bladder… These are the diseases created by the industry to match the pills! 
So educate the public about that. I mean there is some material out there, but 
a drop in the bucket really, in comparison to the amount of advertising (m, 
physician & academic). 
 
4.4.3.2 Relativist Position: Factors Contributing to Socially Responsible DTCA 
In contrast to the absolutist position just outlined, most informants had a relativist 
position toward DTCA. They had concerns regarding DTCA and believed that it is not ethical 
in its current form in New Zealand. They thus suggested some amendments to DTCA and the 
existing regulatory system to help individuals make more informed decisions. 
 Based on the concept of corporate social responsibility, informants’ views on how to 
develop socially responsible DTCA could be divided into four ethical factors and one legal 
factor. Ethical factors were: content of DTCA, types of advertised medicines, types of 
DTCA channel, and DTCA providers. The legal factor found concerns with current 
regulations. 
 
Dimension: Ethicality regarding the Content of DTCA 
 Major concerns were noted about the content of DTCA. Four discrete recommendations 




Theme: DTCA Should Have Credible, Factual, and Not Deceptive Contents 
 DTCA should provide accurate information and avoid active opportunism in order to 
be ethical. DTCA should not exaggerate the efficacy of the advertised drug and not present it 
as a perfect medication:  
It’s best to have accurate information when you are advertising; you’re not 
saying anything untrue (f, pharmacist). 
The advertisements’ permissive perfections [presenting the product without 
imperfection] are to be balanced by the actual facts (f, pharmacist).  
DTCA should not use marketing tactics, and persuasive appeals to emotionally 
influence consumers. Instead, it should offer simple information:  
They should not use special marketing techniques to try to influence people. 
It should be very basic and plain rather than psychologically influencing 
them (f, physician). 
They should not embellish the commercials, because sometimes it is almost 
appealing to take the medication because the people are so pretty, the 
outcome is so nice, you feel almost motivated to do that (m, physician).  
Pharmaceutical companies should be cautious about the content (i.e., wording and 
imagery) so as not to mislead and give unrealistic hopes:  
Be cautious about what they include in their wording because it has a very 
big impact …Have to be quite careful about what they say in an 
advertisement not to mislead anyone that is thinking it is the one and only 
thing that they need (f, pharmacist).  
 
Theme: DTCA Should Provide Complete Information 
 Informants considered that DTCA needs to present comprehensive and balanced 
information and avoid passive opportunism:  
I think ideally it should explain the specific use of the medicine, so the 
potential benefits, which they usually do; also, discuss that there may be 
harms associated with medicines, that there may be costs or inconvenience 
so the patient may have to pay more or there may be a consultation 
involved…. I think probably to focus less on the amazing benefits of a 
medicine but just say that the medicine is available and to discuss it with 
your prescriber and ultimately the prescriber would need to make an 
informed choice (m, pharmacist).  
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DTCA should also provide a warning that if you are taking other medication, you need to 
consult a doctor:  
There should be a level… sort of precautions… level of warning in the ads 
that if you are taking other medication, they need to consult a pharmacist or 
doctor… they need a warning rather than stating it is a wonder drug that 
treats everything (f, pharmacist). 
 It was also reflected that positioning and print-size of side effects are important:  
I rarely think the amount of space given on an advertisement for risk 
information [is enough], and the amount of space and time on TV, it is just 
1 second with all the bad, and that is something that needs to be more 
obvious, more balanced. [In print media] They usually bring the side effects 
at the very bottom in tiny font. It is not good (f, pharmacist). 
It was similarly noted that information on DTCA should be provided in an “accessible 
format”:  
When people are watching television or they’re doing things on their 
computer screen, it has to be readable. So,… I think the information has to 
be in an accessible format. If it’s there, you have to be able to read it (f, 
pharmacist). 
DTCA should also highlight that the advertisement is not health information:  
We can have something that says at the beginning and the end to reinforce 
that it is a prescription medicine; it’s not a real health guideline or advice ... 
Then I think that can make it more ethical (m, pharmacist). 
 Many informants suggested that DTCA should also inform about available alternatives:  
It is not ethical if you portray yourself as the only medication that will work; 
there are other medications out there that could work just as much. 
 I think it’s probably a good idea that they mention that this is one treatment, 
but there may be other treatment options you prescriber may choose ahead 
of this one (m, physician).  
Informants also felt that it was unethical that pharmaceutical companies advertise a brand when 
generics or other cheaper options are available.  
I would say the ethicality of DTCA is extremely limited especially when 
corporations are getting involved, especially when a pharma company 
advertises their particular brand when generic products come out. The most 
obvious one would be Ventolin. We at the moment have subsidies for the 
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generic form, but patients are still coming and requesting Ventolin, while 
they are two inhalers and are the same. The same for Viagra, because there 
is a lot of heavy advertising, and I think it breaches the ethicality of it. 
Because now, we are targeting a particular brand for consumers, but at the 
end, they want a product that works for them, but the generic one should do 
the same. But pharma companies don’t do that. I think at the moment they 
are breaching the ethics (f, physician). 
 Some informants stated that DTCA should provide visual aids since they are easier to 
comprehend and remember than words. They argued that pictures of negative side effects (e.g., 
vomiting or ulcers) in DTCA could help consumers’ informed decision-making:  
I'm a firm believer in pictures, and I think reading a particular word is not 
that good rather than a picture. So, if somebody is going to tell me, "Okay, 
this might lead to vomiting," that's a different thing. But if I see somebody 
vomiting, I know what it is. This might lead to liver cirrhosis. But when I see, 
okay, there is a picture of a liver which is just bloated up, then I know what 
it is. Or if it's a Panadol, and it shows that it might lead to an ulcer, then I 
see an ulcer.... I think at least two to three main things, side effects can be 
put on the advertisement,... more picturesque, more media orientated (m, 
pharmacist). 
Some diagrams, not just wording, to help people who are visual learners; 
pictures, something other than words. Not everyone has the literacy to read 
all the words. Advertising is usually short, and no one is gonna really read 
all the information. Visual aids help people remember and help educate 
people (f, pharmacist).  
 Some informants recommended elaborating on information by providing numbers that 
help consumers to understand the message:  
I think especially if there was some explanation about numbers needed to 
treat and numbers needed to harm... If those two things were included in the 
advertisements, I think that would make it much clearer... 80 people need to 
take this before one person benefits (f, physician & academic). 
 
Theme: DTCA Should Focus on the Disease Rather Than a Specific Drug 
        DTCA should inform about the illness and preventative measures rather than the 
treatment so that DTCA does not result in over-medicalisation. Once people are aware of an 
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illness, they can go and seek the appropriate treatment, which is useful for both the industry 
and the consumers:  
I think as a part of the corporate social responsibility of the pharmaceuticals, 
if they have made a particular medication, while stating it can be helpful to 
society in general, I think there should be more of a preventative aspect of 
the disease, or about the disease. The content should focus more on: what 
diseases, and what are its causes, and how you can reduce it, rather than 
giving an all-out solution, by having this one pill (m, pharmacist). 
 
Theme: DTCA Should Communicate Lifestyle Behaviour 
 DTCA should inform consumers of suitable lifestyle changes. For example, it 
was noted that: “Communicating health behaviour [in DTCA] would be appropriate for most 
people” and the “majority of advertisements should be lifestyle based.” 
Healthy lifestyle behaviours can “help improve the quality of health”, are “easy to 
implement”, and are not expensive. For instance, informants discussed that: 
For example, if they’re promoting, like an asthma medication, they could say 
also beneficial if you stop smoking and don’t drink alcohol daily, and 
exercise. Yeah, maybe lifestyle factors that are easy to implement would 
probably be beneficial as well and save them more money. If they could 
control whatever their problem was with free methods – diet, exercise – then 
you know, they might not even have to spend their money on these 
medications (m, dentist & academic). 
 
Dimension: Ethicality Regarding Types of DTCA Channel 
 Most informants thought that the type of DTCA channel is very important, and some 
channels are not ethical (which can be again due to their content limitations). The following 
themes emerged in this regard. 
 
Theme: Print DTCA Is More Ethical 
 Most informants believed that only printed/written advertisements (e.g., in magazine and 
newspaper) are ethical for prescription drugs since they are “static”, and people have more time 
to read, process, or refer back to the information:  
Actually, I do think that if you want to make it legal/ethical for medicines to 
be advertised, it should only be printed (f, pharmacist). 
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I’m happier with the ones that are least effective if you know what I mean so 
the ones that might be in a newspaper or a magazine because they’re just 
fixed there, it’s not sort of like in your face all the time, and it’s not a moving 
picture. I mean they’re always just static images. I think I’m probably 
happier with those and also because you can read the writing much more 
carefully at the bottom (f, physician & academic).  
It was also felt that it is easier for people to understand new information when they read it 
rather than just listening to it:  
I think written advertisements would help. It is easier because if people listen 
to something for the first time, it is hard for them to take it on board. 
Probably they need to see something like in a magazine advertisement (f, 
physician). 
 
Theme: DTCA on TV and Radio Is Not Ethical 
 Many informants discussed that DTC ads on TV and radio are not ethical since they are 
“the least informative”, “limited”, and “fast”. Moreover, people are not able to “refer back” to 
that information:  
I would ban it on television and radio because that is the least informative 
and the most selling, the most unethical because of the time constraint (m, 
physician & academic). 
 Especially, it was stressed that DTCA on the radio is not ethical since people can only 
hear the information: 
 [On] radio, you don’t always pick up all the information because you’re 
only listening, you’re not seeing or able to refer back to it like a magazine 
[that] you can go back to and look at because a radio ad is so fast that you 
might not pick up all the information that you need (f, pharmacist). 
 Even though there are both visual and audio on TV, DTCA was not seen as ethical on 
the TV since it is very “brief”, “positive” and “designed to attract [people]”. It was highlighted 
that it is hard to provide sufficient health information on a TV advertisement in 30 seconds, so 
the advertisement just suggests ‘asking your doctor if it is right for you’. However, “by the 
time they [people] come to the professional, they might have already made up their mind.” 
Similarly, it was stated that:  
TV, I guess is again a bit like the radio, it’s very fast, and you can’t refer 
back to it, you’ve got the visual and the audio as opposed to the radio, but 
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it’s still fast where you can’t refer back to further information, like look up 
the side effects or look up the contraindications (f, pharmacist). 
 DTCA on TV could be seen as misleading since the visual effects distract consumers 
from reading the written information:  
If it’s the TV advertisements, you’re constantly looking at the picture. I didn’t 
notice the text or what the text was saying so if it’s a TV advertisement, it’s 
really misleading (m, pharmacist).  
Further, the almost news-like nature of some advertorials was considered to be misleading:  
The one that I particularly remember is those news programs, like health 
news10 and all that, they portrayed themselves as very well-informed 
reporters who are providing ethical information to the consumers that are 
not biased and bring to one party. Those ones are the ones that I am worried 
about because it counts as news, not advertising but it looks like the same. 
When the consumers are sitting down, eating dinner and watching TV, and 
think that this is a well-informed news segment. That is the wrong kind of 
advertising (f, physician). 
 
Theme: DTCA on the Internet Is Not Ethical 
 Some informants mentioned that DTCA on the Internet is not ethical because there is 
too much information on the Internet, and it is less regulated and supervised than other 
channels:  
I get very concerned about the internet stuff where it doesn’t matter what you 
do, what you’re looking at... The internet stuff’s a little more shotgun 
approach; it’s a bit more random and somewhat less controlled (f, 
pharmacist). 
 
Dimension: Ethicality regarding Types of Advertised Medicines on DTCA 
 Advertising some types of medicine was perceived as unethical by some informants: 
“Obviously, there are some medicines, which should not be advertised over others if we had to 
choose.” For instance, advertising of controlled drugs, addictive drugs, drugs for life-
threatening conditions, drugs that have serious side effects, psychiatric drugs, and medications 
 
10 The informant is likely to be referring to an advertorial segment like Family Health Diary, often fronted 
by a well-known television personality, with an interview like structure. 
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targeted at kids was considered unethical. However, DTCA was noted to be ethical for public 
health issues, such as social and preventative health measures. 
 
Theme: DTCA for Controlled Drugs and/or Addictive Drugs Is Not Ethical 
 It was stressed that advertising of “controlled drugs”11  is not ethical:  
Controlled drugs should not be advertised… they can be abused, any 
controlled drug with the potential for abuse should not be advertised… 
because they are for the people that really need them (f, pharmacist). 
 
Theme: DTCA for Acute and Life-threatening Conditions Is Not Ethical 
It is not ethical to target lay individuals with acute and life-threatening conditions, “who 
do not understand how that particular medication works”, where “there are too many factors 
that affect decisions about the best treatment for the patient.” DTCA sometimes influences 
people by using emotional techniques, such as ‘fear appeals’. Promoting expensive medicines 
for serious and life-threatening conditions, such as cancer and diabetes, making use of patients’ 
fear, and causing unrealistic hope was stated to be unethical:  
I think promoting oncology drugs and saying go and see an oncologist to see 
if it is right for you. That is trading in fear; it is selling hope. When often it 
is an inappropriate hope. And it is often very expensive (m, physician & 
academic). 
I think when people are feeling desperate, as we were talking before about 
selling hope, advertising of expensive medicines for people who are 
extraordinary unwell is particularly unethical. Particularly if they use kind 
of emotional techniques, which they often do (m, physician & academic). 
It was similarly argued that advertising of medications that are targeting people with 
chronic conditions is unethical:  
I definitely believe anything to do with the heart without getting proper 
physician’s advice, especially any chronic conditions like asthma, arthritis, 
and all that, those ones that are really targeting consumers, because it is a 
life decision for them basically (f, physician). 
 
 
11 Controlled drugs/medicines are the medicines that are more tightly controlled than other prescription 
medicines, reflecting the need to restrict their access, and minimising their misuse, usually because of their 




Theme: DTCA for Medications that Have Serious Side Effects Is Unethical 
 Informants pointed out that DTCA for drugs that have serious side effects is not ethical:  
I think medications that have a heavy set of side effects should be less 
advertised (m, dentist & academic). 
Maybe medicines that have side effects or more powerful side effects, they 
should be cautious with advertising (m, dentist & academic). 
Further, it was discussed that DTCA where the health benefits appear not to outweigh the risks 
is not ethical. For instance, DTCA for cosmetic reasons such as “weight loss” was considered 
unethical:  
Probably not advertise medications that would cause harm more than benefit 
patients, like the weight loss thing [Reductil]… I think maybe patients just 
demand things like that in front of their prescribers (f, pharmacist). 
It was also argued that the ethicality of DTCA depends on the efficacy of the advertised drug 
across the broader population:  
How ethical it is I guess depends on how effective on a population basis 
something is so if it has a high yield and is effective for most people, then it’s 
pretty reasonable and ethical to advertise that knowing that most people are 
going to get some benefit from it. But if it’s a medication where I guess very 
few people will get a questionable benefit, then that’s on the other end of the 
spectrum I guess (m, physician). 
 
Theme: DTCA for Psychiatric Medications Is Unethical 
 Overall, informants argued that DTCA for psychological conditions, such as ‘anxiety’, 
“depression”, and “dementia” is not ethical since the target consumers are not able to make 
informed choices:  
I would think probably some psychiatric medications also would be 
something where you’d have to be careful about as someone who has the 
illness can’t make a judgement (m, physician & academic). 
Things for like anxiety and depression and mental health problems are less 
ethical (f, academic). 
 
Theme: DTCA for Drugs Targeted at Children Is Unethical 
   It was discussed that advertising drugs targeted at children is not ethical since they are 
not able to make choices:  
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I maybe have some concerns about advertising drugs specifically for 
children because the adult will have to buy them and there may be issues 
around the child being able to give consent or agree to it (m, physician, 
academic). 
Further, informants thought that parents with a sick child are often more susceptible to DTCA:  
Advertising to parents [is not ethical], parents are always very vulnerable 
when you’ve got children who are sick because you’ll worry about your child 
and you are concerned about your child. So, adverts that offer better asthma 
control, that’s the only one I can think of at the moment, you know, when 
you’ve been up or had a child who’s been sick for several days, it’s going to 
influence you. You’re going to be more susceptible to that (f, pharmacist). 
 
Theme: DTCA Is Ethical When It Helps Improve Public Health  
DTCA was perceived as positive when it helps increase awareness about the disease 
and improve public health (e.g., for “social and preventative health measures”) since it 
increases individuals’ awareness:  
Yeah, most of the time [it is unethical]. Except when it is based on a gain, 
for social and preventative health measures. For example, medications 
which are particularly in ads to stop smoking,... or to go around other things 
that might be of use for example: cold medications, it's still okay. HPV is 
okay, STD, prevalent diseases, still okay (m, pharmacist). 
Similarly, DTCA was perceived as ethical for communicable diseases, such as 
tuberculosis:  
I think that a disease that has the potential to harm the public, like that is 
very transmissible. If you want to prevent that from happening, then the 
advertisement would be okay (m, dentist & academic).  
 
Dimension: Ethicality regarding DTCA Providers 
 This dimension came up in discussions on the social responsibility of pharmaceutical 
companies promoting their products directly to consumers. Informants believed that 
“pharmaceutical companies have a huge responsibility in this society.”  
 
Theme: Driving Force Should Be Improving People’s Health 
Many respondents thought that the main objective of DTCA is to persuade consumers 
rather than providing useful health information. They expressed that most of the driving force 
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of DTCA is money: “[DTCA] is a tool that the drug company is using to make more money.”  
Similarly, it was discussed that there is a huge financial incentive behind drug 
advertisements:  
They [DTC ads] are commercials, they are made to influence and gain profit 
from them and also they have to make sure that they are pleasant enough (m, 
physician). 
 Informants, however, articulated that manipulating people’s desire for their health is 
not ethical, and thus DTCA should not be commercialised:  
Marketing particular products with the intention of getting money from 
people’s desire for their health I think is wrong (f, physician). 
The main goals of DTCA cannot be just to sell; it should be the ‘promotion of health’:  
If it is done with the purpose of making money, I wouldn’t say that is ethical. 
To use someone’s desire to be healthy, to put it into their head that if they 
take this particular thing when there are other things available that aren’t 
as expensive, I think that is morally and ethically wrong to do that (f, 
physician). 
If it [DTCA] is about the promotion of health, yes [it is ethical], but it is not 
so No [it is not ethical] (m, pharmacist).  
It was noted that consumers’ safety and wellbeing should always come first for 
pharmaceutical companies:  
I think the safety of the consumer has to be the paramount consideration and 
then followed by the cost to society so that you’re talking about the cost of 
the medications, the increased costs to the health system by the advertising. 
And I actually think that the lowest priority should be the business 
considerations because if the product is really good, then it’s gonna be 
prescribed regardless of whether they put advertisements on TV and I think 
the wellbeing of the patient needs to come first (m, pharmacist). 
Moreover, one informant highlighted that pharmaceutical companies need to wait for 
longer-term safety and effectiveness of their drug to be demonstrated before starting DTCA:  
The problem is that companies are kind of pushed to put the product out 
really quickly without possibly waiting for longer-term effects and so that 





Theme: Should Select the Target Audience Ethically 
 It was discussed that pharmaceutical companies should select their target audience 
ethically: “… It [ethicality] depends on who the advertisement is being targeted towards.”  
 Some informants argued that although it is not ethical to advertise to vulnerable groups, 
pharmaceutical companies do sometimes target vulnerable consumers. The following 
references illuminate the unethicality of adverting drugs targeted at vulnerable groups:  
I think the companies would have to be careful not to give patients an 
unrealistic expectation or to target people that might be vulnerable as well. 
Some of them are very unethical. In early 2000, when we had an 
advertisement for instance for Xenical, which works by blocking the 
absorption of fat in the bowl, that was promoted on TV, with a series of 
advertisements, absolutely targeting the poorest section of Maori and Pacific 
people (m, physician & academic). 
 DTCA often employ marketing techniques to target and reach more vulnerable 
consumers:  
…Advertising might be directed at a certain demographic. Pharmaceutical 
companies often employ people with marketing research, and they find out 
what that specific group is looking for, and they mention all the keywords, 
and it’s a done deal (m, pharmacist).  
 However, since vulnerable groups are not able to make informed choices, DTCA should 
not target and influence them:  
…Given the nature of the vulnerable groups, we shouldn’t be advertising to 
these vulnerable groups (m, physician & academic). 
These are the groups that you should be a little bit more careful in terms of 
the wording that you use. Avoid if there is some sort of wording that they 
click when they see it, particular sort of word that advertising uses to prompt 
them to think that this is quite good (f, pharmacist).  
 
Dimension: Current and Future Regulations of DTCA 
 Concerns were noted regarding the current regulation of DTCA in New Zealand. Some 





Theme: There Should Be Stricter Regulations and Supervision Of DTCA 
 It was argued that the current rules on DTCA are not enough to protect consumers:  
Definitely, at the moment, the ethicality of it is a bit borderline. I think 
comparing to other countries, in NZ we have one of the fewer laws towards 
it… Comparing to other countries, in overseas like Hong Kong, Australia,… 
there are a lot more restrictions than NZ on what can be advertised. I 
remember learning in medical school, when a pharmacologist came, they 
said that you have the most relaxed rules regarding drug advertising in NZ. 
It is a little bit unusual and weird in NZ (f, physician). 
  Likewise, some noted that DTCA should not be self-regulated by the industry and 
needs more regulations and tighter controls:  
Self-regulated DTCA is not good. More monitoring is necessary. 
There needs to be good regulations and controls on the advertising to protect 
the consumers from anything going wrong with them, getting a product that 
wasn’t right for them and regulations on what information’s been shared so 
that there’s not anything inappropriate or too pushy (f, pharmacist). 
 Informants believed that the power of evaluating the advertisements should not be left 
to the consumer:  
I don’t think the consumer has that [the ability to detect deception] like I 
don’t think that power should be left to the consumer. I think there should be 
a body which makes sure that everything is ok before it gets to the point 
where it will be advertised to the consumer (f, academic). 
Many informants suggested having a committee in the governing body to filter out DTCA:  
I think someone from outside (not in the company) needs to come to view and 
monitor the ads to see if what they say is true. So, the ads need to pass 
through the government in that way, and not solely be just from the company 
(f, pharmacist). 
It was similarly recommended to have an independent health professional “advisory board” to 
watch pharmaceutical companies and control all drug advertisements before reaching 
consumers:  
I think they need to have some sort of advisory board. If there is an 
independent board who looks at all of these things. A board made up of 
nurses, pharmacists, doctors, healthcare professionals, then they have the 
accountability, and they can read the article, and they can look all the 
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research, and find oh this company puts something here that is not true (f, 
physician). 
 Some informants also recommended having nonprofessional people in the disciplinary 
committee to check DTCA. It is necessary to see what kind of “impression” laypeople get from 
DTCA:  
They should have lay people involved in the disciplinary body, so they can 
say what they think is misleading. People working in the field can filter info 
out (about what is misleading and what is not), but maybe the general public 
can’t.  So they can involve someone in the governing body when formulating 
the ads (f, pharmacist). 
Have lay people involved in formulating the advertisements to see what to 
include, what not to include, what sort of impression they get when they see 
the ads (f, pharmacist). 
 
4.5 Discussion 
 This research studied health professionals’ perceptions of DTCA as they have 
experience and/or knowledge with DTCA. The findings from this study make several 
contributions to the current literature. Overall, conducting this study in New Zealand is 
important as most research on DTCA is from the United States. The core contributions are 
extending the knowledge of informed decision-making in the DTCA context, presenting the 
issues regarding the nature and ethicality of DTCA, indicating the characteristics of consumers 
who are more vulnerable to DTCA, and establishing a framework for socially responsible 
DTCA. This qualitative research also explored and improved understanding of the quantitative 
studies of this Ph.D. thesis, which are discussed in more detail below. 
 Initially, both positive and negative outlooks were captured by exploring informants’ 
thoughts on DTCA; however, only a few informants were in favour of DTCA in its current 
format. According to informants, having autonomy and access to DTCA can increase 
consumers’ empowerment/proactivity, which can be associated with feelings of control over 
treatments. Notably, this feeling of control was further linked to adherence to therapy, which 
could result in being more committed to medication therapy. References were also made about 
DTCA decreasing the hierarchy and power imbalance between doctors and consumers, which 
can give consumers’ the ability to have an active role in their treatment. Most informants, 
however, had negative views on DTCA. They had major reservations about DTCA in New 
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Zealand, perceived DTCA as unethical, and identified factors affecting consumers’ informed 
decision-making. These findings are discussed in the following parts.  
 Many informants were concerned with the ethicality of DTCA, and how it affected 
consumers’ informed decision-making. In the opinion of informants, in order to offer ethical 
advertising, the main goal of drug advertising should be to inform individuals. However, 
informants perceived that the main objective of DTCA is to make money, in agreement with 
extant research (Abel et al., 2006; Schwartz et al., 2009). The current study reinforced previous 
research on advertising that suggests the ultimate goal of advertising is “persuading target 
consumers to adopt a particular product, service, or idea” (Meyers-Levy & Malaviya, 1999, p. 
45). Importantly, the thematic analysis revealed the novel finding that DTCA can be persuasive 
when pharmaceutical companies use ‘the appeal to authority’ to express knowledge/expertise 
(e.g., by showing an expert in a white coat to influence consumers to believe the message). 
According to the Elaboration Likelihood Model (ELM; Petty & Cacioppo, 1981; 2018), 
persuasive advertising can work through informative and/or emotional appeals (Chaiken, 1980; 
Koinig, 2016; Petty et al., 1983; Petty & Cacioppo, 1986), with this study arguing that DTCA 
contains predominantly emotional appeals. The interpretation of results linked persuasiveness 
to the emotional nature of the appeals and showed that DTCA is frequently persuasive by using 
positive or negative emotional appeals to manipulate and induce the emotions of consumers. 
The findings contribute to the extant research (e.g., Koinig, 2016; Main et al., 2004) by 
elaborating at a deeper level the ways in which DTCA can be persuasive, specifically by 
drawing focus away from actual information through inducing emotions in connection with the 
picture, using general words, and/or associating the medication with the sense of the good life 
like happiness and freedom rather than using specific words about the medication. Analysis of 
findings also provided a deeper insight into the persuasive nature of DTCA by discussing the 
employment of sex appeal. For instance, some advertisements feature young women to 
persuade individuals into the advertised drug. Informants also discussed the use of negative 
emotional appeals to arouse fear about a medical condition, for instance, by highlighting the 
risks and consequences of being overweight. This can be linked to the construct of perceived 
susceptibility, the amount of vulnerability or risk people allocate to a specific medical problem, 
and/or the construct of perceived severity, the perception of the severity of consequences 
regarding the disease, consistent with the Health Belief Model (Becker, 1974; Belcher et al., 
2005; de Wit et al., 2005; Koinig, 2016; Rosenstock, 1974). Of concern, informants discussed 
that consumers might not recognise the persuasive intent of DTCA, reducing the extent to 
which they may resist the persuasive message, especially if the message is relevant to them. 
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The outcomes suggested that if pharmaceutical companies employ emotion in persuasion and 
show a medicine as safe and effective, the target cannot process the message well.  
 Informants cited examples of DTCA with information that was not factual and/or 
informative enough and this was referred to as a general concern. This is in agreement with 
earlier research that discussed that DTCA might misinform consumers by offering biased and 
unfair information or by hiding important information on the risks and symptoms (Abel et al., 
2006; Almasi et al., 2006; Gilbody et al., 2005). The findings in this study provide new insights 
into the literature on opportunism in the DTCA context. According to the concept of CSR, 
DTCA is not ethical in its current form, if it is opportunistic. Since the thematic analysis 
revealed the existence of active opportunism (misleading and deceiving information) in DTCA, 
it can be inferred that DTCA is currently unethical. Results showed that DTCA could be 
deceptive and misleading by overplaying the effectiveness of medicine. Moreover, DTCA is 
often too general and gives consumers a very generic view by causing false beliefs that might 
not be met (i.e., the advertised medicine is an appropriate treatment for every experience, or 
for everybody). DTCA can cause a false sense of security and unrealistic expectations, such as 
the drug will make life fantastic and perfect. Findings also revealed that DTCA is likewise 
unethical due to the existence of passive opportunism (partial and selective information) in 
DTCA. Noticeably, the findings showed that opportunism in DTCA could increase the 
effectiveness of drug advertising, generate demands, and subsequently result in poorly 
informed individuals. To the best of my knowledge, this is the first study to discuss the 
existence of opportunism in DTCA and its consequences, and more specifically link 
opportunism to the ethicality of DTCA.  
Overall, the findings from the views of health professionals showed that the general 
public are not able to understand the information provided in DTCA and make informed 
decisions accordingly. Two predominant themes/explanations were the general public’s low 
health literacy (relative to what they would need to successfully understand DTCA), as well as 
the negative effects of DTCA in increasing perceived self-efficacy. The thematic analysis 
revealed that people often could not identify active and passive opportunism (deceptive or 
partial information) in DTCA, particularly if they do not have any medical background. This 
is the first study to associate the ability to identify opportunism with low health literacy and 
revealed that individuals with low health literacy are not able to detect opportunism in DTCA, 
which can result in their poorly informed decision-making. Some informants discussed that 
even if DTCA offers accurate and complete information, ordinary people have limited capacity 
to comprehend and process medical information and employ it in their decision-making. In 
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other words, they may not have the capacity to understand the positive and negative points 
about the drug, and may not understand their own health conditions. This can be associated 
with low health literacy of the general public. Similarly, prior studies discussed that health 
literacy could affect health communication outcomes by influencing consumers’ ability to 
understand and act on medical information (Thompson, 2016; Wynia & Osborn, 2010).  
To frame the findings and provide a broader understanding of the phenomena, I draw 
on the Capacity Theory of Attention, Theory of Bounded Rationality, and Message Response 
Involvement Theory (Rodgers & Thorson, 2012). The results are consistent with two 
components of Message Response Involvement Theory; i.e., opportunity and ability (Batra & 
Ray, 1985; Rodgers & Thorson, 2012). Individuals may have restricted opportunity to process 
advertising if the message is short or if several distractions exist (Rodgers & Thorson, 2012, p. 
342). Therefore, the existence of opportunism in DTCA can result in uninformed decision-
making. Consumers’ restricted ability refers to “the capacity for a message recipient to process 
marketing communications due to insufficient product knowledge/experience, limited 
intelligence, or complex message design” (Rodgers & Thorson, 2012, p. 567). Similarly, based 
on the Capacity Theory of Attention, the amount of accessible cognitive resources is restricted 
(Kahneman, 1973). Capacity Theory is also in line with Simon’s Theory of Bounded 
Rationality (Simon, 1957; 1997), which explains that individuals have bounded rationality. 
Individuals generally do not have access to all necessary information; but, even if they have, 
they would be incapable of processing it thoroughly and rationally enough to make optimal 
decisions (Kalantari, 2010; Simon, 1955; 1957; 1972; 1997; 2009). Accordingly, even if DTCA 
provides complete information, ordinary people may not be able to process and understand it 
thoroughly.  
 The thematic analysis also revealed the association between consumers’ informed 
decision-making with perceived self-efficacy. This study explored informants’ views on the 
effects of DTCA on consumers’ perceived self-efficacy and subsequently the effect of self-
efficacy on behavioural responses to DTCA and decision-making. It was noted that DTCA 
could shape the way consumers think, and increase their self-efficacy and their belief in their 
ability to make informed choices. This is in agreement with previous research that expressed 
that health messages and the information provided in advertising may increase individuals’ 
self-efficacy (Koinig, 2016; Meyerowitz & Chaiken, 1987). It has also been discussed in 
existing research that DTCA may influence consumers’ self-efficacy if it suggests the ability 
to execute a specific task or proposes that the advertised drug can positively influence their 
health (Rodgers & Thorson, 2012). Results of the current study additionally showed that DTCA 
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could harmfully increase self-efficacy by generating a false sense of knowledge as well as 
beliefs that might not be met so that consumers might inaccurately think that they can manage 
their medical conditions with the advertised drug. The current study thus discussed the novel 
findings that increased self-efficacy could result in uninformed decision-making. In addition, 
increased self-efficacy may cause consumers to feel adamant or passionate about a particular 
medication, which may result in unnecessary or inappropriate prescribing. Particularly, 
findings showed that featuring celebrities in DTCA could increase consumers’ self-efficacy 
and people may place too much faith in advertised medicine and may think that the advertised 
drug is completely safe. It was discussed that overconfident individuals could make a doctors’ 
job very tough by imposing their opinion.  
The examination of the data revealed the importance of doctors’ roles in consumers’ 
informed decision-making. Since individuals are not able to make informed decisions based on 
DTCA, they should get the required information from doctors rather than DTCA and doctors 
should educate patients about the medication being advertised and asked. Similarly, existing 
literature suggested that communications between consumers and influencers affect 
consumers’ knowledge, learning process, and behaviour (Lueg & Finney, 2007). Health 
providers play a key role in educating and supporting individuals’ health behaviour changes 
(Ryan, 2009). In addition, the current study linked consumers’ informed decision-making to 
their trust in their doctor so that the greater the trust and confidence they hold in their doctor, 
the greater the ability to make informed choices. Thus, the findings suggest that, in the absence 
of new regulation, one way to help mitigate the potential negative effects of DTCA is to 
increase the trust in the doctor-patient relationship. 
While various studies have examined consumers’ attitudes and behaviours in response 
to DTCA, the characteristics of ‘at risk’ or vulnerable individuals have thus far received little 
attention. Exploring the types of vulnerable individuals is important to study the effects of 
DTCA on consumers. The findings shed new light on past research on consumers’ vulnerability 
by classifying the characteristics of consumers who are more vulnerable to DTCA or who are 
less able to make informed decisions. These factors were discussed with regard to consumers’ 
conditions, abilities, and personality traits and categorised into five themes, namely, health 
conditions, lifestyle habits, demographic status, socio-economic status, and personal 
characteristics.  
Previous studies discussed that generally people with a serious illness, and 
psychological or physical impairment could be classified as vulnerable (Chiang & Jackson, 
2012). The findings of the current study reinforced and extended the existing literature by 
143 
 
revealing three sub-themes of desperation, serious health conditions, and psychological 
disorders (including abnormal health anxiety) as factors causing vulnerability to DTCA. Many 
respondents mentioned that people who have health issues are vulnerable to drug advertising, 
as they may feel desperate to try anything to improve their conditions. More particularly, those 
with serious health conditions could be more vulnerable to drug advertising since they may feel 
distressed or scared and be less able to make an appropriate judgement. It was particularly 
noted that these individuals are commonly willing to believe the positive aspects of advertising 
and thus the advertised unproven alternative therapy may give them unrealistic hope. This is in 
accordance with Toop et al. (2003), who revealed “many patients suffering from chronic 
diseases are vulnerable to advertising, which use emotional appeals to promise relief” (p. 10). 
Notably, the thematic analysis of health professionals’ opinions revealed a link between having 
a mental illness, including abnormal health anxiety, and being more vulnerable to DTCA as 
these people are psychologically fragile and are more likely to be misinformed and influenced 
by DTCA. Accordingly, it is unethical to advertise medicines for these conditions. These 
findings help to complement the survey results since the vulnerability of patients with 
desperation and psychiatric disorders was not addressed in the survey studies (study one and 
study two). Moreover, the current study highlighted that people with a less healthy lifestyle 
could be more vulnerable to DTCA since they are more likely to have health problems, more 
likely to be reluctant to change, or may think that taking drugs can solve all their health issues.  
 The vulnerability literature claimed that an individual who is old, or is a minor could 
be considered as vulnerable in general (Chiang & Jackson, 2012). The present study contributes 
to existing research by stressing that demographic characteristics could affect consumers’ 
informed decision-making in the DTCA context. Four sub-themes of age, gender, parents, and 
culture/ethnicity came up in discussions on the links between consumers’ vulnerability to 
DTCA and their demographic status. Elderly people, chiefly due to the higher prevalence of 
health conditions, including those affecting cognitive capacity, were discussed as more 
vulnerable. Two theoretical perspectives, Cognitive Theory and Socioemotional Selectivity 
Theory (Ball et al., 2016), support these findings with regard to older peoples’ vulnerability to 
DTCA. The cognitive approach discussed that weakening of cognitive functions and reduced 
ability to prevent attention to unsuitable information result in slower and less concentrated 
information processing (Craik & Jennings, 1992; Hasher, Zacks, & May, 1999). According to 
Socioemotional Selectivity Theory, older individuals are more likely to expect a shorter life 
than younger people, and their motivational changes affect cognitive processing so that 
processing of information is not perceived crucial (Ball et al., 2016; Carstensen, 1992; 
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Carstensen et al., 1999). Moreover, in line with previous studies showing that elderly people 
are more likely to be trusting (Castle et al., 2012; Li & Fung, 2013), the thematic analysis 
showed that informants saw older people as more trusting and less sceptical, so similarly they 
might be more likely to trust the information presented in DTCA, and be influenced. It was 
also stated that DTCA intentionally tries to target and manipulate the gender confidence of 
women. Informants discussed that women could be more vulnerable to DTCA since they tend 
to be more influenced by advertising. This is supported by existing research that discussed 
women are easily prompted by advertising in general (Rajagopal & Gales, 2002). More 
specifically, informants argued that young girls who care about beauty and related medications 
could be more vulnerable especially towards positive persuasive appeals so that if DTCA 
prompts their emotions, they will fall prey to them. The study additionally showed the novel 
finding that parents may be very vulnerable to DTCA when they have sick children. Informants 
raised concerns regarding cultural barriers in informed decision-making and discussed that 
some cultures/ethnicities might be more vulnerable to DTCA.  
 Of note, the present study illustrated the novel finding that personal characteristics such 
as higher materialism, inappropriate trust, and thinking emotionally might result in being 
highly influenced by DTCA and consumers’ vulnerability accordingly. This raises concerns 
about medicines being advertised like other consumer goods and indicates the importance of 
offering ethical DTCA. In contrast, outcomes suggest that savvy or sophisticated consumers 
might be more able to make informed decisions since they are more sceptical and more likely 
to criticise the information offered in advertising. This makes them being less vulnerable to 
DTCA. 
 Informants also elaborated that people who belong to the lower socio-economic strata 
of society, in terms of education/knowledge (particularly health literacy), income, and 
employment, might be more vulnerable to DTCA. This is consistent with the survey results in 
study one. This also confirmed previous research that stated that economically or educationally 
disadvantaged people could generally be considered as vulnerable (Chiang & Jackson, 2012). 
As mentioned before, informants considered that ordinary people generally have limited health 
literacy, which affects their capacity to process DTCA and make informed decisions. Thematic 
analysis linked socio-economics to literacy, and analytical thinking ability, which can 
subsequently affect consumers’ decision-making. Of importance, this study further found all 
three levels of health literacy (i.e., “functional health literacy, interactive health literacy, and 
critical health literacy”; Koinig, 2016, p. 41; Nutbeam, 2000) as factors affecting consumers’ 
vulnerability. The outcomes thus supported earlier studies (Davis et al., 2002; Epstein & Street, 
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2007; Street, 2001) and showed how all three levels of poor health literacy might limit 
consumers’ ability to make informed decisions based on DTCA. Furthermore, this study linked 
low income and unemployment to poorer literacy and understanding, which can subsequently 
cause vulnerability to DTCA. It was also demonstrated that people who live in rural areas are 
less likely to make an informed decision about drugs. This could be related to their lower socio-
economic status (especially lower education) or their probable limited Internet access12. 
Overall, the findings related to the characteristics of vulnerable individuals inferred that DTCA 
should not be targeted at vulnerable groups. 
As discussed earlier, the findings revealed that on the whole, DTCA is not perceived as 
ethical in its current format. Overall, informants with negative views on DTCA could be split 
into absolute and relativist positions on DTCA. Those taking the absolute stance suggested a 
plan of banning DTCA since they thought it is not possible to implement effective guidelines 
on DTCA. The main discussed reasons in support of this view were that DTCA is profit-
oriented, has a misleading and unethical nature, cannot be regulated effectively, and thus drugs 
should be advertised only to health professionals. Notably, it was discussed that both central-
regulation and self-regulation strategies are ineffective. A prominent argument was that the 
public should be provided with independent consumer health information rather than DTCA 
so that information could be shared transparently and not through advertising.  
In contrast, most informants took a relativist stance so that the predominant outlook 
was to modify regulations on DTCA in New Zealand. Informants proposed the factors 
contributing to socially responsible DTCA, aimed at helping individuals’ informed decision-
making. Based on the concept of CSR, informants’ recommendations on how to develop 
socially responsible DTCA were classified into four ethical factors of the content of DTCA, 
types of DTCA channel, types of advertised medicines, as well as DTCA providers and the 
legal factor of current regulations.  
 Overall, this study strengthens the idea that the content of DTCA should be informative 
and not persuasive nor deceptive. DTCA should not use persuasive appeals to influence 
consumers emotionally, needs to avoid opportunism and should provide factual, credible, and 
complete information. Pharmaceutical companies should be careful about using words and 
images so as not to mislead people. The results also indicated that DTCA should be disease-
centred (especially preventative aspects of the disease) rather than treatment-centred, in order 
 
12 Individuals living in rural or remote areas are less likely to have Internet access than those living in 




to avoid medicalisation. DTCA could provide numbers and particularly visual aids, as pictures 
and diagrams are easier to comprehend and remember than words. These should include 
pictures of negative side effects (e.g., vomiting or ulcers) as well as positive outcomes to help 
consumers’ choices. This reinforced and extended the findings of previous research, which 
showed that health information should use numbers to show the treatment effects (Büchter et 
al., 2014).  
Showing the advertised medication as the only option that will work is not ethical. 
Informing individuals about available options, like generics and/or lifestyle behaviours, might 
be a practical resolution to offer ethical DTCA. This supports the proposed guiding principles 
of PhRMA in the U.S., about including information on other existing choices such as doing 
exercise, having a particular diet and other lifestyle alterations for the promoted illness, where 
applicable (PhRMA, 2005).  
 The study also contributes to the body of knowledge on DTCA and CSR by highlighting 
that DTCA on some types of channels like TV, and radio are not ethical since they are fast and 
cannot provide sufficient information and consumers are not able to refer back to them. In 
particular, concerns were raised regarding the news-like nature of some advertorials because 
consumers tend to consider them as an informing news program. DTCA on the Internet was 
also argued as unethical since it is less regulated and supervised than other channels. It was 
however argued that DTCA should be offered only on a printed page considering that they are 
fixed and people have more time to read, understand, think about, or refer back to the 
information.  
 Advertising some types of medicines was also considered unethical by informants. 
Earlier research claimed that drugs aimed at treating life-threatening diseases should not be 
promoted (Carter et al., 2010). The outcomes of the current study both supported and extended 
this research by providing a broader range of drugs that are not ethical to advertise. 
Advertisements for drugs to children and for psychological health were not considered ethical 
since the target consumers are more vulnerable and may not be able to make the right choices. 
DTCA was considered unethical for addictive and controlled drugs, branded drugs with 
generics or cheaper alternatives, drugs with serious potential side effects, and drugs for chronic 
illnesses or acute symptoms. Particularly, it was noted that DTCA for treatment of serious and 
life-threatening conditions such as cancer and diabetes is unethical, as it is trading in fear and 
selling hope considering the fragile situation of the patients. Furthermore, too many factors 
need to be considered before choosing the best treatment for these conditions. Nevertheless, 
results showed that DTCA might be more ethical for drugs with high efficacy, and for general 
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knowledge about medications, particularly when it helps public health and creates disease 
awareness. DTCA is, for instance, ethical for social and preventative health and for medicines 
for infectious/communicable diseases. 
 Findings indicated that the main goal of pharmaceutical companies and subsequently 
the main goal of DTCA should be ethical. It was argued that DTCA should not be purely 
commercialised so that the main driving force should be improving people’s health, and the 
lowest priority should be the business considerations. DTCA should select the target audience 
ethically and should not try to influence vulnerable individuals. Moreover, the findings 
revealed that pharmaceutical companies need to wait for data on the longer-term safety and 
effectiveness outcomes of their drug before starting DTCA. These recommendations can be 
grounded on the concept of CSR discussing that corporations are not considered to be 
responsible if they just increase their returns (Polonsky & Hyman, 2007) so that companies 
need to reach acceptable profits while acting socially responsibly (Miles & Manilla, 2004).  
 Informants taking the relativist stance also showed major concerns regarding current 
regulations on DTCA, especially the self-regulation in New Zealand. They argued that stricter 
regulations and supervision of DTCA are required. Findings highlighted that different 
monitoring policies are required for DTCA. For instance, there should be a committee in the 
governing body, encompassing an independent health professional advisory board, in addition 
to nonprofessional people to fully check DTCA before reaching consumers. 
 
4.5.1 Conclusions, Implications, and Future Lines of Research 
 This research set out to assess health professionals’ opinions and experiences of DTCA 
in New Zealand, primarily through the lens of the CSR concept. The findings and discussions 
were divided into two parts. First, health professionals’ views on informed decision-making in 
response to DTCA and the issues affecting it were presented. Most professionals showed major 
concerns regarding consumers’ autonomy in decision-making, as well as their ability to make 
informed decisions and believed that the patient-centred medicine philosophy of DTCA is 
imperfect and cannot lead to informed decision-making. The results reported here suggest that 
consumers’ capability, self-efficacy, and characteristics could play an essential role in their 
informed decision-making. Outcomes showed that although DTCA is legal in New Zealand, it 
does not seem ethical in its current format. Of importance, the outcomes revealed the existence 
of persuasion and opportunism in DTCA, which consumers are generally not able to detect. 
The findings illustrated that even though most consumers are vulnerable to DTCA and are not 
able to make informed decisions, there are particular consumers who are even more vulnerable 
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to DTCA. This made a valuable contribution to a broader understanding of the issues affecting 
consumers’ vulnerability to DTCA. Overall, considering the nature of DTCA and the lack of 
capability of vulnerable consumers to make safe and informed decisions, it is not ethical to 
advertise drugs targeted at vulnerable consumers. Researchers should thus offer solutions for 
advertising balance to protect consumers, especially more vulnerable ones.  
Informants’ thoughts and recommendations on how to offer socially responsible DTCA 
were demonstrated. Considering that the Advertising Standards Authority (ASA) in New 
Zealand is not adequate for protecting the public from misleading information on advertised 
drugs (Toop & Richards, 2004) and based on the findings of this study, it was suggested that 
some fundamental ethicality changes, in addition to regulatory changes, need to be made to 
ensure consumers’ informed decision-making.  Suggestions were made regarding the content 
of DTCA, types of advertising channels, types of advertised medications, social 
responsibility/ethicality of DTCA providers, and stricter regulations and supervision of DTCA.  
 The results are valuable for researchers, marketers and policymakers. This study 
enhances the literature on informed decision-making, and vulnerability. Notably, the findings 
in this study provide new insights into the literature on opportunism in the DTCA context. This 
is the first study to associate the existence of active and passive opportunism with unethicality 
of DTCA, link the ability to identify opportunism with low health literacy, and show that 
individuals with low health literacy are not able to detect opportunism in DTCA, which can 
result in their uninformed decision-making. The study also provides a theoretical extension of 
the CSR and DTCA literature by developing criteria to guide more ethical DTCA. To my 
knowledge, it is the first study to offer an inclusive framework of factors contributing to 
socially responsible DTCA aimed at guiding consumers’ informed decision-making. The 
findings have important implications for policymakers by informing a guide for future policy 
frameworks. It can also help pharmaceutical advertisers to fulfil the consumers’ right to choose 
and to be educated. The findings of this study infer that pharmaceutical companies should 
integrate CSR strategies into their advertising policies. They thus need to balance their 
commercial goals, public health goals, and regulations in order to be socially responsible. This 
can benefit not only consumers to make informed decisions and subsequently improve their 
wellbeing, but also pharmaceutical companies. Research showed that it is in the company’s 
lasting benefit to be socially responsible (Carroll & Shabana, 2010; Wilkes et al., 2000). CSR 
has a constructive effect on attracting more investors (Okpara & Idowu, 2013), and it helps to 
increase a company’s reputation (Stephenson, 2009). It is a competitive advantage for a 
corporation to improve its relationships with its customers and increase its loyal customers on 
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account of its favourable image (Okpara & Idowu, 2013). Considering all the advantages of 
offering socially responsible DTCA, a question that arises is whether the pharmaceutical 
industry is willing to make DTCA more ethical provided that it may reduce the effectiveness 
of it. Given that offering fully ethical DTCA may still be unpalatable to the industry, banning 
it can be a practical solution to protect consumers from its probable harms. 
 It is important to acknowledge the study’s limitations. First, this research explored the 
thoughts of health professionals regarding DTCA and consumers’ informed decision-making. 
Future qualitative research exploring the perceptions of consumers will shed more light on 
understanding the phenomenon. Moreover, the current study explored health experts’ thoughts, 
knowledge, and experience on the effects of DTCA on consumers’ self-efficacy and 
subsequently, the effect of self-efficacy on consumers’ decision-making. Further empirical 
research could also focus on quantifying these effects from consumers’ points of view. This 
research did not compare informants’ opinions based on their characteristics. This can be 
explored as future research. Future study on the social responsibility of advertising and 
consumers’ informed decision-making regarding over the counter (OTC) drugs will complete 





















CHAPTER FIVE: DISCUSSION AND CONCLUSION 
 
 This chapter includes a summary of the research objectives, results, and discussions of 
the three studies of this thesis. It subsequently presents research limitations, directions for 
further research, and implications of the research. It finally provides specific recommendations 
regarding offering and regulations for DTCA to facilitate consumers’ informed decision-
making, particularly for New Zealand. 
 
5.1 Summary of Findings  
 An extensive review of the literature concerning DTCA showed that vast amounts of 
information from DTCA reaches consumers directly, may pose challenges to individuals’ 
ability to make informed choices, and can cause over-consumption or mis-consumption of 
medicines. This exemplifies the need for socially responsible DTCA. The primary objectives 
of this thesis were accordingly to find factors linking to consumers’ behavioural responses to 
DTCA, provide an in-depth understanding of issues affecting consumers’ informed decision-
making after exposure to DTCA, and to explore social responsibility in DTCA. This Ph.D. 
research comprised three studies (Figure 5.1) and answered five novel research questions to 
reach these objectives.  
 
 
Figure 5.1: Overview of three studies conducted in this Ph.D. 
 
 
Study one: Quantitative exploratory study of factors linking to 
consumers' behavioural responses to DTCA (with an emphasis on 
'at risk' individuals’ responses)
Study two: Quantitative exploratory study of 
lifestyle factors linking to consumers' behavioural 
responses to DTCA
Study three: Qualitative study of informants' 
thoughts on consumers' informed 





 In study one, I examined how respondents with different social backgrounds react to 
DTCA by analysing consumers’ self-reported behaviour after exposure to DTCA. I also 
examined the association between personal characteristics, (including consumers’ attitudes 
towards advertising and drug advertising, knowledge about the safety and effectiveness of 
advertised drugs, and materialism), and individuals’ behavioural responses to DTCA. I thus 
answered the research question: “What are the factors associated with individuals’ self-reported 
behavioural responses to DTCA (with an emphasis on ‘at risk’ individuals’ responses)?” The 
results indicated that ‘at-risk’ individuals (i.e., lower-income, older, poorer self-reported health 
status, less educated, and ethnic minorities), women, those who rely on the Internet for medical 
information, and those higher in materialism were more likely to respond to DTCA. These 
findings arguably exemplify the need for DTCA to be executed ethically.  
The outcomes linking materialism to responding to drug advertising suggest that 
materialistic consumers might treat prescription drugs similarly to other consumer goods and 
are at risk of being influenced by the promotional nature of the advertisements. The link 
between responses to DTCA and materialistic consumption further questions whether DTCA 
is ethical in its current form. Moreover, a favourable attitude towards DTCA predicted 
responding to DTCA and individuals held misperceptions of the safety and efficacy of DTCA. 
Of note, a considerable proportion of participants believed that only medicines that are 
completely safe and/or very effective could be promoted (Khalil Zadeh et al., 2017). These 
misperceptions raise questions regarding individuals’ informed decision-making and the 
ethicality of DTCA; especially given that DTCA is persuasive and misleading (Gilbody et al., 
2005; Kravitz et al., 2005; Toop & Mangin, 2015), is “more likely to cause harm than benefit” 
(Lexchin & Menkes, 2019, p. 62), and often advertises medicines that are in initial stages of 
their product lifecycle that may have adverse effects resulting in market withdrawal (e.g., 
Vioxx, as discussed in Bradford et al., 2006; Evans et al., 2011; Gleeson & Menkes, 2018;  
Onakpoya, Heneghan, & Aronson, 2015). 
 As noted earlier, past research has shown that DTCA can be misleading and emotive 
(Toop & Mangin, 2015), and focuses on taking medications as a solution, rather than changing 
lifestyle behaviours (Auton, 2004). Consequently, individuals with less healthy lifestyle 
behaviours might be more ‘at risk’ of responding to DTCA. I thus extended study one by 
answering the research question, “What is the association between lifestyle determinants and 
self-reported behavioural responses triggered by DTCA?” in study 2. The findings revealed 
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that individuals with unhealthier lifestyles (less physical activity, higher levels of alcohol 
consumption, unhealthier nutritional habits, and higher levels of illegal drug use) were more 
likely to respond to DTCA. The findings question the ethicality of DTCA in its current form, 
as it may lead to the misuse or overuse of medicines for health problems that might otherwise 
be solved with an improved lifestyle (Khalil Zadeh et al., 2019). This is particularly concerning 
given that DTCA does not usually focus on public health issues such as nutrition, exercise, 
addictions, and appropriate consumption of current medications (Almasi, 2006), and DTCA is 
self-regulated in New Zealand by the industry. 
 This Ph.D. research also set out to assess DTCA in New Zealand through the lens of 
the Corporate Social Responsibility (CSR) concept and answered the research question “What 
are health professionals’ perceived factors affecting consumers’ informed decision-making, in 
response to DTCA?” by examining the opinions of expert informants. The findings revealed 
that a minority of informants were in favour of DTCA because they thought it facilitates 
autonomy in consumers’ medical decisions and believed it is consumers’ right to have access 
to medical information and to have knowledge about medicine. In line with existing literature 
(e.g., Adams, 2016; U.S. Food and Drug Administration, 2014), findings also revealed that 
DTCA might increase consumers’ awareness about medical problems and available treatments. 
In addition, some informants argued that DTCA could empower consumers by helping them 
to take more responsibility for their health and by giving them the feeling of involvement, 
which can increase their adherence to the therapy. This opinion is however in contrast with a 
recent study’s findings that showed “DTCA exposure was neither directly nor indirectly 
associated with patients’ medication adherence” (Im & Huh, 2019, p. 980). Thus, there was 
some support for DTCA amongst the expert informants in this study, albeit very limited 
support.  
 Most informants voiced major concerns regarding the potential adverse effects of 
DTCA, and discussed the factors that negatively affect consumers’ informed decision-making. 
Notably, the unethical nature of drug advertising was highlighted. Of importance, the outcomes 
revealed the existence of persuasion and opportunism (misleading and partial information) in 
DTCA, which consumers are generally not able to detect. Thematic analysis revealed that even 
if DTCA provides factual and sufficient information, the general public are not capable of 
understanding the information in DTCA or making informed choices, mainly due to their low 
health literacy and the negative effects of DTCA on their self-efficacy. The crucial role of 
doctors in guiding consumers’ informed decision-making was also highlighted, and it was 
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suggested that consumers should be educated and empowered by impartial health professionals 
rather than drug advertising (see Figure 4.1 for more detail). 
 To extend the quantitative findings from studies one and two, I also explored 
informants’ perceptions of the characteristics of ‘at risk’ or vulnerable individuals with regard 
to DTCA. I thus answered the research question “What are health professionals’ perceived 
characteristics of consumers who are less able to make informed decisions in response to 
DTCA (who are more vulnerable)?” The findings showed that individuals with health 
problems, unhealthy lifestyles, and disadvantaged demographic and/or socio-economic status 
were identified as less able to make informed choices and thus were perceived to be more 
vulnerable to DTCA. In addition, personal characteristics, including being materialistic, 
trusting, and impulsive, were also perceived to increase vulnerability to DTCA (see Figure 4.2 
for more detail). The findings corroborated the quantitative findings and revealed new 
vulnerability characteristics, e.g., impulsivity. The outcomes also provided additional 
information on vulnerability characteristics, for instance, the nature of health issues that might 
create vulnerability (e.g., vulnerability of patients with desperation and psychiatric disorders). 
These findings help to further inform understanding of the survey results. The culmination of 
a myriad of factors linked to vulnerability to DTCA questions whether DTCA is ethical, at least 
in its current form.   
 Finally, the questions “Is DTCA perceived ethical in its current format in New 
Zealand?” and “How to offer socially responsible/ethical DTCA in order to help individuals 
make informed decisions?” were answered. The findings revealed that DTCA does not seem 
ethical in its current format. Most informants had a relativist position toward DTCA and 
suggested some changes and the need for more detailed guidelines on the execution of DTCA, 
considering its drawbacks and negative effects on consumers and society (see Figure 4.3). A 
few informants, however, held an absolute position toward DTCA and believed both central-
regulation and self-regulation are problematic and DTCA cannot be offered ethically. They 
argued for the need to provide independent and balanced consumer health information instead. 
These informants called for a complete ban on DTCA in New Zealand similar to most other 
countries that do not allow DTCA. Extrapolating from these findings, I suggest that countries 
that do not permit DTCA should not consider allowing it in the future.  




5.2 Research Contribution and Implications  
  The culmination of the results from the three studies comprising this Ph.D. thesis 
should be valuable for researchers, marketers and policymakers. Overal, conducting this Ph.D. 
thesis in the New Zealand context is important as most research on DTCA is from the United 
States. Also, a strength of this thesis is employing the mixed methods approach so that the 
findings of the qualitative study explored and extended the understanding of the results of the 
quantitative studies. This research contributes to the field of advertising regulation and ethics, 
as well as to consumers’ vulnerability and informed decision-making. The findings have 
theoretical implications, along with managerial and public health implications, which are 
discussed in the following sections. 
 
5.2.1 Theoretical Implications  
 Although much attention has been paid to self-reported behavioural responses to 
medicine advertising, to the best of my knowledge, no study has reported characteristics of ‘at 
risk’ individuals in response to DTCA (Khalil Zadeh et al., 2017). Given that there might be 
differences between social groups in their capability to process and respond to DTCA, it is 
important to examine the consequences of exposure to medicine advertising between various 
social groups (Kontos & Viswanath, 2011). However, there is a dearth of research exploring 
probable communication disparities in response to medicine advertising (Ramanadhan & 
Viswanath, 2006), and researchers have proposed the need for a thorough examination of 
responses of diverse social groups (Kontos & Viswanath, 2011). Study one addressed this 
important gap, being grounded in communication inequality and the Structural Influence 
Model (SIM) of health communication that acknowledges that communication has a role in 
associating social determinants to health outcomes (Kontos & Viswanath, 2011; Ramanadhan 
& Viswanath, 2006; Viswanath et al., 2007). Not only did the findings revealed that ‘at-risk’ 
individuals are more likely to respond to medicine advertising, this was also the first study to 
reveal the concerning link between materialism and behavioural responses to DTCA. 
 Existing research has demonstrated the effects of lifestyle on individuals’ behaviour 
(e.g., buying behaviour; Krishnan, 2011), and health inequalities (Lisspers et al., 2005; 
McGinnis & Foege, 1993; National Center for Health Statistics, 2001; Poortinga, 2007; 
Sapranaviciute-Zabazlajeva et al., 2017; Satcher, 2000; U.S. Department of Health and Human 
Services, 2000). However, to the best of my knowledge, study two is the first to identify the 
links between individuals’ healthy/unhealthy lifestyle behaviours and their self-reported 
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behavioural responses to drug advertising. This study extended the findings of study one as 
well as the existing literature regarding the associations between lifestyle habits and 
individuals’ behaviour by demonstrating that individuals with less healthy lifestyle behaviours 
are more likely to respond to medicine advertising.  
 Consumers’ informed decision-making and social responsibility in DTCA are complex 
issues that lacked theoretical frameworks. Study three provided a theoretical extension of the 
literature on DTCA, CSR, informed decision-making, and vulnerability. The first contribution 
was developing factors affecting consumers’ informed decision-making in the DTCA context 
based on health professionals’ opinions (Figure 4.1). Exploring informants’ thoughts also 
illustrated that even though most consumers are vulnerable to DTCA and are not able to make 
informed decisions, there are some types of consumers who are even more vulnerable to 
DTCA. This extended the results of study one and study two and made a valuable contribution 
to a broader understanding of the issues affecting consumers’ vulnerability to DTCA (Figure 
4.2). The study finally presented recommendations/factors on how to offer socially responsible 
DTCA (Figure 4.3). Notably, to my knowledge, it is the first study to present a framework of 
factors contributing to socially responsible DTCA, and specifically ethical DTCA aimed at 
guiding consumers’ informed decision-making. 
 
5.2.2 Public Health and Managerial Implications 
 The findings of the thesis have several important implications for future practices. As 
discussed earlier, the results of this research raise major concerns regarding the ethicality of 
DTCA and consumers’ informed decision-making and propose a need for stricter regulations 
to ensure that medicine advertisements offered by pharmaceutical firms are ethical (Khalil 
Zadeh et al., 2017). The public health and managerial implications of each study of the thesis 
are discussed below. 
 The results from a representative sample employed in study one and study two can be 
applied to the population in New Zealand and have significant implications for both healthcare 
legislators and pharmaceutical firms (Khalil Zadeh et al., 2017; 2019). The findings suggest 
that health policymakers should raise public awareness about medicine advertising, ensure that 
consumers are aware of how medicine advertising is regulated, and let consumers know that 
advertised medicines are not inevitably safe and effective. They should concentrate on 
individuals’ attitudes towards DTCA and communicate that medicine advertising is a paid 
promotion delivered by a pharmaceutical firm (Khalil Zadeh et al., 2017). The government 
should focus on increasing individuals’ health literacy, monitor advertising of lifestyle 
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medicines and ensure that DTCA is more beneficial than harmful, to help individuals make 
informed decisions. The pharmaceutical industry needs to stress healthy lifestyle behaviours as 
an alternative to taking medications, where applicable (Khalil Zadeh et al., 2019). 
Pharmaceutical firms should not target ‘at risk’ people, not position their products based on 
people’s lifestyle attributes, nor illustrate their product as a wonder drug (Khalil Zadeh et al., 
2019). Pharmaceutical companies could also match their drug advertisement spending with 
donations to independent health information. 
 Considering that DTCA is commonly misjudged as reliable public health information 
(Every-Palmer et al., 2014), is not offered ethically, and is more likely to affect vulnerable 
individuals, a question is raised as to whether DTCA should be banned or further regulated in 
New Zealand. The government has recently considered a new Therapeutic Products Regulatory 
Scheme asking for consultation feedback about regulating or banning DTCA (Ministry of 
Health, 2018). Although some authors have called for a complete ban on DTCA (e.g., Lexchin 
& Menkes, 2019), study three of this Ph.D. research provides specific recommendations for 
offering more ethical DTCA if an outright ban is not considered at this point in time. These 
recommendations informed the submission to the Therapeutic Products Regulatory Scheme 
regarding policy changes (see Appendix D). The findings thus have important implications for 
policymakers by informing a guide for their future policy frameworks, and for pharmaceutical 
companies by helping them to develop their ads in a way that they can fulfil the consumers’ 
right to choose and to be educated. 
 Pharmaceuticals are different from other consumer goods because they directly 
influence people’s health, and in some cases, death or life. Consequently, their advertising 
should be controlled differently. In line with extant research (Applequist & Ball, 2018), the 
outcomes of this research suggest that the current rules on DTCA are not sufficient to protect 
consumers, and reinforce the need for tighter control and regulatory actions on DTCA. 
Moreover, an existing study discussed that DTCA is mainly offered to promote a specific brand 
over another with identical active medical ingredients rather than having an educative purpose 
(Samaranayaka & Green, 2019). Fundamental ethicality and regulatory changes are 
recommended to ensure consumers’ informed decision-making based on the findings of the 
present research, such as the unethical nature of current DTCA, and the incapability of 
consumers, especially those who are more vulnerable, to make safe and informed decisions and  
given that the industry-run system of Advertising Standards Authority in New Zealand is not a 
suitable and strong enough mechanism for protecting the public from misleading information 
on advertised drugs (Toop & Richards, 2004). For instance, the government should ban DTCA 
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for controlled and/or addictive drugs, for acute and life-threatening conditions, for medications 
that have serious side effects, for psychiatric medications, and for drugs targeted at children. 
The government should instead encourage pharmaceutical companies to advertise medicines 
for social and preventative health measures, including infectious/transmissible diseases (e.g., 
for increasing necessary vaccine uptake).  
 Since consumers increasingly use the Internet to seek medical information, Online 
DTCA is an important kind of advertising for pharmaceutical companies (Mackey, 2016). 
Disturbingly, the U.S. Food and Drug Administration revealed that most violations are related 
to online advertising that involved insufficient or deceptive information (Kim, 2015). 
Moreover, although DTCA is legal only in the U.S. and New Zealand, online drug advertising 
may be accessible worldwide regardless of other countries’ prohibition on DTCA. 
Accordingly, restricted policies on paid-online-DTCA, and reinforcing supervision on unpaid 
communications on social media with topics related to pharmaceutical products are required. 
It can, however, be challenging to control social media and online word of mouth. These issues 
highlight the importance of the social responsibilities of pharmaceutical companies to control 
and manage the information they provide. The results of this research hence infer how 
pharmaceutical companies should integrate CSR strategies into their advertising policies. They 
need to balance their commercial goals, their public health goals, and regulations in order to be 
socially responsible. This can benefit not only consumers to make informed decisions and 
subsequently improve their wellbeing, but also pharmaceutical companies, as research has 
shown that it is the company’s lasting interests to be socially responsible (Carroll & Shabana, 
2010; Wilkes et al., 2000). 
 
5.3 Limitations and Future Research 
  This Ph.D. research is subject to several limitations. It did not separately study online 
DTCA and its effects on consumers. The advent of the Internet and its worldwide availability 
has moved access to information and advertising beyond the borders of countries or national 
policies. With recent improvements in digital marketing, especially social media marketing, 
companies can easily advertise to their target market or people with certain demographics, and 
health conditions with no boundaries, which puts ‘at-risk’ groups in more danger. However, it 
is not easy to regulate and supervise information on online DTCA. Further study could involve 
examining the positive and negative effects of online advertising of both prescription and over 
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the counter (OTC) medicines through social media marketing (e.g., influencers marketing, 
content marketing) and identify ways to regulate and supervise it.  
 The results of study one and study two were based on cross-sectional data, therefore 
causal inferences regarding the links between dependent and independent variables could not 
be drawn. Longitudinal studies could shed more light on the revealed associations. The 
participants’ self-reported behavioural responses to DTCA as well as self-reported lifestyle 
behaviours might not reflect their actual behaviour and might result in under- or over-reporting 
of some behaviours (Robertson et al., 2017a). Nonetheless, the anonymity that was assured by 
the online survey platform, a method that is more effective than traditional approaches 
(McCabe et al., 2002), would have assisted respondents’ truthful responses (Robertson et al., 
2017a). Furthermore, study two did not explore tobacco use as an unhealthy lifestyle behaviour 
since it was based on a secondary analysis of survey data that did not examine tobacco use 
behaviours, further research could extend the current findings by examining the relationship 
between smoking and behavioural responses to drug advertising.  
 A limitation of study three is that it explored only the views of health professionals 
regarding DTCA and consumers’ informed decision-making. Further qualitative research on 
exploring the perceptions and experiences of consumers concerning DTCA will shed more 
light on understanding the phenomena. Moreover, study three showed the effects of DTCA on 
consumers’ self-efficacy and the effect of self-efficacy on consumers’ decision-making 
according to health professionals’ outlooks, knowledge, and experience. A further empirical 
study could also involve quantifying these effects from consumers’ viewpoints. This study did 
not compare informants’ responses based on their characteristics. This can be explored as 
future research. 
 As future research, it is also suggested to provide an optimised plan of education for 
consumers, especially for more vulnerable ones, to minimise the risk of being misinformed and 
misled by DTCA and to assess the effects of education on their informed decision-making 
regarding DTCA. Further studies on the social responsibility of drug advertising and 
consumers’ informed decision-making concerning OTC drugs will provide valuable insights 
into the phenomena of interest. Finally, a recently elevated issue is direct to consumer 
advertising of physicians, their activities and promotions (especially in cosmetic medicine) 
through Instagram by influencers. Given that influencers have large audiences and are getting 
paid by these physicians, the ethicality and effects of this kind of advertising on consumers and 




5.4 Concluding Remarks  
  The culmination of the outcomes of the three studies offered in this Ph.D. research 
raises significant concerns regarding DTCA, and consumers’ (especially those who are more 
vulnerable) lack of ability in informed-decision-making. Taken together, the findings of this 
Ph.D. research identified the factors linking to consumers’ behavioural responses to DTCA, 
types of consumers who are at more risk or more vulnerable to DTCA, and factors influencing 
consumers’ informed decision-making. Most importantly, it extended the field of advertising 
regulation and highlighted the importance of providing socially responsible and more 
specifically ethical DTCA and offered several important ethicality and regulatory changes, 
which need to be made to ensure consumers’ informed decision-making.  
 Overall, this research suggests that if banning DTCA is not currently practical in New 
Zealand, there should be stricter regulations and more supervision of DTCA. The study thus 
recommends further regulatory and ethicality actions to help consumers make informed choices 
(see Chapter Four, Recommendation section, for a more detailed discussion of ethicality and 
legality factors contributing to socially responsible DTCA):  
• DTCA should not be self-regulated by the industry in New Zealand, and there should be 
stricter regulations and supervision of DTCA. It was suggested to have a committee, 
including an independent health professional advisory board in addition to nonprofessional 
people, in the governing body, to examine DTCA before it is released.  
• DTCA on TV, radio, and the Internet is less ethical, while print DTCA is more ethical. It 
is suggested to allow only print DTCA in New Zealand and the USA. 
• DTCA for controlled and/or addictive drugs, for acute and life-threatening conditions, for 
medications that have serious side effects, for psychiatric medications, and for drugs 
targeted at children is not ethical. It is suggested to ban DTCA for these groups of medicines 
in both New Zealand and the USA. On the other hand, DTCA may be more ethical for 
social and preventative health measures that help increase awareness about the disease and 
improve public health.  
• Overall, DTCA should present information in a neutral and not emotive or persuasive 
fashion. Pharmaceutical companies should offer credible, factual, and not deceptive 
content, and provide complete information. For instance, it should focus on the disease 
rather than a specific drug, communicate lifestyle behaviour changes as an alternative to 




• The driving force of DTCA for pharmaceutical companies should be improving people’s 
health, not increasing sales. Pharmaceutical companies should also select the target 
audience ethically and not target vulnerable individuals.  
Considering all the advantages of offering socially responsible DTCA, a question that 
arises is whether for-profit pharmaceutical companies are willing to make DTCA more 
ethical provided that it may reduce the effectiveness of it. Offering fully ethical DTCA may 
thus be unpalatable to the industry. Existing literature has discussed that DTCA provides 
minimal and misleading information in the U.S. even though it is regulated and overseen 
by the U.S. Food and Drug Administration (Donohue, Cevasco, & Rosenthal, 2007; Faerber 
& Kreling, 2014; Kim, 2015; Klara, Kim, & Ross, 2018; Lexchin & Menkes, 2019). Thus, 
banning DTCA in the U.S. and New Zealand can be a practical solution to protect 
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Research Topic: Social Responsibility in Direct to Consumer Advertising of Prescription 







Information sheet & consent form: Please read this information sheet and sign the informed 
consent form showing your willingness to participate. 
Brief introduction: You are being asked to participate in a study that focuses on social 
responsibility in direct to consumer advertising of prescription medicines (DTCA) in New 
Zealand. As you may know, they are only two countries in the world that direct to consumer 
advertising of prescription medicines is allowed, namely New Zealand and the United States. 
The purpose of this study is to investigate experts’ point of view regarding the main indicators 
of socially responsible DTCA and to find out whether consumers have the knowledge and 
ability to make informed decisions based on DTCA. In this interview, by advertising of 
medicines, I mean only for prescription medicines and directly to consumers, such as TV 
commercials, print ads, online ads,… (e.g.,  for diabetes, asthma, depression, high cholesterol, 
etc). 
 During the interview, you will be asked to respond to several open-ended questions. 
You may choose not to answer any or all of the questions. The procedure will involve taping 
the interview, and the tape will be transcribed later. Your results will be confident and you will 







1. Have you seen any direct to consumer advertisement of prescription medicines (DTCA) in 
New Zealand before? 
2. What is your general view on direct to consumer advertising of prescription medicine 
(DTCA) in New Zealand? Please explain. 
 
Questions to Gather In-depth Data: 
1. How do you think medicine ads affect consumers? Please consider both positive and 
negative effects.  
2. How do you think medicine ads affect society? Please consider both positive and negative 
effects.  
3. Thinking about the nature of ads promoting drugs to consumers, what is your opinion about 
the ethicality of these ads?  
• Please reflect on the content of these ads.  
➢ Where do you think medicine advertising sits with regard to providing useful 
health information versus selling a product? 
• What is your opinion about the social responsibility of pharmaceutical companies 
promoting their products to consumers?  
• Prescribed medicines are advertised on TV, the radio, the Internet, and in magazines. 
Please explain whether you think some of these channels might be more or less 
appropriate for such advertisements. Please explain why. 
4. Do you think there are some types of medicines that are more ethical to advertise and some 
that are less ethical to advertise? Please explain why.  
5. Please describe the features/attributes that you think would be required in a medicine 
advertisement to make it more ethical.  
6. With regard to the info given in medicine advertisements, what do you think about the 
extent of info and accuracy of info? 
7. What do you think about the ability of consumers/patients to identify each form of 
deceptive medicine advertisements (insufficient or false information)?  
• How do you think these deceptive medicine advertisements influence 
consumers/patients?  
➢ Please explain why. Why is that important?  
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• How could these be avoided? How should the government deal with each form of 
deception?  
8. What do you think about consumers/patients’ capability of making informed decisions 
after being exposed to a medicine ad? Please explain why.  
9. Please describe the characteristics of people who are less able to make informed decisions 
about medicines.  
• Please explain why.  
10. How do you think about patients’ ability to understand the medical information presented 
in medicines’ ads? Please explain why.  
11. In your opinion, how do medicine advertisements influence patients’ beliefs about their 
own ability to make informed choices about medicines? Please explain why. 
12. In your opinion, how do patients’ beliefs about their ability to make informed decisions 
affect their informed choices about medicines? Please explain why.  
13. Please describe the features/attributes that you think would be required in a medicine 
advertisement to help consumers make informed decisions.  
• Please explain why these attributes are important.   
14. We conducted a population-based study as a part of this research and we found that people 
who are most likely to respond to medicine advertising (including ask a doctor for a 
prescription and/or for more information, search the Internet, and ask a pharmacist for more 
information) have less healthy lifestyle behaviours.  
• Based on these findings, please explain your further thoughts on the ethicality of 
medicine advertising. 
• What do you think of communicating health behaviours (For example, lifestyle 
changes) in medicine advertisements if this is an option? (Doing exercise, healthy 
eating,…) 
15. Another finding was that consumers who were more materialistic were more likely to 
respond to medicine advertising. Based on this finding, please explain your further thoughts 
on the ethicality of medicine advertising.  
• Please think of any guidelines, criteria,… that would help to guard against a materialistic 
or consumerist response to medicine advertising.  
16. In your opinion, how can we balance advertising regulations, business rights, and consumer 
protection? 
• Who should do this? (Industry, government, or other groups)? 
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• Do you have any further suggestions regarding the ethical practices of medicine 
advertising in New Zealand? 
 
Closing: 
• Please provide suggestions or comments about the: 
➢ Topic  
➢ This interview session 
 
Thank you for your time and kind cooperation. We may contact you in the future for the 























Appendix B: Sample Information 
   
 Table B.1: Sample information 
  Position Gender Introducer City of Working Place of Interview 
1 Pharmacist Female Introduced by a colleague Dunedin Participant’s house  
2 Emergency doctor Female Introduced by a colleague Dunedin Participant’s house  
3 Emergency doctor Male Introduced by a colleague Dunedin Participant’s House  
4 Pharmacist Female Introduced by a respondent Dunedin Medical Library  
5 General 
practitioner  
Female Introduced by a respondent Dunedin Hospital  
6 Pharmacist Female Introduced by a respondent Dunedin Starbucks  
7 Pharmacist Male Contacted directly at a 
pharmacy 
Dunedin Pharmacy  
8 Dentist and 
academic 
Male Contacted directly-The 
participant was a friend  
Dunedin College study room 
9 Pharmacist Female Contacted directly at a 
pharmacy 
Dunedin Pharmacy  
10 Pharmacist Female Contacted directly- The 
participant was a 
friend/colleague 
Dunedin Hospital  
11 Dentist Male Introduced by a respondent Dunedin College study room 
12 Dentist and 
academic 
(lecturer) 
Male Introduced by a respondent Dunedin College study room 
13 Dentist and 
academic 
Male Contacted directly- The 
participant was a friend 
Dunedin College study room 
14 Pharmacist Female Advertisement at the 
School of Pharmacy 
Dunedin School of Pharmacy  




research fellow)  
Female Email advertisement sent to 
GP Department 









Female Asked by a friend Dunedin School of Pharmacy  
19 General 
practitioner 
Male Hospital advertisement Dunedin College study room 




Male Advertisement at Faculty of 
Dentistry 
Dunedin College Study Room 
21 Pharmacist Male Advertisement at the 
School of Pharmacy 
Dunedin Medical library  
22 Surgeon and 
academic 
(lecturer)  
Male Introduced by a friend Hamilton College study room 
23 Academic 
(professor)  





Male Contacted directly by email Christchurch GP Department  
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25 General surgeon  Male Met in the residential 
college (visiting for a 
course) 
Auckland College study room 





27 Pharmacist  Male Contacted directly at a 
pharmacy 
Dunedin Pharmacy  
28 Pharmacist  Female Advertisement at a 
pharmacy 
Dunedin College study room 
29 • Academic (post-
doc candidate in 
public health)  




























Appendix C: Quotation and Coding Examples 
 
Table C.1: Part one: informed decision-making 










Feeling of control 
and involvement 
 
“I think that’s a sort of an 
empowering thing for consumers that 
they can feel that they have some kind 
of control over their medications.” 
“They want individuals to take more 
responsibility on the part of their 
health.” 
“[DTCA] helps patients to have an 
active role.”  
“I think it is both patients’ and 
physicians’ choice. Because it is the 
patients’ body and they have to know 
their condition, they need to know 
what the options are and how well 
they work, so in the sense that 
patients themselves have to decide.” 
“I think that the positive effect that it 
would have is… I guess, take more 
control of their own health and take 
ownership of that, and it helps them 
to do that.” 
“They feel better in negotiating with 
the doctor when it comes to 
management, and they feel more 
empowered, and they are more likely 









“They think that I am up-to-date 
about the knowledge and what is out 
there.” 
“Positive would be information so 
people may be made aware of 
products that could genuinely help 
them or be an improvement on their 
current treatment.” 
“Definitely it does have a positive 
effect because they’ll educate people 
that such a treatment for such a 
condition is available.” 
“… It is the consumers’ right to know 






“It is true that it can increase the 
awareness of the disease because a 
lot of diseases are undiagnosed.”  
“…if they haven’t been diagnosed 
with something; maybe they can get 
the doctors to look into something 
they feel that they’re having.” 
“It might create awareness of 
diseases or problems that the general 
public might not know a lot about.”  
Issues regarding 
ethicality of 
Unethical objective of 
DTCA (unfair business 
practices) 
Health becomes a 
business 
 
 “I definitely think it is more towards 
selling the products at the moment. 








negative view. It is to push your 
brand, to push your product.”  
“...As I said, when it is marketing, the 
aim of marketing is to sell your 
product. So, DTCA does not always 
give balanced words.” 
“…It comes out of their best interest 
rather than the idea that they might 
be doing this in the patient’s best 
interest. Their aim is to sell their 
product so they’ll do the absolute 
minimum that they have to while 
promoting their product, yeah.” 
“I think there’s no doubt that it’s 
effective, I mean just thinking it 
through logically, even without 
having any kind of objective 
experience data, it has to work or 
otherwise they wouldn’t, you know 
the pharmaceutical companies 
wouldn’t be spending money on it, 
that’s the logical theory and not only 
that, in terms of as a physician and 
having people come in, it’s clear that 
people have, even if they haven’t 
come in and said, doctor, I’ve seen 
this advertisement and that’s why I’m 
here today, they may mention while 
they’re in for something else, while 
I’m here, I’ve seen this and what do 
you think about this, you know this 
medication...” 
“…They’re trying to buy your 
loyalty, they’re not doing it for the 
greater good of society, they’re 
trying to get you to purchase that 
product, that’s all it’s about, they 
don’t care about what’s happening in 
the process. So, many times you’ll 
have a medication that has caused a 
few deaths, not many times but a few 
times in this society, that gets hushed 
over, that doesn’t get reported in the 
newspaper as actively because it’s 
these huge companies that have been 
dealing with it as well...that same 
thing, the same medication gets 
released a few years later, not in that 
country but in another country under 
a different name, well see they’re not 
doing it because they’re trying to 
protect you, they’re doing it because 
they want to sell out…” 
“I know there are guidelines for 
advertising medicines, but I also 
know that people are very good at 
pushing that right to the limit where 
they’re still obeying the law but until 
it goes to test and gets tested, when 
someone gets prosecuted. You know 
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they work it to their best and so it 
comes out of their best interest rather 
than the idea that they might be doing 
this in the patient’s best interest. 
Their aim is to sell their product so 
they’ll do the absolute minimum that 
they have to, while promoting their 
product”.  
“I don’t think it’s ethical. I think 
they’re looking out for their own 
interest, which is selling as many of 
these things as they can.” 
“I think that it is advertising to sell a 
product, and I have concerns 
about...claims being made about 
drug delivered directly to consumers 
who may not have the ability to judge 
or make judgements on those 
claims.”  
“They’re not based to give you info, 
that’s not their aim... their aim is 
always to try and sell you something 
and if that thing looks like it’s easy 
and quick, who would say no to that.”  
Persuasion  “Some of the written ones that have 
got the really really really tiny stuff 
down the bottom is a little bit 
jargon…, and I think that is 
deliberate to bamboozle people, and 
I mean I’m definitely not a marketing 
expert but you can see that the main 
focus of especially you know the text 
ones, is that there’ll be an image, and 
then there’ll be a big text, and then 
there’ll be a product placement...so 
that is also persuasive to, you know 
it’s inducing emotions in connection 
with the picture and you know, the bit 
down the bottom is difficult to read.” 
“The content is very persuading I 
must say especially the manner in 
which they present it.” 
“Of course, they have to make it 
appealing for people to get interested 
and ask the doctor, and healthcare 
providers.” 
“They have to make sure that they are 
pleasant enough, and they are, but 
you know unless it’s not pleasant, it’s 
not something which...it is attractive, 
it is always grim, so portraying 
something on the television, they can 
never educate a patient or a person, 
all they can try to do is influence.” 
“…They are often really emotional. 
Like they often really, most 
advertising are appealing to peoples’ 
emotions more than their logic or 
their thought and so the ones that are 
really stick to my mind are the ones 
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for Xenical years ago. They were very 
emotive about and you know how 
terrible it is to be overweight and 
then Xenical will sort of solve this 
problem.” 
“I think they mostly don’t provide 
any real information at all. It is just 






“I don’t think based on advertising 
they can make well informed and 
proper decisions. Because the 
content alone is betrayed at the 
moment.” 
“…Sometimes I find it can be 
misleading, because like in most of 
the asthmatic advertisements, you 
will find that the patient is always 
active, but even if you aren’t active 
you still have to take it. You know it’s 
that sought of, so, sometimes I find 
that what’s behind the scene, or what 
they’ve depicted, what they are trying 
to paint is misleading.” 
“It is rubbish, and it’s not actually 
giving the public the information that 
they need to be able to make an 
informed decision about that 
medicine.” 
“I think being ethical is, should be the 
first priority but I don’t think it 
necessarily comes across in some of 
the advertising that I have seen 
because it’s difficult to kind of 
promote your product without 
making it sound too good and then 
you create these false beliefs in 
people’s minds that the medication 
will just solve everything.” 
“They present it in such a way that 
those drugs, they’re like once you 
take it, all your pain is gone. Once 
you take it, your asthma is gone, like 
it’s just like whether you take it, no 
asthma again, you will not have pain 
at all, but that is not how drugs 
work.” 
“That’s very dubious… I think it is 
just giving a very generic view which 
patient might think that okay this is 
one medication that I can take and 
forget about everything else. So, I 
think it's a grey area, it is not a good 
thing.” 
“… They are sort of just generalising 
it to everyone, other than telling that 
this number is specifically done on 
this type of patient who does not have 




“I think the bad things are that it 
probably makes people take more 
medicines than they would have 
otherwise, and it probably makes 
people take drugs, take medicines 
that risks overweight benefits. And 
put them into the idea that medicine 
is an appropriate treatment for 
everything, every experience that you 
can have in your life.” 
“The advertising can sometimes 
make misleading comments about 
drugs, often it can overplay the 
effectiveness often to use 
inappropriate graphs and 
inappropriate measures, so for 
example relative risk is often used as 
a place to absolute risk and also there 






“There is minimal medical 
information presented in the 
ad…because they are commercials; 
they are made from well part of you 
to influence and gain profit from 
them…” 
“I think most New Zealand DTCA 
hardly has any medical information! 
I don’t think there is much.” 
“They cannot make information just 
based on info in the ad. Because they 
might not include everything. They 
provide the studies to support their 
claims.” 
“…It's not enough information to 
provide customers with the full 
picture.” 
“I don’t see that DTCA really helps 
you make an informed decision 
because it doesn’t provide enough 
information really... I don’t think 
DTCA really helps.” 
“…It’s impossible to you know, write 
down everything or list everything 
down in a 30-second ad; you can’t 
cover everything as well.” 
“More often, it is partial information, 
so a bit is just not there. So, they take 
“A” fact, which is possibly true, not 
particularly referenced, and used 
that and put all those good bits there. 
I mean why wouldn’t you? When you 
advertise you would say the good 
bits, you wouldn’t say, you wouldn’t 
start an ad by saying this medicine 
can kill you. Would you? That is not 
how you would start your advert.” 
“They are just going to always be 
concise with the truth, you know 
they’re not gonna present the full 
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facts, because by presenting the full 
facts with an open book, they will not 
be as effective and they don’t have to 
be, they’re not obliged to so in terms 
of making it more ethical, more 
information … that’s not gonna 
happen.” 
“The content is gonna be very small, 
and again it’s not intended to present 
the full picture.” 
“It just gives me a brief picture about 
the medications, and so patients can’t 
make judgements based on two 
sentences, whereas if they wait for the 
doctor, they can get the full picture 
and then understand why they are 
being prescribed this rather than 
that. So, that's my ethicality around 
it.” 
“With advertising, you don’t get a lot 
of stories.” 
“It is partial information and often 
misinforms through it partiality as 
much as anything; sometimes 
because what you get is incorrect, 
sometimes because you get a little 
piece of a picture.” 
“In America, at the end of the direct 
to consumer ads on the Television, 
they read out the list of side effects 
and potential complications and 
contraindications as well. But here 
we don’t have anything like that, or 
just like for a second! So, no I don’t 
think New Zealand consumers get 
information at all from 
advertisements, other than saying 
just they should go and ask their 
doctor about.” 
“It tells them there’s a product out 
there, but I don’t think it gives them 
information about the side effects, 
etc… not all of them are informative, 
so I guess it gives them some idea but, 
it definitely doesn’t give them the 
whole story because that’s not what it 
is made to do.” 
“Lots of ads promote advantages. 
They do definitely downplay the side 
effects.”  
“…They don't really mention 
anything about side effects or how to 
avoid that.”  
“I think the aim of marketing is to sell 
your product, so the positives are 
always gonna be emphasised, the 
negatives are always gonna be down 
played.” 
“I think that the advertisement is not 
giving an informed decision like it is 
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hard for the advertisement to give all 
the pros and cons of a particular 
medication,... they hardly spoke 
about the side effects, and they just 
focus on good things in fact… I 
understand like they have just a 
minute or a two minute session and in 
that case, they have to, they should 
try hard to impress the patient but 
that is in no way to educating a 
patient about that particular 
medication and yeah I mean, this is 
way too different from a patient going 
to a doctor and the doctor explaining 
him the pros and cons of a 
medicine...rather than just sitting in 
front of a television getting one 
minute of all the bombardment about 
good things of something. So, this is 
no way an informed decision for the 
patient based on the advertisement.” 
“…They don’t also tell the patient 
what are the side effects and also how 
do you take and if you take it too 
much, you will be abusing it and it 
will lead to maybe liver damage, 
kidney damage, they don’t tell the 
patient.” 
“The advertising can sometimes be 
presented in a biased way,…also, 
there can often be a minimising of the 
side effects.” 
“No [consumers cannot make 
informed decisions] because they’re 
only fed the information that’s gonna 
help sell the product. they’re not 
being told everything about it, they’re 
not being told, or they’re not 
explicitly being told the side effects 
and things that can go wrong or if 
they are, it’ll be like a little fine print 
at the bottom that you know, lots of 
people might not even read anyway.”  
“It [the content] is also very limited, 
and it is also very skewed towards 
positive aspects of products rather 
than negatives. They don’t give 
patients well enough information to 
make informed choices at the 
moment. Not in the current 
presentation anyway.”  
“I think they are very brief. They 






(Negative view)  
 
Health literacy   “People might just not have the 
capacity because they may not 
understand completely their own 
condition, and they might not 
understand all the good and bad 
points about the drug, and it would be 
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quite hard for them to make a 
decision.” 
“There will be a big spectrum, a 
broad spectrum of people who cannot 
understand much at all to those who 
understand a lot about their 
condition.”  
“Impossible. I think if you are taking 
any medication and you open up the 
wrapper, the scientific facts, which 
are given, in particular, medications 
are very difficult. So, any person 
who... It's not like in advertisement 
you would see on a cigarette smoking 
pack, which has a photograph, and 
tells you if you have this you will have 
this.” 
“I was gonna say like educated to 
understand what the ad is saying, you 
know if they don’t understand 
medical terminology, they might not 
actually understand what the ad’s 
telling them in full detail.” 
“They are definitely not capable of 
making informed decisions based on 
these ads. We know the potential 
complications of taking medicine, but 
in such a short time, they cannot 
make [an] informed decision.” 
“As a pharmacist, you understand 
the words, and you understand the 
terminology, but I don’t know 
whether everyone does based on 
talking to family members or my 
husband who doesn’t have medical 
training, they don’t actually 
understand all of the words.” 
“…I know the advertisement; they 
have the technique of doing that so 
they use the same technique for 
drug… unless the patient is in health 
care or something but with the 
general public, I don’t think they 
have the capability. Yeah, I don’t 
think so. But some people who are 
curious or who are much concerned 
about health might Google about it 
and find some more, but most people 
will not do that.” 
“They don’t have the ability to detect 
deceptions (hiding facts), and it can 
influence their informed decision-
making. Even those kinds of things, 
only come about because we learned 
about it, but they do not know about 
it. They just know that I have got 
diabetics and it works on people with 




“It depends on how much the patient 
knows. So, that's also the down side 
of it, is, I find people believe whatever 
the TV says, and it's really hard when 
you know nothing, and someone 
loads you with this amount of 
information, and you would just 
believe it because it's on TV, and you 
would think, they run it through, you 
know, the ethical consent, and that 
sort of thing, surely, it should be 
correct… I personally if I was a 
patient and I didn't know anything 
about my medication, I would take 
everything word for word that's 
advertised as true. So, it just depends 
on how much you know about your 
medications. Where if you knew 
about it you can identify that [if they 
lie or if they hide something].”  
“That makes more difficult shared 
decision-making. So, and some of the 
concepts are complex, some of the 
concepts are difficult. They are not 
easy concepts so having a discussion 
around the benefits of screening. For 
instance, it’s quite a difficult; some 
health professionals have difficulty 
with it so they expect everybody in the 
public to have difficulty so it takes 
time, and sometimes you can’t do it in 
one consultation, it takes time. And 
because people, everybody tends to 
over-estimate benefit and under-
estimate risk, both with medicines 
and with screening particularly, you 
know and the usefulness of tests and 
so on.” 
“I don’t think they can understand all 
the benefits and all the risks because 
as pharmacist and doctors we have 
the understanding the whole body, 
but I don’t think they can fully 
understand just through the 
advertisement anyway.” 
“I’ve been trained in medicine, so the 
way I look at an ad is very different to 
how my mum looks at an ad or the 
way my brother looks at an ad but 
from personal experience, I can tell 
you they read certain things that are 
absolutely garbage on the internet 
but then they’ll come back and tell me 
oh did you know this this this happens 
if you take this this this medication 
and I’m like where did you read it and 
the source that they’ve sighted is so 
not credible that you’ll most question 
why did they even bother wasting 
their time on it so I think the short 
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answer is no I don’t think they have 
the capability to be able to realise 
that there are so many things that are 
hidden in that ad they don’t always 
tell you about, it’s like when you look 
at a bank ad for instance, no-one’s 
gonna tell you the negatives of you 
know, not joining or not signing up 
for a particular account as well, these 
medication companies are no 
different.”  
“For a lot of new medicines, it takes 
time for us to understand them, even 
for us, physicians, scientists.” 
“They can’t make a fully informed 
decision from a medicine ad. Because 
even if they understand fully what is 
being presented to them, they don’t 
have the understanding of the body, 








“I suppose it [DTCA] makes people 
believe they are probably making a 
better choice from having watched 
the advertisement.” 
“The first thing is that I mean the 
advertising is intended to work and 
so the belief would be that, that this 
could offer me something.” 
“I think patients do make that 
decision when they see an 
advertisement or because the 
advertisements always try and make 
it bold and highlight that this will be 
beneficial for you. So, that's how we 
can be misled. So, and consumers 
will always take that on-board over 
anything else. If I was asthmatic, and 
it was out of control, I would take 
anything that would help with 
managing it. So, it definitely helps 
with a patient's decision to, if this 
condition can be managed, but then 
again it also plants the seed, and then 
when they go to the doctor they 
already have the idea that this is the 
inhaler that I should be taking.” 
“I think the ads take people on a 
journey, you know the people who 
have got medical conditions want to 
be healthy, and they want to be free 
from whatever they have and so I 
suppose the ads tap into that, that 
wanting to be healthy, yeah I suppose 
it is trying to tap into that belief of 
wanting to become free from 
whatever ailment they have.” 
“I think DTCA directs you towards 
having a preference for that product 
when it is being advertised.” 
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“I think it could sort of overinflate the 
feel that I can just choose the best one 
for myself, people may feel that if they 
read through five different 
medications for their condition, read 
through the advertisement but after 
that, they can decide what’s best out 
of those five, but I don’t think that is 
the case necessarily.” 
“I think it influences them in such a 
way that it’s, like the drug is being 
advertised, it only does good, like 
when you just take it, everything will 
disappear, everything will be fine and 
so even like I think when we see like 
for instance, some of the adverts, you 
see someone with pain then after that 
the person starts running. So, 
mentally when people see those 






“Once patients have this idea in their 
head that this drug is going to fix 
them, it is very very hard to take them 
out of that thought.” 
“…They will tell the doctor I need 
this drug, and the doctor probably 
especially if you say I want this, it is 
hard to say NO, you should have 
this.” 
“By the time sometimes they come to 
the professional, they might have 
already made up their mind, and even 
if the professional says something, 
they might not listen to.” 
“People who are educated about 
something think that they can make 
decisions about everything and I 
don’t think that is true. I think, you 
know it is a special area of expertise 
of pharmacy and medicine. And if you 
don’t know about that, you don’t 
know about that. You might be a 
really really clever physicist or 
something, but you don’t necessarily 
know anything about medicines.” 
“Those with quite fix fixated on a 
particular idea, it is hard for them to 
make a proper and informed 
decision.” 
“People who just listen to the 
information in ads, oh that sounds 
great, and they don’t process, but I 
don’t think that is fully informed, but 
they might think that they are 
informed.”  
“[Consumers’ positive beliefs 
influence their informed choices] 
negatively mostly in fatal 
circumstances because there are 
some signs and symptoms, which 
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people will not understand. For 
example, there is a high degree of 
silent heart attack, in diabetes 
patients, because of having diabetes, 
the heart…if you have a myocardial 
infarction heart attack, the symptoms 
will not be overtly expressed. So, by 
over-medicating yourself or 
indulging in self-medication can lead 
to potential harm, where a doctor, if 
you have gone to a doctor, and a 
patient sees it, and the doctor sees it, 
and he can say "Oh, this is nice, but 
maybe we need to this," so he can 
make an informed choice. He can tell. 
But as a consumer, you might not do 
that and indulge in the same activity 










from doctors rather 
than DTCA 
 
 “…It does need a clinician’s sort of 
perspective to sort of taking into all 
sort of aspects that their health might 
sort of be affected by…” 
“I would like to emphasise that 
patients can always make informed 
choices, you should always get 
knowledge of all the good, of all the 
treatment available and then he 
should choose which is best for 
him..., but I don’t think that 
advertising something, like 
advertising just one commercial on, 
or advertising a particular drug on 
television should make, like of course 
it can influence a patient but after all, 
like he should go to his care provider, 
he should inform his care provider 
about the advertisement which he has 
seen on the television and then the 
care provider should be able to 
educate that patient about what is 
good for him... and once the care 
provider is able to do that and then 
the patient can do the informed 
decision and then go with the 
particular treatment.” 
“Most of the ads do not include 
information on negative side effects. 
They need to… find more information 
from health professionals.” 
“I think there is a certain degree, if 
they sit down again with the same 
advertisement but written down and 
they had a health professional 
meeting with them to lay out, to 
explain to them, because some of the 
medical terms can be quite. Quite 
hard to understand, even for me, I 
don’t understand a lot so if I had 
someone who can make the language 
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simpler and explain to me what the 
medication would do to me, how it 
would affect me personally, then I 
think the consumers can make a 
decision about that.” 
“I can see that that would be ok if it 
was a non-prescription item but when 
you need to see a doctor to get that 
prescription item, then I think I feel 
like drug companies should go 
through doctors and promote their 
product to the doctors and then 
doctors promote it to their patients, 
but then in saying that if drug 
companies go straight to the 
customers, the customers have still 
gotta go back to their doctor for a 
consultation but I also know that it’s 
tricky if patients actually put pressure 
on doctors, you know I saw this and I 
want it so, and it can be sometimes 
hard for doctors to say no so.” 
“... Making an informed decision 
about a drug is a really hard thing 
and is not just that you have to be 
clever but you have to know those 
stuff, and I think it is unrealistic to 
expect that. What do we have doctors 
for? It’s like you know if it is that easy 
to decide if what drug is right for you 
then what is the point of going to 
doctor really? And those things are 
really difficult, understanding 
absolute risk and relative risk and 
numbers needed to treat and stuff like 
that. Normal people would not know 
anything about that kind of stuff, and 
they shouldn’t have to. Because they 
have sort of that’s what doctors are 
supposed to know about and 
pharmacists.” 
“…It’s very hard to explain relative 
benefits of medicines sometimes to 
people who don’t understand the way 
the medicine works so you know, even 
medications that most people would 
say are very useful medicines, the 
actual benefit can be quite small, and 
it can depend a lot on a patient and I 
don’t know how you include that in 
an advertisement but yeah, that’s 
when it becomes very tricky. Yeah, I 
think probably to focus less on the 
amazing benefits of a medicine but 
just say that the medicine is available 
and to discuss it with your prescriber 
and ultimately you’d need to, the 
prescriber would need to make an 
informed choice I guess.” “I think 
once the patient goes to a doctor, they 
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think about the pros and cons of 
different medicines, then the patient 
can make an informed decision and 
go with the particular treatment.” 
“…Maybe the patient has to have a 
consultation with the pharmacist or 
the doctor first that isn’t explained in 
the content of the ad, so I think all 
those things need to be outlined, the 
fact that the medication may not be 
the best choice for them and that 
ultimately it should be left to the 
pharmacist or the doctor or whoever 





Table C.2: Part two: consumers/patients’ vulnerability 





Less healthy lifestyle  
 
Health issues “They [people who have less healthy 
lifestyle] are more likely to be 
influenced because these people are 
more likely to have a lot of health 
issues.” 
“People who think that they can just 
abuse their body. For example, we 
know smoking is bad, but some 
people choose to smoke. After 15, 20 
years they think there are some drugs 
that they can take, and they want 
those drugs, but already the damage 
has been done.” 
“Because of their less healthy 
lifestyle, that means they may not 
have taken care of their health and 
that means those people are less 
likely to be aware of medicines like 
their side effects and all that so they 
are more likely to be influenced.” 
Being reluctant to 
change 
“So maybe they think that there’s a 
quick answer to whatever their 
problem is and they’ve heard it on TV 
or radio, and so they just go and try 
and find out about this, and they’re 
happy about hearing it in that way. 
It’s an easy way; they’re looking for 
an easy way to solve their problems.” 
Overestimating the 
efficacy of drugs 
“They believe that you can fix 
everything with a pill, and they are 
unhealthy, when they see something 
new, they say oh let’s try it to fix it.” 




“I think when you are, when things 
are not working well, I think 
desperation is a problem because 
people will try anything if they think 
it’s going to make them feel better.” 
“I think when people are feeling 
desperate, as we were talking before 
about selling hope, advertising of 
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expensive medicines for people who 
are extraordinary unwell is 
particularly unethical. Particularly if 
they use kind of emotional 
techniques, which they often do.” 
“The sick ones that are medically 
compromised, they are usually and 
when they see there’s a drug and 
saying the good things they’ll… and 
yeah did affect these people more.” 
“…People who have a health 
problem, because they saw all this 
advert, the person because that 
person wants the thing to go away 
and the person has also seen this, the 
person, no matter what the person 
will just forget about side effect and 
just get it. So, people who are 




“Who are in pain or have a serious 
illness that’s really affecting their 
quality of life are more inclined to 
accept claims that this medicine will 
help them because they want to 
believe that the medicine’s gonna 
help them, so they are probably more 
willing to believe the positive aspects 
of that advertising.”  
“Patients who are very sick are going 
to grasp at everything, especially if 
they are very sick.”  
“It may also be difficult for people to 
make a decision if they’re recovering 
from a serious illness so I think 
there’s a range of areas where I think 





“People who, like people who are 
like mentally ill, they are less likely to 
make informed decisions about it.” 
“Maybe people with like mental 
deficits as well that could be like a 
congenital thing.” 
“The less healthy ones think that the 
drugs are going to fix them rather 
than taking care of their bodies from 
the beginning. So, I think with that 
knowledge that is why I think it is 
important not to advertise to the 
psyche because they are very easily 
influenced.” 
“I would say anyone with any kind of 
mental health issues...I think that 
should definitely be something that 
should be done, advertising directly 
to consumers about mental health 
medications because it just needs to 




“Who are a bit more fragile so you 
know, people who might have an 
anxious disorder, anxiety disorder, 
people who might have psychiatric 
illnesses, are less able to make an 
informed decision based on ads.” 
 “Someone with depression or 
anyone who’s mentally, not unstable 
but you know, who’s mentally fragile 
because they might be of an anxious 
nature, they might have a personality 
disorder as well, they’re more likely 
to listen to someone like there’s an 
absolute ...gospel..., even though it 
might not be the case as well and are 
more likely to be influenced by 
medicine advertising.” 
“People who suffer from bipolar 
illnesses, they can have this 
misconception, or they can think that 
what is shown on the TV is better for 
them rather than what their care 





“Young people…, people who don’t 
have very good skills and reading so 
that would be younger people.” 
“[Young people] don’t fully 
understand what they are listening to 
or watching.”  
“Old people…, who are older that 
cannot see very well…they cannot 
make informed decisions.” 
“Very old; they are suffering a lot 
and because of their mental 
capability or the condition they 
have.”  
“I’d say maybe the elderly seem to be 
maybe a little more, I don’t know if 
gullible is the right word but perhaps 
they haven’t been exposed to as much 
advertising as younger people so 
younger people maybe, not all but 
some are a little more sceptical of 
advertising because they’re exposed 
to it all the time. Yeah, whereas older 
people may be a little bit more, put 
more faith in the companies.” 
“...Maybe they [older people] are not 
used to questioning as much, … well 
I mean that’s my perception is that 
they’re far more trusting, and so if 
they read something, then it has to be 
true, particularly if it’s printed in the 
newspaper, even if it’s an 
advertisement, so there’ll be that.” 
“It could be maybe just elderly 




“I think that's again a grey area, but 
I don't like to talk about it, is 
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medications which are the gender 
focus in females. So, I think to a very 
large extent they are not able to... the 
focus is too much about the cosmetic 
availability or for them to reduce 
weight or things like this. So, it 
becomes a little shady area. I know a 
lot of people especially females who 
are having prescriptive medicines to 




“Parents are always very vulnerable 
when you’ve got children who are 
sick because you’ll worry about your 
child and you are concerned about 
your child so adverts that offer better 
asthma control, that’s the only one I 
can think of at the moment, you know, 
when you’ve been up or had a child 
who’s been sick for several days, it’s 
like it’s going to influence you... 




“So if he or she is telling me that this 
is good because it’s good, so it is 
social-economic status, but it’s also 
personality, or even culture, some 
cultures for example: they are not 
taught to argue against with the 
doctor, with the provider, because it 
is either impolite, or it is not possible, 
so they don’t do it. So, if you tell me 
to take this, I will take it. So, it is 
social-economic status, but also 






“Their socio-economic status is 
always a tricky one because you may 
not have access to all the resources to 
check information,...” 
“…If your socio-economic standing 
is not that great, like you don’t have 
a lot of money, that will definitely 
affect your decisions, either because 
you just can’t choose so you go for 
the cheapest alternative or you kind 
of have so many other things on as 
well that you kind of feel oh I’ll just 
grab something, and oh that sounds 
good, I’ll just take it, so you don’t 
actually think about it because yeah, 





 “People with lower education are 
less likely to make informed 
decisions.” 
“Who are at less educated … will be 
more affected by advertising…” 
“I think these people [who are less 
able to make informed decisions] 
may belong to a lower socio-
216 
 
economic strata of society with 
probably education skills that are not 
up to the average or up to the norm 
as well.” 
“…Lower educational level, cannot 
search for more information, and 
cannot understand medical 
information. 
“Some may not have such higher 
education, and they don’t consider 
other things as well, or ask questions 
and just take it as it is. So, these 
people might be misled.” 
“People who come from a low socio-
economic group are people who have 
a lower educational level, they can 
have difficulty or they can have 
prejudices or they can start to believe 
in a particular advertisement.” 
Health literacy 
 
“We know that people who have low 
health literacy really will struggle to 
make, make good judgements. People 
with low health literacy are typically; 
they don’t have English as their first 
language..., are commonly Maori or 
Pacific families, they may well be 
poorer and have lower educational 
levels.” 
“To be honest, I think the ability is 
pretty low, limited; I want to say it’s 
limited because you definitely need to 
have a medical background to fully 
understand what’s the benefits of 
your health... because if everyone can 
understand what’s the benefits, 
what’s the … consequences, then we 
wouldn’t have a need for doctors or 
we wouldn’t have need for medical 
professionals who are there for the 
primary purpose of taking care of 
myself so to understand the medical 
information from advertisements 
where the language has been dumbed 
down or made simpler for the simple 
fact of attracting people’s attention.” 
“And one thing for the opponents, the 
patients may not be able to 
understand medical information, that 
is another thing. Like when I see an 
ad I know the name of drugs, or I can 
link the name of a drug to a class, so 
I have an idea if it is new. I have an 
idea of what it might be doing, and I 
would know what sort of side effects 
it might happen, or what kind of 
contradictions they might have, like 
you know children might not be able 
to take it, but then people who watch 
TV they might not have any 
background, they would have no 
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“I guess people are probably 
unaware of the subtleties of the way 
advertising operates, so if you’re 
unaware of that, then rather than 
them, you know, rather being critical 
of it, it’s going to influence what you 





“…They like to buy things, they like 
to use things and so if they hear of 
something, oh that’s good, I’ll try it. 
Yeah, I can kind of understand that 
some people might be like that, they 
have to have it. They’ve got a desire 





“Who also rely on other 
people,…they cannot make informed 
decisions.” 
“…There are a lot of people out there 
who assume that because it’s in print, 
it’s fine because it’s on television, oh 
I could use that, they don’t question 
beyond that, they don’t question the 
marketing, they don’t question 
whether all medications come with 
problems, they have a lot of faith in 
modern technology and 
medicalisation and they just assume 
that everything will be fine.” 
 
Customer Savviness/Sophistication: 
“Some people will seek more 
information whether it’s from the 
internet or their GP or wherever and 
quite capable of making a decision.” 
Impulsiveness 
 
“Some people are more impulsive 
than others. They’ll walk past 
something and say I want that and 
they’ll go and get it… I mean we’re 
all different, aren’t we?”  
 
 
Table C.3: Part three: recommendations on the social responsibility of DTCA 




DTCA cannot be 
regulated 
 
 “There are only two places where it 
is generally accepted to be legal 
though in other places they do it 
through the Internet you know in 
various ways. But in those two places 
no one comes up with a way to 
regulate it properly so, I am 
pessimistic it can be.”  
“I think they all should be banned. I 
don’t think that there is any way that 
you can really expect the advertisers 
to communicate really kind of the 
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balanced account of risks and 
benefits.” 
Unethical nature of 
DTCA 
 “I think being ethical is, should be the 
first priority but I don’t think it 
necessarily comes across in some of 
the advertising that I have seen 
because it’s difficult to kind of 
promote your product without making 
it sound too good and then you create 
these false beliefs in people’s minds 
that the medication will just solve 
everything whereas it needs a bit of, 
someone to put it into context whether 
it will actually directly be that 
beneficial for you particularly or 
whether it’s like a generalisation, 
yeah I think.” 
“I think drug companies are there to 
make money for their shareholders 
and so that they are always gonna 
push the boundaries what they are 
allowed to say. The industry will 
always try to overestimate the 
positive things and underestimate the 
negative things. And that is really up 
to the government to try and work out 
how to regulate that so I think the 
responsibility is really on 
governments to come up with some 
way of regulation medicine 
advertising, and that could be just 
banning it and I think that is probably 
my biggest argument for banning 
DTCA. Which is remove the problem 
of how to regulate it! You just ban it 
and then concentrate on regulating 
other advertisements that are for 
other categories of medicines.” 
Drugs should be 




 “I think it is not ethical for the 
pharmaceutical companies to go 
straight to the consumers.” 
“I think it's fine that they would 
advertise it to health professionals, 
and they can make the judgement 
call.” 
“I believe, because it is prescription 
medicine and I believe the best way is 
to target the health provider...Yeah 
not the consumer.” 
“I think it’s unwise to try and leave a 
non-trained health professional, 
namely the general public, to make a 
decision about whether they feel that 
the medicine’s appropriate for them 
or not...” 




rather than DTCA 
 “I think the resource would be much 
better spent providing independent 
consumer health information.” 
“You can put that money into 
providing independent consumer 
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health information. Like the British 
system! We have a New Zealand 
version of this. There is a New 
Zealand adaptation of it, it is online! 
It does not have a drug advertisement 
in it. It talks about drugs in groups 
and not just one by one. And it helps, 
that is designed for prescribers, so 
you need a companion version for 
consumers.” 
“I think that I would strongly support 
open access to information on drugs 
and fully available for patients and 
doctors and for that information to be 
shared in a transparent way but that’s 
not the same as advertising which is 
about selling a product.” 
“If you imagine you had a medicine 
that was incredibly efficacious, and 
the information around including side 
effects was all there, if you had decent 
independent health information for 
consumers, I am sure you wouldn’t 
need to advertise it! Everyone would 
find out about it. You’d put it up, 
Pharmac would fund it and it would 
find its place, why would you need to 
advertise it?” 
 “I mean if somebody wants to put a 
three-page thing in a magazine that’s 
balanced, then that might be helpful 
and the investigative journalists do 
that. I mean I hand out this thing 
about PSA testing for prostate cancer 
that I think it was Di Chisholm in 
North and South or whatever, it was 
about three or four pages and it 
actually does put both sides but it is 
quite informative. I can say look go 
read that but that fits into my 
independent consumer health 








DTCA should have 
credible, factual, and 
not deceptive contents  
 “I think it’s best to give customers the 
information about the medicine but 
not push it in... you know that they’ve 
got accurate and true information, I 
think that’s important...Yeah, that 
you’ve got accurate information 
when you’re advertising, you’re not 
saying anything untrue.”  
“I don’t think you can rely on people 
being ethical. You have to have rules 
about these things. For advertisers, 
there need to be some kinds of rules 
about fairness. You cannot just go on 
TV and say go buy this and if you buy 
this, you won’t have heart attack. 
There have to be some kinds of 




“The idea of it, kind of promising that 
might not happen, it is a little 
unethical.” 
“It only showed happy people like, it 
was all sunny, everyone was smiling... 
They could have done it in lots of 
different ways. I think that what that 
bug me, they could have done it 
differently and they chose to do it like 
that sounds perfection. That was 
unethical.” 
DTCA should provide 
complete information  
 “I think that any advert should 
actually have a link and make it very 
clear where people can access more 
detailed information; hopefully do a 
web link. And I think that information 
I think should give an objective 
description of the benefits and harms 
of the drug. So, I would like to see the 
benefits for example expressed in 
terms, so for example of absolute risk 
reduction, potential numbers needed 
to treat for conditions.  I’d like to see 
a similar thing in terms of the harms/ 
side effects.” 
“The things that could potentially go 
wrong rather than just getting one 
side of the story so that people be able 
to make the judgment call after 
listening to the story.” 
“The thing that I can think of is an 
equal amount of advertising for 
benefits and adverse effects as well. 
People know all potential side effects 
or at least the common side effects of 
medicines, with the same font, the 
same size, as benefits of drugs. Then 
they will be a little bit more well 
informed. And also presenting an 
equal argument as well that this drug 
is beneficial and has all the properly 
informed research and peer review 
research saying that a trial.” 
“If you are trying to paint a picture to 
the patient they should be ethically be 
given the full picture about both the 
benefit and the negative side of 
things, and that is how you would help 
them to make an inform decision on 
whether this is appropriate or not.” 
“So what we talk about right, being 
clear. What is the medication, 
outlining wither side effects or 
contraindications, of you are taking 
this medication you cannot do this, or 
these are the side effects you should 
expect from this medication.” 
“Side effects, clinical trials. They 




“Maybe potentially how long they 
should expect before they see 
improvements in terms of information 
in there. There is a lot of unrealistic 
expectations, partly due to the 
advertising because the claim so 
positive that it cures everything, so 
people think that I have this problem 
and this bottle will cure it. Maybe info 
on how long to expect before seeing 
improvements (long term or course of 
6 months).” 
“We can have something that says at 
the beginning and the end to reinforce 
that…. there are other options.” 
“If you portray yourself as the only 
medication that will work, they are 
other medications out there that could 
work just as much.” 
“They say their brand and say it is 
what you want, but ethically it would 
be better if they say: do you have 
these conditions? It is one of the 
things/treatments that you can have.” 
“…That’s just one medication for quit 
smoking. What about the other 
companies, or other products to 
use…”  
“They should name the generic name 
rather than their trade name. That is 
the only possible way to be ethical to 
be honest”. 
“I think generic is not as advertised 
as the brand name, so they might 
think that only [branded drug] works, 
and the generic cost much less.”  
“If it is showing that you can have a 
generic over another product so, for 
example, I don’t know if it is 
advertised too much but Celebrex is a 
medication for... It is generic which is 
much cheaper but not many people 
know about it, so tell patients.” 
“I think to make it ethical particularly 
is to provide information about the 
generic content.” 
“If their prescription medicine is 
identifying the side effect, it may be 
helpful, but to a very large extent, I 
think people don't do that. But it 
should be done, a requirement. I think 
that the data especially in what you 
can see in the clinical trials should be 
presented in a way that is more, 
people can understand it. Because 
everything is fine, but if the trial data 
is not presented nicely I think that 
creates a problem.” 
“...A message at the very end saying 
this is a prescription medicine, this is 
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not true health advice, and you should 
consult your doctor and pharmacist 
before you are set in taking that 
medicine.” 
“If it really was providing useful 
health information, it would give you 
a selection; it wouldn’t just be an 
advertisement for one drug or their 
drug, it would be a choice of drugs.” 
“The potential outcome as well 
because we don’t want to give people 
the idea that it is going to cure 
everything. For example, if you take 
this drug, 60 % of people had noticed 
% 70 improvement. Put it into 
numbers so they can understand it.” 
DTCA should focus on 
the disease rather than 
a specific drug 
 “The idea is to have the content of the 
advertisement more focused on the 
disease, rather than being focused on 
medicine, and the preventative aspect 
rather than particular defined 
prescriptive treatment. It just makes 
sense.” 
“You should not have a particular 
advertisement for prescriptive 
medicine. Your advertisement should 
be based on making more awareness 
of a particular disease.” 
“I think my main focus has always 
been to bring more awareness about 
the disease rather than the treatment. 
And if there is a particular disease 
that is prevalent, and they are 
suffering from it, of course they will 
go and find [a] solution for it. So, it is 
in the interest of both the businesses 
and the interest of the consumers that 
an awareness of the problem is more 
important than actually the treatment 
of it. Because you are not aware that 
you have a particular disease or how 
it can be prevented, you will not be a 
participant in the actual doctor-
patient relationship, or in the health 
system. You will not indulge in health 
system. People having osteoporosis 
they know they are having an 
osteoporotic problem. They are 
having chronic pain, but they might 
live with it 5-6 years before actually 
going to a doctor. So, this will not 
only bring more patients in, and will 
not only be beneficial only for the 
businesses but it will be beneficial for 
the patients as well.” 
“The idea is to have the content of the 
advertisement more focused on the 
disease, rather than being focused on 
medicine, and [focused on] the 
preventative aspect, rather than 
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 “A little bit information will definitely 
help in the ad just to emphasise that 
this the drug to help lowering the 
cholesterol and it should work 
alongside with lifestyle changes.” 
“I think just a few words to say it 
should be used alongside with 
lifestyle changes. that could be quite 
good.” 
“It is good to add lifestyle changes in 
ads that would be good to do because 
not everything is meaning to be 
treated by medicine.” 
“I think communicating health 
behaviour would be more 
appropriate for most people. The 
majority of advertisements should be 
lifestyle base.” 
“I guess with advertisements they just 
want to target their product rather 
then you know what else can a patient 
do to help improve the quality of 
health. In saying that, I think it would 
be ethical to let patients know, that 
not only they have to take their 
medication, they also have to change 
how they eat, or their physical 
activity. So, I think there is a good 
side of it if you were to add all on to 
an advertisement.” 
“I think communicating lifestyle 
changes is really really important. 
Because I am Breastfeeding, 
sometimes I see advertisements for 
formula and they are very good. Still 
say at the beginning if you can 
breastfeed your baby you should 
breastfeed your baby, and 
breastfeeding is the best, the most 
important, and if for some reason you 
are not able to breastfeed, you can 
use this formula, I really respect 
that… The companies that are 
advertising treatment for lung things, 
they should still tell people about 
living healthy lifestyle, not smoking 
and regular exercise. I think that is 








Printed DTCA is more 
ethical 
 “I think a printed advertisement; you 
can possibly have a little bit more 
time reading it through.” 
“If you’ve got a print ad, you know 
you’ve got more time to read the fine 
print” 
“It has to be on a printed page.” 
“I feel like magazines are a good one 
because people can read it… a 
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magazine you can go back to and look 
at.” 
“I think magazines would be 
probably more ethical. Because when 
you are reading services, you take the 
time to notice everything on the 
page.” 
“[DTCA on] magazine [is more 
ethical] because it gives people time 
to think about it.” 
DTCA on TV and radio 
is not ethical 
 “I think it [information] is very 
limited when it is on the TV, on the 
radio. It is not enough.” 
“No, actually I do think that if you 
want to make it legal/ethical for 
medicines to be advertised, it should 
only be printed. On TV, and radio are 
not enough. Even on a printed page, 
it is not enough. So, TV and radio is 
really short.” 
“You know a radio and a TV ad being 
fast and not being able to refer back.” 
“Useful health information is 
minimal on a TV ad.” 
“It’s a time thing...can’t really put too 
many things on a TV advertisement 
for 30 seconds but I guess a print one 
is a bit easier.” 
“I think it’s hard for them to provide 
sufficient information on a TV advert 
because it’s not enough time and they 
just say to ask your doctor if it’s right 
for you.” 
“Would be particularly against the 
ones that are on television or you 
know, because they can be very 
closely targeted to the audience. You 
know if you’re watching a football 
game or something and there’s gonna 
be ones for men because they choose 
the right time to advertise and...but 
the Internet is the same and in fact, it 
seems to be even more closely 
targeted to what your demographic is 
and um...yeah.” 
“A TV advertisement is a lot more 
visual effects, which kind of, and 
since there’s a 30 second gap, even if 
they wanted to give you information, 
they cannot so hence a lot of the times 
you see talk to your professional and 
by the time sometimes they come to 
the professional, they might have 
already made up their mind and even 
if the professional says something, 
they might not listen to and think you 
know what, the TV looks pretty 
good.” 
“I think the radio would not be 
suitable because you only hear, you 
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can’t sort of see...and sort of think 
about it more, it’s just a brief thing.” 
DTCA on Internet is 
not ethical 
 
 “[DTCA] has to go to the advertising 
board before, but with the Internet, I 
don’t think that is likely to happen.” 
“They can just pop it under maybe 
some website, the address bar or 
something and then they are 
advertising their medicine without 
proper regulations.” 
“I personally do not like things 
online, and on the Internet, just 
because they can flood you with a 









DTCA for controlled 
drugs and/or addictive 
drugs is not ethical 
 
 “I think addictive medications are 
unethical. Some people are addicted 
to Morphine. Advertising Morphine is 
not ethical. Anything that is addictive 
it is not OK.” 
“Controlled drugs should not be 
advertised… they can be abused, any 
controlled drug with the potential for 
abuse should not be advertised… 
They shouldn’t be advertised because 
they are for the people that really 
need them”.  
“I think [advertising] addictive 
medications are unethical. Some 
people are addicted to Morphine. 
Advertising Morphine is not ethical. 
Anything that is addictive it is not 
OK.” 
DTCA for acute and 
life-threatening 
conditions is not ethical  
 “DTCA for cancer medicines is not 
ethical. Since there are too many 
factors that affect decisions about the 
best treatment for the patient, like 
age, stage of the disease, pathology of 
cancer, immunity of the patient, type 
of cancer,… and physicians should 
decide about it.” 
“Definitely [advertising of] 
medications that are targeting 
chronic conditions, are for those who 
are vulnerable [is not ethical].” 
“Probably [advertising of] any life-
threatening or drugs for serious 
illness [is not ethical], again I would 
have concern that advertising may 
promote benefits as opposed to 
harms, and not give an informed 
choice about options really.” 
“Would have concerns as well about 
promoting drugs for life-threatening 
or severe conditions again to 
advertising is the nature of the scary 
fact or basically you know, really 
pushing someone to take this 
particular drug than another really.” 
“Well, I think it is unethical probably 
to advertise medicines for palliative 
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care, like when you’re talking about 
cancer treatments.” 
“[DTCA for] drugs for like 
potentially fatal conditions, are less 
ethical to advertise.” 
“When it comes to the precise 
treatment of chronic illnesses or 
acute symptoms, I think it's not 
[ethical].” 
“[DTCA] for painkillers, it might be 
OK. For those, which do not have 
severe damage to the individuals is 
good but for like diabetes and all that 
and even asthma, I don’t think it is 
good to advertise … More can be 
done to improve patients’ safety.” 
DTCA for medications 
that have serious side 
effects is unethical  
 “Maybe medicines that have side 
effects or more powerful side effects, 
they should be cautious with 
advertising.”  
DTCA for psychiatric 
medications is 
unethical  
 “If you said to me that this sort of 
advertising that was worse than 
other, then I think you know, for 
example, direct to consumer 
advertising of dementia drugs would 
be one because of course the person 
concerned can’t make an informed 
decision.” 
“I would think probably some 
psychiatric medications also would 
be something where you’d have to be 
careful about.” 
“Mostly psychiatric conditions would 
be the one.” 
DTCA for drugs 
targeted at kids is 
unethical 
 “The main ones were really around, 
it would be worse for conditions in 
which a child can’t give consent.” 
“I guess probably it would be airing 
on the side of unethical to advertise 
medicines to parents with children I 
think, I’m a bit uneasy with that 
because, or that’s another harm that 
can come from medicines, it may be 
parents feel like they’re not doing the 
right thing by their children if they 
don’t give the child this medication..., 
whereas in actual fact, the child may 
not need the medication at all.” 
DTCA is ethical when it 
helps improve public 
health  
 
 “If they had ads for the flu vaccine or 
ads for your childhood vaccines, I’m 
very happy to see those 
advertisements, but they’re, you know 
the drug companies don’t push those 
do they, they don’t need because the 
Government’s already bought a lot of 
that stock,...or if they had, you know 
advertisements for kind of like 
smoking cessation medicines and 
things like that which you know, 
sometimes they do so ones that either 
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have, we recommend already like the 
vaccines or have other health benefits 
like smoking cessation.... Yeah; 
maybe even the new Hepatitis C 
medicines.” 
“I think where the medications are to 
be done in cases of public health. For 
example, when there is an 
advertisement for the HPV virus or 
vaccinations for the flu virus, H1N1 
virus. So, it creates awareness about 
the disease and it says you should use 
this particular vaccine, or you should 
get yourself this vaccination. So, it's 












 “Feel like they should have one that 
they cannot encourage people that 
this is what you need. If we continue 
to do it, it should be promotional 
about this is available, and what this 
is for this; rather than encouraging 
people to buy this specific product.” 
“This concept of social responsibility, 
come from industry, where the 
industry in general, meaning if we are 
using consumers to give us money 
because they buy our products, we 
have to give it back at some point, so 
that the socially responsible industry 
come out of that, I don’t know how 
much they are giving back, again they 
are there to make money. Well, I do 
not think they are measuring the 
impact right, because once you put 
that out there, how many people, are 
not being affected by that. How many 
people are? what are the 
consequences? I don’t think, I don’t 
know, are they measuring that? So 
that could be an important point to 
keep in mind.”  
“I think social responsibility in terms 
of pharmaceutical companies... they 
should be more involved in explaining 
the disease, rather than giving 
prescriptive treatment. So, the 
awareness is good but the part where 
they have come down to make it 
purely commercialised by giving 
okay... this is one medicine that will 
cover all your symptoms, that's that 
part [that is not ethical].” 
Should select the target 
audience ethically 
 
 “I wouldn’t say it’s all together 
unethical to advertise medicines and 
I wouldn’t say it’s, yeah not all 
together unethical, not all together 
ethical so it depends on the way the 
advertisement’s presented, it depends 
on who the advertisement is being 
targeted towards, like you know if, 
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and the kind of wording or the, yeah 
the wording or images presented in 
the advertisement so I think the 
companies would have to be careful 
not to give patients an unrealistic 
expectation of yeah or to target 
people that might be vulnerable as 
well.” 
“It [DTCA] always reaches people 
who are most vulnerable. 
“Yeah, I do not think promoting 
medicine directly to consumers is 
right. Yeah, I think it is preying on 
people who are vulnerable already.” 
“Definitely [advertisements of] 
medications that are targeting 
chronic conditions, are for those who 
are vulnerable [are not ethical]” 
“Very young (because of their 
background, they don’t have all the 
information because they have not 
been exposed to many of them), very 
old (they are suffering a lot and 
because of their mental capability or 
the condition they have), mentally 
disabled people, who with psychiatric 
disorders that can affect their 
judgments…because of conditions 
they have. It depends on the 
particular mood that you have while 
watching an ad. If they are depressed 
and they see an ad for anti-
depressant, they think that no it does 
not work because I am taking all these 
medications and these are not making 
me happier. And they will be more 
negative towards it. Those people 
tend to be affected more and they 
probably need more help when 








There should be 
stricter regulations and 
supervision of DTCA 
DTCA should not be 
self-regulated 
“I think [it] needs more monitoring, I 
think it would be good to have an 
evaluation of what is actually being 
advertised to consumers and is it 
actually being, is it a beneficial thing 
for our community. So, a review, 
yeah.” 
“Self-regulated DTCA is not good.” 
“I think if we just try to find a better 
way to regulate it, even if that means 
the government step in and take the 
whole advertising rather than leaving 
it to drug companies do it.” 
“I think guidelines need to be very 
clear, they also need to be very 
straightforward.” 
“When people come and say that they 
want a special brand of drug, then the 
government has to provide for them. 
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More expensive drugs which does 
exactly the same thing as the 
generics. That is skewing peoples’ 
ideas at the moment. We definitely 
need tighter regulations at the 
moment.” 
To have a committee 
to filter out the ads 
“I would like to see more sort of 
governing and sort of the watchdogs 
being really alert that they, 
pharmaceutical companies don’t 
promise too much.” 
“Government get involved in 
protecting the public from marketing, 
false marketing.” 
“I definitely think there should be a 
sort of, some kind of an agency that 
watches all these.” 
“They should come up with a proper 
governing body who supervises these 
pharmaceutical companies and who 
can, like they shouldn’t be just 
advertising what they want to, there 
should be a governing authority and 
yeah, so government should come up 
with laws or changes in the judiciary 
system.”  
“…Have that advisory board and a 
group of people who can advise on 
what is appropriate and what is not, 
who can realise that patients are very 
vulnerable.” 
“So it could be more regulated, but as 
to specifics, I don’t know, maybe they 
have to pass it through a, like a 
private group or something like that 
to see whether or not you know, it has 
the potential to, or whether it’s 
completely transparent their ads and 
truthful and if it’s not, then maybe 
they can say no you can’t advertise it 
this way or you need to change this 
fact that you’ve got.” 
“Maybe like implementing something 
like a Regulatory Board… Ministry of 
Health, by somebody whose interests 
are the consumers or the patients 
rather than the companies.” 
“As I said before having a layperson 
in reviewing part of it could be quite 
good. Because he/she can be the 
person who says that when I see this I 
can think of that. So, he/she can be the 
person to say how DTCA should be 
offered.” 
“…Limit what information they put 
out or have, you know they need to 
say this, they need to say that it’s 
prescription medicine and it’s up to 
the doctor to prescribe them, yeah, if 
it’s not done by the Minister of 
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Health, I think it probably does need 
to be supervised.” 
“People would not know the side 
effects and like they wouldn’t know 
much about that drug and what that 
drug does to their body so I think 
apart from them, also regulating it, I 
think there’s the need for other health 
bodies like the Ministry of Health or 
some agency which, who knows much 
about health to also influence how 
those things are being advertised… 
The consumer doesn’t have much 
knowledge about the drug, they are 
being advertised something, they 
don’t know the chemistry, etc, behind 
it…..for it to get to this screen, the 
consumer screen, there should be a 
health body in place which will do 
those check and balancing before its 
gets there, then the consumer can 
choose.” 
“There should be a health body in 
place apart from the advertising, 
which that medicine have to go 
through so that you tell them this and 
that, if you’re advertising, you need to 
state this, you need to follow this 
requirement without it, yes that 
should be in place.” 
“Having a doctor to oversee the ad 
before; or not necessarily a doctor, 
just any health professional.” 
“Maybe the advertisers could get 
some sort of medical professionals to 
see the ad before it gets advertised, 
make the ad legal thing and then more 
ethical. Someone from outside with 
no link to the company, at the end, to 
oversee, to watch the final product 
and say that is fine or not. For 
example, doctors may be thinking of 
their own patients, rather than how 















Appendix D: A Submission for Therapeutic Products Regulatory 
Scheme Consultation, April 2019 
 
 The submission provided below was related to the questions C52 and C53 of the 
therapeutic products bill regarding the issue of direct to consumer advertising of prescription 
medicines (DTCA). 
  
Name (of individual or organisation): Dr Kirsten Robertson, Dr James Green, Neda Khalil 
Zadeh  
 
Email address: kirsten.robertson@otago.ac.nz; James.Green@ul.ie; 
neda.khalilzadeh@postgrad.otago.ac.nz   
 
Dr Kirsten Robertson, Senior Lecturer, Department of Marketing, University of Otago 
Dr James Green, Senior Lecturer, School of Allied Health, University of Limerick 
Neda Khalil Zadeh, PhD student, Department of Marketing, University of Otago 
 
Summary: 
Question C52: We oppose the proposed regulatory scheme for therapeutic products, as it 
does not have the capacity to: 
• Ensure DTCA communicates that healthy lifestyle behaviours might be an alternative 
to taking the advertised medicine (evidence presented in Section 1). 
• Ensure that consumers are aware of how medicine advertising is regulated. In 
particular, the proposed Bill will not address misperceptions that only medicines that 
are completely safe and effective can be advertised (evidence presented in Section 2). 
• Ensure that individuals, especially those at-risk, are aware that medicine advertising is 
a paid communication conveyed by a pharmaceutical company (evidence presented in 
Section 3). 
• Ensure that DTCA serves a public good, educative purpose; rather, the evidence 
presented in Section 4 suggests it is primarily used to undermine take-up of 




Question C53: On balance, it is unlikely that direct-to-consumer advertising can have any 
positive health benefits, and comes with downside health risks, so should not continue to 
be permitted. 
• However, if advertising of medicines is to be retained, they should be pre-vetted by a 
fully independent panel, rather than a single person with a marketing rather than a health 
background who may delegate this role to the pharmaceutical company (the current 
vetting regime). 
• Instead, we suggest that an independent panel should be convened by the regulator, 
containing at least 1) a public health specialist, 2) a Medsafe or PHARMAC 
representative, ideally one who was involved in the evaluation of the product and 3) a 
consumer representative. This panel should be administered under the authority of the 
Ministry of Health, with costs being met by the applicant. 
• The independent panel should ensure that the advertisement:  
1) Contains explicit and impartial information about lifestyle or behaviour changes that 
could be as effective as the advertised medicine (evidence presented in Section 1).  
2) States that the medicine advertised is not necessarily any better than other non-
advertised medicines, and where applicable, present comparison information on price 
and effectiveness (evidence presented in Section 2).  
3) Communicates that the advertisement is a paid promotion conveyed by a 
pharmaceutical company (evidence presented in Section 3).  
4) Presents information in a neutral and not emotive or persuasive fashion.  
5) Does not principally exist to promote one brand over another product that contains 
the same active medical ingredient (evidence presented in Section 4) 
 
Section 1: Advertising of medicines for diseases/illnesses that may otherwise be improved 
by a healthier lifestyle promotes pharmaceuticalisation over healthy lifestyle choices.   
 A survey that we conducted of a nationally representative sample of 2,057 adults in 
New Zealand revealed that individuals who had unhealthier lifestyle behaviours (physical 
inactivity, unhealthy eating, illegal drug consumption, higher alcohol consumption, and a less 
positive attitude towards doing exercise) were more likely to respond to medicine advertising 
than were those with a healthy lifestyle (Khalil Zadeh, Robertson & Green, 2019). 
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 Previous research argues that DTCA promotes lifestyle medicines (e.g., weight loss 
pills), which individuals perceive as ‘magical’ (Fox et al., 2008), resulting in 
pharmaceuticalisation over healthy lifestyle choices (e.g., Almasi et al., 2006; Abraham 2010). 
 
Section 2: Individuals have misperceptions of the safety and efficacy of DTCA, perceiving 
that only ‘extremely effective’ medicines are advertised. 
 A survey that we conducted of a nationally representative sample of 2,057 adults in 
New Zealand revealed that “43.7% [of respondents] thought that only drugs that are completely 
safe could be advertised, and 35.3% believed that only drugs that are extremely effective could 
be advertised” (Khalil Zadeh, Robertson & Green, 2017, p. 4). The findings show that 
participants lack knowledge about the regulation and safety of medicine advertising (Khalil 
Zadeh et al., 2017). 
 Furthermore, previous research shows that some medicines that have been advertised 
have serious side effects. For example, Vioxx was heavily promoted for five years in over 80 
countries, involving New Zealand. It was later withdrawn from the global market in 2004 due 
to the safety alarms regarding the heightened risk of heart attack and stroke (Bradford et al., 
2006; Evans et al., 2011; Khalil Zadeh et al., 2017). 
 
Section 3: DTCA influences at-risk individuals (e.g., less educated, more materialistic) 
who appear to be influenced by the promotional nature of the advertisements.  
 The study we conducted with a nationally representative survey of 2,057 New 
Zealanders revealed ‘at-risk’ individuals (i.e., older, less educated, poorer self-reported health 
status, lower-income, ethnic minorities, and more materialistic values), were more likely to 
respond to medicine advertising and thus may be more vulnerable to medicine advertising 
(Khalil Zadeh et al., 2017). Furthermore, a favourable attitude towards medicine advertising 
predicted responding to medicine advertising. Taken together with the fact that individuals had 
incorrect understanding about the safety and effectiveness of advertised medicines (see Section 
2), the findings suggest that these “individuals are at risk of being influenced by the 
promotional nature of the advertisements” (Khalil Zadeh et al., 2017, p. 6). 
 
Section 4: Rather than having an educational or health benefit (discussion point 600) 
much existing medicine advertising promotes one brand over another with the same 
active medical ingredient.  
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 An analysis that one of us was involved in found that print advertising for medicines 
(2005-2009) coincided with PHARMAC funding a new generic medicine (Samaranayaka & 
Green, 2019). Thus, rather than having an educational purpose, the advertisement aims to have 
New Zealanders pay more money for a non-subsided version, where a fully equivalent (in terms 
of safety and efficacy) product with the same active medical ingredient exists, and is being 
subsidised by PHARMAC.  
 For example, as can be seen in the figure below (taken from Samaranayaka and Green, 
2019) most advertising for Losec occurred at the point that Losec was losing subsidy to Dr 
Reddy’s Omeprazole. This advertising is protecting market share for a particular brand of an 
active medical ingredient, rather than serving an educative purpose.  
 Similarly, Salamol was advertised when it gained subsidy, with Ventolin being 
















Figure D.1: Volume of subsidised Omeprazole (Losec and Dr Reddy’s) dispensed by month 
compared to Losec advertising (taken from Samaranayaka and Green, 2019) 
 
 
Figure D.2: Volume of subsidised Salbutamol (Ventolin, Salamol, and Respigen) dispensed by 
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Appendix E: Summary of Research Questions and Results 
 







RQ1. What are the factors 
associated with individuals’ self-
reported behavioural responses to 
DTCA (with an emphasis on ‘at 
risk’ individuals’ responses)? 
‘At-risk’ individuals (i.e., lower-income, poorer self-
reported health status, older, less educated, and ethnic 
minorities), women, who base their decisions on their 
attitudes, those higher in materialism, and who rely on 
the internet for medical information were more likely to 
respond to DTCA. 
Study 1  
 
RQ2. What is the association 
between lifestyle determinants and 
self-reported behavioural 
responses triggered by DTCA? 
Individuals with unhealthier lifestyles (less physical 
activity, higher levels of alcohol consumption, 
unhealthier nutritional habits, and higher levels of 
illegal drug use) were more likely to respond to DTCA. 
The negative attitude towards doing exercise also 
influenced asking a doctor for a prescription. 
Study 2 
RQ3. What are health 
professionals’ perceived factors 
affecting consumers’ informed 
decision-making, in response to 
DTCA? 
Positive views: Consumers’ autonomy 
(empowerment/proactivity and awareness) influence 
consumers’ decision-making positively. 
Negative views: Unethicality of DTCA and individuals’ 
incapability affect their decision-making negatively. 
Doctors have key roles in consumers’ informed 
decision-making (see Figure 4.1 for more detail). 
Study 3 
RQ4. What are health 
professionals’ perceived 
characteristics of consumers who 
are less able to make informed 
decisions in response to DTCA 
(who are more vulnerable)? 
Individuals with health problems, unhealthy lifestyles, 
and disadvantaged demographic and/or socio-economic 
status were identified as less able to make informed 
choices and thus more vulnerable to DTCA. In addition, 
some personal characteristics, including being 
materialistic, trusting, and impulsive were also 
perceived to increase vulnerability to DTCA. 
Study 3 
RQ5.  Is DTCA perceived ethical 
in its current format in New 
Zealand? 
 
RQ5.1. How to offer socially 
responsible/ethical DTCA in 




Overall, DTCA does not seem ethical in its current 
format. Recommendations on how to offer socially 
responsible DTCA are: 
• DTCA should have credible, factual, and not 
deceptive contents, provide complete information, 
focus on the disease rather than a specific drug, and 
communicate lifestyle behaviour. 
• Print DTCA is more ethical, while DTCA on 
TV, radio, and the Internet is less ethical. 
• DTCA for controlled and/or addictive drugs, 
for acute and life-threatening conditions, for 
medications that have serious side effects, for 
psychiatric medications, for drugs targeted at children 
is not ethical. Nonetheless, DTCA is ethical when it 
helps improve public health. 
• The driving force of DTCA for pharmaceutical 
companies should be improving people’s health, not 
increasing sales. Pharmaceutical companies should 
thus select the target audience ethically. 
• There should be stricter regulations and 








Appendix F: Ethics Forms 
 
 






















